Genes	O
Chromosomes	O
Cancer	O
.	O
2003	O
Nov;38	O
(	O
3	O
)	O
:226-33	O
.	O
Clustering	O
of	O
hypermethylated	O
genes	O
in	O
neuroblastoma	O
.	O
van	O
Noesel	O
MM	O
,	O
van	O
Bezouw	O
S	O
,	O
Voute	O
PA	O
,	O
Herman	O
JG	O
,	O
Pieters	O
R	O
,	O
Versteeg	O
R.	O
Department	O
of	O
Human	O
Genetics	O
,	O
Academic	O
Medical	O
Center	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
m	O
.vannoesel@erasmusmc.nl	O
CpG	O
-island	O
hypermethylation	O
of	O
gene	O
promoters	O
is	O
a	O
frequent	O
mechanism	O
for	O
gene	O
inactivation	O
in	O
tumors	O
.	O
Many	O
neuroblastomas	O
have	O
hypermethylation	O
and	O
down	O
-	O
regulation	O
of	O
CASP8	B-GENE
,	O
leading	O
to	O
resistance	O
to	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
.	O
We	O
recently	O
found	O
hypermethylation	O
of	O
the	O
four	O
TRAIL	B-GENE
receptors	I-GENE
in	O
9	O
neuroblastoma	O
cell	O
lines	O
.	O
Here	O
,	O
we	O
analyzed	O
methylation	O
of	O
34	O
genes	O
in	O
22	O
neuroblastoma	O
cell	O
lines	O
.	O
Of	O
the	O
29	O
newly	O
analyzed	O
genes	O
,	O
only	O
FLIP	B-GENE
at	O
chromosome	O
band	O
2q33	O
was	O
methylated	O
in	O
8	O
/	O
22	O
cell	O
lines	O
.	O
The	O
FLIP	B-GENE
protein	O
is	O
a	O
negative	O
regulator	O
of	O
Caspase	B-GENE
8	I-GENE
.	O
FLIP	B-GENE
maps	O
adjacent	O
to	O
CASP8	B-GENE
,	O
and	O
their	O
methylation	O
patterns	O
showed	O
a	O
moderate	O
correlation	O
.	O
Furthermore	O
,	O
co	O
-	O
methylation	O
patterns	O
were	O
observed	O
for	O
the	O
TRAIL	B-GENE
receptor	I-GENE
pairs	O
DCR1	B-GENE
and	O
DCR2	B-GENE
and	O
between	O
DR4	B-GENE
and	O
DR5	B-GENE
.	O
All	O
four	O
receptors	O
co	O
-	O
localize	O
in	O
chromosome	O
band	O
8p21	O
.	O
The	O
6	O
genes	O
methylated	O
in	O
neuroblastomas	O
appeared	O
to	O
occur	O
in	O
pairs	O
.	O
The	O
genes	O
within	O
each	O
pair	O
have	O
a	O
strong	O
sequence	O
homology	O
and	O
originated	O
from	O
gene	O
duplication	O
.	O
We	O
found	O
no	O
evidence	O
for	O
regional	O
spreading	O
of	O
methylation	O
,	O
given	O
that	O
we	O
did	O
not	O
observe	O
de	O
novo	O
methylation	O
in	O
additional	O
local	O
CpG	O
islands	O
.	O
However	O
,	O
the	O
gene	O
pairs	O
showed	O
a	O
striking	O
co	O
-	O
regulation	O
at	O
the	O
mRNA	O
expression	O
level	O
.	O
Down	O
-	O
regulation	O
of	O
FLIP	B-GENE
strongly	O
corresponds	O
with	O
down	O
-	O
regulation	O
of	O
CASP8	B-GENE
,	O
and	O
this	O
was	O
also	O
found	O
for	O
DCR1	B-GENE
and	O
DCR2	B-GENE
.	O
Only	O
a	O
subset	O
of	O
the	O
down	O
-	O
regulated	O
genes	O
was	O
methylated	O
.	O
This	O
suggests	O
a	O
mechanism	O
of	O
co	O
-	O
regulated	O
transcriptional	O
silencing	O
of	O
the	O
gene	O
pairs	O
,	O
followed	O
by	O
a	O
methylation	O
event	O
that	O
is	O
less	O
penetrating	O
.	O
The	O
methylation	O
pattern	O
therefore	O
supports	O
a	O
model	O
in	O
which	O
CpG	O
islands	O
are	O
not	O
randomly	O
targeted	O
by	O
methylation	O
in	O
cancer	O
.	O
Specific	O
transcriptional	O
silencing	O
probably	O
marks	O
genes	O
that	O
can	O
become	O
methylated	O
.	O
Copyright	O
2003	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
14506696	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1998	O
Mar	O
3;95	O
(	O
5	O
)	O
:2475	O
-80	O
.	O
Erratum	O
in	O
:	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
2000	O
Mar	O
28;9	O
7	O
(	O
7	O
)	O
:	O
3782	O
.	O
Gene	O
therapy	O
with	O
a	O
single	B-GENE
chain	I-GENE
interleukin	I-GENE
12	I-GENE
fusion	O
protein	O
induces	O
T	O
cell	O
-	O
dependent	O
protective	O
immunity	O
in	O
a	O
syngeneic	O
model	O
of	O
murine	O
neuroblastoma	O
.	O
Lode	O
HN	O
,	O
Dreier	O
T	O
,	O
Xiang	O
R	O
,	O
Varki	O
NM	O
,	O
Kang	O
AS	O
,	O
Reisfeld	O
RA.	O
Department	O
of	O
Immunology	O
,	O
The	O
Scripps	O
Research	O
Institute	O
,	O
La	O
Jolla	O
,	O
CA	O
92037	O
,	O
USA	O
.	O
A	O
major	O
goal	O
of	O
tumor	O
immunotherapy	O
is	O
the	O
effective	O
eradication	O
of	O
established	O
metastases	O
associated	O
with	O
the	O
induction	O
of	O
a	O
T	O
cell	O
-	O
mediated	O
protective	O
immunity	O
.	O
We	O
achieved	O
this	O
in	O
a	O
poorly	O
immunogenic	O
murine	O
neuroblastoma	O
model	O
by	O
gene	O
therapy	O
with	O
a	O
single	B-GENE
chain	I-GENE
interleukin	I-GENE
12	I-GENE
(	O
scIL-12	B-GENE
)	O
fusion	O
protein	O
that	O
assures	O
equal	O
expression	O
of	O
its	O
p35	B-GENE
and	O
p40	B-GENE
subunits	O
.	O
Thus	O
,	O
NXS2	O
hybrid	O
neuroblastoma	O
cells	O
(	O
C1300	O
x	O
dorsal	O
root	O
ganglion	O
cells	O
)	O
,	O
which	O
form	O
experimental	O
bone	O
marrow	O
and	O
liver	O
metastases	O
in	O
syngeneic	O
A	O
/	O
J	O
mice	O
,	O
were	O
transduced	O
with	O
a	O
gene	O
encoding	O
murine	O
interleukin	B-GENE
12	I-GENE
,	O
monomerized	O
by	O
introduction	O
of	O
a	O
protein	O
linker	O
between	O
the	O
p35	B-GENE
and	O
p40	B-GENE
protein	O
chains	O
of	O
this	O
heterodimeric	B-GENE
cytokine	I-GENE
.	O
We	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
subcutaneous	O
vaccination	O
with	O
these	O
transduced	O
cells	O
induces	O
a	O
protective	O
immunity	O
,	O
as	O
indicated	O
by	O
the	O
complete	O
absence	O
of	O
liver	O
and	O
bone	O
marrow	O
metastasis	O
after	O
challenge	O
with	O
NXS2	O
wild-type	O
tumor	O
cells	O
.	O
Furthermore	O
,	O
vaccination	O
of	O
animals	O
with	O
established	O
liver	O
and	O
bone	O
marrow	O
metastases	O
completely	O
eradicated	O
liver	O
metastases	O
and	O
suppressed	O
bone	O
marrow	O
metastases	O
.	O
The	O
local	O
and	O
systemic	O
immune	O
response	O
against	O
scIL-12	B-GENE
-transduced	O
NXS2	O
cells	O
is	O
largely	O
dependent	O
on	O
CD8	B-GENE
(+)	O
T	O
cells	O
.	O
This	O
was	O
demonstrated	O
in	O
vivo	O
by	O
depletion	O
of	O
immunocompetent	O
A	O
/	O
J	O
mice	O
with	O
monoclonal	O
anti	B-GENE
-	I-GENE
CD4	I-GENE
and	O
anti	B-GENE
-	I-GENE
CD8	I-GENE
antibodies	I-GENE
and	O
in	O
vitro	O
by	O
specific	O
major	B-GENE
histocompatibility	I-GENE
complex	I-GENE
,	I-GENE
class	I-GENE
I-	I-GENE
restricted	O
CD8	B-GENE
(+)	O
T	O
cell	O
-	O
mediated	O
killing	O
of	O
NXS2	O
and	O
their	O
parental	O
C1300	O
neuroblastoma	O
cells	O
.	O
In	O
conclusion	O
,	O
we	O
demonstrate	O
successful	O
anti	O
-	O
tumor	O
immunotherapy	O
with	O
an	O
scIL-12	B-GENE
fusion	O
protein	O
that	O
could	O
facilitate	O
clinical	O
application	O
of	O
interleukin	B-GENE
12	I-GENE
gene	O
therapy	O
.	O
PMID	O
:	O
9482910	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuroscience	O
.	O
1999;9	O
3	O
(	O
3	O
)	O
:	O
1041	O
-	O
9.	O
Differential	O
effects	O
of	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta(s)	I-GENE
and	O
glial	B-GENE
cell	I-GENE
line	I-GENE
-	I-GENE
derived	I-GENE
neurotrophic	I-GENE
factor	I-GENE
on	O
gene	O
expression	O
of	O
presenilin-1	B-GENE
in	O
human	O
post	O
-	O
mitotic	O
neurons	O
and	O
astrocytes	O
.	O
Ren	O
RF	O
,	O
Lah	O
JJ	O
,	O
Diehlmann	O
A	O
,	O
Kim	O
ES	O
,	O
Hawver	O
DB	O
,	O
Levey	O
AI	O
,	O
Beyreuther	O
K,	O
Flanders	O
KC.	O
Laboratory	O
of	O
Cell	O
Regulation	O
and	O
Carcinogenesis	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
MD	O
20892	O
,	O
USA	O
.	O
Mutations	O
in	O
the	O
presenilin-1	B-GENE
gene	O
are	O
linked	O
to	O
the	O
majority	O
of	O
early-onset	O
familial	O
Alzheimer	O
's	O
disease	O
cases	O
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
expression	O
of	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta	I-GENE
is	O
altered	O
in	O
Alzheimer	O
's	O
patients	O
,	O
compared	O
to	O
controls	O
.	O
Here	O
we	O
examine	O
presenilin	B-GENE
-	O
expression	O
in	O
human	O
post	O
-	O
mitotic	O
neurons	O
(	O
hNT	O
cells	O
)	O
,	O
normal	O
human	O
astrocytes	O
,	O
and	O
human	O
brain	O
tumor	O
cell	O
lines	O
following	O
treatment	O
with	O
three	O
isoforms	O
of	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta	I-GENE
,	O
or	O
glial	B-GENE
cell	I-GENE
line	I-GENE
-	I-GENE
derived	I-GENE
neurotrophic	I-GENE
factor	I-GENE
,	O
a	O
member	O
of	O
the	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta	I-GENE
superfamily	O
.	O
As	O
the	O
NT2	O
/	O
D1	O
teratocarcinoma	O
cell	O
line	O
is	O
treated	O
with	O
retinoic	O
acid	O
to	O
induce	O
differentiation	O
to	O
hNT	O
cells	O
,	O
presenilin-1	B-GENE
messenger	O
RNA	O
expression	O
is	O
dramatically	O
increased	O
.	O
Furthermore	O
,	O
there	O
is	O
a	O
2-3	O
-	O
fold	O
increase	O
in	O
presenilin-1	B-GENE
messenger	O
RNA	O
expression	O
following	O
treatment	O
of	O
hNT	O
cells	O
with	O
growth	O
factors	O
and	O
similar	O
results	O
are	O
found	O
by	O
Western	O
blotting	O
and	O
with	O
immunohistochemical	O
staining	O
for	O
presenilin-1	B-GENE
protein	O
.	O
However	O
,	O
treatment	O
of	O
normal	O
human	O
astrocytes	O
with	O
cytokines	O
results	O
in	O
minimal	O
changes	O
in	O
presenilin-1	B-GENE
messenger	O
RNA	O
and	O
protein	O
.	O
Interestingly	O
,	O
the	O
expression	O
of	O
presenilin-1	B-GENE
in	O
human	O
U87	O
MG	O
astrocytoma	O
and	O
human	O
SK-N-SH	O
neuroblastoma	O
cells	O
is	O
only	O
increased	O
when	O
cells	O
are	O
treated	O
with	O
glial	B-GENE
cell	I-GENE
line	I-GENE
-	I-GENE
derived	I-GENE
neurotrophic	I-GENE
factor	I-GENE
or	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta3	I-GENE
.	O
These	O
findings	O
suggest	O
that	O
endogenous	O
presenilin-1	B-GENE
gene	O
expression	O
in	O
human	O
neurons	O
can	O
be	O
induced	O
by	O
growth	O
factors	O
present	O
in	O
normal	O
and	O
diseased	O
brain	O
tissue	O
.	O
Cytokines	O
may	O
play	O
a	O
major	O
role	O
in	O
regulating	O
expression	O
of	O
presenilin-1	B-GENE
which	O
may	O
affect	O
its	O
biological	O
actions	O
in	O
physiological	O
and	O
pathological	O
conditions	O
.	O
PMID	O
:	O
10473269	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Malar	O
J.	O
2003	O
Feb	O
27;	O
2	O
(	O
1	O
)	O
:4	O
.	O
Effect	O
of	O
sample	O
size	O
and	O
P-value	O
filtering	O
techniques	O
on	O
the	O
detection	O
of	O
transcriptional	O
changes	O
induced	O
in	O
rat	O
neuroblastoma	O
(	O
NG108	O
)	O
cells	O
by	O
mefloquine	O
.	O
Dow	O
GS	O
.	O
Department	O
of	O
Parasitology	O
,	O
Division	O
of	O
Experimental	O
Therapeutics	O
,	O
Walter	O
Reed	O
Army	O
Institute	O
of	O
Research	O
,	O
Silver	O
Spring	O
,	O
MD	O
20910	O
,	O
USA	O
.	O
geoffrey	O
.dow@na	O
.amedd	O
.army	O
.mil	O
BACKGROUND	O
:	O
There	O
is	O
no	O
known	O
biochemical	O
basis	O
for	O
the	O
adverse	O
neurological	O
events	O
attributed	O
to	O
mefloquine	O
.	O
Identification	O
of	O
genes	O
modulated	O
by	O
toxic	O
agents	O
using	O
microarrays	O
may	O
provide	O
sufficient	O
information	O
to	O
generate	O
hypotheses	O
regarding	O
their	O
mode	O
of	O
action	O
.	O
However	O
,	O
this	O
utility	O
may	O
be	O
compromised	O
if	O
sample	O
sizes	O
are	O
too	O
low	O
or	O
the	O
filtering	O
methods	O
used	O
to	O
identify	O
differentially	O
expressed	O
genes	O
are	O
inappropriate	O
.	O
METHODS	O
:	O
The	O
transcriptional	O
changes	O
induced	O
in	O
rat	O
neuroblastoma	O
cells	O
by	O
a	O
physiological	O
dose	O
of	O
mefloquine	O
(	O
10	O
micro-molar	O
)	O
were	O
investigated	O
using	O
Affymetrix	O
arrays	O
.	O
A	O
large	O
sample	O
size	O
was	O
used	O
(	O
total	O
of	O
16	O
arrays	O
)	O
.	O
Genes	O
were	O
ranked	O
by	O
P-value	O
(	O
t-test	O
)	O
.	O
RT-PCR	O
was	O
used	O
to	O
confirm	O
(	O
or	O
reject	O
)	O
the	O
expression	O
changes	O
of	O
several	O
of	O
the	O
genes	O
with	O
the	O
lowest	O
P-values	O
.	O
Different	O
P-value	O
filtering	O
methods	O
were	O
compared	O
in	O
terms	O
of	O
their	O
ability	O
to	O
detect	O
these	O
differentially	O
expressed	O
genes	O
.	O
A	O
retrospective	O
power	O
analysis	O
was	O
then	O
performed	O
to	O
determine	O
whether	O
the	O
use	O
of	O
lower	O
sample	O
sizes	O
might	O
also	O
have	O
detected	O
those	O
genes	O
with	O
altered	O
transcription	O
.	O
RESULTS	O
:	O
Based	O
on	O
RT-PCR	O
,	O
mefloquine	O
upregulated	O
cJun	B-GENE
,	O
IkappaB	B-GENE
and	O
GADD153	B-GENE
.	O
Reverse	O
Holm-Bonferroni	O
P-value	O
filtering	O
was	O
superior	O
to	O
other	O
methods	O
in	O
terms	O
of	O
maximizing	O
detection	O
of	O
differentially	O
expressed	O
genes	O
but	O
not	O
those	O
with	O
unaltered	O
expression	O
.	O
Reduction	O
of	O
total	O
microarray	O
sample	O
size	O
(	O
<	O
10	O
)	O
impaired	O
the	O
capacity	O
to	O
detect	O
differentially	O
expressed	O
genes	O
.	O
CONCLUSIONS	O
:	O
Adequate	O
sample	O
sizes	O
and	O
appropriate	O
selection	O
of	O
P-value	O
filtering	O
methods	O
are	O
essential	O
for	O
the	O
reliable	O
detection	O
of	O
differentially	O
expressed	O
genes	O
.	O
The	O
changes	O
in	O
gene	O
expression	O
induced	O
by	O
mefloquine	O
suggest	O
that	O
the	O
ER	O
might	O
be	O
a	O
neuronal	O
target	O
of	O
the	O
drug	O
.	O
PMID	O
:	O
12675948	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Klin	O
Padiatr	O
.	O
2003	O
Nov-Dec;215	O
(	O
6	O
)	O
:	O
298-302	O
.	O
Microarray-analysis	O
:	O
a	O
new	O
approach	O
to	O
study	O
the	O
molecular	O
mechanisms	O
of	O
thermo-chemotherapy	O
.	O
Schulte	O
JH	O
,	O
Schramm	O
A	O
,	O
Pressel	O
T	O
,	O
Klein-Hitpass	O
L,	O
Kremens	O
B	O
,	O
Eils	O
J,	O
Havers	O
W	O
,	O
Eggert	O
A	O
.	O
University	O
Children	O
's	O
Hospital	O
of	O
Essen	O
,	O
Germany	O
.	O
BACKGROUND	O
:	O
Experimental	O
studies	O
for	O
the	O
treatment	O
of	O
relapsed	O
neuroblastoma	O
include	O
the	O
use	O
of	O
hyperthermia	O
in	O
combination	O
with	O
chemotherapeutic	O
drugs	O
.	O
Cytotoxic	O
effects	O
of	O
alkylants	O
and	O
platinum	O
compounds	O
on	O
tumor	O
cells	O
can	O
be	O
enhanced	O
by	O
hyperthermia	O
in	O
various	O
in	O
vitro	O
models	O
.	O
However	O
,	O
the	O
underlying	O
molecular	O
mechanisms	O
are	O
still	O
largely	O
unknown	O
.	O
METHOD	O
:	O
In	O
this	O
study	O
,	O
we	O
used	O
microarray-analysis	O
as	O
a	O
new	O
biological	O
approach	O
to	O
gain	O
insight	O
into	O
the	O
pharmacogenomics	O
and	O
possible	O
target	O
genes	O
of	O
thermochemotherapy	O
.	O
As	O
a	O
model	O
,	O
LAN	O
1	O
neuroblastoma	O
cells	O
were	O
treated	O
for	O
1	O
h	O
with	O
low	O
doses	O
of	O
cisplatin	B-GENE
alone	O
,	O
with	O
simultaneous	O
heating	O
to	O
42	O
degrees	O
C	O
or	O
with	O
hyperthermia	O
alone	O
.	O
Gene	O
expression	O
was	O
analyzed	O
at	O
five	O
time	O
points	O
0	O
to	O
24	O
h	O
after	O
treatment	O
using	O
U95Av2	O
oligonucleotide	O
arrays	O
(	O
Affymetrix	O
Inc	O
)	O
.	O
Significant	O
changes	O
of	O
gene	O
expression	O
levels	O
were	O
calculated	O
by	O
similarity	O
metrices	O
and	O
Pearson	O
correlation	O
.	O
RESULTS	O
:	O
Only	O
a	O
few	O
genes	O
(	O
n	O
=	O
23	O
)	O
demonstrated	O
altered	O
expression	O
following	O
treatment	O
of	O
LAN	O
1	O
cells	O
with	O
cisplatin	B-GENE
alone	O
.	O
Hyperthermia	O
alone	O
resulted	O
in	O
significant	O
expression	O
changes	O
of	O
136	O
genes	O
in	O
comparison	O
to	O
untreated	O
control	O
cells	O
.	O
Combination	O
therapy	O
of	O
cisplatin	B-GENE
and	O
hyperthermia	O
resulted	O
in	O
expression	O
changes	O
of	O
251	O
genes	O
,	O
interestingly	O
including	O
131	O
genes	O
with	O
unchanged	O
expression	O
under	O
treatment	O
with	O
either	O
cisplatin	B-GENE
or	O
hyperthermia	O
alone	O
.	O
Significant	O
changes	O
of	O
expression	O
levels	O
could	O
be	O
annotated	O
to	O
genes	O
involved	O
in	O
heat	O
shock	O
response	O
,	O
protein	O
degradation	O
and	O
apoptosis	O
.	O
These	O
results	O
are	O
now	O
being	O
validated	O
on	O
mRNA	O
-	O
and	O
protein	O
levels	O
by	O
RT-PCR	O
and	O
Western	O
Blot	O
analysis	O
.	O
CONCLUSION	O
:	O
Microarray-Analysis	O
is	O
a	O
suitable	O
new	O
approach	O
for	O
the	O
identification	O
of	O
target	O
genes	O
,	O
which	O
might	O
play	O
an	O
important	O
role	O
for	O
the	O
synergistic	O
effect	O
of	O
hyperthermia	O
and	O
chemotherapy	O
in	O
tumor	O
cells	O
.	O
PMID	O
:	O
14677092	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
1994	O
May	O
;23(	O
3	O
)	O
:253	O
-	O
65	O
.	O
Trans	O
-	O
activation	O
by	O
thyroid	B-GENE
hormone	I-GENE
receptors	I-GENE
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
human	O
ChAT	B-GENE
gene	O
.	O
Quirin-Stricker	O
C	O
,	O
Nappey	O
V	O
,	O
Simoni	O
P,	O
Toussaint	O
JL	O
,	O
Schmitt	O
M.	O
Institut	O
de	O
Chimie	O
Biologique	O
de	O
la	O
Faculte	O
de	O
Medecine	O
,	O
CNRS	O
,	O
Unite	O
184	O
,	O
INSERM	O
,	O
Strasbourg	O
,	O
France	O
.	O
Fusion	O
gene	O
constructs	O
containing	O
the	O
human	O
choline	B-GENE
acetyltransferase	I-GENE
5	O
'	O
flanking	O
region	O
are	O
stimulated	O
by	O
thyroid	B-GENE
hormone	I-GENE
(	O
T3	B-GENE
)	O
in	O
neuronal	O
NG108-15	O
and	O
NE1	O
-	O
115	O
cells	O
but	O
not	O
in	O
non	O
neuronal	O
COS-1	O
and	O
JEG-3	O
cells	O
.	O
To	O
identify	O
potential	O
T3	B-GENE
receptor	I-GENE
binding	O
elements	O
(	O
T3RE	O
)	O
,	O
chimeric	O
plasmids	O
containing	O
various	O
lengths	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
hChAT	B-GENE
gene	O
linked	O
to	O
the	O
CAT	B-GENE
reporter	O
gene	O
were	O
assayed	O
by	O
transient	O
transfections	O
into	O
NG108-15	O
,	O
NE1	O
-	O
115	O
and	O
COS-1	O
cells	O
.	O
We	O
show	O
that	O
regulation	O
is	O
T3	B-GENE
specific	O
as	O
estrogen	O
,	O
dexamethasone	O
,	O
dihydrotestosterone	O
,	O
all-trans	O
-	O
retinoic	O
acid	O
and	O
9-cis	O
-	O
retinoic	O
acid	O
have	O
no	O
effect	O
.	O
We	O
localized	O
several	O
potential	O
T3REs	O
and	O
characterized	O
the	O
most	O
proximal	O
T3RE	O
(	O
position	O
3280	O
-	O
3291	O
)	O
which	O
contains	O
two	O
hexameric	O
half	O
-sites	O
arranged	O
as	O
a	O
direct	O
repeat	O
without	O
a	O
base	O
pair	O
spacer	O
.	O
An	O
oligonucleotide	O
containing	O
this	O
sequence	O
confers	O
T3	B-GENE
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
.	O
The	O
transcriptional	O
response	O
of	O
this	O
T3RE	O
is	O
markedly	O
reduced	O
after	O
mutation	O
of	O
the	O
first	O
or	O
second	O
half	O
-site	O
indicating	O
that	O
both	O
half	O
-sites	O
are	O
required	O
for	O
a	O
maximal	O
T3	B-GENE
response	O
.	O
We	O
have	O
found	O
that	O
RAR	B-GENE
alpha	I-GENE
,	O
RXR	B-GENE
alpha	I-GENE
and	O
COUP-TF	B-GENE
do	O
not	O
enhance	O
T3	B-GENE
responsiveness	O
and	O
therefore	O
they	O
may	O
not	O
interact	O
with	O
T3R	B-GENE
alpha	I-GENE
in	O
NG108-15	O
cells	O
on	O
this	O
regulatory	O
sequence	O
.	O
T3R	B-GENE
monomer	O
and	O
dimer	O
specific	O
binding	O
to	O
the	O
proximal	O
T3RE	O
is	O
demonstrated	O
by	O
gel	O
-	O
retardation	O
DNA	O
binding	O
assays	O
and	O
by	O
methylation	O
interference	O
experiments	O
.	O
In	O
COS-1	O
cells	O
,	O
T3R	B-GENE
inhibits	O
transcriptional	O
activation	O
by	O
the	O
transcription	O
factor	O
AP-1	B-GENE
whereas	O
in	O
NE1	O
-	O
115	O
cells	O
T3R	B-GENE
enhances	O
AP-1	B-GENE
mediated	O
activation	O
in	O
a	O
T3	B-GENE
dependant	O
fashion	O
.	O
It	O
is	O
likely	O
that	O
these	O
effects	O
involve	O
protein	O
-	O
protein	O
interactions	O
.	O
These	O
results	O
suggest	O
that	O
the	O
T3	B-GENE
receptor	I-GENE
can	O
act	O
as	O
a	O
positive	O
transcriptional	O
regulatory	O
factor	O
on	O
the	O
hChAT	B-GENE
gene	O
.	O
PMID	O
:	O
8057782	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Mol	O
Biol	O
.	O
2003	O
May	O
30	O
;329(	O
2	O
)	O
:	O
323-33	O
.	O
Cooperative	O
binding	O
of	O
dominant-	O
negative	O
prion	B-GENE
protein	O
to	O
kringle	O
domains	O
.	O
Ryou	O
C	O
,	O
Prusiner	O
SB	O
,	O
Legname	O
G.	O
Institute	O
for	O
Neurodegenerative	O
Diseases	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94143	O
-0518	O
,	O
USA	O
.	O
Conversion	O
of	O
the	O
cellular	O
prion	B-GENE
protein	O
(	O
PrP(C)	B-GENE
)	O
to	O
the	O
pathogenic	O
isoform	O
(	O
PrP(Sc)	B-GENE
)	O
is	O
a	O
major	O
biochemical	O
alteration	O
in	O
the	O
progression	O
of	O
prion	B-GENE
disease	O
.	O
This	O
conversion	O
process	O
is	O
thought	O
to	O
require	O
interaction	O
between	O
PrP(C	B-GENE
)	I-GENE
and	O
an	O
as	O
yet	O
unidentified	O
auxiliary	O
factor	O
,	O
provisionally	O
designated	O
protein	B-GENE
X	I-GENE
.	O
In	O
searching	O
for	O
protein	B-GENE
X	I-GENE
,	O
we	O
screened	O
a	O
phage	O
display	O
cDNA	O
expression	O
library	O
constructed	O
from	O
prion	B-GENE
-	O
infected	O
neuroblastoma	O
(	O
ScN2a	O
)	O
cells	O
and	O
identified	O
a	O
kringle	B-GENE
protein	O
domain	O
using	O
full	O
-	O
length	O
recombinant	O
mouse	O
PrP	B-GENE
(	O
recMoPrP(23-231	B-GENE
)	I-GENE
,	O
hereafter	O
recMoPrP	B-GENE
)	O
expressing	O
a	O
dominant-	O
negative	O
mutation	O
at	O
codon	O
218	O
(	O
recMoPrP	B-GENE
(	O
Q	O
218	O
K	O
)	O
)	O
.	O
In	O
vitro	O
binding	O
analysis	O
using	O
ELISA	O
verified	O
specific	O
interaction	O
of	O
recMoPrP	B-GENE
to	O
kringle	B-GENE
domains	O
(	O
K(1+2	O
+3	O
)	O
)	O
with	O
higher	O
binding	O
by	O
recMoPrP	B-GENE
(	O
Q	O
218	O
K	O
)	O
than	O
by	O
full	O
-	O
length	O
recMoPrP	B-GENE
without	O
the	O
mutation	O
.	O
This	O
interaction	O
was	O
confirmed	O
by	O
competitive	O
binding	O
analysis	O
,	O
in	O
which	O
the	O
addition	O
of	O
either	O
a	O
specific	O
anti	B-GENE
-	I-GENE
kringle	I-GENE
antibody	I-GENE
or	O
L-lysine	O
abolished	O
the	O
interaction	O
.	O
Biochemical	O
studies	O
of	O
the	O
interactions	O
between	O
K(1+2	O
+3	O
)	O
and	O
various	O
concentrations	O
of	O
both	O
recMoPrP	B-GENE
molecules	O
demonstrated	O
binding	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
A	O
Hill	O
plot	O
analysis	O
of	O
the	O
data	O
indicates	O
positive	O
cooperative	O
binding	O
of	O
both	O
recMoPrP	B-GENE
(	O
Q	O
218	O
K	O
)	O
and	O
recMoPrP	B-GENE
to	O
K(1+2	O
+3	O
)	O
with	O
stronger	O
binding	O
by	O
recMoPrP	B-GENE
(	O
Q	O
218	O
K	O
)	O
.	O
Using	O
full	O
-	O
length	O
and	O
an	O
N-terminally	O
truncated	O
MoPrP	B-GENE
(	I-GENE
89	I-GENE
-	I-GENE
231	I-GENE
)	I-GENE
,	O
we	O
demonstrate	O
that	O
N-terminal	O
sequences	O
enable	O
PrP	B-GENE
to	O
bind	O
strongly	O
to	O
K(1+2	O
+3	O
)	O
.	O
Further	O
characterization	O
with	O
truncated	O
MoPrP	B-GENE
(	I-GENE
89	I-GENE
-	I-GENE
231	I-GENE
)	I-GENE
refolded	O
in	O
different	O
conformations	O
revealed	O
that	O
both	O
alpha-helical	O
and	O
beta-sheet	O
conformations	O
bind	O
to	O
K(1+2	O
+3	O
)	O
.	O
Our	O
data	O
demonstrate	O
specific	O
,	O
high	O
-	O
affinity	O
binding	O
of	O
a	O
dominant-	O
negative	O
PrP	B-GENE
as	O
well	O
as	O
binding	O
of	O
other	O
PrPs	B-GENE
to	O
K(1+2	O
+3	O
)	O
.	O
The	O
relevance	O
of	O
such	O
interactions	O
during	O
prion	B-GENE
pathogenesis	O
remains	O
to	O
be	O
established	O
.	O
PMID	O
:	O
12758079	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Biol	O
Int	O
.	O
1998;22	O
(	O
2	O
)	O
:95-	O
103	O
.	O
Rapid	O
syncytium	O
formation	O
between	O
human	O
T-cell	O
leukaemia	O
virus	O
type-	O
I	O
(	O
HTLV-I)	O
-	O
infected	O
T-cells	O
and	O
human	O
nervous	O
system	O
cells	O
:	O
a	O
possible	O
implication	O
for	O
tropical	O
spastic	O
paraparesis	O
/	O
HTLV-	O
I	O
associated	O
myelopathy	O
.	O
Mor	O
-	O
Vaknin	O
N	O
,	O
Turgeman	O
H,	O
Torgeman	O
A	O
,	O
Wolfson	O
M,	O
Huleihel	O
M,	O
Aboud	O
M.	O
Department	O
of	O
Microbiology	O
and	O
Immunology	O
,	O
Faculty	O
of	O
Health	O
Sciences	O
,	O
Ben	O
Gurion	O
University	O
of	O
the	O
Negev	O
,	O
Beer	O
Sheva	O
,	O
84105	O
,	O
Israel	O
.	O
Tropical	O
spastic	O
paraparesis	O
/	O
HTLV-	O
I	O
associated	O
myelopathy	O
(	O
TSP/HAM	O
)	O
,	O
is	O
characterized	O
by	O
infiltration	O
of	O
human	O
T	O
cell	O
leukaemia	O
virus	O
type-	O
I	O
(	O
HTLV-I)	O
-	O
infected	O
T-cells	O
,	O
anti	O
-HTLV-	O
I	O
cytotoxic	O
T	O
cells	O
and	O
macrophages	O
into	O
the	O
patients	O
'	O
cerebrospinal	O
fluid	O
and	O
by	O
intrathecally	O
formed	O
anti	B-GENE
-HTLV-	I-GENE
I	I-GENE
antibodies	I-GENE
.	O
This	O
implies	O
that	O
the	O
disease	O
involves	O
a	O
breakdown	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O
Since	O
astrocytes	O
play	O
a	O
central	O
role	O
in	O
establishing	O
this	O
barrier	O
,	O
the	O
authors	O
investigated	O
the	O
hypothesis	O
that	O
the	O
HTLV-	O
I	O
infected	O
T	O
cells	O
disrupt	O
this	O
barrier	O
by	O
damaging	O
the	O
astrocytes	O
.	O
The	O
present	O
study	O
revealed	O
the	O
HTLV-	O
I-	O
producing	O
T	O
cells	O
conferred	O
a	O
severe	O
cytopathic	O
effect	O
upon	O
monolayers	O
of	O
astrocytoma	O
cell	O
line	O
in	O
co	O
-	O
cultures	O
.	O
Following	O
co	O
-	O
cultivation	O
,	O
HTLV-	B-GENE
I	I-GENE
DNA	O
and	O
proteins	O
appeared	O
in	O
the	O
monolayer	O
cells	O
,	O
but	O
after	O
reaching	O
a	O
peak	O
their	O
level	O
gradually	O
declined	O
.	O
This	O
appearance	O
of	O
the	O
viral	O
components	O
was	O
proved	O
to	O
result	O
from	O
a	O
fusion	O
of	O
the	O
astrocytic	O
cells	O
with	O
the	O
virus	O
-	O
producing	O
T	O
cells	O
,	O
whereas	O
their	O
subsequent	O
decline	O
reflected	O
the	O
destruction	O
of	O
the	O
resulting	O
syncytia	O
.	O
This	O
fusion	O
could	O
be	O
specifically	O
blocked	O
by	O
anti	O
HTLV-	B-GENE
I	I-GENE
Env	I-GENE
antibodies	I-GENE
,	O
indicating	O
that	O
it	O
was	O
mediated	O
by	O
the	O
viral	B-GENE
Env	I-GENE
proteins	I-GENE
expressed	O
on	O
the	O
surface	O
of	O
the	O
virus	O
-	O
producing	O
cells	O
.	O
Similar	O
fusion	O
was	O
observed	O
between	O
the	O
HTLV-	O
I-	O
producing	O
cells	O
and	O
certain	O
other	O
human	O
nervous	O
system	O
cell	O
lines	O
.	O
If	O
such	O
fusion	O
of	O
HTLV-	O
I-	O
infected	O
T	O
cells	O
occurs	O
also	O
with	O
astrocytes	O
and	O
other	O
nervous	O
system	O
cells	O
in	O
TSP/HAM	O
patients	O
,	O
it	O
may	O
account	O
,	O
at	O
least	O
partially	O
,	O
for	O
the	O
blood	O
-	O
brain	O
barrier	O
breakdown	O
and	O
some	O
of	O
the	O
neural	O
lesions	O
in	O
this	O
syndrome	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
PMID	O
:	O
9878096	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Bull	O
Cancer	O
.	O
1995	O
Jan;82	O
(	O
2	O
)	O
:	O
131	O
-6.	O
[	O
CD44	B-GENE
expression	O
:	O
a	O
new	O
prognostic	O
factor	O
in	O
neuroblastoma	O
]	O
[	O
Article	O
in	O
French	O
]	O
Combaret	O
V	O
,	O
Lasset	O
C	O
,	O
Bouvier	O
R	O
,	O
Frappaz	O
D	O
,	O
Thiesse	O
P,	O
Rebillard	O
AC	O
,	O
Philip	O
T	O
,	O
Favrot	O
MC	O
.	O
Laboratoire	O
de	O
biologie	O
cellulaire	O
,	O
centre	O
Leon	O
-	O
Berard	O
,	O
Lyon	O
,	O
France	O
.	O
CD44	B-GENE
gene	O
products	O
are	O
potential	O
markers	O
of	O
aggressiveness	O
in	O
different	O
tumor	O
models	O
,	O
a	O
result	O
which	O
prompted	O
us	O
to	O
study	O
clinical	O
neuroblastoma	O
(	O
NB	O
)	O
specimens	O
.	O
CD44	B-GENE
expression	O
was	O
determined	O
by	O
immunostaining	O
of	O
52	O
NB	O
with	O
a	O
monoclonal	O
antibody	O
(	O
J173	B-GENE
)	O
directed	O
against	O
an	O
epitope	O
common	O
to	O
all	O
CD44	B-GENE
isoforms	O
.	O
All	O
tumors	O
were	O
from	O
patients	O
(	O
pts	O
)	O
with	O
newly	O
diagnosed	O
NB	O
treated	O
with	O
standardized	O
protocols	O
.	O
They	O
were	O
classified	O
according	O
to	O
international	O
criteria	O
[11]	O
.	O
CD44	B-GENE
immunoreactivity	O
was	O
detected	O
in	O
37	O
tumors	O
(	O
71	O
%	O
)	O
.	O
CD44	B-GENE
was	O
expressed	O
in	O
100	O
%	O
of	O
favorable	O
NB	O
stages	O
(	O
1	O
,	O
2	O
or	O
4S	O
)	O
,	O
but	O
only	O
50	O
%	O
of	O
advanced	O
NB	O
(	O
stages	O
3	O
and	O
4	O
)	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
suggesting	O
that	O
the	O
absence	O
rather	O
that	O
the	O
overexpression	O
of	O
CD44	B-GENE
is	O
a	O
signal	O
of	O
tumor	O
aggressiveness	O
.	O
The	O
cumulative	O
event	O
-	O
free	O
survival	O
was	O
significantly	O
longer	O
in	O
pts	O
with	O
CD44	B-GENE
-	O
positive	O
tumors	O
as	O
compared	O
to	O
pts	O
with	O
CD44	B-GENE
tumors	O
(	O
p	O
<	O
10(-5	O
)	O
)	O
.	O
More	O
importantly	O
,	O
progression	O
-	O
free	O
survival	O
was	O
also	O
significantly	O
higher	O
in	O
CD44	B-GENE
-	O
positive	O
pts	O
within	O
the	O
high	O
-risk	O
group	O
(	O
p	O
<	O
0.01	O
)	O
.	O
In	O
univariate	O
analyses	O
,	O
we	O
tested	O
the	O
prognostic	O
value	O
of	O
tumor	O
expression	O
of	O
CD44	B-GENE
in	O
comparison	O
with	O
tumor	O
stage	O
,	O
age	O
,	O
tumor	O
histology	O
and	O
presence	O
or	O
absence	O
of	O
N-myc	B-GENE
proto	O
-	O
oncogene	O
amplification	O
.	O
All	O
five	O
measures	O
had	O
significant	O
prognostic	O
value	O
.	O
The	O
expression	O
of	O
CD44	B-GENE
and	O
the	O
absence	O
of	O
N-myc	B-GENE
amplification	O
were	O
the	O
most	O
powerful	O
predictors	O
of	O
a	O
favorable	O
clinical	O
outcome	O
.	O
In	O
a	O
multivariate	O
analysis	O
of	O
these	O
measures	O
,	O
CD44	B-GENE
expression	O
and	O
tumor	O
stage	O
were	O
the	O
only	O
independent	O
prognostic	O
factors	O
for	O
the	O
prediction	O
of	O
patient	O
survival	O
.	O
NB	O
is	O
the	O
first	O
clinical	O
model	O
described	O
in	O
which	O
tumor	O
aggressiveness	O
correlates	O
with	O
a	O
repression	O
rather	O
than	O
a	O
stimulation	O
of	O
CD44	B-GENE
expression	O
.	O
We	O
recommend	O
the	O
use	O
of	O
CD44	B-GENE
as	O
an	O
additional	O
biological	O
marker	O
in	O
the	O
initial	O
staging	O
of	O
neuroblastoma	O
.	O
PMID	O
:	O
10846530	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
.	O
2000	O
Aug;36	O
(	O
12	O
)	O
:1544	O
-51	O
.	O
Assessment	O
of	O
percutaneous	O
fine	O
needle	O
aspiration	O
cytology	O
as	O
a	O
technique	O
to	O
provide	O
diagnostic	O
and	O
prognostic	O
information	O
in	O
neuroblastoma	O
.	O
Thiesse	O
P,	O
Hany	O
MA	O
,	O
Combaret	O
V	O
,	O
Ranchere	O
-	O
Vince	O
D	O
,	O
Bouffet	O
E	O
,	O
Bergeron	O
C.	O
Department	O
of	O
Radiology	O
,	O
Centre	O
Regional	O
Leon	O
Berard	O
,	O
28	O
rue	O
Laennec	O
,	O
F-69373	O
,	O
Cedex	O
08	O
,	O
Lyon	O
,	O
France	O
.	O
thiesse@lyon	O
.fnclcc	O
.fr	O
The	O
International	O
Neuroblastoma	O
Staging	O
System	O
(	O
INSS	O
)	O
criteria	O
for	O
diagnosis	O
requires	O
an	O
unequivocal	O
pathological	O
diagnosis	O
and	O
favours	O
the	O
identification	O
of	O
prognostic	O
markers	O
in	O
the	O
samples	O
.	O
Surgical	O
biopsies	O
of	O
the	O
primary	O
tumour	O
and	O
bone	O
marrow	O
(	O
BM	O
)	O
sampling	O
in	O
metastatic	O
disease	O
constitute	O
the	O
major	O
sources	O
of	O
tumour	O
material	O
for	O
the	O
laboratory	O
.	O
We	O
analysed	O
the	O
possibility	O
of	O
percutaneous	O
fine	O
needle	O
aspiration	O
cytology	O
(	O
FNAC	O
)	O
constituting	O
an	O
alternative	O
procedure	O
to	O
the	O
conventional	O
technique	O
of	O
sampling	O
of	O
the	O
primary	O
tumour	O
in	O
children	O
with	O
advanced	O
neuroblastoma	O
.	O
From	O
July	O
1987	O
through	O
July	O
1998	O
,	O
64	O
consecutive	O
children	O
suspected	O
of	O
having	O
advanced	O
neuroblastoma	O
and	O
referred	O
to	O
our	O
institution	O
underwent	O
percutaneous	O
FNAC	O
of	O
deeply	O
located	O
tumours	O
.	O
FNAC	O
was	O
performed	O
using	O
22	O
-gauge	O
needles	O
under	O
ultrasound	O
guidance	O
,	O
before	O
any	O
chemotherapy	O
and	O
within	O
the	O
first	O
days	O
following	O
admission	O
.	O
No	O
complication	O
occurred	O
after	O
FNAC	O
.	O
The	O
median	O
number	O
of	O
the	O
extracted	O
tumour	O
cells	O
was	O
2.3x10(6)	O
(	O
range	O
:	O
0-	O
40.6x10(	O
6)	O
)	O
.	O
Cytology	O
analysis	O
was	O
possible	O
in	O
59	O
/	O
64	O
cases	O
(	O
92	O
%	O
)	O
and	O
immunocytochemistry	O
in	O
56	O
/	O
64	O
(	O
88	O
%	O
)	O
allowing	O
confirmation	O
of	O
the	O
diagnosis	O
.	O
N-Myc	B-GENE
analysis	O
was	O
available	O
in	O
46	O
/	O
64	O
(	O
72	O
%	O
)	O
.	O
In	O
addition	O
,	O
the	O
presence	O
of	O
a	O
partial	O
deletion	O
of	O
chromosome	O
1p	O
(	O
del	O
1p	O
)	O
was	O
assessed	O
,	O
since	O
1992	O
,	O
in	O
24	O
/	O
47	O
cases	O
(	O
51	O
%	O
)	O
,	O
where	O
enough	O
cells	O
were	O
available	O
.	O
FNAC	O
of	O
deeply	O
located	O
advanced	O
neuroblastoma	O
is	O
safe	O
and	O
information	O
is	O
available	O
in	O
a	O
few	O
hours	O
after	O
admission	O
.	O
The	O
provided	O
material	O
is	O
reliable	O
for	O
confirmation	O
of	O
diagnosis	O
and	O
analysis	O
of	O
biological	O
prognostic	O
markers	O
in	O
the	O
majority	O
of	O
cases	O
.	O
More	O
invasive	O
tumour	O
sampling	O
procedures	O
are	O
required	O
only	O
in	O
selected	O
cases	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10930802	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Carcinogenesis	O
.	O
1998	O
Jun;19	O
(	O
6	O
)	O
:991	O
-	O
7.	O
Genistein	O
modulates	O
neuroblastoma	O
cell	O
proliferation	O
and	O
differentiation	O
through	O
induction	O
of	O
apoptosis	O
and	O
regulation	O
of	O
tyrosine	B-GENE
kinase	I-GENE
activity	O
and	O
N-myc	B-GENE
expression	O
.	O
Brown	O
A	O
,	O
Jolly	O
P,	O
Wei	O
H.	O
Department	O
of	O
Environmental	O
Health	O
Sciences	O
,	O
University	O
of	O
Alabama	O
,	O
Birmingham	O
35294	O
,	O
USA	O
.	O
Genistein	O
is	O
a	O
specific	O
inhibitor	O
of	O
protein	B-GENE
tyrosine	I-GENE
kinase	I-GENE
(	O
PTK	B-GENE
)	O
and	O
is	O
considered	O
as	O
a	O
therapeutic	O
candidate	O
for	O
various	O
cancers	O
.	O
In	O
this	O
paper	O
we	O
investigate	O
the	O
effects	O
of	O
genistein	O
on	O
cell	O
proliferation	O
and	O
differentiation	O
in	O
neuroblastoma	O
(	O
NB	O
)	O
cell	O
lines	O
and	O
its	O
possible	O
mechanism	O
of	O
action	O
.	O
Genistein	O
substantially	O
inhibited	O
the	O
growth	O
of	O
five	O
(	O
N2A	O
,	O
JC	O
,	O
SKNSH	O
,	O
MSN	O
and	O
Lan5	O
)	O
of	O
the	O
six	O
tumor	O
cell	O
lines	O
examined	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
an	O
IC50	O
value	O
of	O
approximately	O
5	O
microg	O
/	O
ml	O
.	O
The	O
exception	O
was	O
GC	O
cells	O
.	O
N2A	O
cells	O
were	O
treated	O
with	O
genistein	O
for	O
6	O
days	O
and	O
exhibited	O
morphological	O
features	O
of	O
differentiation	O
,	O
as	O
evidenced	O
by	O
the	O
development	O
of	O
dendritic	O
extensions	O
.	O
Terminal	B-GENE
deoxynucleotidyl	I-GENE
transferase	I-GENE
(	O
TDT	B-GENE
)	O
histochemical	O
staining	O
showed	O
a	O
significant	O
elevation	O
in	O
darkly	O
stained	O
nuclei	O
in	O
genistein	O
-	O
treated	O
N2A	O
cells	O
compared	O
with	O
controls	O
,	O
indicating	O
the	O
occurrence	O
of	O
apoptosis	O
.	O
Fluorescent	O
quantitation	O
of	O
DNA	O
fragments	O
confirmed	O
apoptosis	O
in	O
genistein	O
-	O
treated	O
N2A	O
cells	O
.	O
To	O
further	O
elucidate	O
the	O
possible	O
mechanisms	O
by	O
which	O
genistein	O
modulates	O
NB	O
cell	O
growth	O
and	O
differentiation	O
we	O
investigated	O
the	O
effect	O
of	O
genistein	O
on	O
the	O
activities	O
of	O
PTK	B-GENE
and	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
(	I-GENE
MAP	I-GENE
)	I-GENE
kinase	I-GENE
and	O
N-myc	B-GENE
proto	O
-	O
oncogene	O
expression	O
in	O
N2A	O
cells	O
.	O
The	O
results	O
showed	O
that	O
genistein	O
down	O
-	O
regulated	O
intrinsic	O
PTK	B-GENE
activity	O
by	O
approximately	O
33	O
%	O
and	O
inhibited	O
insulin	B-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factor	I-GENE
(	O
IGF	B-GENE
)	O
-	O
stimulated	O
PTK	B-GENE
activity	O
by	O
75	O
%	O
.	O
The	O
effect	O
of	O
genistein	O
on	O
the	O
intrinsic	O
activity	O
of	O
MAP	B-GENE
kinase	I-GENE
was	O
insignificant	O
.	O
In	O
addition	O
,	O
genistein	O
significantly	O
reduced	O
N-myc	B-GENE
expression	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O
Our	O
study	O
suggests	O
that	O
genistein	O
arrests	O
cell	O
growth	O
and	O
induces	O
NB	O
cell	O
differentiation	O
by	O
mediating	O
apoptosis	O
and	O
modulating	O
PTK	B-GENE
activity	O
and	O
N-myc	B-GENE
proto	O
-	O
oncogene	O
expression	O
.	O
PMID	O
:	O
9667736	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
.	O
2002	O
Jul;161	O
(	O
1	O
)	O
:	O
291-300	O
.	O
Comment	O
in	O
:	O
Am	O
J	O
Pathol	O
.	O
2003	O
Jul;163(	O
1	O
)	O
:	O
373	O
-	O
5	O
;	O
author	O
reply	O
375	O
-6.	O
Complicated	O
mechanisms	O
of	O
class	B-GENE
II	I-GENE
transactivator	I-GENE
transcription	O
deficiency	O
in	O
small	O
cell	O
lung	O
cancer	O
and	O
neuroblastoma	O
.	O
Yazawa	O
T	O
,	O
Ito	O
T	O
,	O
Kamma	O
H,	O
Suzuki	O
T	O
,	O
Okudela	O
K,	O
Hayashi	O
H,	O
Horiguchi	O
H,	O
Ogata	O
T	O
,	O
Mitsui	O
H,	O
Ikeda	O
M,	O
Kitamura	O
H.	O
Department	O
of	O
Pathology	O
,	O
Yokohama	O
City	O
University	O
School	O
of	O
Medicine	O
,	O
Kanagawa	O
,	O
Japan	O
.	O
tkyazawa@med	O
.yokohama-cu.ac.jp	O
Small	O
cell	O
lung	O
cancer	O
(	O
SCLC	O
)	O
and	O
neuroblastoma	O
(	O
NB	O
)	O
,	O
the	O
most	O
aggressive	O
adult	O
and	O
infant	O
neuroendocrine	O
cancers	O
,	O
respectively	O
,	O
are	O
immunologically	O
characterized	O
by	O
a	O
severe	O
reduction	O
in	O
major	B-GENE
histocompatibility	I-GENE
complex	I-GENE
(	O
MHC	B-GENE
)	O
that	O
is	O
indispensable	O
for	O
anti	O
-	O
tumor	O
immunity	O
.	O
We	O
had	O
reported	O
that	O
the	O
severe	O
reduction	O
of	O
MHC	B-GENE
in	O
SCLC	O
was	O
caused	O
by	O
a	O
deficient	O
interferon	B-GENE
(	I-GENE
IFN)-gamma	I-GENE
-	O
inducible	O
expression	O
of	O
class	B-GENE
II	I-GENE
transactivator	I-GENE
(	O
CIITA	B-GENE
)	O
that	O
is	O
known	O
as	O
a	O
very	O
important	O
transcription	O
factor	O
for	O
IFN-gamma	B-GENE
-	O
inducible	O
class	O
II	O
and	O
class	O
I	O
MHC	B-GENE
expression	O
(	O
Yazawa	O
T	O
,	O
Kamma	O
H,	O
Fujiwara	O
M,	O
Matsui	O
M,	O
Horiguchi	O
H,	O
Satoh	O
H,	O
Fujimoto	O
M,	O
Yokohama	O
K,	O
Ogata	O
T	O
:	O
Lack	O
of	O
class	B-GENE
II	I-GENE
transactivator	I-GENE
causes	O
severe	O
deficiency	O
of	O
HLA-	B-GENE
DR	I-GENE
expression	O
in	O
small	O
cell	O
lung	O
cancer	O
.	O
J	O
Pathol	O
1999	O
,	O
187	O
:191-199	O
)	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
the	O
reduction	O
of	O
MHC	B-GENE
in	O
NB	O
was	O
also	O
caused	O
by	O
a	O
deficient	O
IFN-gamma	B-GENE
-inducible	O
expression	O
of	O
CIITA	B-GENE
and	O
that	O
the	O
deficiency	O
in	O
SCLC	O
and	O
NB	O
was	O
caused	O
by	O
similar	O
mechanisms	O
Human	B-GENE
achaete	I-GENE
-	I-GENE
scute	I-GENE
complex	I-GENE
homologue	I-GENE
(	O
HASH	B-GENE
)	O
-	B-GENE
1	I-GENE
,	O
L-	B-GENE
myc	I-GENE
,	O
and	O
N-	B-GENE
myc	I-GENE
,	O
which	O
are	O
specifically	O
overexpressed	O
in	O
SCLC	O
and	O
NB	O
,	O
bound	O
to	O
the	O
E-box	O
in	O
CIITA	B-GENE
promoter	O
IV	O
and	O
reduced	O
the	O
transcriptional	O
activity	O
.	O
Anti-sense	O
oligonucleotide	O
experiments	O
revealed	O
that	O
overexpressed	O
L-	B-GENE
myc	I-GENE
and	O
N-	B-GENE
myc	I-GENE
lie	O
upstream	O
in	O
the	O
regulatory	O
pathway	O
of	O
HASH-1	B-GENE
expression	O
.	O
The	O
expression	O
of	O
HASH-1	B-GENE
was	O
also	O
up	O
-	O
regulated	O
by	O
IFN-gamma	B-GENE
.	O
Our	O
results	O
suggest	O
that	O
SCLC	O
and	O
NB	O
have	O
complicated	O
mechanisms	O
of	O
IFN-gamma	B-GENE
-	O
inducible	O
CIITA	B-GENE
transcription	O
deficiency	O
through	O
the	O
overexpressed	O
HASH	B-GENE
-1	I-GENE
,	O
L-myc	B-GENE
,	O
and	O
N-myc	B-GENE
.	O
These	O
complicated	O
mechanisms	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
escape	O
from	O
anti	O
-	O
tumor	O
immunity	O
.	O
PMID	O
:	O
12107114	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochemistry	O
.	O
1995	O
Sep	O
12;34(	O
36	O
)	O
:	O
11500	O
-	O
7.	O
Glycosphingolipid	O
composition	O
of	O
murine	O
neuroblastoma	O
cells	O
:	O
O-acetylesterase	B-GENE
gene	O
downregulates	O
the	O
expression	O
of	O
O-acetylated	O
GD3	O
.	O
Ariga	O
T	O
,	O
Blaine	O
GM	O
,	O
Yoshino	O
H,	O
Dawson	O
G	O
,	O
Kanda	O
T	O
,	O
Zeng	O
GC	O
,	O
Kasama	O
T	O
,	O
Kushi	O
Y	O
,	O
Yu	O
RK	O
.	O
Department	O
of	O
Biochemistry	O
and	O
Molecular	O
Biophysics	O
,	O
Medical	O
College	O
of	O
Virginia	O
,	O
Virginia	O
Commonwealth	O
University	O
,	O
Richmond	O
23298	O
,	O
USA	O
.	O
We	O
have	O
studied	O
the	O
glycosphingolipid	O
composition	O
in	O
an	O
F-11	O
neuroblastoma	O
cell	O
line	O
originated	O
from	O
hybridization	O
of	O
a	O
mouse	O
neuroblastoma	O
cell	O
line	O
(	O
N18TG-2	O
)	O
with	O
rat	O
dorsal	O
root	O
ganglion	O
cells	O
.	O
The	O
total	O
lipid	O
-bound	O
glucose	O
of	O
F-11	O
cells	O
was	O
estimated	O
to	O
be	O
0.28	O
micrograms	O
/	O
mg	O
of	O
protein	O
and	O
the	O
total	O
lipid	O
-bound	O
sialic	O
acid	O
was	O
0.82	O
micrograms	O
/	O
mg	O
of	O
protein	O
.	O
The	O
major	O
neutral	O
glycosphingolipids	O
were	O
Gb4	O
(	O
37	O
%	O
of	O
the	O
total	O
neutral	O
glycosphingolipids	O
)	O
,	O
Gb3	O
(	O
15	O
%	O
)	O
,	O
LacCer	O
(	O
21	O
%	O
)	O
,	O
and	O
GlcCer	O
(	O
15	O
%	O
)	O
.	O
The	O
major	O
gangliosides	O
were	O
found	O
to	O
be	O
GM3	O
(	O
37	O
%	O
of	O
the	O
total	O
gangliosides	O
)	O
,	O
GD3	O
(	O
27	O
%	O
)	O
,	O
O-acetylated	O
GD3	O
(	O
18	O
%	O
)	O
,	O
and	O
GD1a	O
(	O
4	O
%	O
)	O
,	O
with	O
trace	O
amounts	O
of	O
GD2	O
.	O
The	O
unusually	O
high	O
concentration	O
of	O
O-acetylated	O
GD3	O
is	O
consistent	O
with	O
its	O
putative	O
role	O
as	O
a	O
tumor	O
marker	O
.	O
Immunocytochemical	O
localization	O
studies	O
of	O
GD3	O
and	O
O-acetylated	O
GD3	O
,	O
examined	O
by	O
mouse	O
monoclonal	O
antibodies	O
R24	B-GENE
and	O
D1.1	B-GENE
,	O
respectively	O
,	O
revealed	O
that	O
the	O
cell	O
bodies	O
and	O
processes	O
were	O
all	O
positively	O
stained	O
.	O
To	O
elucidate	O
the	O
role	O
of	O
O-acetylated	O
GD3	O
in	O
tumorigenesis	O
,	O
we	O
transfected	O
F-11	O
cells	O
with	O
the	O
O-acetylesterase	B-GENE
gene	O
from	O
influenza	O
C	O
virus	O
.	O
Compared	O
with	O
the	O
original	O
cell	O
line	O
,	O
the	O
transfected	O
cells	O
showed	O
a	O
dramatic	O
increase	O
in	O
the	O
level	O
of	O
GD3	O
(	O
150	O
%	O
of	O
that	O
in	O
the	O
control	O
cells	O
)	O
and	O
a	O
significant	O
decrease	O
of	O
the	O
concentration	O
of	O
O-acetylated	O
GD3	O
(	O
27	O
%	O
of	O
control	O
cells	O
)	O
.	O
In	O
addition	O
,	O
the	O
transfected	O
F-11	O
cells	O
exhibited	O
a	O
morphology	O
different	O
from	O
the	O
parental	O
cells	O
with	O
enlarged	O
cell	O
bodies	O
and	O
elongated	O
neurites	O
.	O
We	O
conclude	O
that	O
alteration	O
of	O
ganglioside	O
composition	O
,	O
particularly	O
the	O
expression	O
of	O
GD3	O
and	O
O-acetylated	O
GD3	O
,	O
may	O
be	O
associated	O
with	O
the	O
morphological	O
changes	O
observed	O
in	O
this	O
cell	O
line	O
.(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
7547879	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1992	O
Nov	O
1;52(	O
21	O
)	O
:	O
5954	O
-	O
62	O
.	O
A	O
murine	O
model	O
for	O
antibody-directed	O
targeting	O
of	O
vascular	O
endothelial	O
cells	O
in	O
solid	O
tumors	O
.	O
Burrows	O
FJ	O
,	O
Watanabe	O
Y	O
,	O
Thorpe	O
PE.	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Department	O
of	O
Pharmacology	O
,	O
Dallas	O
75230	O
.	O
An	O
attractive	O
approach	O
to	O
the	O
therapy	O
of	O
solid	O
tumors	O
would	O
be	O
to	O
target	O
cytotoxic	O
agents	O
or	O
coagulants	O
to	O
the	O
vasculature	O
of	O
the	O
tumor	O
rather	O
than	O
to	O
the	O
tumor	O
cells	O
themselves	O
.	O
This	O
strategy	O
has	O
3	O
advantages	O
:	O
(	O
a	O
)	O
it	O
should	O
be	O
applicable	O
to	O
many	O
types	O
of	O
solid	O
tumors	O
because	O
all	O
require	O
a	O
blood	O
supply	O
for	O
survival	O
and	O
growth	O
;	O
(	O
b)	O
the	O
target	O
endothelial	O
cells	O
are	O
directly	O
accessible	O
through	O
the	O
blood	O
and	O
are	O
normal	O
cells	O
,	O
making	O
the	O
outgrowth	O
of	O
resistant	O
mutants	O
unlikely	O
;	O
and	O
(	O
c)	O
there	O
is	O
an	O
in	O
-	O
built	O
amplification	O
mechanism	O
because	O
thousands	O
of	O
tumor	O
cells	O
are	O
reliant	O
on	O
each	O
capillary	O
for	O
nutrients	O
and	O
oxygen	O
.	O
Despite	O
its	O
theoretical	O
attractions	O
,	O
the	O
approach	O
of	O
tumor	O
vascular	O
targeting	O
has	O
not	O
been	O
testable	O
because	O
antibodies	O
that	O
recognize	O
tumor	O
vascular	O
endothelial	O
cell	O
antigens	O
with	O
adequate	O
specificity	O
are	O
currently	O
not	O
available	O
.	O
In	O
this	O
study	O
,	O
we	O
developed	O
a	O
model	O
system	O
in	O
which	O
to	O
investigate	O
the	O
antibody-directed	O
targeting	O
of	O
vascular	O
endothelial	O
cells	O
in	O
solid	O
tumors	O
in	O
mice	O
.	O
A	O
neuroblastoma	O
transfected	O
with	O
the	O
mouse	O
interferon	B-GENE
-	I-GENE
gamma	I-GENE
gene	O
,	O
C1300	B-GENE
(	O
Mu	B-GENE
gamma	I-GENE
)	O
,	O
was	O
grown	O
in	O
antibiotic	O
-	O
treated	O
BALB/	O
c	O
nude	O
mice	O
.	O
The	O
interferon	B-GENE
-	I-GENE
gamma	I-GENE
secreted	O
by	O
the	O
tumor	O
induces	O
the	O
expression	O
of	O
major	B-GENE
histocompatibility	I-GENE
complex	I-GENE
Class	I-GENE
II	I-GENE
antigens	O
on	O
the	O
tumor	O
vascular	O
endothelium	O
.	O
Class	B-GENE
II	I-GENE
antigens	O
are	O
absent	O
from	O
the	O
vasculature	O
of	O
normal	O
tissues	O
,	O
although	O
they	O
are	O
present	O
on	O
B	O
-lymphocytes	O
,	O
cells	O
of	O
monocyte	O
/	O
macrophage	O
lineage	O
,	O
and	O
some	O
epithelial	O
cells	O
.	O
Anti	B-GENE
-Class	I-GENE
II	I-GENE
antibody	I-GENE
administered	O
i.v	O
.	O
strongly	O
stains	O
the	O
tumor	O
vasculature	O
,	O
whereas	O
an	O
antitumor	O
antibody	O
directed	O
against	O
a	O
major	B-GENE
histocompatibility	I-GENE
complex	I-GENE
Class	I-GENE
I	I-GENE
antigen	O
of	O
the	O
tumor	O
allograft	O
produces	O
classical	O
perivascular	O
tumor	O
cell	O
staining	O
.	O
This	O
model	O
should	O
enable	O
the	O
theoretical	O
superiority	O
of	O
tumor	O
vascular	O
targeting	O
over	O
conventional	O
tumor	O
cell	O
targeting	O
to	O
be	O
tested	O
.	O
PMID	O
:	O
1394221	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1997	O
Mar	O
20;14(	O
11	O
)	O
:	O
1341-50	O
.	O
Concomitant	O
down	O
-	O
regulation	O
of	O
expression	O
of	O
integrin	B-GENE
subunits	O
by	O
N-myc	B-GENE
in	O
human	O
neuroblastoma	O
cells	O
:	O
differential	O
regulation	O
of	O
alpha2	B-GENE
,	O
alpha3	B-GENE
and	O
beta1	B-GENE
.	O
Judware	O
R	O
,	O
Culp	O
LA.	O
Case	O
Western	O
Reserve	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Department	O
of	O
Molecular	O
Biology	O
and	O
Microbiology	O
,	O
Cleveland	O
,	O
Ohio	O
44106	O
,	O
USA	O
.	O
Amplification	O
and	O
over	O
-	O
expression	O
of	O
the	O
N-myc	B-GENE
oncogene	O
is	O
associated	O
with	O
the	O
progression	O
of	O
neuroblastoma	O
in	O
children	O
and	O
in	O
a	O
nude	O
mouse	O
model	O
system	O
.	O
Neuroblastoma	O
cell	O
lines	O
with	O
widely	O
different	O
levels	O
of	O
N-myc	B-GENE
illustrate	O
an	O
inverse	O
relationship	O
between	O
N-myc	B-GENE
over	O
-	O
expression	O
and	O
reduced	O
expression	O
of	O
several	O
integrin	B-GENE
extracellular	O
matrix	O
receptors	O
.	O
Transfection	O
and	O
over	O
-	O
expression	O
of	O
N-myc	B-GENE
in	O
a	O
neuroblastoma	O
cell	O
line	O
not	O
normally	O
expressing	O
the	O
protein	O
resulted	O
in	O
cells	O
that	O
grew	O
loosely	O
associated	O
with	O
tissue	O
culture	O
plates	O
;	O
this	O
correlated	O
with	O
reduced	O
levels	O
of	O
beta1	B-GENE
integrin	I-GENE
subunit	O
.	O
Evidence	O
is	O
now	O
presented	O
that	O
alpha2	B-GENE
and	O
alpha3	B-GENE
integrin	I-GENE
subunit	O
levels	O
are	O
also	O
reduced	O
in	O
cells	O
that	O
over	O
-	O
express	O
N-myc	B-GENE
,	O
with	O
virtually	O
no	O
association	O
of	O
alpha2	B-GENE
or	O
alpha3	B-GENE
subunits	O
with	O
beta1	B-GENE
.	O
Consequently	O
,	O
maturation	O
of	O
the	O
beta1	B-GENE
subunit	O
and	O
cell	O
surface	O
expression	O
of	O
the	O
integrins	B-GENE
are	O
greatly	O
reduced	O
in	O
N-my	B-GENE
c	I-GENE
-	O
transfected	O
cells	O
.	O
A	O
small	O
amount	O
of	O
beta1	B-GENE
protein	O
does	O
get	O
to	O
the	O
cell	O
surface	O
,	O
however	O
,	O
suggesting	O
that	O
an	O
as	O
yet	O
unidentified	O
alpha	B-GENE
subunit	O
is	O
produced	O
by	O
the	O
N-my	B-GENE
c-	I-GENE
expressing	O
cells	O
.	O
Finally	O
,	O
the	O
observed	O
reductions	O
in	O
integrin	B-GENE
protein	O
levels	O
are	O
reflections	O
of	O
greatly	O
reduced	O
levels	O
of	O
integrin	B-GENE
alpha2	I-GENE
and	O
alpha3	B-GENE
mRNAs	O
,	O
as	O
well	O
as	O
a	O
smaller	O
reduction	O
in	O
beta1	B-GENE
mRNA	O
(	O
80	O
%	O
,	O
94	O
%	O
and	O
52	O
%	O
,	O
respectively	O
)	O
.	O
Post	O
-	O
transcriptional	O
mechanisms	O
modulating	O
beta1	B-GENE
integrin	I-GENE
levels	O
are	O
also	O
operative	O
.	O
These	O
results	O
indicate	O
that	O
over	O
-	O
expression	O
of	O
N-myc	B-GENE
from	O
a	O
transfected	O
gene	O
in	O
a	O
neuroblastoma	O
cell	O
line	O
that	O
does	O
not	O
normally	O
produce	O
the	O
protein	O
generates	O
cell	O
lines	O
with	O
many	O
of	O
the	O
characteristics	O
of	O
naturally	O
metastatic	O
cells	O
with	O
amplified	O
N-myc	B-GENE
genes	O
.	O
Modulation	O
of	O
N-myc	B-GENE
and	O
integrin	B-GENE
expressions	O
may	O
play	O
a	O
significant	O
role	O
in	O
progression	O
of	O
human	O
neuroblastoma	O
.	O
PMID	O
:	O
9178894	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pathol	O
.	O
1997	O
Nov;18	O
3	O
(	O
3	O
)	O
:	O
339	O
-	O
44	O
.	O
N-myc	B-GENE
amplification	O
and	O
cell	O
proliferation	O
rate	O
in	O
human	O
neuroblastoma	O
.	O
Pession	O
A	O
,	O
Trere	O
D	O
,	O
Perri	O
P,	O
Rondelli	O
R	O
,	O
Montanaro	O
L,	O
Mantovani	O
W	O
,	O
Derenzini	O
M,	O
Paolucci	O
G.	O
Dipartimento	O
di	O
Patologia	O
Sperimentale	O
,	O
Universita	O
di	O
Bologna	O
,	O
Italy	O
.	O
In	O
neuroblastoma	O
,	O
N-myc	B-GENE
amplification	O
has	O
been	O
found	O
to	O
be	O
strikingly	O
associated	O
with	O
rapid	O
tumour	O
progression	O
and	O
poor	O
prognosis	O
.	O
Recent	O
studies	O
have	O
demonstrated	O
that	O
cell	O
proliferative	O
activity	O
also	O
significantly	O
predicts	O
the	O
clinical	O
outcome	O
in	O
patients	O
with	O
neuroblastoma	O
.	O
In	O
order	O
to	O
define	O
the	O
correlation	O
between	O
N-myc	B-GENE
amplification	O
and	O
cell	O
proliferation	O
rate	O
,	O
in	O
the	O
present	O
investigation	O
the	O
two	O
parameters	O
were	O
first	O
assessed	O
in	O
48	O
neuroblastoma	O
tumours	O
.	O
N-myc	B-GENE
amplification	O
was	O
evaluated	O
in	O
frozen	O
specimens	O
by	O
Southern	O
-	O
blot	O
analysis	O
using	O
the	O
NB	O
19-21	O
probe	O
and	O
it	O
was	O
detected	O
in	O
nine	O
patients	O
.	O
Cell	O
proliferative	O
activity	O
was	O
determined	O
by	O
measuring	O
the	O
AgNOR	B-GENE
protein	O
area	O
in	O
histological	O
sections	O
selectively	O
stained	O
by	O
silver	O
.	O
The	O
mean	O
AgNOR	B-GENE
protein	O
area	O
value	O
of	O
neuroblastomas	O
with	O
N-myc	B-GENE
amplification	O
(	O
3.63	O
+/-	O
1.62	O
microns2	O
)	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
neuroblastomas	O
without	O
N-myc	B-GENE
amplification	O
(	O
2.46	O
+/-	O
1.57	O
microns2	O
;	O
P	O
=	O
0.30	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
both	O
N-myc	B-GENE
amplification	O
and	O
AgNOR	B-GENE
protein	O
expression	O
were	O
found	O
to	O
be	O
significantly	O
related	O
to	O
the	O
clinical	O
outcome	O
of	O
the	O
disease	O
(	O
P	O
<	O
0.001	O
and	O
P	O
=	O
0.0143	O
,	O
respectively	O
;	O
median	O
follow-up	O
time	O
=	O
47	O
months	O
;	O
range	O
18-	O
106	O
months	O
)	O
.	O
In	O
a	O
second	O
set	O
of	O
experiments	O
,	O
the	O
relationship	O
between	O
N-myc	B-GENE
amplification	O
and	O
cell	O
proliferation	O
rate	O
was	O
assessed	O
in	O
seven	O
established	O
human	O
neuroblastoma	O
cell	O
lines	O
.	O
N-myc	B-GENE
amplification	O
was	O
found	O
to	O
be	O
completely	O
independent	O
of	O
the	O
population	O
doubling	O
time	O
(	O
DT	O
)	O
,	O
which	O
,	O
on	O
the	O
contrary	O
,	O
was	O
strictly	O
related	O
to	O
the	O
quantitative	O
expression	O
of	O
AgNOR	B-GENE
protein	O
(	O
r	O
=	O
-	O
0.947	O
;	O
P	O
<	O
0.001	O
)	O
.	O
Altogether	O
,	O
the	O
present	O
results	O
indicate	O
that	O
N-myc	B-GENE
amplification	O
and	O
cell	O
proliferation	O
rate	O
are	O
not	O
interrelated	O
in	O
neuroblastoma	O
,	O
each	O
representing	O
an	O
independent	O
biological	O
parameter	O
of	O
cancer	O
cells	O
associated	O
with	O
the	O
clinical	O
behaviour	O
of	O
the	O
disease	O
.	O
PMID	O
:	O
9422991	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2001	O
Apr	O
1;61	O
(	O
7	O
)	O
:	O
3045-52	O
.	O
Use	O
of	O
a	O
modified	O
ornithine	B-GENE
decarboxylase	I-GENE
promoter	O
to	O
achieve	O
efficient	O
c-MYC	B-GENE
-	O
or	O
N-MYC	B-GENE
-	O
regulated	O
protein	O
expression	O
.	O
Iyengar	O
RV	O
,	O
Pawlik	O
CA	O
,	O
Krull	O
EJ	O
,	O
Phelps	O
DA	O
,	O
Burger	O
RA	O
,	O
Harris	O
LC	O
,	O
Potter	O
PM	O
,	O
Danks	O
MK.	O
Department	O
of	O
Molecular	O
Pharmacology	O
,	O
St.	O
Jude	O
Children	O
's	O
Research	O
Hospital	O
,	O
Memphis	O
,	O
Tennessee	O
38105	O
,	O
USA	O
.	O
One	O
of	O
the	O
advantages	O
of	O
viral	O
-directed	O
enzyme	O
prodrug	O
therapy	O
(	O
VDEPT	O
)	O
is	O
its	O
potential	O
for	O
tumor	O
-	O
specific	O
cytotoxicity	O
.	O
However	O
,	O
the	O
viruses	O
used	O
to	O
deliver	O
cDNAs	O
encoding	O
prodrug	O
-	O
activating	O
enzymes	O
transduce	O
normal	O
cells	O
as	O
well	O
as	O
tumor	O
cells	O
,	O
and	O
several	O
approaches	O
to	O
achieve	O
tumor	O
-	O
specific	O
expression	O
of	O
the	O
delivered	O
cDNAs	O
are	O
being	O
investigated	O
.	O
One	O
such	O
approach	O
is	O
to	O
regulate	O
transcription	O
of	O
the	O
prodrug	O
-	O
activating	O
enzyme	O
with	O
a	O
promoter	O
that	O
is	O
preferentially	O
activated	O
by	O
tumor	O
cells	O
.	O
Published	O
data	O
suggest	O
that	O
the	O
most	O
promising	O
transcription	O
factor	O
/	O
promoter	O
/	O
enhancer	O
combinations	O
are	O
those	O
activated	O
by	O
a	O
tumor	O
-	O
specific	O
transcription	O
factor	O
to	O
retain	O
tumor	O
cell	O
specificity	O
but	O
that	O
are	O
equal	O
in	O
strength	O
to	O
nonspecific	O
viral	O
promoters	O
in	O
their	O
ability	O
to	O
up	O
-	O
regulate	O
target	O
cDNAs	O
.	O
This	O
report	O
identifies	O
MYC	B-GENE
-	O
responsive	O
,	O
modified	O
ornithine	B-GENE
decarboxylase	I-GENE
(	O
ODC	B-GENE
)	O
promoter	O
/	O
enhancer	O
sequences	O
that	O
up	O
-	O
regulate	O
target	O
protein	O
expression	O
in	O
tumor	O
cells	O
overexpressing	O
either	O
N-MYC	B-GENE
or	O
c-MYC	B-GENE
protein	O
.	O
The	O
most	O
efficient	O
of	O
the	O
four	O
constructs	O
assessed	O
contained	O
six	O
additional	O
CACGTG	O
MYC	B-GENE
binding	O
sites	O
5	O
'	O
to	O
the	O
endogenous	O
ODC	B-GENE
promoter	O
(	O
R6ODC	O
)	O
.	O
Reporter	O
assays	O
with	O
this	O
chimeric	O
promoter	O
/	O
enhancer	O
regulating	O
expression	O
of	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
demonstrated	O
50	O
-	O
250	O
-	O
fold	O
more	O
activity	O
in	O
MYC	B-GENE
-	O
expressing	O
cells	O
compared	O
with	O
similar	O
assays	O
with	O
promoterless	O
plasmids	O
.	O
The	O
R6ODC	O
regulatory	O
sequence	O
was	O
approximately	O
equivalent	O
to	O
the	O
CMV	O
promoter	O
in	O
inducing	O
expression	O
of	O
the	O
neomycin	O
resistance	O
gene	O
in	O
c-MYC	B-GENE
-	O
expressing	O
SW480	O
and	O
HT-29	O
colon	O
carcinoma	O
cells	O
and	O
in	O
N-MYC	B-GENE
-	O
expressing	O
NB-	O
1691	O
neuroblastoma	O
cells	O
.	O
The	O
modified	O
ODC	B-GENE
promoter	O
may	O
,	O
therefore	O
,	O
be	O
useful	O
in	O
achieving	O
tissue	O
-	O
specific	O
expression	O
of	O
target	O
proteins	O
in	O
tumor	O
cells	O
that	O
overexpress	O
c	B-GENE
-	I-GENE
or	O
N	B-GENE
MYC	I-GENE
.	O
PMID	O
:	O
11306486	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anticancer	O
Res	O
.	O
2000	O
Mar	O
-	O
Apr;20(	O
2A	O
)	O
:	O
853	O
-	O
9.	O
Bovine	B-GENE
seminal	I-GENE
ribonuclease	I-GENE
exerts	O
selective	O
cytotoxicity	O
toward	O
neuroblastoma	O
cells	O
both	O
sensitive	O
and	O
resistant	O
to	O
chemotherapeutic	O
drugs	O
.	O
Cinatl	O
J	O
Jr	O
,	O
Cinatl	O
J,	O
Kotchetkov	O
R	O
,	O
Matousek	O
J,	O
Woodcock	O
BG	O
,	O
Koehl	O
U	O
,	O
Vogel	O
JU	O
,	O
Kornhuber	O
B	O
,	O
Schwabe	O
D.	O
Institute	O
of	O
Medical	O
Virology	O
,	O
Center	O
of	O
Hygiene	O
,	O
Frankfurt	O
am	O
Main	O
,	O
Germany	O
.	O
cinatl@em	O
.uni	O
-	O
frankfurt	O
.de	O
BACKGROUND	O
:	O
Bovine	B-GENE
seminal	I-GENE
ribonuclease	I-GENE
(	O
BS-RNase	B-GENE
)	O
exerts	O
selective	O
cytotoxicity	O
toward	O
different	O
types	O
of	O
tumor	O
cells	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
BS-RNase	B-GENE
on	O
cultured	O
neuroblastoma	O
(	O
NB	O
)	O
cells	O
resistant	O
to	O
chemotherapeutic	O
agents	O
.	O
The	O
selectivity	O
of	O
the	O
antitumoral	O
activity	O
of	O
BS-RNase	B-GENE
was	O
evaluated	O
using	O
cultures	O
of	O
CD34	B-GENE
+	O
hematopoietic	O
stem	O
cells	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
NB	O
cell	O
lines	O
including	O
IMR-32	O
,	O
UKF-NB-2	O
and	O
UKF-NB-3	O
were	O
selected	O
for	O
resistance	O
against	O
vincristine	O
,	O
doxorubicin	O
or	O
cisplatin	O
by	O
exposure	O
to	O
increasing	O
concentrations	O
of	O
the	O
respective	O
drug	O
.	O
The	O
cytotoxicity	O
of	O
the	O
drugs	O
to	O
NB	O
cells	O
was	O
evaluated	O
using	O
a	O
clonogenic	O
assay	O
in	O
a	O
methylcellulose	O
medium	O
.	O
Peripheral	O
blood	O
progenitor	O
cells	O
were	O
obtained	O
from	O
adult	O
healthy	O
donors	O
by	O
positive	O
selection	O
using	O
specific	O
anti	B-GENE
-	I-GENE
CD34	I-GENE
+	I-GENE
antibodies	I-GENE
.	O
The	O
toxicity	O
of	O
BS-RNase	B-GENE
to	O
CD34	B-GENE
+	O
cells	O
was	O
assessed	O
in	O
the	O
direct	O
clonogenic	O
assay	O
using	O
methylcellulose	O
medium	O
or	O
in	O
ex	O
vivo	O
expansion	O
culture	O
supplemented	O
with	O
hematopoietic	O
growth	O
factors	O
.	O
RESULTS	O
:	O
In	O
the	O
clonogenic	O
assay	O
it	O
was	O
shown	O
that	O
BS-RNase	B-GENE
completely	O
inhibits	O
growth	O
of	O
both	O
parental	O
NB	O
cells	O
and	O
their	O
sublines	O
resistant	O
to	O
chemotherapeutic	O
drugs	O
at	O
concentrations	O
(	O
up	O
to	O
50	O
micrograms	O
/	O
ml	O
)	O
which	O
have	O
no	O
significant	O
influence	O
on	O
the	O
growth	O
of	O
colony	O
-	O
forming	O
units	O
,	O
granulocyte	O
macrophage	O
and	O
erythroid	O
burst	O
-	O
forming	O
units	O
.	O
Moreover	O
,	O
BS-RNase	B-GENE
had	O
no	O
effect	O
on	O
the	O
ex	O
vivo	O
expansion	O
of	O
total	O
hematopoietic	O
cells	O
or	O
of	O
colony	O
-	O
forming	O
cells	O
from	O
CD34	B-GENE
+	O
progenitors	O
.	O
CONCLUSIONS	O
:	O
BS-RNase	B-GENE
is	O
a	O
highly	O
efficient	O
agent	O
against	O
NB	O
cells	O
resistant	O
to	O
chemotherapeutic	O
drugs	O
.	O
The	O
lack	O
of	O
toxicity	O
to	O
hematopoietic	O
progenitor	O
cells	O
suggests	O
that	O
BS-RNase	B-GENE
is	O
also	O
likely	O
to	O
have	O
tolerable	O
hematopoietic	O
toxicity	O
.	O
PMID	O
:	O
10810366	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Immunol	O
Cell	O
Biol	O
.	O
2003	O
Jun;81	O
(	O
3	O
)	O
:	O
230	O
-	O
6.	O
Infection	O
of	O
mouse	O
neurones	O
by	O
West	O
Nile	O
virus	O
is	O
modulated	O
by	O
the	O
interferon	O
-	O
inducible	O
2'-5	B-GENE
'	I-GENE
oligoadenylate	I-GENE
synthetase	I-GENE
1b	I-GENE
protein	O
.	O
Lucas	O
M,	O
Mashimo	O
T	O
,	O
Frenkiel	O
MP	O
,	O
Simon	O
-	O
Chazottes	O
D	O
,	O
Montagutelli	O
X	O
,	O
Ceccaldi	O
PE	O
,	O
Guenet	O
JL	O
,	O
Despres	O
P.	O
Unite	O
des	O
Interactions	O
Moleculaires	O
Flavivirus-Hotes	O
,	O
Institut	O
Pasteur	O
,	O
Paris	O
,	O
France	O
.	O
Over	O
the	O
past	O
7	O
years	O
,	O
West	O
Nile	O
zoonosis	O
has	O
been	O
an	O
emerging	O
concern	O
for	O
public	O
health	O
in	O
Europe	O
,	O
Middle	O
East	O
and	O
more	O
recently	O
in	O
North	O
America	O
.	O
West	O
Nile	O
virus	O
causes	O
epidemic	O
outbreaks	O
in	O
humans	O
and	O
infected	O
patients	O
may	O
exhibit	O
severe	O
neurological	O
symptoms	O
.	O
Because	O
susceptibility	O
and	O
sensitivity	O
to	O
West	O
Nile	O
virus	O
infections	O
may	O
depend	O
on	O
host	O
genetic	O
factors	O
,	O
a	O
mouse	O
model	O
has	O
been	O
established	O
to	O
investigate	O
the	O
genetic	O
determinism	O
of	O
host	O
susceptibility	O
to	O
West	O
Nile	O
virus	O
.	O
A	O
nonsense	O
mutation	O
in	O
gene	O
encoding	O
the	O
1b	B-GENE
isoform	I-GENE
of	I-GENE
the	I-GENE
2'-5'oligoadenylate	I-GENE
synthetase	I-GENE
(	O
OAS1b	B-GENE
)	O
was	O
constantly	O
associated	O
with	O
the	O
susceptibility	O
of	O
mouse	O
strains	O
to	O
experimental	O
West	O
Nile	O
virus	O
infection	O
.	O
Oligoadenylate	B-GENE
synthetase	I-GENE
are	O
interferon	O
-	O
inducible	O
proteins	O
playing	O
a	O
role	O
in	O
the	O
endogeneous	O
antiviral	O
pathway	O
.	O
It	O
was	O
of	O
interest	O
to	O
establish	O
whether	O
interferon	B-GENE
-	I-GENE
alpha	I-GENE
and	O
OAS	B-GENE
1B	I-GENE
were	O
sufficient	O
to	O
mediate	O
resistance	O
to	O
West	O
Nile	O
virus	O
infection	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
interferon	B-GENE
-	I-GENE
alpha	I-GENE
had	O
the	O
ability	O
to	O
modulate	O
West	O
Nile	O
virus	O
infection	O
in	O
mouse	O
.	O
In	O
vitro	O
,	O
interferon	B-GENE
-	I-GENE
alpha	I-GENE
protected	O
mouse	O
neuroblastoma	O
cells	O
against	O
West	O
Nile	O
virus	O
infection	O
if	O
cells	O
have	O
been	O
pretreated	O
with	O
the	O
cytokine	O
for	O
several	O
hours	O
.	O
As	O
a	O
consequence	O
of	O
the	O
presence	O
of	O
a	O
stop	O
codon	O
,	O
the	O
Oas1b	B-GENE
gene	O
of	O
the	O
susceptible	O
mice	O
encodes	O
a	O
truncated	O
and	O
presumably	O
inactive	O
form	O
,	O
while	O
resistant	O
mice	O
have	O
a	O
normal	O
copy	O
of	O
the	O
gene	O
.	O
Stable	O
mouse	O
neuroblastoma	O
cell	O
clones	O
overexpressing	O
mutant	O
or	O
wild-type	O
OAS	B-GENE
1B	I-GENE
were	O
established	O
.	O
Replication	O
of	O
West	O
Nile	O
virus	O
was	O
less	O
efficient	O
in	O
cells	O
that	O
produce	O
the	O
normal	O
copy	O
of	O
OAS	B-GENE
1B	I-GENE
as	O
compared	O
to	O
those	O
expressing	O
the	O
truncated	O
form	O
.	O
Our	O
data	O
illustrate	O
the	O
notion	O
that	O
interferon	B-GENE
-	I-GENE
alpha	I-GENE
and	O
Oas	B-GENE
genes	O
may	O
be	O
critical	O
for	O
West	O
Nile	O
virus	O
pathogenesis	O
.	O
PMID	O
:	O
12752688	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1998	O
Mar	O
27;273	O
(	O
13	O
)	O
:7675	O
-83	O
.	O
Genomic	O
structure	O
and	O
promoter	O
activity	O
of	O
the	O
mouse	O
polysialic	B-GENE
acid	I-GENE
synthase	I-GENE
(	O
mST8Sia	B-GENE
IV	I-GENE
/	I-GENE
PST	I-GENE
)	O
gene	O
.	O
Takashima	O
S	O
,	O
Yoshida	O
Y	O
,	O
Kanematsu	O
T	O
,	O
Kojima	O
N	O
,	O
Tsuji	O
S.	O
Department	O
of	O
Molecular	O
Glycobiology	O
,	O
Frontier	O
Research	O
Program	O
,	O
The	O
Institute	O
of	O
Physical	O
and	O
Chemical	O
Research	O
(	O
RIKEN	O
)	O
,	O
Wako	O
,	O
Saitama	O
351	O
-01	O
,	O
Japan	O
.	O
The	O
mouse	O
gene	O
encoding	O
ST8Sia	B-GENE
IV	I-GENE
/	I-GENE
PST	I-GENE
,	O
one	O
of	O
two	O
polysialic	B-GENE
acid	I-GENE
synthases	I-GENE
,	O
was	O
isolated	O
and	O
characterized	O
.	O
The	O
mST8Sia	B-GENE
IV	I-GENE
/	I-GENE
PST	I-GENE
gene	O
was	O
found	O
to	O
comprise	O
over	O
60	O
kilobases	O
and	O
to	O
be	O
composed	O
of	O
five	O
exons	O
.	O
Primer	O
extension	O
analysis	O
revealed	O
that	O
transcription	O
started	O
from	O
333	O
nucleotides	O
upstream	O
of	O
the	O
translational	O
initiation	O
site	O
.	O
Transfection	O
with	O
nested	O
deletion	O
mutants	O
of	O
the	O
5'	O
-flanking	O
region	O
fused	O
to	O
the	O
luciferase	B-GENE
reporter	I-GENE
gene	O
revealed	O
that	O
the	O
promoter	O
activity	O
of	O
the	O
-	O
107	O
/	O
+145	O
region	O
was	O
correlated	O
with	O
the	O
gene	O
expression	O
of	O
mST8Sia	B-GENE
IV	I-GENE
/	I-GENE
PST	I-GENE
in	O
embryonal	O
carcinoma	O
P19	O
and	O
neuroblastoma	O
F11	O
cells	O
.	O
This	O
proximal	O
promoter	O
region	O
lacks	O
an	O
apparent	O
TATA	O
box	O
but	O
has	O
putative	O
binding	O
sites	O
for	O
transcription	O
factors	O
Sp1	B-GENE
and	O
NF	B-GENE
-Y	I-GENE
(	O
CCAAT	B-GENE
binding	I-GENE
protein	I-GENE
)	O
at	O
nucleotide	O
positions	O
-	O
66/-57	O
and	O
-	O
47/-37	O
,	O
respectively	O
.	O
Individual	O
deletions	O
and	O
mutations	O
of	O
the	O
inverted	O
Sp1	B-GENE
binding	O
site	O
or	O
inverted	O
NF	B-GENE
-Y	I-GENE
binding	O
site	O
caused	O
significant	O
reduction	O
of	O
the	O
promoter	O
activity	O
,	O
indicating	O
that	O
each	O
binding	O
site	O
was	O
involved	O
in	O
essential	O
transcription	O
control	O
.	O
Mobility	O
shift	O
assaying	O
also	O
revealed	O
that	O
Sp1	B-GENE
and	O
NF	B-GENE
-Y	I-GENE
in	O
a	O
nuclear	O
extract	O
of	O
P19	O
cells	O
bind	O
to	O
the	O
promoter	O
region	O
of	O
the	O
mST8Sia	B-GENE
IV	I-GENE
/	I-GENE
PST	I-GENE
gene	O
.	O
Deletion	O
of	O
the	O
region	O
from	O
-	O
60	O
to	O
-	O
40	O
,	O
which	O
contains	O
parts	O
of	O
both	O
the	O
Sp1	B-GENE
and	O
NF	B-GENE
-Y	I-GENE
binding	O
sites	O
,	O
completely	O
abolished	O
the	O
promoter	O
activity	O
,	O
suggesting	O
that	O
both	O
Sp1	B-GENE
and	O
NF	B-GENE
-Y	I-GENE
are	O
synergetically	O
involved	O
in	O
transcription	O
regulation	O
of	O
the	O
mST8Sia	B-GENE
IV	I-GENE
/	I-GENE
PST	I-GENE
gene	O
in	O
P19	O
and	O
F11	O
cells	O
.	O
Although	O
the	O
overall	O
structures	O
of	O
the	O
two	O
polysialic	B-GENE
acid	I-GENE
synthase	I-GENE
genes	O
(	O
ST8Sia	B-GENE
II	I-GENE
/STX	I-GENE
and	O
IV	B-GENE
/	I-GENE
PST	I-GENE
)	O
are	O
very	O
similar	O
,	O
there	O
is	O
no	O
extensive	O
sequence	O
homology	O
between	O
the	O
5'	O
-flanking	O
regions	O
of	O
the	O
ST8Sia	B-GENE
II	I-GENE
/STX	I-GENE
and	O
IV	B-GENE
/	I-GENE
PST	I-GENE
genes	O
,	O
suggesting	O
that	O
these	O
two	O
genes	O
are	O
expressed	O
under	O
different	O
regulatory	O
systems	O
.	O
PMID	O
:	O
9516473	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1998	O
Jan	O
15	O
;58(	O
2	O
)	O
:	O
367	O
-72	O
.	O
Persistent	O
human	O
cytomegalovirus	O
infection	O
induces	O
drug	O
resistance	O
and	O
alteration	O
of	O
programmed	O
cell	O
death	O
in	O
human	O
neuroblastoma	O
cells	O
.	O
Cinatl	O
J	O
Jr	O
,	O
Cinatl	O
J,	O
Vogel	O
JU	O
,	O
Kotchetkov	O
R	O
,	O
Driever	O
PH	O
,	O
Kabickova	O
H,	O
Kornhuber	O
B	O
,	O
Schwabe	O
D	O
,	O
Doerr	O
HW	O
.	O
Zentrum	O
der	O
Hygiene	O
,	O
Institut	O
fur	O
Medizinische	O
Virologie	O
,	O
Klinikum	O
der	O
Johann	O
Wolfgang	O
Goethe-Universitat	O
,	O
Frankfurt	O
am	O
Main	O
,	O
Germany	O
.	O
Infection	O
with	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
a	O
common	O
and	O
generally	O
asymptomatic	O
affection	O
in	O
childhood	O
.	O
Its	O
role	O
in	O
neuroblastoma	O
(	O
NB	O
)	O
patients	O
has	O
not	O
yet	O
been	O
elucidated	O
.	O
As	O
evidence	O
grows	O
that	O
HCMV	O
interacts	O
with	O
apoptotic	O
signaling	O
due	O
to	O
the	O
interaction	O
of	O
HCMV	O
gene	O
products	O
with	O
cellular	O
proteins	O
of	O
apoptotic	O
pathways	O
,	O
we	O
used	O
human	O
NB	O
cell	O
line	O
UKF-NB-2	O
persistently	O
infected	O
with	O
HCMV	O
strain	O
AD169	O
to	O
study	O
the	O
effects	O
of	O
long-term	O
HCMV	O
infection	O
on	O
programmed	O
cell	O
death	O
of	O
neuroectodermal	O
tumor	O
cells	O
.	O
The	O
cells	O
designated	O
UKF-NB-	O
2AD169	O
continued	O
to	O
produce	O
infectious	O
virus	O
in	O
successive	O
subcultures	O
over	O
a	O
period	O
of	O
more	O
than	O
1	O
year	O
.	O
Up	O
to	O
20	O
%	O
of	O
cells	O
expressed	O
viral	O
genes	O
or	O
produced	O
infectious	O
virus	O
after	O
initiation	O
of	O
infection	O
.	O
UKF-NB-	O
2AD169	O
cells	O
were	O
significantly	O
less	O
sensitive	O
to	O
the	O
cytotoxic	O
agents	O
cisplatinum	O
and	O
etoposide	O
than	O
parental	O
(	O
noninfected	O
)	O
UKF-NB-2	O
cells	O
.	O
These	O
effects	O
were	O
associated	O
with	O
decreased	O
ability	O
of	O
UKF-NB-	O
2AD169	O
cells	O
to	O
undergo	O
apoptosis	O
and	O
continuous	O
viral	O
replication	O
.	O
UKF-NB-	O
2AD169	O
cells	O
showed	O
increased	O
levels	O
of	O
antiapoptosis	O
Bcl-2	B-GENE
protein	O
(	O
up	O
to	O
12	O
-	O
fold	O
)	O
,	O
whereas	O
expression	O
of	O
p53	B-GENE
and	O
c-myc	B-GENE
was	O
not	O
changed	O
.	O
Treatment	O
of	O
UKF-NB-	O
2AD169	O
cells	O
with	O
ganciclovir	O
,	O
abolishing	O
virus	O
production	O
,	O
reestablished	O
sensitivity	O
to	O
chemotherapy	O
,	O
lowered	O
Bcl-2	B-GENE
expression	O
,	O
and	O
facilitated	O
inducibility	O
of	O
apoptosis	O
to	O
the	O
level	O
of	O
the	O
parental	O
cell	O
line	O
.	O
The	O
results	O
demonstrate	O
that	O
persistent	O
HCMV	O
infection	O
confers	O
resistance	O
to	O
cytotoxic	O
agents	O
on	O
neuroectodermal	O
tumor	O
cells	O
and	O
protects	O
from	O
apoptosis	O
,	O
probably	O
due	O
to	O
increased	O
levels	O
of	O
Bcl-2	B-GENE
protein	O
.	O
Hence	O
,	O
it	O
is	O
conceivable	O
that	O
HCMV	O
infection	O
before	O
or	O
during	O
tumorigenesis	O
may	O
contribute	O
in	O
some	O
NB	O
patients	O
to	O
failure	O
of	O
therapy	O
.	O
PMID	O
:	O
9443419	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1998	O
Nov	O
20;273	O
(	O
47	O
)	O
:	O
30870	O
-	O
8.	O
Sp1	B-GENE
-	O
binding	O
elements	O
in	O
the	O
promoter	O
of	O
RAGE	B-GENE
are	O
essential	O
for	O
amphoterin	B-GENE
-	O
mediated	O
gene	O
expression	O
in	O
cultured	O
neuroblastoma	O
cells	O
.	O
Li	O
J,	O
Qu	O
X	O
,	O
Schmidt	O
AM	O
.	O
Division	O
of	O
Surgical	O
Science	O
,	O
Department	O
of	O
Surgery	O
,	O
and	O
Departments	O
of	O
Physiology	O
and	O
Medicine	O
,	O
Columbia	O
University	O
College	O
of	O
Physicians	O
and	O
Surgeons	O
,	O
New	O
York	O
,	O
New	O
York	O
10032	O
,	O
USA	O
.	O
Receptor	B-GENE
for	I-GENE
AGE	I-GENE
(	O
RAGE	B-GENE
)	O
and	O
the	O
polypeptide	O
amphoterin	B-GENE
are	O
highly	O
expressed	O
and	O
co	O
-	O
localized	O
in	O
neurons	O
of	O
the	O
developing	O
central	O
nervous	O
system	O
of	O
the	O
rat	O
.	O
In	O
vitro	O
,	O
the	O
interaction	O
of	O
amphoterin	B-GENE
with	O
neuronal	O
RAGE	B-GENE
induces	O
neurite	O
outgrowth	O
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
interaction	O
of	O
amphoterin	B-GENE
with	O
neuronal	O
cells	O
enhances	O
RAGE	B-GENE
expression	O
,	O
thereby	O
providing	O
a	O
mechanism	O
by	O
which	O
amphoterin	B-GENE
-	O
mediated	O
regulation	O
of	O
RAGE	B-GENE
might	O
contribute	O
to	O
promotion	O
of	O
neurite	O
growth	O
and	O
spreading	O
.	O
Incubation	O
of	O
cultured	O
neuroblastoma	O
cells	O
with	O
amphoterin	B-GENE
resulted	O
in	O
increased	O
transcription	O
and	O
translation	O
of	O
RAGE	B-GENE
,	O
a	O
process	O
largely	O
inhibited	O
in	O
the	O
presence	O
of	O
anti	B-GENE
-	I-GENE
RAGE	I-GENE
IgG	I-GENE
but	O
not	O
by	O
nonimmune	B-GENE
IgG	I-GENE
.	O
To	O
begin	O
to	O
delineate	O
molecular	O
mechanisms	O
underlying	O
these	O
findings	O
,	O
we	O
identified	O
multiple	O
putative	O
binding	O
elements	O
within	O
the	O
5'	O
-flanking	O
region	O
of	O
the	O
RAGE	B-GENE
gene	O
for	O
Sp1	B-GENE
,	O
a	O
transcription	O
factor	O
that	O
has	O
been	O
critically	O
linked	O
to	O
the	O
process	O
of	O
normal	O
development	O
.	O
DNase	B-GENE
I	I-GENE
footprinting	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
multiple	O
functional	O
Sp1	B-GENE
-	O
binding	O
sites	O
within	O
the	O
region	O
-	O
245	O
to	O
-	O
40	O
of	O
the	O
RAGE	B-GENE
promoter	O
.	O
Transient	O
transfection	O
of	O
cultured	O
SK-N-SH	O
neuroblastoma	O
cells	O
with	O
chimeric	O
5'-deletion	O
constructs	O
linked	O
to	O
luciferase	B-GENE
reporter	I-GENE
revealed	O
that	O
the	O
region	O
containing	O
Sp1	B-GENE
-	O
binding	O
elements	O
did	O
not	O
contribute	O
uniquely	O
to	O
basal	O
expression	O
of	O
the	O
RAGE	B-GENE
gene	O
.	O
Simultaneous	O
mutation	O
of	O
the	O
multiple	O
Sp1	B-GENE
-	O
binding	O
elements	O
in	O
this	O
region	O
did	O
not	O
affect	O
basal	O
promoter	O
function	O
;	O
however	O
,	O
promoter	O
responsiveness	O
to	O
amphoterin	B-GENE
was	O
markedly	O
attenuated	O
.	O
These	O
results	O
point	O
to	O
Sp1	B-GENE
-	O
dependent	O
mechanisms	O
underlying	O
amphoterin	B-GENE
-	O
mediated	O
increases	O
in	O
RAGE	B-GENE
expression	O
in	O
neuroblastoma	O
cells	O
and	O
further	O
link	O
amphoterin	B-GENE
-	O
RAGE	B-GENE
interaction	O
to	O
development	O
of	O
the	O
nervous	O
system	O
.	O
PMID	O
:	O
9812979	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
.	O
1996	O
Oct;2	O
(	O
10	O
)	O
:1757	O
-	O
65	O
.	O
Quantitation	O
of	O
somatostatin	B-GENE
receptor	I-GENE
type	I-GENE
2	I-GENE
gene	O
expression	O
in	O
neuroblastoma	O
cell	O
lines	O
and	O
primary	O
tumors	O
using	O
competitive	O
reverse	O
transcription	O
-	O
polymerase	B-GENE
chain	O
reaction	O
.	O
Sestini	O
R	O
,	O
Orlando	O
C	O
,	O
Peri	O
A	O
,	O
Tricarico	O
C	O
,	O
Pazzagli	O
M,	O
Serio	O
M,	O
Pagani	O
A	O
,	O
Bussolati	O
G	O
,	O
Granchi	O
S	O
,	O
Maggi	O
M.	O
Clinical	O
Biochemistry	O
,	O
Endocrinology	O
,	O
and	O
Andrology	O
Units	O
,	O
Department	O
of	O
Clinical	O
Physiopathology	O
,	O
University	O
of	O
Florence	O
viale	O
Pieraccini	O
6	O
,	O
50139	O
Florence	O
,	O
Italy	O
.	O
We	O
previously	O
reported	O
the	O
presence	O
of	O
somatostatin	B-GENE
(	O
SS	B-GENE
-14	I-GENE
)	O
-binding	O
sites	O
in	O
a	O
wide	O
panel	O
of	O
human	O
neuroblastoma	O
(	O
NB	O
)	O
tumor	O
cell	O
lines	O
.	O
Given	O
that	O
the	O
adrenal	O
gland	O
and	O
its	O
relative	O
embryonal	O
and	O
adult	O
tumors	O
express	O
an	O
abundance	O
of	O
mRNA	O
for	O
somatostatin	B-GENE
receptor	I-GENE
type	I-GENE
2	I-GENE
(	O
sst2	B-GENE
)	O
mRNA	O
,	O
we	O
studied	O
the	O
quantitative	O
expression	O
of	O
sst2	B-GENE
in	O
6	O
NB	O
cell	O
lines	O
and	O
15	O
primary	O
tumors	O
using	O
competitive	O
reverse	O
transcription	O
(	O
RT	O
)	O
-PCR	O
.	O
This	O
method	O
uses	O
an	O
insertion	O
mutant	O
of	O
the	O
target	O
gene	O
as	O
a	O
competitor	O
for	O
the	O
RT-PCR	O
reaction	O
,	O
thus	O
allowing	O
exact	O
quantitation	O
of	O
sst2	B-GENE
mRNA	O
abundance	O
.	O
We	O
found	O
expression	O
of	O
specific	O
transcripts	O
for	O
sst2	B-GENE
in	O
all	O
of	O
the	O
NB	O
cell	O
lines	O
and	O
tumors	O
investigated	O
(	O
range	O
,	O
9	O
x	O
10(	O
5)-4	O
x	O
10(	O
9	O
)	O
molecules	O
/	O
microg	O
RNA	O
)	O
.	O
In	O
NB	O
cells	O
,	O
the	O
expression	O
of	O
sst2	B-GENE
was	O
highly	O
correlated	O
with	O
SS	B-GENE
-14	I-GENE
-	O
binding	O
sites	O
(	O
R	O
=	O
0.93	O
)	O
.	O
In	O
primary	O
tumors	O
,	O
sst2	B-GENE
was	O
positively	O
related	O
to	O
the	O
expression	O
of	O
the	O
neuroendocrine	O
marker	O
secretogranin	B-GENE
II	I-GENE
(	O
P	O
<	O
0.05	O
)	O
and	O
negatively	O
related	O
to	O
N-myc	B-GENE
amplification	O
(	O
a	O
poor	O
prognostic	O
factor	O
,	O
P	O
<	O
0.005	O
)	O
and	O
metastatic	O
dissemination	O
(	O
P	O
<	O
0.05	O
)	O
.	O
In	O
addition	O
,	O
Kaplan-Meier	O
curves	O
indicate	O
that	O
sst2	B-GENE
expression	O
is	O
positively	O
related	O
to	O
survival	O
(	O
P	O
=	O
0.01	O
)	O
.	O
In	O
a	O
patient	O
with	O
stage	O
IVs	O
disease	O
(	O
a	O
spontaneously	O
regressing	O
form	O
)	O
,	O
we	O
found	O
the	O
highest	O
sst2	B-GENE
expression	O
(	O
4	O
x	O
10(	O
9	O
)	O
molecules	O
/	O
microgram	O
RNA	O
)	O
,	O
a	O
value	O
relatively	O
similar	O
to	O
that	O
of	O
normal	O
adrenal	O
.	O
In	O
conclusion	O
,	O
these	O
data	O
indicate	O
that	O
quantitation	O
of	O
sst2	B-GENE
,	O
as	O
assessed	O
with	O
competitive	O
RT-PCR	O
,	O
could	O
represent	O
a	O
new	O
prognostic	O
tool	O
in	O
the	O
neuroendocrine	O
tumor	O
NB	O
.	O
Since	O
sst2	B-GENE
recognizes	O
octreotide	B-GENE
with	O
high	O
affinity	O
,	O
these	O
findings	O
could	O
also	O
have	O
both	O
diagnostic	O
and	O
therapeutic	O
value	O
.	O
PMID	O
:	O
9816127	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Pharmacol	O
.	O
2000	O
Dec;58	O
(	O
6	O
)	O
:159	O
3	O
-600	O
.	O
Expression	O
profiling	O
of	O
neural	O
cells	O
reveals	O
specific	O
patterns	O
of	O
ethanol	O
-	O
responsive	O
gene	O
expression	O
.	O
Thibault	O
C	O
,	O
Lai	O
C	O
,	O
Wilke	O
N	O
,	O
Duong	O
B	O
,	O
Olive	O
MF	O
,	O
Rahman	O
S	O
,	O
Dong	O
H,	O
Hodge	O
CW	O
,	O
Lockhart	O
DJ	O
,	O
Miles	O
MF.	O
The	O
Ernest	O
Gallo	O
Clinic	O
and	O
Research	O
Center	O
and	O
Department	O
of	O
Neurology	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
,	O
California	O
,	O
USA	O
.	O
Adaptive	O
changes	O
in	O
gene	O
expression	O
are	O
thought	O
to	O
contribute	O
to	O
dependence	O
,	O
addiction	O
and	O
other	O
behavioral	O
responses	O
to	O
chronic	O
ethanol	O
abuse	O
.	O
DNA	O
array	O
studies	O
provide	O
a	O
nonbiased	O
detection	O
of	O
networks	O
of	O
gene	O
expression	O
changes	O
,	O
allowing	O
insight	O
into	O
functional	O
consequences	O
and	O
mechanisms	O
of	O
such	O
molecular	O
responses	O
.	O
We	O
used	O
oligonucleotide	O
arrays	O
to	O
study	O
nearly	O
6000	O
genes	O
in	O
human	O
SH-SY5Y	O
neuroblastoma	O
cells	O
exposed	O
to	O
chronic	O
ethanol	O
.	O
A	O
set	O
of	O
42	O
genes	O
had	O
consistently	O
increased	O
or	O
decreased	O
mRNA	O
abundance	O
after	O
3	O
days	O
of	O
ethanol	O
treatment	O
.	O
Groups	O
of	O
genes	O
related	O
to	O
norepinephrine	O
production	O
,	O
glutathione	B-GENE
metabolism	O
,	O
and	O
protection	O
against	O
apoptosis	O
were	O
identified	O
.	O
Genes	O
involved	O
in	O
catecholamine	O
metabolism	O
are	O
of	O
special	O
interest	O
because	O
of	O
the	O
role	O
of	O
this	O
pathway	O
in	O
mediating	O
ethanol	O
withdrawal	O
symptoms	O
(	O
physical	O
dependence	O
)	O
.	O
Ethanol	O
treatment	O
elevated	O
dopamine	B-GENE
beta-hydroxylase	I-GENE
(	O
DBH	B-GENE
,	O
EC	O
1.14.17.1	O
)	O
mRNA	O
and	O
protein	O
levels	O
and	O
increased	O
releasable	O
norepinephrine	O
in	O
SH-SY5Y	O
cultures	O
.	O
Acute	O
ethanol	O
also	O
increased	O
DBH	B-GENE
mRNA	O
levels	O
in	O
mouse	O
adrenal	O
gland	O
,	O
suggesting	O
in	O
vivo	O
functional	O
consequences	O
for	O
ethanol	O
regulation	O
of	O
DBH	B-GENE
.	O
In	O
SH-SY5Y	O
cells	O
,	O
ethanol	O
also	O
decreased	O
mRNA	O
and	O
secreted	O
protein	O
levels	O
for	O
monocyte	B-GENE
chemotactic	I-GENE
protein	I-GENE
1	I-GENE
,	O
an	O
effect	O
that	O
could	O
contribute	O
to	O
the	O
protective	O
role	O
of	O
moderate	O
ethanol	O
consumption	O
in	O
atherosclerotic	O
vascular	O
disease	O
.	O
Finally	O
,	O
we	O
identified	O
a	O
subset	O
of	O
genes	O
similarly	O
regulated	O
by	O
both	O
ethanol	O
and	O
dibutyryl-cAMP	O
treatment	O
in	O
SH-SY5Y	O
cells	O
.	O
This	O
suggests	O
that	O
ethanol	O
and	O
cAMP	O
signaling	O
share	O
mechanistic	O
features	O
in	O
regulating	O
a	O
subset	O
of	O
ethanol	O
-	O
responsive	O
genes	O
.	O
Our	O
findings	O
offer	O
new	O
insights	O
regarding	O
possible	O
molecular	O
mechanisms	O
underlying	O
behavioral	O
responses	O
or	O
medical	O
consequences	O
of	O
ethanol	O
consumption	O
and	O
alcoholism	O
.	O
PMID	O
:	O
11093800	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
.	O
2001	O
Jan;36	O
(	O
1	O
)	O
:157	O
-	O
9.	O
Biological	O
aspects	O
of	O
neuroblastomas	O
identified	O
by	O
mass	O
screening	O
in	O
Quebec.	O
Brodeur	O
GM	O
,	O
Look	O
AT	O
,	O
Shimada	O
H,	O
Hamilton	O
VM	O
,	O
Maris	O
JM	O
,	O
Hann	O
HW	O
,	O
Leclerc	O
JM	O
,	O
Bernstein	O
M,	O
Brisson	O
LC	O
,	O
Brossard	O
J,	O
Lemieux	O
B	O
,	O
Tuchman	O
M,	O
Woods	O
WG.	O
Division	O
of	O
Oncology	O
,	O
Children	O
's	O
Hospital	O
of	O
Philadelphia	O
,	O
PA	O
19104-4318	O
,	O
USA	O
.	O
brodeur@email	O
.chop.edu	O
BACKGROUND	O
:	O
Neuroblastoma	O
has	O
several	O
characteristics	O
that	O
suggest	O
that	O
preclinical	O
diagnosis	O
might	O
improve	O
outcome	O
.	O
Therefore	O
,	O
the	O
Quebec	O
Neuroblastoma	O
Screening	O
Project	O
was	O
undertaken	O
from	O
1989	O
to	O
1994	O
to	O
examine	O
infants	O
at	O
3	O
weeks	O
and	O
6	O
months	O
by	O
measuring	O
urinary	O
catecholamine	O
metabolites	O
.	O
PROCEDURE	O
:	O
Over	O
the	O
5-yr	O
period	O
,	O
45	O
tumors	O
were	O
detected	O
by	O
screening	O
,	O
20	O
were	O
identified	O
clinically	O
prior	O
to	O
the	O
third	O
week	O
,	O
and	O
64	O
were	O
identified	O
clinically	O
at	O
a	O
later	O
time	O
.	O
We	O
analyzed	O
available	O
tumors	O
for	O
Shimada	O
histopathology	O
,	O
tumor	O
ploidy	O
,	O
MYCN	B-GENE
copy	O
number	O
and	O
serum	O
ferritin	B-GENE
.	O
RESULTS	O
:	O
Of	O
the	O
tumors	O
detected	O
by	O
screening	O
,	O
only	O
2	O
of	O
45	O
tested	O
had	O
unfavorable	O
histology	O
,	O
2	O
of	O
45	O
had	O
diploid	O
or	O
tetraploid	O
DNA	O
content	O
,	O
0	O
of	O
43	O
had	O
MYCN	B-GENE
amplification	O
,	O
and	O
4	O
of	O
44	O
had	O
elevated	O
serum	O
ferritin	B-GENE
.	O
All	O
of	O
these	O
patients	O
are	O
alive	O
and	O
well	O
.	O
The	O
20	O
patients	O
detected	O
prior	O
to	O
the	O
3-week	O
screen	O
had	O
similar	O
biological	O
characteristics	O
.	O
In	O
contrast	O
,	O
of	O
the	O
patients	O
detected	O
clinically	O
after	O
3	O
weeks	O
of	O
age	O
,	O
19	O
of	O
51	O
testedhad	O
unfavorable	O
histology	O
,	O
25	O
of	O
66	O
had	O
diploid	O
or	O
tetraploid	O
tumors	O
,	O
12	O
of	O
56	O
had	O
MYCN	B-GENE
amplification	O
,	O
and	O
14	O
of	O
54	O
had	O
elevated	O
ferritin	B-GENE
.	O
CONCLUSIONS	O
:	O
The	O
difference	O
between	O
the	O
screened	O
and	O
clinically	O
detected	O
cases	O
was	O
highly	O
significant	O
for	O
each	O
biological	O
variable	O
.	O
Preliminary	O
data	O
on	O
other	O
biological	O
variables	O
,	O
such	O
as	O
neurotrophin	B-GENE
expression	O
and	O
allelic	O
loss	O
on	O
1	O
p	O
in	O
these	O
patients	O
are	O
consistent	O
with	O
the	O
above	O
findings	O
.	O
These	O
data	O
suggest	O
that	O
mass	O
screening	O
for	O
neuroblastoma	O
at	O
or	O
before	O
6	O
months	O
of	O
age	O
detects	O
almost	O
exclusively	O
tumors	O
that	O
have	O
favorable	O
biological	O
characteristics	O
,	O
many	O
of	O
which	O
might	O
have	O
regressed	O
spontaneously	O
.	O
Thus	O
,	O
continued	O
mass	O
screening	O
for	O
neuroblastoma	O
at	O
6	O
months	O
is	O
unlikely	O
to	O
accomplish	O
its	O
intended	O
goal	O
,	O
and	O
should	O
probably	O
be	O
discontinued	O
.	O
PMID	O
:	O
11464873	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurosurg	O
.	O
1995	O
Oct;8	O
3	O
(	O
4	O
)	O
:	O
672	O
-	O
81	O
.	O
Inhibition	O
of	O
proliferation	O
and	O
induction	O
of	O
differentiation	O
in	O
medulloblastoma	O
-	O
and	O
astrocytoma	O
-	O
derived	O
cell	O
lines	O
with	O
phenylacetate	O
.	O
Stockhammer	O
G	O
,	O
Manley	O
GT	O
,	O
Johnson	O
R	O
,	O
Rosenblum	O
MK	O
,	O
Samid	O
D	O
,	O
Lieberman	O
FS	O
.	O
Cotzias	O
Laboratory	O
of	O
Neuro-Oncology	O
,	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
New	O
York	O
,	O
USA	O
.	O
The	O
authors	O
investigated	O
the	O
effects	O
of	O
a	O
nontoxic	O
differentiation	O
inducer	O
,	O
phenylacetate	O
(	O
PA	O
)	O
,	O
on	O
neuroectodermal	O
tumor	O
-	O
derived	O
cell	O
lines	O
.	O
Treatment	O
of	O
medulloblastoma	O
(	O
Daoy	O
and	O
D283	O
MED)	O
and	O
glioma	O
(	O
U-251MG	O
,	O
C6	O
,	O
and	O
RG2	O
)	O
cell	O
lines	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
decline	O
in	O
DNA	O
synthesis	O
and	O
cell	O
proliferation	O
,	O
associated	O
with	O
accumulation	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O
Phenylacetate	O
decreased	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
(	I-GENE
TGF	I-GENE
)	I-GENE
-beta	I-GENE
2	I-GENE
production	O
by	O
medulloblastoma	O
Daoy	O
cells	O
.	O
Neutralizing	O
antibodies	O
against	O
either	O
TGF	B-GENE
beta	I-GENE
2	I-GENE
or	O
TGF	B-GENE
beta	I-GENE
1	I-GENE
failed	O
to	O
block	O
the	O
growth	O
arrest	O
observed	O
.	O
This	O
suggests	O
that	O
,	O
unlike	O
other	O
differentiation	O
agents	O
,	O
such	O
as	O
retinoic	O
acid	O
,	O
the	O
effect	O
of	O
PA	O
on	O
medulloblastoma	O
proliferation	O
is	O
not	O
mediated	O
by	O
a	O
TGF	B-GENE
beta	I-GENE
pathway	O
.	O
In	O
addition	O
to	O
cytostasis	O
,	O
PA	O
induced	O
marked	O
morphological	O
changes	O
in	O
U-251MG	O
and	O
C6	O
glioma	O
cells	O
associated	O
with	O
increased	O
abundance	O
of	O
glial	B-GENE
fibrillary	I-GENE
acidic	I-GENE
protein	I-GENE
-	O
positive	O
processes	O
.	O
Although	O
the	O
morphology	O
of	O
PA	O
-	O
treated	O
medulloblastoma	O
cells	O
was	O
not	O
significantly	O
altered	O
,	O
the	O
D283	O
MED	O
cells	O
exhibited	O
increased	O
expression	O
of	O
neurofilament	B-GENE
proteins	I-GENE
and	O
Hu	B-GENE
antigen	I-GENE
,	O
indicative	O
of	O
differentiation	O
along	O
a	O
neuronal	O
pathway	O
.	O
The	O
effects	O
of	O
PA	O
on	O
the	O
medulloblastoma	O
cell	O
lines	O
were	O
compared	O
to	O
its	O
effects	O
on	O
the	O
human	O
neuroblastoma	O
cell	O
line	O
BE(2)C	O
,	O
which	O
is	O
capable	O
of	O
a	O
bidirectional	O
differentiation	O
toward	O
a	O
neuronal	O
or	O
a	O
glial	O
/	O
schwann	O
cell	O
pathway	O
.	O
In	O
BE(2)	O
C	O
cells	O
,	O
PA	O
induced	O
differentiation	O
toward	O
a	O
schwann	O
/	O
glial	O
cell	O
-	O
like	O
phenotype	O
,	O
suggesting	O
that	O
the	O
choice	O
of	O
differentiation	O
pathway	O
is	O
cell	O
type	O
and	O
agent	O
specific	O
.	O
These	O
in	O
vitro	O
antiproliferative	O
and	O
differentiation	O
inducing	O
effects	O
of	O
PA	O
suggest	O
that	O
this	O
agent	O
warrants	O
further	O
evaluation	O
as	O
a	O
potential	O
therapeutic	O
modality	O
for	O
the	O
treatment	O
of	O
medulloblastoma	O
and	O
malignant	O
glioma	O
in	O
humans	O
.	O
PMID	O
:	O
7674018	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dev	O
Neurosci	O
.	O
1997;19(	O
5	O
)	O
:	O
375	O
-83	O
.	O
Expression	O
of	O
the	O
brain	B-GENE
creatine	I-GENE
kinase	I-GENE
gene	O
is	O
low	O
in	O
neuroblastoma	O
cell	O
lines	O
.	O
Wilson	O
CD	O
,	O
Shen	O
W	O
,	O
Molloy	O
GR.	O
Department	O
of	O
Biology	O
,	O
University	O
of	O
Delaware	O
,	O
Newark	O
19716	O
,	O
USA	O
.	O
The	O
cytoplasmic	B-GENE
creatine	I-GENE
kinase	I-GENE
(	O
CKB	B-GENE
)	O
enzyme	O
has	O
a	O
central	O
role	O
in	O
the	O
regeneration	O
of	O
ATP	O
in	O
the	O
brain	O
.	O
We	O
have	O
shown	O
previously	O
that	O
CKB	B-GENE
mRNA	O
levels	O
in	O
cultured	O
primary	O
rat	O
brain	O
astrocytes	O
and	O
oligodendrocytes	O
are	O
much	O
higher	O
than	O
in	O
primary	O
neurons	O
.	O
It	O
has	O
been	O
suggested	O
that	O
high	O
CKB	B-GENE
expression	O
is	O
essential	O
for	O
the	O
energy-demanding	O
functions	O
of	O
glial	O
cells	O
.	O
Conversely	O
,	O
CKB	B-GENE
may	O
be	O
repressed	O
in	O
most	O
neuronal	O
cells	O
;	O
however	O
,	O
CKB	B-GENE
protein	O
has	O
previously	O
been	O
detected	O
by	O
immunohistochemistry	O
in	O
several	O
distinct	O
groups	O
of	O
neurons	O
in	O
the	O
adult	O
rodent	O
brain	O
.	O
Presently	O
,	O
little	O
is	O
known	O
of	O
the	O
factors	O
responsible	O
for	O
the	O
high	O
CKB	B-GENE
expression	O
in	O
glia	O
and	O
possible	O
repression	O
in	O
neurons	O
.	O
In	O
this	O
report	O
,	O
we	O
investigated	O
if	O
low	O
CKB	B-GENE
mRNA	O
was	O
characteristic	O
of	O
some	O
established	O
neuronal	O
cell	O
lines	O
.	O
CKB	B-GENE
mRNA	O
was	O
found	O
to	O
be	O
extremely	O
low	O
in	O
mouse	O
C1300	O
neuroblastomas	O
NS20Y	O
and	O
N1E-115	O
but	O
10	O
-	O
fold	O
higher	O
in	O
NG108-15	O
,	O
a	O
hybrid	O
cell	O
composed	O
of	O
a	O
C1300	O
neuroblastoma	O
and	O
a	O
rat	O
C6	O
glioma	O
.	O
Since	O
we	O
showed	O
NG108-15	O
contained	O
only	O
rat	O
CKB	B-GENE
mRNA	O
transcribed	O
from	O
the	O
C6	O
glioma	O
CKB	B-GENE
gene	O
,	O
expression	O
of	O
CKB	B-GENE
mRNA	O
may	O
be	O
a	O
manifestation	O
of	O
a	O
glial	O
property	O
in	O
NG108-15	O
cells	O
.	O
However	O
,	O
CKB	B-GENE
mRNA	O
expression	O
in	O
NG108-15	O
appeared	O
not	O
to	O
be	O
fully	O
activated	O
since	O
it	O
was	O
still	O
5	O
-	O
fold	O
lower	O
than	O
in	O
(	O
parental	O
)	O
C6	O
glioma	O
and	O
10	O
-	O
fold	O
lower	O
than	O
in	O
cellular	O
RNA	O
from	O
either	O
total	O
rat	O
brain	O
or	O
cultured	O
primary	O
astrocytes	O
.	O
When	O
neuronal	O
differentiation	O
was	O
increased	O
in	O
NS20Y	O
and	O
N1E-115	O
by	O
treating	O
cells	O
with	O
prostaglandin	O
E1	O
and	O
theophylline	O
,	O
the	O
extremely	O
low	O
CKB	B-GENE
mRNA	O
level	O
was	O
not	O
significantly	O
changed	O
.	O
In	O
a	O
comparative	O
study	O
,	O
the	O
CKB	B-GENE
mRNA	O
levels	O
in	O
NS20Y	O
,	O
N1E-115	O
and	O
neuronal	O
RT4-B8	O
and	O
RT4-E5	O
cells	O
(	O
from	O
the	O
rat	O
RT4	O
peripheral	O
neurotumor	O
)	O
were	O
at	O
least	O
50	O
-	O
fold	O
lower	O
than	O
that	O
in	O
C6	O
glioma	O
and	O
100	O
-	O
fold	O
lower	O
than	O
in	O
cultured	O
primary	O
astrocytes	O
.	O
These	O
cell	O
lines	O
may	O
provide	O
a	O
system	O
for	O
the	O
identification	O
of	O
factors	O
involved	O
in	O
the	O
possible	O
repression	O
of	O
CKB	B-GENE
in	O
many	O
neuronal	O
cells	O
.	O
PMID	O
:	O
9323458	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
.	O
1993	O
Dec	O
1;72	O
(	O
11	O
)	O
:	O
3331	O
-	O
9.	O
Growth	O
patterns	O
of	O
human	O
neuroblastoma	O
xenografts	O
and	O
their	O
relationship	O
to	O
treatment	O
outcome	O
.	O
George	O
BA	O
,	O
Yanik	O
G	O
,	O
Wells	O
RJ	O
,	O
Martin	O
LW	O
,	O
Soukup	O
S	O
,	O
Ballard	O
ET	O
,	O
Gartside	O
PS	O
,	O
Lampkin	O
BC	O
.	O
Division	O
of	O
Hematology	O
/Oncology	O
,	O
Children	O
's	O
Hospital	O
Medical	O
Center	O
,	O
Cincinnati	O
,	O
OH	O
45229	O
-	O
2899	O
.	O
BACKGROUND.	O
Several	O
investigators	O
have	O
reported	O
the	O
ability	O
to	O
establish	O
xenografts	O
in	O
nude	O
mice	O
from	O
children	O
with	O
neuroblastomas	O
,	O
but	O
a	O
correlation	O
of	O
prognosis	O
with	O
this	O
establishment	O
and	O
the	O
growth	O
patterns	O
of	O
the	O
neuroblastomas	O
has	O
not	O
been	O
reported	O
.	O
METHODS	O
.	O
Tumor	O
specimens	O
from	O
58	O
children	O
with	O
neuroblastomas	O
were	O
heterotransplanted	O
into	O
BALB/	O
c	O
nude	O
mice	O
.	O
In	O
34	O
patients	O
,	O
heterotransplantation	O
was	O
done	O
before	O
therapy	O
;	O
in	O
24	O
patients	O
,	O
tumors	O
were	O
obtained	O
after	O
at	O
least	O
one	O
course	O
of	O
chemotherapy	O
or	O
radiation	O
therapy	O
.	O
The	O
histology	O
,	O
cytogenetics	O
,	O
and	O
growth	O
characteristics	O
of	O
serial	O
passages	O
of	O
the	O
xenografts	O
were	O
studied	O
.	O
RESULTS	O
.	O
The	O
engraftment	O
rate	O
was	O
34	O
%	O
.	O
Neuroblastomas	O
with	O
diploid	O
chromosome	O
numbers	O
did	O
not	O
engraft	O
.	O
Chromosomal	O
abnormalities	O
involving	O
1p	O
were	O
seen	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
xenografts	O
.	O
Cytogenetic	O
features	O
were	O
retained	O
between	O
original	O
tumors	O
and	O
resultant	O
xenografts	O
.	O
Xenografts	O
could	O
be	O
established	O
only	O
from	O
tumors	O
with	O
unfavorable	O
histology	O
,	O
as	O
defined	O
by	O
Shimada	O
classification	O
criteria	O
.	O
The	O
histology	O
of	O
each	O
xenograft	O
line	O
was	O
strikingly	O
similar	O
,	O
and	O
each	O
was	O
highly	O
undifferentiated	O
.	O
Engraftment	O
rates	O
,	O
doubling	O
times	O
,	O
and	O
lag	O
times	O
did	O
not	O
vary	O
appreciably	O
between	O
xenografts	O
established	O
from	O
treated	O
tumors	O
compared	O
with	O
xenografts	O
established	O
from	O
untreated	O
tumors	O
.	O
There	O
was	O
no	O
correlation	O
between	O
doubling	O
or	O
lag	O
times	O
and	O
prognosis	O
.	O
Patients	O
whose	O
tumors	O
engrafted	O
had	O
only	O
a	O
5	O
%	O
3-year	O
survival	O
rate	O
.	O
CONCLUSIONS	O
.	O
From	O
these	O
results	O
,	O
it	O
appears	O
that	O
successful	O
engraftment	O
is	O
the	O
most	O
important	O
prognostic	O
indicator	O
for	O
patients	O
with	O
neuroblastomas	O
.	O
Because	O
of	O
the	O
commonality	O
of	O
the	O
histologic	O
features	O
and	O
the	O
stability	O
of	O
the	O
tumor	O
clones	O
from	O
patients	O
before	O
and	O
after	O
heterotransplantation	O
,	O
these	O
xenografts	O
may	O
be	O
useful	O
as	O
an	O
in	O
vivo	O
model	O
for	O
studying	O
drug	O
resistance	O
and	O
for	O
designing	O
treatment	O
regimens	O
.	O
PMID	O
:	O
8242560	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Exp	O
Metastasis	O
.	O
1995	O
Mar;13(	O
2	O
)	O
:	O
123-33	O
.	O
Inverse	O
expressions	O
of	O
the	O
N-myc	B-GENE
oncogene	O
and	O
beta	B-GENE
1	I-GENE
integrin	I-GENE
in	O
human	O
neuroblastoma	O
:	O
relationships	O
to	O
disease	O
progression	O
in	O
a	O
nude	O
mouse	O
model	O
system	O
.	O
Judware	O
R	O
,	O
Lechner	O
R	O
,	O
Culp	O
LA.	O
Department	O
of	O
Molecular	O
Biology	O
and	O
Microbiology	O
,	O
Case	O
Western	O
Reserve	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Cleveland	O
,	O
OH	O
44106	O
.	O
A	O
nude	O
mouse	O
model	O
for	O
human	O
neuroblastoma	O
has	O
been	O
developed	O
to	O
examine	O
possible	O
relationships	O
between	O
amplification	O
/	O
over	O
-	O
expression	O
of	O
the	O
N-myc	B-GENE
oncogene	O
and	O
altered	O
regulation	O
of	O
expression	O
of	O
specific	O
integrin	B-GENE
subunits	O
during	O
tumor	O
progression	O
.	O
Subcutaneous	O
(	O
ectopic	O
)	O
or	O
intra-adrenal	O
(	O
orthotopic	O
)	O
injection	O
of	O
the	O
neuroblastoma	O
cell	O
lines	O
SK-N-SH	O
or	O
IMR-32	O
has	O
generated	O
a	O
number	O
of	O
derivative	O
tumor	O
cell	O
lines	O
.	O
Tumor	O
cell	O
lines	O
derived	O
from	O
SK-N-SH	O
cells	O
(	O
which	O
do	O
not	O
express	O
N-myc	B-GENE
)	O
or	O
IMR-32	O
cells	O
(	O
which	O
over	O
-	O
express	O
N-myc	B-GENE
)	O
produce	O
tumors	O
at	O
higher	O
rates	O
when	O
re	O
-	O
injected	O
into	O
the	O
subcutaneous	O
space	O
of	O
nude	O
mice	O
.	O
Moreover	O
,	O
cell	O
lines	O
derived	O
from	O
tumors	O
initiated	O
by	O
IMR-32	O
cells	O
exhibit	O
shorter	O
latent	O
periods	O
than	O
do	O
IMR-32	O
cells	O
direct	O
from	O
tissue	O
culture	O
.	O
With	O
regard	O
to	O
integrin	B-GENE
subunit	O
expression	O
,	O
SK-N-SH	O
and	O
related	O
cell	O
lines	O
express	O
high	O
levels	O
of	O
beta	B-GENE
1	I-GENE
integrin	I-GENE
,	O
which	O
is	O
associated	O
with	O
the	O
alpha	B-GENE
2	I-GENE
and	O
alpha	B-GENE
3	I-GENE
integrin	I-GENE
subunits	O
(	O
predominantly	O
alpha	B-GENE
3	I-GENE
)	O
.	O
IMR-32	O
cells	O
display	O
reduced	O
beta	B-GENE
1	I-GENE
expression	O
,	O
and	O
that	O
which	O
is	O
produced	O
is	O
not	O
associated	O
with	O
common	O
alpha	B-GENE
subunits	O
.	O
LaN1	O
cells	O
,	O
which	O
express	O
N-myc	B-GENE
at	O
even	O
higher	O
levels	O
than	O
do	O
IMR-32	O
cells	O
,	O
express	O
even	O
less	O
beta	B-GENE
1	I-GENE
.	O
Interestingly	O
,	O
the	O
tumor	O
-	O
derived	O
cell	O
lines	O
(	O
especially	O
those	O
from	O
tumors	O
initiated	O
in	O
adrenal	O
glands	O
)	O
also	O
exhibit	O
reduced	O
integrin	B-GENE
expression	O
compared	O
with	O
the	O
parental	O
cell	O
lines	O
;	O
this	O
reduction	O
is	O
associated	O
with	O
the	O
enhanced	O
tumor	O
take	O
rate	O
observed	O
when	O
the	O
cells	O
are	O
re	O
-	O
injected	O
into	O
nude	O
mice	O
.	O
Our	O
results	O
raise	O
the	O
possibility	O
of	O
a	O
relationship	O
between	O
over	O
-	O
expression	O
of	O
N-myc	B-GENE
and	O
down	O
-	O
regulation	O
of	O
beta	B-GENE
1	I-GENE
integrin	I-GENE
expression	O
(	O
possibly	O
some	O
alpha	B-GENE
subunits	O
also	O
)	O
.	O
In	O
addition	O
,	O
the	O
data	O
suggest	O
that	O
human	O
neuroblastoma	O
-	O
derived	O
cell	O
lines	O
which	O
exhibit	O
reduced	O
integrin	B-GENE
expression	O
display	O
more	O
aggressive	O
tumor	O
growth	O
in	O
nude	O
mice	O
.	O
PMID	O
:	O
7533687	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
1984	O
Apr	O
10	O
;259	O
(	O
7	O
)	O
:	O
4096-104	O
.	O
Down	O
-	O
regulation	O
of	O
opiate	B-GENE
receptor	I-GENE
in	O
neuroblastoma	O
x	O
glioma	O
NG108-15	O
hybrid	O
cells	O
.	O
Chloroquine	O
promotes	O
accumulation	O
of	O
tritiated	O
enkephalin	B-GENE
in	O
the	O
lysosomes	O
.	O
Law	O
PY	O
,	O
Hom	O
DS	O
,	O
Loh	O
HH.	O
Opiate	B-GENE
receptor	I-GENE
down	O
-	O
regulation	O
in	O
neuroblastoma	O
X	O
glioma	O
NG108-15	O
hybrid	O
cells	O
possibly	O
involved	O
the	O
internalization	O
of	O
ligand	O
-	O
receptor	O
complexes	O
during	O
chronic	O
treatment	O
.	O
However	O
,	O
receptor	O
internalization	O
was	O
not	O
supported	O
by	O
the	O
observed	O
decrease	O
in	O
[3H]	B-GENE
enkephalin(	I-GENE
D-	I-GENE
Ala2	I-GENE
,D-	I-GENE
Leu5	I-GENE
)	I-GENE
(	O
[3H]DADLE	B-GENE
)	O
associated	O
with	O
the	O
hybrid	O
cells	O
during	O
prolonged	O
incubation	O
with	O
10	O
nM	O
[3H]DADLE	B-GENE
at	O
37	O
degrees	O
C.	O
This	O
decrease	O
in	O
[3H]DADLE	B-GENE
bound	O
was	O
determined	O
to	O
be	O
due	O
to	O
degradation	O
of	O
the	O
ligand	O
-	O
receptor	O
complexes	O
,	O
for	O
a	O
time	O
-	O
dependent	O
increase	O
in	O
[3H]DADLE	B-GENE
bound	O
was	O
observed	O
when	O
the	O
incubations	O
were	O
carried	O
out	O
in	O
the	O
presence	O
of	O
0.1	O
mM	O
chloroquine	O
.	O
The	O
increase	O
did	O
not	O
exceed	O
the	O
amount	O
of	O
down	O
-	O
regulated	O
receptor	O
,	O
could	O
be	O
blocked	O
by	O
naloxone	O
,	O
and	O
was	O
not	O
observed	O
at	O
24	O
degrees	O
C.	O
The	O
[3H]DADLE	B-GENE
bound	O
in	O
the	O
presence	O
of	O
chloroquine	O
was	O
not	O
sensitive	O
to	O
trypsin	B-GENE
or	O
to	O
20	O
microM	O
diprenorphine	O
.	O
The	O
accumulated	O
[3H]DADLE	B-GENE
was	O
demonstrated	O
to	O
be	O
intracellularly	O
located	O
by	O
the	O
fractionation	O
of	O
the	O
homogenates	O
in	O
self-generating	O
Percoll	O
gradients	O
.	O
In	O
the	O
presence	O
of	O
chloroquine	O
,	O
a	O
time	O
-	O
dependent	O
translocation	O
of	O
[3H]DADLE	B-GENE
from	O
the	O
plasma	O
membrane	O
-	O
enriched	O
fractions	O
to	O
the	O
lysosome	O
-	O
enriched	O
fractions	O
was	O
observed	O
.	O
The	O
translocation	O
was	O
not	O
observed	O
at	O
24	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
chloroquine	O
or	O
at	O
37	O
degrees	O
C	O
in	O
the	O
absence	O
of	O
chloroquine	O
.	O
The	O
[3H]DADLE	B-GENE
in	O
the	O
lysosome	O
-	O
enriched	O
fractions	O
was	O
not	O
sensitive	O
to	O
trypsin	B-GENE
and	O
remained	O
bound	O
in	O
the	O
presence	O
of	O
chloroquine	O
.	O
With	O
the	O
removal	O
of	O
chloroquine	O
,	O
an	O
increase	O
in	O
the	O
release	O
of	O
[3H]DADLE	B-GENE
into	O
the	O
medium	O
was	O
observed	O
.	O
Sephadex	O
G-50	O
column	O
chromatography	O
of	O
the	O
sodium	O
deoxycholate	O
extracts	O
of	O
the	O
lysosome	O
-	O
enriched	O
fractions	O
suggested	O
that	O
the	O
[3H]DADLE	B-GENE
was	O
bound	O
to	O
macromolecules	O
intracellularly	O
.	O
Thus	O
,	O
chronic	O
[3H]DADLE	B-GENE
treatment	O
of	O
the	O
hybrid	O
cells	O
resulted	O
in	O
an	O
internalization	O
of	O
ligand	O
-	O
receptor	O
complexes	O
which	O
were	O
degraded	O
in	O
the	O
lysosomes	O
.	O
Subsequently	O
,	O
the	O
[3H]DADLE	B-GENE
was	O
regurgitated	O
by	O
the	O
hybrid	O
cells	O
.	O
PMID	O
:	O
6323457	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pediatr	O
Neurosurg	O
.	O
2003	O
Dec;39	O
(	O
6	O
)	O
:	O
291-	O
8.	O
Treatment	O
of	O
spinal	O
involvement	O
in	O
neuroblastoma	O
patients	O
.	O
Sandberg	O
DI	O
,	O
Bilsky	O
MH	O
,	O
Kushner	O
BH	O
,	O
Souweidane	O
MM	O
,	O
Kramer	O
K,	O
Laquaglia	O
MP	O
,	O
Panageas	O
KS	O
,	O
Cheung	O
NK.	O
Department	O
of	O
Surgery	O
,	O
Division	O
of	O
Neurosurgery	O
,	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
1275	O
York	O
Avenue	O
,	O
New	O
York	O
,	O
N.Y.	O
10021	O
,	O
USA	O
.	O
INTRODUCTION	O
:	O
Considerable	O
controversy	O
exists	O
regarding	O
the	O
appropriate	O
management	O
of	O
spinal	O
involvement	O
in	O
neuroblastoma	O
(	O
NB	O
)	O
patients	O
.	O
We	O
review	O
a	O
large	O
group	O
of	O
such	O
patients	O
and	O
offer	O
treatment	O
recommendations	O
.	O
METHODS	O
:	O
Forty	O
-six	O
patients	O
with	O
epidural	O
and/or	O
neural	O
foraminal	O
involvement	O
treated	O
between	O
1987	O
and	O
1998	O
were	O
staged	O
according	O
to	O
the	O
International	O
NB	O
Staging	O
System	O
(	O
INSS	O
)	O
and	O
classified	O
as	O
high	O
-risk	O
(	O
INSS	O
stage	O
4	O
;	O
n	O
=	O
31	O
)	O
or	O
low-risk	O
(	O
INSS	O
stage	O
<4	O
;	O
n	O
=	O
15	O
)	O
.	O
Of	O
13	O
high	O
-	O
risk	O
patients	O
with	O
normal	O
neurologic	O
examinations	O
and	O
no	O
radiographic	O
high-grade	O
spinal	O
cord	O
compression	O
(	O
HGSCC	O
)	O
,	O
12	O
were	O
treated	O
initially	O
with	O
chemotherapy	O
,	O
and	O
only	O
1	O
demonstrated	O
neurologic	O
deterioration	O
.	O
HGSCC	O
was	O
present	O
in	O
18	O
patients	O
with	O
high	O
-risk	O
NB	O
;	O
7	O
of	O
10	O
(	O
70	O
%	O
)	O
treated	O
initially	O
with	O
chemotherapy	O
and	O
6	O
of	O
6	O
(	O
100	O
%	O
)	O
managed	O
initially	O
with	O
operation	O
improved	O
or	O
remained	O
stable	O
.	O
All	O
9	O
low-risk	O
patients	O
with	O
normal	O
neurologic	O
examinations	O
and	O
no	O
HGSCC	O
remained	O
neurologically	O
intact	O
following	O
operations	O
(	O
n	O
=	O
7	O
)	O
or	O
chemotherapy	O
(	O
n	O
=	O
2	O
)	O
.	O
All	O
4	O
low-risk	O
patients	O
with	O
HGSCC	O
treated	O
with	O
operations	O
improved	O
or	O
remained	O
stable	O
,	O
and	O
0	O
of	O
2	O
(	O
0	O
%	O
)	O
low-risk	O
patients	O
treated	O
initially	O
with	O
chemotherapy	O
remained	O
stable	O
.	O
Spinal	O
deformities	O
occurred	O
in	O
2	O
of	O
16	O
patients	O
(	O
12.5	O
%	O
)	O
treated	O
nonoperatively	O
and	O
in	O
9	O
of	O
30	O
(	O
30.0	O
%	O
)	O
who	O
underwent	O
operations	O
.	O
CONCLUSIONS	O
:	O
High	O
-risk	O
NB	O
patients	O
with	O
spinal	O
involvement	O
but	O
normal	O
neurologic	O
examinations	O
should	O
be	O
offered	O
chemotherapy	O
.	O
High	O
-risk	O
patients	O
with	O
HGSCC	O
may	O
respond	O
to	O
chemotherapy	O
,	O
but	O
a	O
small	O
percentage	O
will	O
require	O
operations	O
for	O
progressive	O
neurologic	O
deficits	O
.	O
Chemotherapy	O
may	O
be	O
avoided	O
in	O
low-risk	O
patients	O
who	O
are	O
offered	O
potentially	O
curative	O
operations	O
.	O
Patients	O
treated	O
with	O
operations	O
for	O
epidural	O
disease	O
are	O
at	O
high	O
risk	O
of	O
subsequently	O
developing	O
spinal	O
deformity	O
.	O
Copyright	O
2003	O
S.	O
Karger	O
AG	O
,	O
Basel	O
PMID	O
:	O
14734862	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
.	O
2000	O
Nov	O
10	O
;160	O
(	O
1	O
)	O
:	O
59	O
-	O
66	O
.	O
Aminohexanoic	O
hydroxamate	O
is	O
a	O
potent	O
inducer	O
of	O
the	O
differentiation	O
of	O
mouse	O
neuroblastoma	O
cells	O
.	O
Lu	O
J,	O
Chen	O
ZP	O
,	O
Yan	O
YP	O
,	O
Knapp	O
S	O
,	O
Schugar	O
H,	O
Chen	O
KY.	O
Department	O
of	O
Chemistry	O
,	O
Rutgers	O
University	O
,	O
The	O
State	O
University	O
of	O
New	O
Jersey	O
,Piscataway	O
,	O
NJ	O
08854	O
-8087	O
,	O
USA	O
.	O
Deoxyhypusine	B-GENE
synthase	I-GENE
is	O
the	O
key	O
enzyme	O
for	O
modifying	O
a	O
lysine	O
residue	O
to	O
hypusine	O
in	O
the	O
cellular	O
protein	O
eukaryotic	B-GENE
initiation	I-GENE
factor	I-GENE
5A	I-GENE
(	O
eIF-5A	B-GENE
)	O
.	O
Deletion	O
of	O
the	O
deoxyhypusine	B-GENE
synthase	I-GENE
or	O
the	O
eIF-5A	B-GENE
gene	O
in	O
yeast	O
produces	O
lethal	O
phenotype	O
.	O
Inhibition	O
of	O
deoxyhypusine	B-GENE
synthase	I-GENE
by	O
1-guanidino-	O
7-aminoheptane	O
(	O
GC7	O
)	O
suppresses	O
tumor	O
cell	O
growth	O
.	O
Hypusine	O
formation	O
represents	O
one	O
of	O
the	O
most	O
specific	O
polyamine	O
-	O
dependent	O
biochemical	O
reactions	O
.	O
In	O
view	O
of	O
the	O
importance	O
of	O
polyamines	O
in	O
growth	O
regulation	O
and	O
cancer	O
biology	O
,	O
deoxyhypusine	B-GENE
synthase	I-GENE
has	O
been	O
considered	O
to	O
be	O
a	O
good	O
target	O
for	O
chemotherapeutic	O
drug	O
design	O
.	O
Using	O
GC7	O
as	O
a	O
prototype	O
we	O
have	O
synthesized	O
and	O
tested	O
three	O
classes	O
of	O
diamine	O
analogs	O
,	O
namely	O
,	O
guanidino	O
-	O
,	O
pyrimidino	O
-	O
,	O
and	O
hydroxamate	O
derivatives	O
,	O
as	O
potential	O
inhibitors	O
for	O
deoxyhypusine	B-GENE
synthase	I-GENE
.	O
Our	O
study	O
shows	O
that	O
(	O
i)	O
among	O
all	O
the	O
compounds	O
tested	O
,	O
GC7	O
remained	O
to	O
be	O
the	O
most	O
potent	O
inhibitor	O
for	O
deoxyhypusine	B-GENE
synthase	I-GENE
;	O
(ii)	O
N,N'-bispyrimidino-1	O
,	O
9-diaminononane	O
,	O
although	O
a	O
poor	O
inhibitor	O
of	O
deoxyhypusine	B-GENE
synthase	I-GENE
,	O
was	O
a	O
potent	O
growth	O
inhibitor	O
;	O
and	O
(iii)	O
one	O
of	O
the	O
hydroxamate	O
derivatives	O
,	O
6-aminohexanoic	O
hydroxamate	O
(	O
HC6	O
)	O
,	O
prominently	O
induced	O
the	O
differentiation	O
of	O
mouse	O
neuroblastoma	O
cells	O
at	O
sub-millimolar	O
concentrations	O
.	O
Interestingly	O
,	O
other	O
hydroxamates	O
with	O
different	O
chain	O
length	O
were	O
not	O
nearly	O
as	O
effective	O
as	O
HC6	O
in	O
inducing	O
neuroblastoma	O
cell	O
differentiation	O
.	O
The	O
effect	O
of	O
HC6	O
was	O
also	O
unique	O
in	O
that	O
it	O
could	O
induce	O
neurite	O
outgrowth	O
and	O
the	O
expression	O
of	O
neuron	O
-	O
specific	O
genes	O
such	O
as	O
synapsin	B-GENE
I	I-GENE
and	O
MAP-2	B-GENE
in	O
neuroblastoma	O
cells	O
in	O
the	O
absence	O
of	O
other	O
promoting	O
agents	O
such	O
as	O
cAMP	O
.	O
The	O
effect	O
of	O
HC6	O
on	O
neuroblastoma	O
cell	O
differentiation	O
was	O
comparable	O
with	O
,	O
or	O
better	O
than	O
that	O
of	O
N(	O
6)	O
,O(2)	O
'-dibutyryl	O
cAMP	O
(	O
Bt(2)cAMP	O
)	O
,	O
a	O
standard	O
reagent	O
commonly	O
used	O
for	O
inducing	O
the	O
differentiation	O
of	O
mouse	O
and	O
human	O
neuroblastoma	O
cells	O
in	O
culture	O
.	O
PMID	O
:	O
11098085	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
1999	O
Jun	O
8;69	O
(	O
2	O
)	O
:249-	O
62	O
.	O
Neurotensin	B-GENE
-	O
SPDP	O
-	O
poly-L-lysine	B-GENE
conjugate	O
:	O
a	O
nonviral	O
vector	O
for	O
targeted	O
gene	O
delivery	O
to	O
neural	O
cells	O
.	O
Martinez-Fong	O
D	O
,	O
Navarro-Quiroga	O
I	O
,	O
Ochoa	O
I	O
,	O
Alvarez-Maya	O
I	O
,	O
Meraz	O
MA	O
,	O
Luna	O
J,	O
Arias-Montano	O
JA	O
.	O
Departamento	O
de	O
Fisiologia	O
,	O
Biofisica	O
y	O
Neurociencias	O
,	O
Centro	O
de	O
Investigacion	O
y	O
de	O
Estudios	O
Avanzados	O
del	O
Instituto	O
Politecnico	O
Nacional	O
de	O
Mexico	O
,	O
Apartado	O
postal	O
14	O
-740	O
,	O
07000	O
,	O
Mexico	O
D.F.	O
,	O
Mexico	O
.	O
dmartine@fisio.cinvestav.mx	O
We	O
report	O
herein	O
the	O
synthesis	O
of	O
a	O
novel	O
DNA	O
delivery	O
system	O
and	O
in	O
vitro	O
evidence	O
of	O
its	O
ability	O
to	O
transfect	O
cell	O
lines	O
by	O
binding	O
to	O
the	O
high	O
-	O
affinity	O
neurotensin	B-GENE
receptor	I-GENE
and	O
subsequent	O
internalization	O
of	O
ligand	O
-	O
receptor	O
complexes	O
.	O
The	O
targeting	O
vehicle	O
consisted	O
of	O
neurotensin	B-GENE
crosslinked	O
with	O
poly-L-lysine	O
via	O
N-	O
succinimidyl-3-(2-pyridyldithio	O
)	O
propionate	O
(	O
SPDP	O
)	O
.	O
The	O
SPDP-derivatives	O
with	O
either	O
neurotensin	B-GENE
or	O
poly-L-lysine	B-GENE
were	O
purified	O
by	O
gel	O
filtration	O
.	O
The	O
conjugate	O
resulting	O
of	O
the	O
reaction	O
of	O
neurotensin	B-GENE
-	O
SPDP	O
with	O
HS-SPDP-	O
poly-L-lysine	B-GENE
was	O
purified	O
through	O
Biogel	O
A	O
1.5	O
.	O
The	O
neurotensin	B-GENE
-	O
SPDP	O
-	O
poly-L-lysine	B-GENE
conjugate	O
was	O
able	O
to	O
bind	O
plasmidic	O
DNAs	O
(	O
pSV2cat	O
and	O
pGreen	O
Lantern	O
-1	O
)	O
at	O
optimal	O
molar	O
ratios	O
of	O
1	O
:	O
5	O
and	O
1	O
:	O
6	O
(	O
DNA	O
:	O
conjugate	O
)	O
,	O
respectively	O
.	O
The	O
conjugate	O
internalized	O
those	O
plasmids	O
in	O
the	O
cell	O
lines	O
(	O
N1E-115	O
and	O
HT-29	O
)	O
bearing	O
the	O
high	O
-	O
affinity	O
neurotensin	B-GENE
receptor	I-GENE
.	O
Expression	O
of	O
the	O
plasmid	O
products	O
,	O
chloramphenicol	O
acetyltransferase	B-GENE
and	O
green	B-GENE
fluorescent	I-GENE
protein	I-GENE
,	O
was	O
observed	O
in	O
such	O
cell	O
lines	O
.	O
Both	O
internalization	O
and	O
expression	O
of	O
the	O
plasmids	O
transferred	O
by	O
the	O
neurotensin	B-GENE
-	O
SPDP	O
-	O
poly-L-lysine	B-GENE
conjugate	O
were	O
prevented	O
by	O
neurotensin	B-GENE
(	O
1	O
microM	O
)	O
and	O
SR-48692	O
(	O
100	O
nM	O
)	O
,	O
a	O
specific	O
antagonist	O
of	O
the	O
high	O
-	O
affinity	O
neurotensin	B-GENE
receptor	I-GENE
.	O
The	O
neurotensin	O
-	O
SPDP	O
-	O
poly-L-lysine	B-GENE
conjugate	O
was	O
unable	O
to	O
transfect	O
cell	O
lines	O
lacking	O
the	O
neurotensin	B-GENE
receptor	I-GENE
(	O
COS-7	O
and	O
L-929	O
)	O
.	O
In	O
rat	O
brain	O
,	O
the	O
high	O
-	O
affinity	O
neurotensin	B-GENE
receptor	I-GENE
is	O
expressed	O
by	O
specific	O
neurons	O
such	O
as	O
those	O
of	O
the	O
nigrostriatal	O
and	O
mesolimbic	O
dopaminergic	O
systems	O
.	O
Therefore	O
,	O
the	O
neurotensin	B-GENE
-	O
SPDP	O
-	O
poly-L-lysine	B-GENE
conjugate	O
could	O
be	O
a	O
useful	O
tool	O
for	O
gene	O
delivery	O
to	O
those	O
neuronal	O
systems	O
.	O
Copyright	O
1999	O
Elsevier	O
Science	O
B.V	O
.	O
PMID	O
:	O
10366746	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Pharmacol	O
.	O
1995	O
Sep;48	O
(	O
3	O
)	O
:	O
407	O
-16	O
.	O
Molecular	O
cloning	O
of	O
human	O
5-hydroxytryptamine3	B-GENE
receptor	I-GENE
:	O
heterogeneity	O
in	O
distribution	O
and	O
function	O
among	O
species	O
.	O
Miyake	O
A	O
,	O
Mochizuki	O
S	O
,	O
Takemoto	O
Y	O
,	O
Akuzawa	O
S.	O
Molecular	O
Medicine	O
Research	O
Laboratory	O
,	O
Yamanouchi	O
Pharmaceutical	O
Co.	O
,	O
Ltd.	O
,	O
Ibaraki	O
,	O
Japan	O
.	O
The	O
5-hydroxytryptamine3	B-GENE
receptor	I-GENE
5-HT3R	I-GENE
has	O
been	O
implicated	O
in	O
gut	O
and	O
cardiac	O
motility	O
and	O
in	O
behavioral	O
disorders	O
.	O
Characteristics	O
of	O
5-HT3Rs	B-GENE
appear	O
to	O
be	O
heterogeneous	O
among	O
species	O
,	O
but	O
human	O
5-HT3R	B-GENE
cDNA	O
has	O
not	O
been	O
identified	O
.	O
We	O
isolated	O
a	O
cDNA	O
encoding	O
5-HT3R	B-GENE
from	O
human	O
hippocampus	O
.	O
The	O
mouse	O
5-HT3R	B-GENE
gene	O
has	O
been	O
reported	O
to	O
generate	O
two	O
alternative	O
splicing	O
isoforms	O
that	O
differ	O
by	O
six	O
amino	O
acids	O
.	O
All	O
of	O
our	O
isolated	O
human	O
clones	O
corresponded	O
to	O
the	O
shorter	O
isoform	O
.	O
Amino	O
acid	O
identities	O
with	O
mouse	O
neuroblastoma	O
N1E-115	O
and	O
rat	O
brain	O
5-HT3Rs	B-GENE
were	O
84	O
%	O
for	O
each	O
.	O
Southern	O
blot	O
analysis	O
of	O
human	O
genomic	O
DNA	O
suggested	O
that	O
our	O
cloned	O
transcript	O
encoded	O
a	O
human	O
counterpart	O
for	O
the	O
rodent	O
5-HT3Rs	B-GENE
.	O
This	O
gene	O
was	O
assigned	O
to	O
chromosome	O
11	O
using	O
polymerase	B-GENE
chain	O
reaction	O
analysis	O
of	O
a	O
human	O
/	O
rodent	O
somatic	O
cell	O
hybrid	O
panel	O
.	O
With	O
the	O
use	O
of	O
Northern	O
blot	O
analysis	O
,	O
5-HT3R	B-GENE
transcripts	O
were	O
identified	O
in	O
human	O
small	O
intestine	O
,	O
colon	O
,	O
and	O
brain	O
regions	O
including	O
hippocampus	O
,	O
amygdala	O
,	O
and	O
striatum	O
.	O
In	O
human	O
heart	O
,	O
5-HT3R	B-GENE
expression	O
was	O
not	O
detectable	O
even	O
with	O
reverse	B-GENE
transcriptase	I-GENE
-	O
polymerase	B-GENE
chain	O
reaction	O
analysis	O
,	O
although	O
it	O
was	O
detectable	O
in	O
mouse	O
heart	O
.	O
Transfection	O
of	O
COS-1	B-GENE
with	O
human	O
5-HT3R	B-GENE
cDNA	O
induced	O
specific	O
binding	O
of	O
the	O
5-HT3R	B-GENE
-	O
selective	O
radioligand	O
[3H]YM060	O
.	O
Human	O
5-HT3R	B-GENE
showed	O
typical	O
characteristics	O
of	O
the	O
5-HT3R	B-GENE
,	O
but	O
its	O
affinity	O
for	O
the	O
5-HT3R	B-GENE
agonist	O
m-	O
chlorophenylbiguanide	O
was	O
much	O
lower	O
than	O
that	O
of	O
rat	O
5-HT3R	B-GENE
.	O
When	O
injected	O
with	O
human	O
5-HT3R	B-GENE
cRNA	O
,	O
the	O
oocytes	O
responded	O
to	O
5-HT3R	B-GENE
agonists	O
with	O
a	O
rapidly	O
developing	O
inward	O
current	O
.	O
The	O
potency	O
of	O
the	O
agonists	O
to	O
induce	O
inward	O
current	O
paralleled	O
that	O
to	O
compete	O
with	O
the	O
radioligand	O
binding	O
,	O
and	O
2-methyl-	O
5-hydroxytryptamine	O
,	O
a	O
partial	O
agonist	O
for	O
mouse	O
5-HT3R	B-GENE
,	O
was	O
a	O
full	O
agonist	O
for	O
human	O
5-HT3R	B-GENE
.	O
Our	O
data	O
revealed	O
that	O
the	O
5-HT3R	B-GENE
molecule	O
has	O
interspecies	O
differences	O
in	O
both	O
tissue	O
distribution	O
and	O
functional	O
profile	O
.	O
PMID	O
:	O
7565620	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Glia	O
.	O
2003	O
Jun;42(	O
4	O
)	O
:433	O
-46	O
.	O
Oncostatin	B-GENE
M	I-GENE
enhances	O
the	O
expression	O
of	O
prostaglandin	O
E2	O
and	O
cyclooxygenase-2	B-GENE
in	O
astrocytes	O
:	O
synergy	O
with	O
interleukin	B-GENE
-	I-GENE
1beta	I-GENE
,	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
,	O
and	O
bacterial	O
lipopolysaccharide	O
.	O
Repovic	O
P,	O
Mi	O
K,	O
Benveniste	O
EN	O
.	O
Department	O
of	O
Cell	O
Biology	O
,	O
University	O
of	O
Alabama	O
at	O
Birmingham	O
,	O
Birmingham	O
,	O
Alabama	O
35294	O
,	O
USA	O
.	O
Oncostatin	B-GENE
M	I-GENE
(	O
OSM	B-GENE
)	O
,	O
a	O
cytokine	O
of	O
the	O
interleukin	B-GENE
-	I-GENE
6	I-GENE
family	O
,	O
is	O
expressed	O
in	O
rheumatoid	O
arthritis	O
,	O
multiple	O
sclerosis	O
,	O
multiple	O
myeloma	O
,	O
and	O
other	O
inflammatory	O
and	O
neoplastic	O
conditions	O
.	O
Prostaglandin	O
E(2	O
)	O
(	O
PGE(2)	O
)	O
,	O
an	O
eicosanoid	O
also	O
associated	O
with	O
inflammation	O
and	O
cancer	O
,	O
has	O
recently	O
been	O
shown	O
to	O
induce	O
OSM	B-GENE
expression	O
.	O
We	O
report	O
here	O
that	O
OSM	B-GENE
in	O
turn	O
induces	O
PGE(2	O
)	O
production	O
by	O
astrocytes	O
and	O
astroglioma	O
cells	O
.	O
More	O
importantly	O
,	O
in	O
combination	O
with	O
the	O
inflammatory	O
mediators	O
IL-1beta	B-GENE
,	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
,	O
and	O
lipopolysaccharide	O
,	O
OSM	B-GENE
exhibits	O
a	O
striking	O
synergy	O
,	O
resulting	O
in	O
up	O
to	O
50	O
-	O
fold	O
higher	O
PGE(2	O
)	O
production	O
by	O
astrocytes	O
,	O
astroglioma	O
,	O
and	O
neuroblastoma	O
cell	O
lines	O
.	O
Enhanced	O
PGE(2	O
)	O
production	O
by	O
OSM	B-GENE
and	O
IL-1beta	B-GENE
treatment	O
is	O
explained	O
by	O
their	O
effect	O
on	O
cyclooxygenase-2	B-GENE
(	O
COX-2	B-GENE
)	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
committed	O
step	O
in	O
PGE(2	O
)	O
synthesis	O
.	O
Of	O
the	O
enzymes	O
involved	O
in	O
PGE(2	O
)	O
biosynthesis	O
,	O
only	O
COX-2	B-GENE
mRNA	O
and	O
protein	O
levels	O
are	O
synergistically	O
amplified	O
by	O
OSM	B-GENE
and	O
IL-1beta	B-GENE
.	O
Nuclear	O
run	O
-	O
on	O
assays	O
demonstrate	O
that	O
OSM	B-GENE
and	O
IL-1beta	B-GENE
synergistically	O
upregulate	O
transcription	O
of	O
the	O
COX-2	B-GENE
gene	O
,	O
and	O
the	O
mRNA	O
stability	O
assay	O
indicates	O
that	O
COX-2	B-GENE
mRNA	O
is	O
posttranscriptionally	O
stabilized	O
by	O
OSM	B-GENE
and	O
IL-1beta	B-GENE
.	O
To	O
effect	O
synergy	O
on	O
the	O
PGE(2	O
)	O
level	O
,	O
OSM	B-GENE
signals	O
in	O
part	O
through	O
its	O
gp130	B-GENE
/	I-GENE
OSMRbeta	I-GENE
receptor	I-GENE
,	O
since	O
neutralizing	O
antibodies	O
against	O
gp130	B-GENE
and	O
OSMRbeta	B-GENE
,	O
but	O
not	O
LIFRbeta	B-GENE
,	O
decrease	O
PGE(2	O
)	O
production	O
in	O
response	O
to	O
OSM	B-GENE
plus	O
IL-1beta	B-GENE
.	O
SB202190	O
and	O
U0126	O
,	O
inhibitors	O
of	O
p38	B-GENE
MAPK	B-GENE
and	O
ERK	B-GENE
1	I-GENE
/	O
2	B-GENE
activation	O
,	O
respectively	O
,	O
inhibit	O
IL-1beta	B-GENE
and	O
OSM	B-GENE
upregulation	O
of	O
COX-2	B-GENE
and	O
PGE(2	O
)	O
,	O
indicating	O
that	O
these	O
MAPK	B-GENE
cascades	O
are	O
utilized	O
by	O
both	O
stimuli	O
.	O
This	O
mechanism	O
of	O
PGE(2	O
)	O
amplification	O
may	O
be	O
active	O
in	O
brain	O
pathologies	O
where	O
both	O
OSM	B-GENE
and	O
IL-1beta	B-GENE
are	O
present	O
,	O
such	O
as	O
glioblastomas	O
and	O
multiple	O
sclerosis	O
.	O
Copyright	O
2003	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
12730964	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Carcinog	O
.	O
1996	O
Jun;16(	O
2	O
)	O
:	O
101	O
-	O
8.	O
p53	B-GENE
transactivation	O
through	O
various	O
p53	B-GENE
-	O
responsive	O
elements	O
.	O
Park	O
DJ	O
,	O
Chumakov	O
AM	O
,	O
Miller	O
CW	O
,	O
Pham	O
EY	O
,	O
Koeffler	O
HP	O
.	O
Division	O
of	O
Hematology	O
/Oncology	O
,	O
Cedars-Sinai	O
Medical	O
Center	O
,	O
University	O
of	O
California-Los	O
Angeles	O
School	O
of	O
Medicine	O
,	O
90048	O
-0750	O
,	O
USA	O
.	O
p53	B-GENE
is	O
a	O
nuclear	O
phosphoprotein	O
whose	O
function	O
is	O
classified	O
as	O
tumor	O
suppression	O
.	O
Studies	O
have	O
shown	O
that	O
p53	B-GENE
functions	O
by	O
binding	O
to	O
p53	B-GENE
DNA	O
recognition	O
sequences	O
and	O
regulates	O
transcription	O
of	O
growth-	O
regulatory	O
genes	O
.	O
Various	O
p53	B-GENE
recognition	O
sequences	O
have	O
recently	O
been	O
identified	O
.	O
pOST2	B-GENE
contained	O
two	O
copies	O
of	O
a	O
palindromic	O
high	O
-	O
affinity	O
DNA	O
-	O
binding	O
sequence	O
for	O
p53	B-GENE
;	O
the	O
other	O
p53	B-GENE
recognition	O
sequences	O
included	O
p53	B-GENE
-	O
binding	O
fragments	O
found	O
in	O
the	O
human	O
ribosomal	B-GENE
gene	I-GENE
cluster	I-GENE
(	I-GENE
pRGC	I-GENE
)	I-GENE
region	I-GENE
and	O
in	O
the	O
murine	O
muscle	B-GENE
creatine	I-GENE
kinase	I-GENE
promoter	I-GENE
(	O
pMCK	B-GENE
)	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
abilities	O
of	O
various	O
p53	B-GENE
recognition	O
sequences	O
to	O
mediate	O
transcription	O
in	O
the	O
presence	O
of	O
endogenously	O
produced	O
wild-type	O
(	O
wt	O
)	O
or	O
mutant	O
p53	B-GENE
.	O
Three	O
p53	B-GENE
-	O
responsive	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	I-GENE
CAT	I-GENE
)	I-GENE
reporter	I-GENE
constructs	O
(	O
pOST2	B-GENE
,	O
pRGC	B-GENE
,	O
and	O
pMCK	B-GENE
)	O
that	O
contain	O
one	O
or	O
two	O
copies	O
of	O
p53	B-GENE
recognition	O
sequences	O
upstream	O
of	O
a	O
herpes	O
thymidine	B-GENE
kinase	I-GENE
(	I-GENE
TK	I-GENE
)	I-GENE
promoter	I-GENE
and	O
CAT	B-GENE
reporter	I-GENE
cDNA	O
were	O
constructed	O
.	O
Either	O
a	O
p53	B-GENE
-	O
responsive	O
gene	O
or	O
a	O
control	O
reporter	O
gene	O
was	O
transfected	O
into	O
human	O
carcinoma	O
cell	O
lines	O
(	O
having	O
various	O
p53	B-GENE
mutations	O
)	O
either	O
with	O
or	O
without	O
a	O
wt	O
or	O
mutant	O
p53	B-GENE
expression	O
vector	O
.	O
CAT	B-GENE
activity	O
was	O
assayed	O
to	O
measure	O
transactivation	O
through	O
the	O
various	O
p53	B-GENE
-	O
responsive	O
elements	O
.	O
We	O
showed	O
that	O
pOST2	B-GENE
had	O
a	O
greater	O
ability	O
to	O
mediate	O
transactivation	O
by	O
p53	B-GENE
than	O
either	O
pRGC	B-GENE
or	O
pMCK	B-GENE
.	O
p53	B-GENE
with	O
a	O
mutation	O
at	O
either	O
codon	O
175	O
or	O
248	O
was	O
unable	O
to	O
transactivate	O
a	O
reporter	O
gene	O
with	O
pOST2	B-GENE
,	O
pRGC	B-GENE
,	O
or	O
pMCK	B-GENE
.	O
We	O
found	O
it	O
interesting	O
that	O
pOST2	B-GENE
,	O
but	O
not	O
pRGC	B-GENE
or	O
pMCK	B-GENE
,	O
was	O
able	O
to	O
mediate	O
transactivation	O
in	O
cell	O
lines	O
that	O
produce	O
codon	O
273	O
-	O
mutant	O
p53	B-GENE
.	O
These	O
findings	O
suggest	O
that	O
various	O
sensitivities	O
of	O
the	O
different	O
p53	B-GENE
-	O
responsive	O
elements	O
to	O
specific	O
mutant	O
and	O
wt	O
p53s	B-GENE
may	O
be	O
an	O
important	O
factor	O
in	O
the	O
role	O
of	O
p53	B-GENE
as	O
a	O
transcriptional	O
activator	O
both	O
under	O
normal	O
physiological	O
conditions	O
and	O
during	O
carcinogenesis	O
.	O
PMID	O
:	O
8645424	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Chemother	O
Pharmacol	O
.	O
2002	O
Nov;50(	O
5	O
)	O
:	O
39	O
7-404	O
.	O
Epub	O
2002	O
Aug	O
14	O
.	O
Ras	B-GENE
-	O
mediated	O
activation	O
of	O
ERK	B-GENE
by	O
cisplatin	B-GENE
induces	O
cell	O
death	O
independently	O
of	O
p53	B-GENE
in	O
osteosarcoma	O
and	O
neuroblastoma	O
cell	O
lines	O
.	O
Woessmann	O
W	O
,	O
Chen	O
X	O
,	O
Borkhardt	O
A	O
.	O
Department	O
of	O
Pediatric	O
Hematology	O
and	O
Oncology	O
,	O
Justus	O
-	O
Liebig	O
-	O
University	O
,	O
35385	O
Giessen	O
,	O
Germany	O
.	O
wilhelm	O
.woessmann@paediat	O
.med	O
.uni-	O
giessen	O
.de	O
Activation	O
of	O
the	O
mitogen	B-GENE
-	I-GENE
activated	I-GENE
protein	I-GENE
kinases	I-GENE
ERK	B-GENE
1	I-GENE
/	O
2	B-GENE
by	O
the	O
chemotherapeutic	O
agent	O
cisplatin	B-GENE
has	O
been	O
shown	O
to	O
result	O
in	O
either	O
survival	O
or	O
cell	O
death	O
.	O
The	O
downstream	O
mediators	O
of	O
these	O
opposing	O
effects	O
are	O
unknown	O
,	O
as	O
are	O
the	O
upstream	O
signaling	O
molecules	O
.	O
Activation	O
of	O
ERK	B-GENE
is	O
required	O
for	O
accumulation	O
and	O
phosphorylation	O
of	O
p53	B-GENE
following	O
cisplatin	B-GENE
treatment	O
.	O
We	O
studied	O
the	O
role	O
of	O
ERK	B-GENE
activation	O
after	O
cisplatin	B-GENE
treatment	O
under	O
p53	B-GENE
-negative	O
and	O
p53	B-GENE
-	O
positive	O
conditions	O
using	O
a	O
tetracycline	O
-	O
dependent	O
expression	O
vector	O
in	O
Saos-2	O
osteosarcoma	O
cells	O
.	O
Dose	O
-	O
dependent	O
activation	O
of	O
ERK	B-GENE
first	O
occurred	O
3-6	O
h	O
after	O
a	O
2-	O
h	O
cisplatin	B-GENE
incubation	O
and	O
declined	O
after	O
12-24	O
h	O
in	O
several	O
tumor	O
cell	O
lines	O
.	O
Incubation	O
of	O
cell	O
lines	O
with	O
the	O
MEK1	B-GENE
inhibitors	O
PD98059	O
or	O
UO126	O
after	O
,	O
but	O
not	O
during	O
,	O
cisplatin	B-GENE
treatment	O
completely	O
inhibited	O
cisplatin	B-GENE
-	O
induced	O
activation	O
of	O
ERK	B-GENE
.	O
The	O
activation	O
of	O
ERK	B-GENE
by	O
cisplatin	B-GENE
was	O
inhibited	O
by	O
transient	O
transfection	O
with	O
dominant-	O
negative	O
Ras-	B-GENE
N17	I-GENE
in	O
Saos-2	O
cells	O
.	O
Treatment	O
of	O
cells	O
with	O
PD98059	O
or	O
UO126	O
after	O
cisplatin	B-GENE
incubation	O
or	O
inhibition	O
of	O
signaling	O
through	O
ERK	B-GENE
by	O
tetracycline	O
-	O
regulated	O
expression	O
of	O
dominant	O
-	O
inhibitory	O
ERK	B-GENE
enhanced	O
resistance	O
to	O
cisplatin	B-GENE
in	O
p53	B-GENE
-negative	O
osteosarcoma	O
cells	O
and	O
reduced	O
cisplatin	B-GENE
-	O
induced	O
apoptosis	O
.	O
P53	B-GENE
was	O
stabilized	O
and	O
phosphorylated	O
in	O
a	O
MEK1	B-GENE
-	O
dependent	O
manner	O
after	O
cisplatin	B-GENE
incubation	O
in	O
Kelly	O
neuroblastoma	O
cells	O
.	O
Inhibition	O
of	O
signaling	O
through	O
ERK	B-GENE
increased	O
cell	O
survival	O
after	O
cisplatin	B-GENE
treatment	O
in	O
these	O
cells	O
as	O
well	O
.	O
Expression	O
of	O
functional	O
p53	B-GENE
did	O
not	O
change	O
the	O
proapoptotic	O
effects	O
of	O
ERK	B-GENE
activation	O
in	O
response	O
to	O
cisplatin	B-GENE
in	O
Saos-2	O
cells	O
.	O
Our	O
results	O
suggest	O
that	O
cisplatin	B-GENE
-	O
induced	O
activation	O
of	O
ERK	B-GENE
is	O
mediated	O
by	O
Ras	B-GENE
.	O
ERK	B-GENE
activation	O
increased	O
cisplatin	B-GENE
-	O
induced	O
cell	O
death	O
independently	O
of	O
p53	B-GENE
in	O
osteosarcoma	O
and	O
neuroblastoma	O
cell	O
lines	O
.	O
PMID	O
:	O
12439598	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurosci	O
.	O
1998	O
Nov	O
1;18	O
(	O
21	O
)	O
:	O
8692	O
-	O
9.	O
Selective	O
activation	O
of	O
Galphao	O
by	O
D2L	B-GENE
dopamine	I-GENE
receptors	I-GENE
in	O
NS20Y	O
neuroblastoma	O
cells	O
.	O
Watts	O
VJ	O
,	O
Wiens	O
BL	O
,	O
Cumbay	O
MG	O
,	O
Vu	O
MN	O
,	O
Neve	O
RL	O
,	O
Neve	O
KA	O
.	O
Medical	O
Research	O
Service	O
,	O
Veterans	O
Affairs	O
Medical	O
Center	O
,	O
and	O
Department	O
of	O
Behavioral	O
Neuroscience	O
,	O
Oregon	O
Health	O
Sciences	O
University	O
,	O
Portland	O
,	O
Oregon	O
97201	O
,	O
USA	O
.	O
D2L	B-GENE
dopamine	I-GENE
receptor	I-GENE
activation	O
results	O
in	O
rapid	O
inhibition	O
and	O
delayed	O
heterologous	O
sensitization	O
of	O
adenylate	B-GENE
cyclase	I-GENE
in	O
several	O
host	O
cell	O
types	O
.	O
The	O
D2L	B-GENE
dopamine	I-GENE
receptor	I-GENE
was	O
stably	O
transfected	O
into	O
NS20Y	O
neuroblastoma	O
cells	O
to	O
examine	O
inhibition	O
and	O
sensitization	O
in	O
a	O
neuronal	O
cell	O
environment	O
and	O
to	O
identify	O
the	O
particular	O
G-proteins	B-GENE
involved	O
.	O
Acute	O
activation	O
of	O
D2L	B-GENE
receptors	I-GENE
with	O
the	O
selective	O
D2	O
agonist	O
quinpirole	O
inhibited	O
forskolin	O
-	O
stimulated	O
cAMP	O
accumulation	O
,	O
whereas	O
prolonged	O
incubation	O
(	O
2	O
hr	O
)	O
with	O
quinpirole	O
resulted	O
in	O
heterologous	O
sensitization	O
(	O
more	O
than	O
twofold	O
)	O
of	O
forskolin	O
-	O
stimulated	O
cAMP	O
accumulation	O
in	O
NS20Y-D2L	O
cells	O
.	O
To	O
unambiguously	O
identify	O
the	O
pertussis	B-GENE
toxin	I-GENE
(	O
PTX	B-GENE
)	O
-	O
sensitive	O
G-proteins	B-GENE
responsible	O
for	O
inhibition	O
and	O
sensitization	O
,	O
we	O
used	O
viral	O
-	O
mediated	O
gene	O
delivery	O
to	O
assess	O
the	O
ability	O
of	O
genetically	O
engineered	O
PTX	B-GENE
-	O
resistant	O
G-proteins	B-GENE
(	O
Galphai1*	B-GENE
,	O
Galphai2*	B-GENE
,	O
Galphai3*	B-GENE
,	O
and	O
Galphao*	B-GENE
)	O
to	O
rescue	O
both	O
responses	O
after	O
PTX	B-GENE
treatment	O
.	O
The	O
expression	O
and	O
function	O
of	O
individual	O
recombinant	O
G-proteins	B-GENE
was	O
confirmed	O
with	O
Western	O
blotting	O
and	O
inhibition	O
of	O
GTPgammaS	O
-	O
stimulated	O
adenylate	B-GENE
cyclase	I-GENE
,	O
respectively	O
.	O
To	O
assess	O
the	O
specificity	O
of	O
D2L-Galpha	B-GENE
coupling	O
,	O
cells	O
were	O
infected	O
with	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
recombinants	O
expressing	O
individual	O
PTX	B-GENE
-	O
resistant	O
G-protein	B-GENE
alpha	I-GENE
subunits	I-GENE
and	O
treated	O
with	O
PTX	B-GENE
,	O
and	O
quinpirole	O
-	O
induced	O
responses	O
were	O
measured	O
.	O
Infection	O
of	O
NS20Y-D2L	O
cells	O
with	O
HSV-	O
Galphao*	B-GENE
rescued	O
both	O
inhibition	O
and	O
sensitization	O
in	O
PTX	B-GENE
-	O
treated	O
cells	O
,	O
whereas	O
infection	O
with	O
HSV-	O
Galphai1*	B-GENE
,	O
HSV-	O
Galphai2*	B-GENE
,	O
or	O
HSV-	O
Galphai3*	B-GENE
failed	O
to	O
rescue	O
either	O
response	O
.	O
In	O
summary	O
,	O
the	O
current	O
study	O
provides	O
strong	O
evidence	O
that	O
the	O
D2L	B-GENE
dopamine	I-GENE
receptor	I-GENE
couples	O
to	O
Galphao	B-GENE
in	O
neuronal	O
cells	O
,	O
and	O
that	O
this	O
coupling	O
is	O
responsible	O
for	O
both	O
the	O
acute	O
and	O
subacute	O
effects	O
of	O
D2	B-GENE
receptor	I-GENE
activation	O
on	O
adenylate	B-GENE
cyclase	I-GENE
activity	O
.	O
PMID	O
:	O
9786976	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
.	O
2001	O
Feb;158(	O
2	O
)	O
:	O
663	O
-72	O
.	O
Expression	O
of	O
SMARCF1	B-GENE
,	O
a	O
truncated	O
form	O
of	O
SWI1	B-GENE
,	O
in	O
neuroblastoma	O
.	O
Takeuchi	O
T	O
,	O
Nicole	O
S	O
,	O
Misaki	O
A	O
,	O
Furihata	O
M,	O
Iwata	O
J,	O
Sonobe	O
H,	O
Ohtsuki	O
Y	O
.	O
Department	O
of	O
Pathology	O
,	O
Kochi	O
Medical	O
School	O
,	O
Kochi	O
,	O
Japan	O
.	O
takeutit@med	O
.kochi-	O
ms	O
.ac.jp	O
Previously	O
we	O
cloned	O
and	O
mapped	O
a	O
B120	B-GENE
gene	O
to	O
human	O
chromosome	O
1p35-36.1	O
where	O
possible	O
suppressor	O
genes	O
for	O
various	O
neuroendocrine	O
tumors	O
including	O
neuroblastoma	O
have	O
been	O
mapped	O
.	O
Very	O
recently	O
,	O
B120	B-GENE
was	O
identified	O
as	O
a	O
truncated	O
form	O
of	O
p270	B-GENE
,	O
a	O
putative	O
human	O
counterpart	O
of	O
SWI1	B-GENE
.	O
In	O
the	O
present	O
study	O
,	O
expression	O
of	O
the	O
B120	B-GENE
gene	O
product	O
was	O
immunohistochemically	O
investigated	O
in	O
23	O
neuroblastomas	O
.	O
We	O
also	O
examined	O
B120	B-GENE
expression	O
in	O
neural	O
stem	O
cells	O
in	O
developing	O
brain	O
and	O
intact	O
adrenal	O
medulla	O
.	O
Four	O
of	O
23	O
neuroblastomas	O
strongly	O
expressed	O
B120	B-GENE
gene	O
product	O
in	O
both	O
cytoplasm	O
and	O
nucleus	O
.	O
The	O
other	O
neuroblastomas	O
expressed	O
B120	B-GENE
gene	O
product	O
in	O
the	O
nucleus	O
;	O
however	O
,	O
the	O
intensity	O
of	O
staining	O
was	O
much	O
weaker	O
and	O
equivalent	O
to	O
that	O
in	O
developing	O
human	O
brain	O
stem	O
cells	O
in	O
the	O
subventricular	O
region	O
.	O
B120	B-GENE
gene	O
product	O
was	O
less	O
strongly	O
expressed	O
in	O
intact	O
adrenal	O
medulla	O
.	O
Subsequently	O
,	O
we	O
performed	O
loss	O
of	O
heterozygosity	O
studies	O
on	O
19	O
neuroblastomas	O
using	O
the	O
polymorphic	O
markers	O
D1S195	O
and	O
D1S511	O
located	O
near	O
the	O
B120	B-GENE
gene	O
.	O
Loss	O
of	O
heterozygosity	O
was	O
observed	O
in	O
three	O
of	O
19	O
tumors	O
that	O
abundantly	O
expressed	O
B120	B-GENE
protein	O
.	O
Furthermore	O
,	O
neuroblastoma	O
cells	O
were	O
transfected	O
with	O
B120	B-GENE
expression	O
vector	O
.	O
These	O
transfected	O
neuroblastoma	O
cells	O
adhered	O
to	O
each	O
other	O
and	O
aggregated	O
.	O
Differential	O
display	O
experiments	O
followed	O
by	O
reverse	B-GENE
transcriptase	I-GENE
-	O
polymerase	B-GENE
chain	O
reaction	O
and	O
Northern	O
blot	O
analysis	O
were	O
performed	O
and	O
three	O
molecules	O
with	O
altered	O
expression	O
in	O
B120	B-GENE
-	O
transfected	O
neuroblastoma	O
cells	O
were	O
identified	O
.	O
One	O
of	O
three	O
genes	O
seemed	O
to	O
be	O
a	O
proliferation	O
-	O
related	O
and	O
cell	O
cycle	O
-	O
related	O
nucleolar	O
protein	O
,	O
p120	B-GENE
,	O
encoding	O
gene	O
.	O
We	O
further	O
characterized	O
the	O
genomic	O
structure	O
of	O
B120	B-GENE
.	O
B120	B-GENE
appeared	O
to	O
be	O
encoded	O
by	O
17	O
exons	O
in	O
more	O
than	O
20-kbp	O
genomic	O
DNA	O
.	O
The	O
present	O
findings	O
contribute	O
to	O
understanding	O
of	O
the	O
B120	B-GENE
gene	O
,	O
a	O
truncated	O
form	O
of	O
human	O
SWII1	B-GENE
,	O
an	O
approved	O
term	O
for	O
which	O
is	O
SMARCF1	B-GENE
,	O
in	O
normal	O
cells	O
and	O
neuroblastomas	O
.	O
PMID	O
:	O
11159203	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Mol	O
Genet	O
.	O
2003	O
Jun	O
15	O
;12(	O
12	O
)	O
:	O
1427	O
-37	O
.	O
The	O
p38	B-GENE
subunit	O
of	O
the	O
aminoacyl-tRNA	B-GENE
synthetase	I-GENE
complex	O
is	O
a	O
Parkin	O
substrate	O
:	O
linking	O
protein	O
biosynthesis	O
and	O
neurodegeneration	O
.	O
Corti	O
O	O
,	O
Hampe	O
C	O
,	O
Koutnikova	O
H,	O
Darios	O
F	O
,	O
Jacquier	O
S	O
,	O
Prigent	O
A	O
,	O
Robinson	O
JC	O
,	O
Pradier	O
L,	O
Ruberg	O
M,	O
Mirande	O
M,	O
Hirsch	O
E	O
,	O
Rooney	O
T	O
,	O
Fournier	O
A	O
,	O
Brice	O
A	O
.	O
INSERM	O
U289	O
,	O
Hopital	O
de	O
la	O
Salpetriere	O
,	O
Batiment	O
Pharmacie	O
,	O
47	O
boulevard	O
de	O
l'Hopital	O
,	O
75651	O
Paris	O
Cedex	O
13	O
,	O
France	O
.	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
a	O
severe	O
neurological	O
disorder	O
,	O
characterized	O
by	O
the	O
progressive	O
degeneration	O
of	O
the	O
dopaminergic	O
nigrostriatal	O
pathway	O
and	O
the	O
presence	O
of	O
Lewy	O
bodies	O
(	O
LBs	O
)	O
.	O
The	O
discovery	O
of	O
genes	O
responsible	O
for	O
familial	O
forms	O
of	O
the	O
disease	O
has	O
provided	O
insights	O
into	O
its	O
pathogenesis	O
.	O
Mutations	O
in	O
the	O
parkin	B-GENE
gene	O
,	O
which	O
encodes	O
an	O
E3	B-GENE
ubiquitin	I-GENE
-	I-GENE
protein	I-GENE
ligase	I-GENE
involved	O
in	O
the	O
ubiquitylation	O
and	O
proteasomal	O
degradation	O
of	O
specific	O
protein	O
substrates	O
,	O
have	O
been	O
found	O
in	O
nearly	O
50	O
%	O
of	O
patients	O
with	O
autosomal	O
-	O
recessive	O
early-onset	O
parkinsonism	O
.	O
The	O
abnormal	O
accumulation	O
of	O
substrates	O
due	O
to	O
loss	O
of	O
Parkin	O
function	O
may	O
be	O
the	O
cause	O
of	O
neurodegeneration	O
in	O
parkin	O
-	O
related	O
parkinsonism	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
Parkin	O
interacts	O
with	O
,	O
ubiquitylates	O
and	O
promotes	O
the	O
degradation	O
of	O
p38	B-GENE
,	O
a	O
key	O
structural	O
component	O
of	O
the	O
mammalian	O
aminoacyl-tRNA	B-GENE
synthetase	I-GENE
complex	O
.	O
We	O
found	O
that	O
the	O
ubiquitylation	O
of	O
p38	B-GENE
is	O
abrogated	O
by	O
truncated	O
variants	O
of	O
Parkin	O
lacking	O
essential	O
functional	O
domains	O
,	O
but	O
not	O
by	O
the	O
pathogenic	O
Lys	O
161	O
Asn	O
point	O
mutant	O
.	O
Expression	O
of	O
p38	B-GENE
in	O
COS7	O
cells	O
resulted	O
in	O
the	O
formation	O
of	O
aggresome	O
-	O
like	O
inclusions	O
in	O
which	O
Parkin	O
was	O
systematically	O
sequestered	O
.	O
In	O
the	O
human	O
dopaminergic	O
neuroblastoma	O
-	O
derived	O
SH-SY5Y	O
cell	O
line	O
,	O
Parkin	O
promoted	O
the	O
formation	O
of	O
ubiquitylated	O
p38	B-GENE
-	O
positive	O
inclusions	O
.	O
Moreover	O
,	O
the	O
overexpression	O
of	O
p38	B-GENE
in	O
SH-SY5Y	O
cells	O
caused	O
significant	O
cell	O
death	O
against	O
which	O
Parkin	O
provided	O
protection	O
.	O
Analysis	O
of	O
p38	B-GENE
expression	O
in	O
the	O
human	O
adult	O
midbrain	O
revealed	O
strong	O
immunoreactivity	O
in	O
normal	O
dopaminergic	O
neurons	O
and	O
the	O
labeling	O
of	O
LBs	O
in	O
idiopathic	O
PD.	O
This	O
suggests	O
that	O
p38	B-GENE
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
PD	O
,	O
opening	O
the	O
way	O
for	O
a	O
detailed	O
examination	O
of	O
its	O
potential	O
non	O
-	O
canonical	O
role	O
in	O
neurodegeneration	O
.	O
PMID	O
:	O
12783850	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
2003	O
Apr	O
11;303(	O
3	O
)	O
:	O
82	O
8-41	O
.	O
A	O
method	O
to	O
improve	O
selection	O
of	O
molecular	O
targets	O
by	O
circumventing	O
the	O
ADME	O
pharmacokinetic	O
system	O
utilizing	O
PharmArray	O
DNA	O
microarrays	O
.	O
Dooley	O
TP	O
,	O
Curto	O
EV	O
,	O
Reddy	O
SP	O
,	O
Davis	O
RL	O
,	O
Lambert	O
G	O
,	O
Wilborn	O
TW	O
.	O
IntegriDerm	O
Inc.	O
,	O
2800	O
Milan	O
Court	O
,	O
Birmingham	O
,	O
AL	O
35211-6908	O
,	O
USA	O
.	O
dooley@intergriderm	O
.com	O
DNA	O
microarrays	O
may	O
be	O
used	O
to	O
identify	O
potential	O
molecular	O
targets	O
for	O
drug	O
discovery	O
.	O
Yet	O
,	O
DNA	O
microarray	O
experiments	O
provide	O
massive	O
amounts	O
of	O
data	O
.	O
To	O
limit	O
the	O
choice	O
of	O
potential	O
molecular	O
targets	O
,	O
it	O
may	O
be	O
desirable	O
to	O
eliminate	O
genes	O
coincidentally	O
up	O
-	O
regulated	O
in	O
tissues	O
implicated	O
in	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
,	O
and	O
excretion	O
(	O
ADME	O
)	O
pharmacokinetics	O
.	O
DNA	O
microarray	O
experiments	O
were	O
performed	O
to	O
demonstrate	O
a	O
gene	O
-	O
exclusion	O
approach	O
using	O
as	O
an	O
example	O
RNA	O
samples	O
of	O
neural	O
origin	O
,	O
i.e.	O
,	O
a	O
human	O
neuroblastoma	O
cell	O
line	O
(	O
SK-N-SH	O
)	O
and	O
brain	O
tissue	O
,	O
as	O
the	O
intended	O
hypothetical	O
site(s)	O
of	O
drug	O
action	O
.	O
Biomarkers	O
were	O
identified	O
using	O
PharmArray	O
DNA	O
microarrays	O
.	O
The	O
lists	O
of	O
neuroblastoma	O
and	O
neural	O
biomarkers	O
were	O
constrained	O
by	O
limiting	O
selection	O
to	O
the	O
subset	O
of	O
genes	O
that	O
were	O
not	O
highly	O
expressed	O
in	O
three	O
transformed	O
cell	O
lines	O
from	O
liver	O
,	O
colon	O
,	O
and	O
kidney	O
(	O
HepG2	O
,	O
Caco-2	O
,	O
and	O
786-O,	O
respectively	O
)	O
that	O
are	O
routinely	O
used	O
as	O
representatives	O
of	O
the	O
ADME	O
system	O
during	O
in	O
vitro	O
pharmacology	O
and	O
toxicology	O
experiments	O
.	O
Principal	O
component	O
analysis	O
methods	O
with	O
likelihood	O
ratio	O
-	O
related	O
bioinformatic	O
tools	O
were	O
utilized	O
to	O
identify	O
robust	O
potential	O
biomarker	O
genes	O
for	O
the	O
three	O
ADME-related	O
cell	O
lines	O
,	O
neuroblastoma	O
,	O
and	O
normal	O
brain	O
.	O
Biomarkers	O
of	O
each	O
sample	O
were	O
identified	O
and	O
selected	O
genes	O
were	O
validated	O
by	O
qRT-PCR	O
.	O
Hundreds	O
of	O
biomarkers	O
of	O
the	O
three	O
ADME-related	O
cell	O
types	O
,	O
representing	O
hepatocytes	O
,	O
kidney	O
epithelium	O
,	O
and	O
gastrointestinal	O
tract	O
,	O
may	O
now	O
be	O
used	O
as	O
a	O
valuable	O
database	O
to	O
restrict	O
selection	O
of	O
biomarkers	O
as	O
potential	O
molecular	O
targets	O
from	O
the	O
intended	O
samples	O
(	O
e.g.	O
,	O
neuroblastoma	O
in	O
this	O
work	O
)	O
.	O
In	O
addition	O
to	O
biomarker	O
discovery	O
per	O
se	O
,	O
this	O
demonstration	O
suggests	O
that	O
our	O
model	O
method	O
may	O
be	O
viable	O
to	O
help	O
restrict	O
gene	O
lists	O
during	O
selection	O
of	O
potential	O
molecular	O
targets	O
for	O
subsequent	O
drug	O
discovery	O
.	O
PMID	O
:	O
12670486	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Physiol	O
.	O
1998	O
Jul	O
1;5	O
10	O
(	O
Pt	O
1	O
)	O
:93	O
-	O
102	O
.	O
K	O
+	O
channel	O
block	O
-	O
induced	O
mammalian	O
neuroblastoma	O
cell	O
swelling	O
:	O
a	O
possible	O
mechanism	O
to	O
influence	O
proliferation	O
.	O
Rouzaire	O
-	O
Dubois	O
B	O
,	O
Dubois	O
JM	O
.	O
Laboratoire	O
de	O
Neurobiologie	O
cellulaire	O
et	O
moleculaire	O
,	O
CNRS	O
,	O
91198	O
Gif	O
-	O
sur	O
-	O
Yvette	O
Cedex	O
,	O
France	O
.	O
beatrice@wat	O
.nbcm	O
.cnrs	O
-	O
gif.fr	O
1	O
.	O
A	O
variety	O
of	O
studies	O
have	O
suggested	O
that	O
K	O
+	O
channel	O
activity	O
is	O
a	O
key	O
determinant	O
for	O
cell	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
mitosis	O
.	O
We	O
have	O
previously	O
proposed	O
that	O
K	O
+	O
channels	O
control	O
the	O
activity	O
of	O
cell	O
cycle	O
-	O
regulating	O
proteins	O
via	O
regulation	O
of	O
cell	O
volume	O
.	O
In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
measured	O
,	O
with	O
a	O
Coulter	O
counter	O
and	O
under	O
different	O
experimental	O
conditions	O
,	O
the	O
volume	O
and	O
rate	O
of	O
proliferation	O
of	O
neuroblastoma	O
x	O
glioma	O
hybrid	O
NG108-15	O
cells	O
.	O
2.	O
The	O
K	O
+	O
channel	O
blockers	O
TEA	O
(	O
1-	O
10	O
mM	O
)	O
,	O
4-aminopyridine	O
(	O
0.2-2	O
mM	O
)	O
and	O
Cs	O
+	O
(	O
2.5	O
-	O
10	O
mM	O
)	O
increased	O
the	O
cell	O
volume	O
and	O
decreased	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O
Proliferation	O
was	O
fully	O
inhibited	O
when	O
cell	O
volume	O
was	O
increased	O
by	O
25	O
%	O
.	O
3	O
.	O
A	O
40	O
%	O
increase	O
in	O
the	O
culture	O
medium	O
osmolarity	O
with	O
NaCl	O
induced	O
a	O
25	O
%	O
increase	O
in	O
cell	O
volume	O
and	O
an	O
82	O
%	O
decrease	O
in	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O
A	O
40	O
%	O
increase	O
in	O
the	O
culture	O
medium	O
osmolarity	O
with	O
mannitol	O
induced	O
a	O
9	O
%	O
increase	O
in	O
cell	O
volume	O
and	O
a	O
60	O
%	O
decrease	O
in	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O
4	O
.	O
The	O
Cl	O
-	O
channel	O
blocker	O
NPPB	O
(	O
5-nitro-2-(3-phenylpropylamino)	O
benzoic	O
acid	O
;	O
50	O
microM	O
)	O
induced	O
a	O
12	O
%	O
increase	O
in	O
cell	O
volume	O
and	O
a	O
77	O
%	O
decrease	O
in	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O
5	O
.	O
A	O
24	O
%	O
reduction	O
in	O
the	O
culture	O
medium	O
osmolarity	O
with	O
H2O	O
induced	O
a	O
21	O
%	O
decrease	O
in	O
cell	O
volume	O
and	O
a	O
32	O
%	O
increase	O
in	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O
6	O
.	O
Under	O
whole	O
-	O
cell	O
patch-clamp	O
conditions	O
,	O
antibiotics	O
(	O
penicillin	O
plus	O
streptomycin	O
)	O
decreased	O
the	O
voltage	O
-	O
dependent	O
K	O
+	O
current	O
.	O
Omission	O
of	O
antibiotics	O
from	O
the	O
culture	O
medium	O
induced	O
a	O
10	O
%	O
decrease	O
in	O
the	O
cell	O
volume	O
and	O
a	O
32	O
%	O
increase	O
in	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O
7	O
.	O
These	O
results	O
suggest	O
that	O
the	O
mechanisms	O
controlling	O
cell	O
proliferation	O
are	O
strongly	O
influenced	O
by	O
the	O
factors	O
which	O
determine	O
cell	O
volume	O
.	O
This	O
could	O
take	O
into	O
account	O
the	O
role	O
in	O
mitogenesis	O
of	O
K	O
+	O
channels	O
and	O
of	O
other	O
ionic	O
pathways	O
involved	O
in	O
cell	O
volume	O
regulation	O
.	O
PMID	O
:	O
9625869	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
.	O
2001	O
Jun	O
15	O
;19(	O
12	O
)	O
:	O
3080	O
-	O
90	O
.	O
Comprehensive	O
genetic	O
and	O
histopathologic	O
study	O
reveals	O
three	O
types	O
of	O
neuroblastoma	O
tumors	O
.	O
Lastowska	O
M,	O
Cullinane	O
C	O
,	O
Variend	O
S	O
,	O
Cotterill	O
S	O
,	O
Bown	O
N	O
,	O
O'Neill	O
S	O
,	O
Mazzocco	O
K,	O
Roberts	O
P,	O
Nicholson	O
J,	O
Ellershaw	O
C	O
,	O
Pearson	O
AD	O
,	O
Jackson	O
MS	O
;	O
United	O
Kingdom	O
Children	O
Cancer	O
Study	O
Group	O
and	O
the	O
United	O
Kingdom	O
Cancer	O
Cytogenetics	O
Group	O
.	O
Human	O
Genetics	O
Unit	O
,	O
School	O
of	O
Biochemistry	O
and	O
Genetics	O
,	O
University	O
of	O
Newcastle	O
upon	O
Tyne	O
,	O
United	O
Kingdom	O
.	O
M.A.Lastowska@ncl	O
.ac.uk	O
PURPOSE	O
:	O
To	O
determine	O
the	O
relationship	O
between	O
multiple	O
genetic	O
features	O
,	O
tumor	O
morphology	O
,	O
and	O
prognosis	O
in	O
neuroblastoma	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
The	O
genetic	O
alterations	O
and	O
morphologic	O
features	O
that	O
underpin	O
three	O
histopathologic	O
risk	O
classifications	O
were	O
analyzed	O
in	O
108	O
neuroblastoma	O
patients	O
.	O
Tumors	O
were	O
subdivided	O
into	O
four	O
groups	O
based	O
on	O
the	O
three	O
most	O
frequent	O
and	O
prognostically	O
significant	O
genetic	O
alterations	O
(	O
17q	O
gain	O
,	O
1p	O
deletion	O
,	O
and	O
MYCN	B-GENE
amplification	O
)	O
,	O
and	O
all	O
other	O
genetic	O
,	O
morphologic	O
,	O
and	O
clinical	O
data	O
were	O
analyzed	O
with	O
respect	O
to	O
these	O
groups	O
.	O
RESULTS	O
:	O
Our	O
analyses	O
identify	O
three	O
nonoverlapping	O
tumor	O
types	O
with	O
distinct	O
genetic	O
and	O
morphologic	O
features	O
,	O
defined	O
here	O
as	O
types	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O
Type	O
1	O
tumors	O
show	O
none	O
of	O
the	O
three	O
significant	O
genetic	O
alterations	O
and	O
have	O
good	O
prognosis	O
.	O
Both	O
type	O
2	O
(	O
17q	O
gain	O
only	O
or	O
17q	O
gain	O
and	O
1p	O
del	O
)	O
and	O
type	O
3	O
(	O
17q	O
gain	O
,	O
1p	O
del	O
,	O
and	O
MYCN	B-GENE
amplification	O
)	O
tumors	O
progress	O
.	O
However	O
,	O
these	O
tumor	O
types	O
are	O
distinguished	O
clinically	O
by	O
having	O
significantly	O
different	O
median	O
age	O
at	O
diagnosis	O
and	O
median	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
.	O
Multivariate	O
analysis	O
indicates	O
that	O
17q	O
gain	O
is	O
the	O
only	O
independent	O
prognostic	O
factor	O
among	O
all	O
genetic	O
,	O
histopathologic	O
,	O
and	O
clinical	O
factors	O
analyzed	O
.	O
Among	O
histopathologic	O
risk	O
systems	O
,	O
the	O
International	O
Neuroblastoma	O
Pathology	O
Classification	O
was	O
the	O
best	O
predictor	O
of	O
PFS	O
.	O
CONCLUSION	O
:	O
Our	O
results	O
indicate	O
that	O
specific	O
combinations	O
of	O
genetic	O
changes	O
in	O
neuroblastoma	O
tumors	O
contribute	O
to	O
distinct	O
morphologic	O
and	O
clinical	O
features	O
.	O
Furthermore	O
,	O
the	O
identification	O
of	O
two	O
genetically	O
and	O
morphologically	O
distinct	O
types	O
of	O
progressing	O
tumors	O
suggests	O
that	O
possibilities	O
for	O
different	O
therapeutic	O
regimens	O
should	O
be	O
investigated	O
.	O
PMID	O
:	O
11408505	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2002	O
Nov	O
22	O
;277	O
(	O
47	O
)	O
:45518	O
-28	O
.	O
Epub	O
2002	O
Aug	O
26	O
.	O
An	O
iron	O
-	O
responsive	O
element	O
type	O
II	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
Alzheimer	O
's	O
amyloid	B-GENE
precursor	I-GENE
protein	I-GENE
transcript	I-GENE
.	O
Rogers	O
JT	O
,	O
Randall	O
JD	O
,	O
Cahill	O
CM	O
,	O
Eder	O
PS	O
,	O
Huang	O
X	O
,	O
Gunshin	O
H,	O
Leiter	O
L,	O
McPhee	O
J,	O
Sarang	O
SS	O
,	O
Utsuki	O
T	O
,	O
Greig	O
NH	O
,	O
Lahiri	O
DK	O
,	O
Tanzi	O
RE	O
,	O
Bush	O
AI	O
,	O
Giordano	O
T	O
,	O
Gullans	O
SR.	O
Genetics	O
and	O
Aging	O
Research	O
Unit	O
,	O
Department	O
of	O
Psychiatry	O
,	O
Massachusetts	O
General	O
Hospital	O
,	O
Charlestown	O
,	O
Massachusetts	O
02129-	O
4404	O
,	O
USA	O
.	O
Iron	O
-	O
responsive	O
elements	O
(	O
IREs	O
)	O
are	O
the	O
RNA	O
stem	O
loops	O
that	O
control	O
cellular	O
iron	O
homeostasis	O
by	O
regulating	O
ferritin	B-GENE
translation	O
and	O
transferrin	B-GENE
receptor	I-GENE
mRNA	O
stability	O
.	O
We	O
mapped	O
a	O
novel	O
iron	O
-	O
responsive	O
element	O
(	O
IRE-Type	O
II	O
)	O
within	O
the	O
5'-untranslated	O
region	O
(	O
5'-UTR	O
)	O
of	O
the	O
Alzheimer	B-GENE
's	I-GENE
amyloid	I-GENE
precursor	I-GENE
protein	I-GENE
(	O
APP	B-GENE
)	O
transcript	O
(	O
+51	O
to	O
+94	O
from	O
the	O
5'-cap	O
site	O
)	O
.	O
The	O
APP	B-GENE
mRNA	O
IRE	O
is	O
located	O
immediately	O
upstream	O
of	O
an	O
interleukin-1	B-GENE
responsive	O
acute	O
box	O
domain	O
(	O
+101	O
to	O
+146	O
)	O
.	O
APP	O
5'-UTR	O
conferred	O
translation	O
was	O
selectively	O
down	O
-	O
regulated	O
in	O
response	O
to	O
intracellular	O
iron	O
chelation	O
using	O
three	O
separate	O
reporter	O
assays	O
(	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
,	O
luciferase	B-GENE
,	O
and	O
red	B-GENE
fluorescent	I-GENE
protein	I-GENE
reflecting	O
an	O
inhibition	O
of	O
APP	B-GENE
holoprotein	I-GENE
translation	O
in	O
response	O
to	O
iron	O
chelation	O
.	O
Iron	O
influx	O
reversed	O
this	O
inhibition	O
.	O
As	O
an	O
internal	O
control	O
to	O
ensure	O
specificity	O
,	O
a	O
viral	O
internal	O
ribosome	O
entry	O
sequence	O
was	O
unresponsive	O
to	O
intracellular	O
iron	O
chelation	O
with	O
desferrioxamine	O
.	O
Using	O
RNA	O
mobility	O
shift	O
assays	O
,	O
the	O
APP	B-GENE
5'-UTRs	O
,	O
encompassing	O
the	O
IRE	O
,	O
bind	O
specifically	O
to	O
recombinant	O
iron	B-GENE
-	I-GENE
regulatory	I-GENE
proteins	I-GENE
(	O
IRP	B-GENE
)	O
and	O
to	O
IRP	B-GENE
from	O
neuroblastoma	O
cell	O
lysates	O
.	O
IRP	B-GENE
binding	O
to	O
the	O
APP	B-GENE
5'-UTR	O
is	O
reduced	O
after	O
treatment	O
of	O
cells	O
with	O
desferrioxamine	O
and	O
increased	O
after	O
interleukin-1	B-GENE
stimulation	O
.	O
IRP	B-GENE
binding	O
is	O
abrogated	O
when	O
APP	B-GENE
cRNA	O
probe	O
is	O
mutated	O
in	O
the	O
core	O
IRE	O
domain	O
(	O
Delta4	O
bases	O
:	O
Delta	O
83	O
AGAG	O
86	O
)	O
.	O
Iron	O
regulation	O
of	O
APP	B-GENE
mRNA	O
through	O
the	O
APP	B-GENE
5'-UTR	O
points	O
to	O
a	O
role	O
for	O
iron	O
in	O
the	O
metabolism	O
of	O
APP	B-GENE
and	O
confirms	O
that	O
this	O
RNA	O
structure	O
can	O
be	O
a	O
target	O
for	O
the	O
selection	O
of	O
small	O
molecule	O
drugs	O
,	O
such	O
as	O
desferrioxamine	O
(	O
Fe	O
chelator	O
)	O
and	O
clioquinol	O
(	O
Fe	O
,	O
Cu	O
,	O
and	O
Zn	O
chelator	O
)	O
,	O
which	O
reduce	O
Abeta	B-GENE
peptide	O
burden	O
during	O
Alzheimer	O
's	O
disease	O
.	O
PMID	O
:	O
12198135	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
1994	O
Dec;27	O
(	O
2	O
)	O
:	O
205	O
-14	O
.	O
Characterization	O
of	O
the	O
promoter	O
region	O
and	O
flanking	O
sequences	O
of	O
the	O
neuron	O
-	O
specific	O
gene	O
RC3	B-GENE
(	O
neurogranin	B-GENE
)	O
.	O
Iniguez	O
MA	O
,	O
Morte	O
B	O
,	O
Rodriguez-Pena	O
A	O
,	O
Munoz	O
A	O
,	O
Gerendasy	O
D	O
,	O
Sutcliffe	O
JG	O
,	O
Bernal	O
J.	O
Instituto	O
de	O
Investigaciones	O
Biomedicas	O
,	O
CSIC	O
,	O
Facultad	O
de	O
Medicina	O
,	O
UAM	O
,	O
Madrid	O
,	O
Spain	O
.	O
RC3	B-GENE
encodes	O
a	O
thyroid	B-GENE
hormone	I-GENE
-	O
dependent	O
,	O
calmodulin	B-GENE
-	O
binding	O
,	O
protein	B-GENE
kinase	I-GENE
C	I-GENE
substrate	O
(	O
neurogranin	B-GENE
,	O
p17	B-GENE
)	O
present	O
in	O
the	O
dendritic	O
spines	O
of	O
discrete	O
neuronal	O
populations	O
in	O
the	O
forebrain	O
.	O
Its	O
physiological	O
role	O
could	O
be	O
related	O
to	O
synaptic	O
plasticity	O
,	O
memory	O
,	O
and	O
other	O
processes	O
.	O
In	O
the	O
present	O
work	O
we	O
have	O
isolated	O
and	O
sequenced	O
2.4	O
kbp	O
of	O
genomic	O
DNA	O
upstream	O
from	O
the	O
origin	O
of	O
transcription	O
and	O
determined	O
its	O
nucleotide	O
sequence	O
.	O
The	O
major	O
features	O
of	O
the	O
RC3	B-GENE
promoter	O
are	O
the	O
absence	O
of	O
TATA	O
and	O
CAAT	O
boxes	O
and	O
the	O
presence	O
of	O
an	O
Initiator	O
sequence	O
surrounding	O
the	O
cap	O
site	O
.	O
By	O
sequence	O
analysis	O
we	O
identified	O
several	O
cis	O
-	O
acting	O
regulatory	O
elements	O
,	O
among	O
them	O
response	O
elements	O
for	O
retinoic	O
acid	O
and	O
steroid	B-GENE
(	I-GENE
glucocorticoids	I-GENE
/	I-GENE
progesterone	I-GENE
)	I-GENE
hormone	I-GENE
receptors	I-GENE
.	O
An	O
oligonucleotide	O
containing	O
the	O
retinoic	O
acid	O
responsive	O
element	O
bound	O
to	O
retinoic	B-GENE
acid	I-GENE
receptors	I-GENE
specifically	O
in	O
vitro	O
and	O
conferred	O
retinoic	O
acid	O
regulation	O
to	O
a	O
heterologous	O
promoter	O
after	O
transfection	O
in	O
COS-7	O
cells	O
.	O
Retinoic	O
acid	O
and	O
dexamethasone	O
,	O
respectively	O
,	O
increased	O
activity	O
of	O
the	O
RC3	B-GENE
promoter	O
in	O
neuroblastoma	O
cells	O
when	O
a	O
deletion	O
construct	O
containing	O
the	O
retinoic	O
acid	O
and	O
the	O
glucocorticoid	O
responsive	O
elements	O
was	O
cotransfected	O
with	O
retinoic	B-GENE
acid	I-GENE
receptor	I-GENE
or	O
glucocorticoid	B-GENE
receptor	I-GENE
expression	O
vectors	O
.	O
When	O
added	O
together	O
all-trans	O
retinoic	O
acid	O
and	O
dexamethasone	O
had	O
additive	O
effects	O
.	O
Despite	O
the	O
fact	O
that	O
RC3	B-GENE
expression	O
in	O
vivo	O
is	O
thyroid	B-GENE
hormone	I-GENE
-	O
dependent	O
,	O
no	O
evidence	O
for	O
the	O
presence	O
of	O
a	O
thyroid	B-GENE
hormone	I-GENE
responsive	O
element	O
was	O
found	O
within	O
the	O
2.4	O
kbp	O
flanking	O
region	O
analyzed	O
and	O
thyroid	B-GENE
hormone	I-GENE
did	O
not	O
increase	O
reporter	O
activity	O
after	O
cotransfection	O
of	O
suitable	O
constructs	O
with	O
thyroid	B-GENE
hormone	I-GENE
receptor	I-GENE
expression	O
vectors	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
RC3	B-GENE
in	O
vivo	O
could	O
be	O
subject	O
to	O
complex	O
physiological	O
signals	O
,	O
including	O
retinoids	O
and	O
steroid	O
hormones	O
in	O
addition	O
to	O
thyroid	B-GENE
hormones	I-GENE
.	O
PMID	O
:	O
7898304	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2003	O
Nov	O
14;278	O
(	O
46	O
)	O
:45224-30	O
.	O
Epub	O
2003	O
Aug	O
27	O
.	O
A	O
tissue	O
-	O
restricted	O
cAMP	O
transcriptional	O
response	O
:	O
SOX10	O
modulates	O
alpha-melanocyte	O
-	O
stimulating	O
hormone	O
-	O
triggered	O
expression	O
of	O
microphthalmia	O
-	O
associated	O
transcription	O
factor	O
in	O
melanocytes	O
.	O
Huber	O
WE	O
,	O
Price	O
ER	O
,	O
Widlund	O
HR	O
,	O
Du	O
J,	O
Davis	O
IJ	O
,	O
Wegner	O
M,	O
Fisher	O
DE.	O
Division	O
of	O
Pediatric	O
Hematology	O
/Oncology	O
,	O
Dana-Farber	O
Cancer	O
Institute	O
and	O
Children	O
's	O
Hospital	O
,	O
Harvard	O
Medical	O
School	O
,	O
Boston	O
,	O
Massachusetts	O
02115	O
,	O
USA	O
.	O
alpha-Melanocyte	B-GENE
-	I-GENE
stimulating	I-GENE
hormone	I-GENE
(	O
MSH	B-GENE
)	O
utilizes	O
cAMP	O
to	O
trigger	O
pigmentation	O
of	O
melanocytes	O
via	O
activation	O
of	O
melanocyte	B-GENE
-	I-GENE
restricted	I-GENE
microphthalmia	I-GENE
-	I-GENE
associated	I-GENE
transcription	I-GENE
factor	I-GENE
(	O
M-MITF	B-GENE
)	O
expression	O
.	O
M-MITF	B-GENE
is	O
a	O
melanocyte	O
-	O
restricted	O
helix-loop-helix	O
transcription	O
factor	O
capable	O
of	O
transactivating	O
promoters	O
for	O
multiple	O
genes	O
whose	O
products	O
modulate	O
pigmentation	O
.	O
Although	O
M-MITF	B-GENE
promoter	O
activation	O
by	O
MSH	B-GENE
is	O
known	O
to	O
occur	O
through	O
a	O
conserved	O
cAMP	O
-response	O
element	O
(	O
CRE	O
)	O
,	O
it	O
remains	O
unclear	O
how	O
this	O
CRE	O
exhibits	O
such	O
exquisitely	O
tissue	O
-	O
restricted	O
responsiveness	O
.	O
Here	O
we	O
show	O
that	O
cAMP	O
-	O
mediated	O
CRE-binding	O
protein	O
activation	O
of	O
the	O
M-MITF	B-GENE
promoter	O
requires	O
a	O
second	O
DNA	O
element	O
located	O
approximately	O
100	O
bp	O
upstream	O
,	O
a	O
site	O
that	O
is	O
bound	O
and	O
activated	O
by	O
SOX10	B-GENE
.	O
Mutations	O
in	O
the	O
SOX10	B-GENE
transcription	O
factor	O
,	O
like	O
MITF	B-GENE
,	O
results	O
in	O
a	O
disorder	O
known	O
as	O
Waardenburg	O
Syndrome	O
.	O
The	O
cAMP	O
response	O
of	O
the	O
M-MITF	B-GENE
promoter	O
was	O
analyzed	O
in	O
melanoma	O
and	O
neuroblastoma	O
cells	O
(	O
which	O
are	O
neural	O
crest	O
-	O
derived	O
but	O
lack	O
both	O
M-MITF	B-GENE
and	O
SOX10	B-GENE
expression	O
)	O
.	O
M-MITF	B-GENE
promoter	O
responsiveness	O
to	O
cAMP	O
was	O
found	O
to	O
depend	O
upon	O
SOX10	B-GENE
,	O
and	O
reciprocally	O
,	O
SOX10	B-GENE
transactivation	O
was	O
dependent	O
upon	O
the	O
CRE.	O
Ectopic	O
SOX10	B-GENE
expression	O
,	O
in	O
cooperation	O
with	O
cAMP	O
signaling	O
,	O
activated	O
the	O
M-MITF	B-GENE
promoter	O
function	O
and	O
the	O
expression	O
of	O
measurable	O
endogenous	O
M-MITF	B-GENE
transcripts	O
in	O
neuroblastoma	O
cells	O
.	O
SOX10dom	B-GENE
,	O
a	O
mutant	O
allele	O
,	O
failed	O
to	O
cooperate	O
with	O
cAMP	O
in	O
neuroblastoma	O
cells	O
and	O
attenuated	O
the	O
cAMP	O
responsiveness	O
of	O
the	O
M-MITF	B-GENE
promoter	O
in	O
melanoma	O
cells	O
.	O
These	O
observations	O
demonstrate	O
a	O
means	O
whereby	O
the	O
ubiquitous	O
cAMP	O
signaling	O
machinery	O
is	O
harnessed	O
to	O
produce	O
a	O
highly	O
tissue	O
-	O
restricted	O
transcriptional	O
response	O
by	O
cooperating	O
with	O
architectural	O
factors	O
,	O
in	O
this	O
case	O
SOX10	B-GENE
.	O
PMID	O
:	O
12944398	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1993	O
Jun;60	O
(	O
6	O
)	O
:	O
2046-58	O
.	O
Oxidative	O
stress	O
in	O
a	O
clonal	O
cell	O
line	O
of	O
neuronal	O
origin	O
:	O
effects	O
of	O
antioxidant	O
enzyme	O
modulation	O
.	O
Buckman	O
TD	O
,	O
Sutphin	O
MS	O
,	O
Mitrovic	O
B.	O
Department	O
of	O
Environmental	O
Health	O
Sciences	O
,	O
UCLA	O
School	O
of	O
Public	O
Health	O
90024	O
.	O
The	O
effects	O
of	O
intracellularly	O
generated	O
H2O2	O
on	O
cell	O
viability	O
,	O
morphology	O
,	O
and	O
biochemical	O
markers	O
of	O
injury	O
have	O
been	O
investigated	O
in	O
a	O
clonal	O
cell	O
line	O
of	O
neuronal	O
origin	O
(	O
140	O
-3	O
,	O
mouse	O
neuroblastoma	O
X	O
rat	O
glioma	O
)	O
as	O
a	O
cell	O
culture	O
model	O
for	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
the	O
long-term	O
loss	O
of	O
neurons	O
in	O
the	O
brain	O
.	O
The	O
H2O2	O
was	O
generated	O
from	O
the	O
redox	O
cycling	O
of	O
menadione	O
,	O
or	O
by	O
the	O
oxidation	O
of	O
serotonin	O
catalyzed	O
by	O
monoamine	B-GENE
oxidase	I-GENE
,	O
to	O
simulate	O
the	O
effect	O
of	O
amine	O
neurotransmitter	O
turnover	O
.	O
Incubation	O
with	O
menadione	O
at	O
concentrations	O
as	O
low	O
as	O
10	O
microM	O
for	O
several	O
hours	O
resulted	O
in	O
significant	O
losses	O
of	O
cell	O
viability	O
and	O
altered	O
morphology	O
.	O
Similar	O
effects	O
were	O
evident	O
in	O
the	O
presence	O
of	O
serotonin	O
only	O
after	O
incubation	O
overnight	O
with	O
concentrations	O
>	O
1	O
mM	O
.	O
The	O
cytotoxicity	O
of	O
either	O
agent	O
was	O
potentiated	O
by	O
preincubation	O
with	O
specific	O
inhibitors	O
of	O
two	O
enzymes	O
important	O
to	O
cellular	O
antioxidant	O
defenses	O
,	O
3-amino-1,2,4-triazole	O
for	O
catalase	B-GENE
and	O
1,3-	O
bis(chloromethyl)-1-nitrosourea	O
for	O
glutathione	B-GENE
reductase	I-GENE
.	O
Activity	O
of	O
another	O
antioxidant	O
enzyme	O
of	O
particular	O
importance	O
to	O
antioxidant	O
defenses	O
in	O
brain	O
,	O
the	O
selenoprotein	B-GENE
glutathione	I-GENE
peroxidase	I-GENE
,	O
was	O
stimulated	O
fourfold	O
by	O
growth	O
of	O
cultures	O
in	O
the	O
presence	O
of	O
sodium	O
selenite	O
as	O
a	O
source	O
of	O
active	O
-	O
site	O
Se	O
for	O
the	O
enzyme	O
.	O
The	O
only	O
effect	O
of	O
the	O
selenite	O
on	O
other	O
functionally	O
coupled	O
antioxidant	O
enzymes	O
was	O
a	O
decrease	O
in	O
activity	O
of	O
superoxide	B-GENE
dismutase	I-GENE
at	O
concentrations	O
>	O
200	O
nM	O
.	O
The	O
selenite	O
substantially	O
protected	O
cells	O
against	O
oxidative	O
stress	O
induced	O
by	O
combinations	O
of	O
menadione	O
,	O
3-amino-1,2,4-triazole	O
,	O
and	O
1,3-	O
bis(chloromethyl)-1-nitrosourea	O
,	O
but	O
was	O
only	O
marginally	O
effective	O
with	O
serotonin	O
as	O
a	O
source	O
of	O
oxidative	O
stress	O
.	O
The	O
monoamine	B-GENE
oxidase	I-GENE
inhibitor	O
pargyline	O
increased	O
cell	O
survival	O
in	O
the	O
presence	O
of	O
serotonin	O
,	O
demonstrating	O
the	O
role	O
of	O
this	O
enzyme	O
in	O
its	O
cytotoxicity	O
.	O
DNA	O
damage	O
(	O
single	O
strand	O
breaks	O
)	O
,	O
but	O
not	O
lipid	O
peroxidation	O
,	O
correlated	O
with	O
the	O
cytotoxic	O
effects	O
of	O
menadione	O
.	O
PMID	O
:	O
8492117	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
.	O
1996	O
Apr	O
4;12(	O
7	O
)	O
:1583	O
-	O
7.	O
Investigation	O
of	O
co	O
-	O
amplification	O
of	O
the	O
candidate	O
genes	O
ornithine	B-GENE
decarboxylase	I-GENE
,	O
ribonucleotide	B-GENE
reductase	I-GENE
,	O
syndecan-1	B-GENE
and	O
a	O
DEAD	B-GENE
box	I-GENE
gene	O
,	O
DDX1	B-GENE
,	O
with	O
N-myc	B-GENE
in	O
neuroblastoma	O
.	O
United	O
Kingdom	O
Children	O
's	O
Cancer	O
Study	O
Group	O
.	O
George	O
RE	O
,	O
Kenyon	O
RM	O
,	O
McGuckin	O
AG	O
,	O
Malcolm	O
AJ	O
,	O
Pearson	O
AD	O
,	O
Lunec	O
J.	O
Department	O
of	O
Child	O
Health	O
,	O
Medical	O
School	O
,	O
University	O
of	O
Newcastle	O
upon	O
Tyne	O
,	O
UK.	O
Although	O
N-myc	B-GENE
amplification	O
is	O
strongly	O
associated	O
with	O
a	O
poor	O
prognosis	O
,	O
not	O
all	O
patients	O
with	O
neuroblastomas	O
having	O
N-myc	B-GENE
amplification	O
fare	O
badly	O
.	O
To	O
investigate	O
whether	O
genes	O
other	O
than	O
N-myc	B-GENE
are	O
responsible	O
for	O
contributing	O
to	O
the	O
prognosis	O
,	O
we	O
examined	O
seven	O
cell	O
lines	O
and	O
87	O
primary	O
tumours	O
for	O
co	O
-	O
amplification	O
of	O
candidate	O
genes	O
known	O
to	O
be	O
present	O
near	O
the	O
normal	O
N-myc	B-GENE
locus	O
:	O
ornithine	B-GENE
decarboxylase	I-GENE
(	O
ODC	B-GENE
)	O
,	O
ribonucleotide	B-GENE
reductase	I-GENE
(	O
RRM2	B-GENE
)	O
,	O
syndecan-1	B-GENE
and	O
a	O
DEAD	B-GENE
box	I-GENE
protein	O
gene	O
,	O
DDX1	B-GENE
.	O
Sequence	O
analysis	O
of	O
the	O
pG21	B-GENE
cDNA	O
clone	O
previously	O
reported	O
to	O
represent	O
an	O
expressed	O
gene	O
frequently	O
co	O
-	O
amplified	O
with	O
N-myc	B-GENE
,	O
showed	O
this	O
to	O
be	O
from	O
the	O
DDX1	B-GENE
gene	O
.	O
No	O
co	O
-	O
amplification	O
with	O
the	O
first	O
three	O
genes	O
was	O
found	O
in	O
any	O
of	O
the	O
cell	O
lines	O
or	O
tumour	O
samples	O
.	O
DDX1	B-GENE
,	O
however	O
was	O
found	O
to	O
be	O
amplified	O
along	O
with	O
N-myc	B-GENE
in	O
4	O
/	O
6	O
(	O
67	O
%	O
)	O
cell	O
lines	O
and	O
6	O
/	O
16	O
(	O
38	O
%	O
)	O
of	O
the	O
N-myc	B-GENE
amplified	O
tumours	O
.	O
Co	O
-	O
amplification	O
of	O
DDX1	B-GENE
and	O
N-myc	B-GENE
was	O
found	O
more	O
frequently	O
in	O
stage	O
4	O
or	O
4S	O
tumours	O
than	O
lower	O
stage	O
(	O
1-3)	O
tumours	O
.	O
With	O
the	O
exclusion	O
of	O
a	O
single	O
4S	O
case	O
,	O
there	O
was	O
a	O
highly	O
significant	O
reduction	O
in	O
the	O
mean	O
disease	O
-	O
free	O
interval	O
from	O
24.4	O
+/-	O
4.7	O
(	O
SE	O
,	O
n	O
=	O
10	O
)	O
months	O
for	O
cases	O
with	O
co	O
-	O
amplification	O
of	O
N-myc	B-GENE
and	O
DDX1	B-GENE
compared	O
with	O
9.2	O
+/-	O
1.8	O
(	O
SE	O
,	O
n	O
=	O
5	O
)	O
months	O
for	O
those	O
cases	O
showing	O
amplification	O
of	O
N-myc	B-GENE
alone	O
(	O
P	O
=	O
0.0056	O
,	O
Welch	O
's	O
unpaired	O
t	O
-test	O
)	O
.	O
No	O
amplification	O
of	O
DDX1	B-GENE
,	O
ODC	B-GENE
,	O
RRM2	B-GENE
,	O
or	O
syndecan-1	B-GENE
was	O
found	O
in	O
the	O
absence	O
of	O
N-myc	B-GENE
amplification	O
.	O
These	O
observation	O
indicate	O
that	O
the	O
N-myc	B-GENE
amplicon	O
is	O
of	O
varied	O
size	O
and/or	O
position	O
relative	O
to	O
the	O
N-myc	B-GENE
gene	O
,	O
with	O
DDX1	B-GENE
representing	O
at	O
least	O
one	O
other	O
gene	O
frequently	O
co	O
-	O
amplified	O
with	O
N-myc	B-GENE
.	O
Further	O
studies	O
are	O
required	O
to	O
confirm	O
the	O
biological	O
and	O
prognostic	O
significance	O
of	O
DDX1	B-GENE
co	O
-	O
amplification	O
and	O
to	O
elucidate	O
the	O
role	O
that	O
DDX1	B-GENE
plays	O
in	O
tumour	O
genesis	O
and	O
progression	O
.	O
PMID	O
:	O
8622876	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
.	O
2003	O
Aug	O
15;	O
9	O
(	O
9	O
)	O
:	O
333	O
8-44	O
.	O
Development	O
of	O
a	O
real	O
-time	O
polymerase	B-GENE
chain	O
reaction	O
assay	O
for	O
prediction	O
of	O
the	O
uptake	O
of	O
meta-[	O
(131)I]iodobenzylguanidine	O
by	O
neuroblastoma	O
tumors	O
.	O
Carlin	O
S	O
,	O
Mairs	O
RJ	O
,	O
McCluskey	O
AG	O
,	O
Tweddle	O
DA	O
,	O
Sprigg	O
A	O
,	O
Estlin	O
C	O
,	O
Board	O
J,	O
George	O
RE	O
,	O
Ellershaw	O
C	O
,	O
Pearson	O
AD	O
,	O
Lunec	O
J,	O
Montaldo	O
PG	O
,	O
Ponzoni	O
M,	O
van	O
Eck	O
-Smit	O
BL	O
,	O
Hoefnagel	O
CA	O
,	O
van	O
den	O
Brug	O
MD	O
,	O
Tytgat	O
GA	O
,	O
Caron	O
HN	O
.	O
Departments	O
of	O
Radiation	O
Oncology	O
and	O
Child	O
Health	O
,	O
University	O
of	O
Glasgow	O
,	O
Cancer	O
Research	O
UK	O
Beatson	O
Laboratories	O
,	O
Glasgow	O
G61	O
1BD	O
,	O
United	O
Kingdom	O
.	O
PURPOSE	O
:	O
The	O
suitability	O
of	O
neuroblastoma	O
patients	O
for	O
therapy	O
using	O
radiolabeled	O
meta	O
-	O
iodobenzylguanidine	O
(	O
MIBG	O
)	O
is	O
determined	O
by	O
scintigraphy	O
after	O
the	O
administration	O
of	O
a	O
tracer	O
dose	O
of	O
radioiodinated	O
MIBG	O
whose	O
uptake	O
is	O
dependent	O
upon	O
the	O
cellular	O
expression	O
of	O
the	O
noradrenaline	O
transporter	O
(	O
NAT	O
)	O
.	O
As	O
a	O
possible	O
alternative	O
to	O
gamma	O
camera	O
imaging	O
,	O
we	O
developed	O
a	O
novel	O
molecular	O
assay	O
of	O
NAT	O
expression	O
.	O
mRNA	O
extracted	O
from	O
neuroblastoma	O
biopsy	O
samples	O
,	O
obtained	O
retrospectively	O
,	O
was	O
reverse	O
transcribed	O
,	O
and	O
NAT	O
-	O
specific	O
cDNA	O
was	O
quantified	O
by	O
real	O
-time	O
PCR	O
,	O
referenced	O
against	O
the	O
expression	O
of	O
the	O
housekeeping	O
gene	O
glyceraldehyde	B-GENE
-	I-GENE
3-phosphate	I-GENE
dehydrogenase	I-GENE
.	O
EXPERMENTAL	O
DESIGN	O
:	O
Tumor	O
specimens	O
from	O
54	O
neuroblastoma	O
patients	O
were	O
analyzed	O
using	O
real	O
-time	O
PCR	O
,	O
and	O
NAT	O
expression	O
was	O
compared	O
with	O
the	O
corresponding	O
diagnostic	O
scintigrams	O
.	O
RESULTS	O
:	O
Forty-eight	O
of	O
54	O
(	O
89	O
%	O
)	O
of	O
tumors	O
showed	O
MIBG	O
uptake	O
by	O
scintigraphy	O
.	O
NAT	O
expression	O
was	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
MIBG	O
uptake	O
(	O
P	O
<	O
0.0001	O
,	O
Fisher	O
's	O
exact	O
test	O
)	O
.	O
None	O
of	O
the	O
samples	O
from	O
the	O
six	O
tumors	O
that	O
failed	O
to	O
concentrate	O
MIBG	O
expressed	O
detectable	O
levels	O
of	O
the	O
NAT	O
(	O
specificity	O
=	O
1.0	O
)	O
.	O
However	O
,	O
of	O
the	O
48	O
MIBG	O
uptake	O
-	O
positive	O
tumors	O
,	O
only	O
43	O
(	O
90	O
%	O
)	O
expressed	O
NAT	O
(	O
sensitivity	O
=	O
0.9	O
)	O
.	O
The	O
real	O
-time	O
PCR	O
test	O
has	O
a	O
positive	O
predictive	O
value	O
of	O
1.0	O
but	O
a	O
negative	O
predictive	O
value	O
of	O
0.55	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
indicate	O
that	O
whereas	O
this	O
method	O
has	O
substantial	O
ability	O
to	O
predict	O
the	O
capacity	O
of	O
neuroblastoma	O
tumors	O
to	O
accumulate	O
MIBG	O
,	O
confirmation	O
is	O
required	O
in	O
prospective	O
studies	O
to	O
determine	O
more	O
accurately	O
the	O
predictive	O
strength	O
of	O
the	O
test	O
and	O
its	O
role	O
in	O
the	O
management	O
of	O
patients	O
with	O
neuroblastoma	O
.	O
PMID	O
:	O
12960120	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

J	O
Lab	O
Clin	O
Med	O
.	O
1997	O
Sep;130	O
(	O
3	O
)	O
:	O
297-306	O
.	O
Standardization	O
of	O
a	O
single-	O
cell	O
assay	O
for	O
sensitive	O
detection	O
of	O
multidrug	B-GENE
resistance	I-GENE
protein	I-GENE
expression	O
in	O
normal	O
and	O
malignant	O
cells	O
in	O
archival	O
clinical	O
samples	O
.	O
Chan	O
HS	O
,	O
Grogan	O
TM	O
,	O
Haddad	O
G	O
,	O
Hipfner	O
DR	O
,	O
Deeley	O
RG	O
,	O
Cole	O
SP	O
.	O
Department	O
of	O
Pediatrics	O
,	O
The	O
Hospital	O
for	O
Sick	O
Children	O
and	O
the	O
University	O
of	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O
Multidrug	B-GENE
resistance	I-GENE
protein	I-GENE
(	O
MRP	B-GENE
)	O
,	O
like	O
P170	B-GENE
,	O
confers	O
multidrug	O
resistance	O
,	O
but	O
its	O
clinical	O
relevance	O
is	O
uncertain	O
,	O
whereas	O
P170	B-GENE
is	O
an	O
accepted	O
cause	O
of	O
chemotherapy	O
failure	O
for	O
which	O
ongoing	O
reversal	O
trials	O
are	O
being	O
conducted	O
.	O
Because	O
such	O
trials	O
have	O
been	O
only	O
modestly	O
successful	O
,	O
we	O
must	O
investigate	O
alternative	O
drug	O
resistance	O
mechanisms	O
such	O
as	O
MRP	B-GENE
,	O
which	O
is	O
poorly	O
blocked	O
by	O
P170	B-GENE
inhibitors	O
.	O
The	O
significance	O
of	O
MRP	B-GENE
has	O
remained	O
undefined	O
because	O
MRP	B-GENE
mRNA	O
is	O
difficult	O
to	O
assay	O
in	O
archival	O
material	O
,	O
does	O
not	O
necessarily	O
reflect	O
MRP	B-GENE
levels	O
,	O
and	O
is	O
widely	O
expressed	O
in	O
normal	O
or	O
hematopoietic	O
cells	O
within	O
tumors	O
and	O
bone	O
marrow	O
.	O
Because	O
conventional	O
immunoblot	O
or	O
immunocytochemistry	O
may	O
not	O
be	O
sensitive	O
enough	O
to	O
detect	O
low	O
or	O
heterogeneous	O
MRP	B-GENE
expression	O
in	O
clinical	O
samples	O
,	O
we	O
elected	O
to	O
score	O
MRP	B-GENE
in	O
single	O
tumor	O
cells	O
by	O
modifying	O
our	O
P170	B-GENE
assays	O
that	O
have	O
proven	O
valuable	O
for	O
correlating	O
P170	B-GENE
expression	O
with	O
the	O
outcome	O
of	O
pediatric	O
cancer	O
chemotherapy	O
.	O
We	O
enhanced	O
the	O
signal	O
-to-noise	O
ratio	O
with	O
several	O
peroxidase	B-GENE
-	O
tagged	O
secondary	O
antibody	O
layers	O
and	O
staining	O
refinements	O
,	O
standardizing	O
the	O
assay	O
with	O
MRP	B-GENE
negative	O
and	O
MRP	B-GENE
-	O
positive	O
but	O
P170	B-GENE
-	O
negative	O
transfected	O
or	O
drug	O
-	O
selected	O
controls	O
in	O
which	O
MRP	B-GENE
was	O
quantified	O
by	O
immunoblot	O
.	O
We	O
confirmed	O
sensitivity	O
by	O
staining	O
a	O
very	O
low	O
MRP	B-GENE
expressing	O
revertant	O
line	O
and	O
"	O
mixed	O
"	O
samples	O
containing	O
small	O
numbers	O
of	O
positive	O
cells	O
;	O
we	O
confirmed	O
specificity	O
by	O
applying	O
two	O
antibodies	O
directed	O
against	O
separate	O
MRP	B-GENE
epitopes	O
.	O
We	O
examined	O
neuroblastoma	O
,	O
osteosarcoma	O
,	O
rhabdomyosarcoma	O
,	O
and	O
retinoblastoma	O
samples	O
,	O
identifying	O
MRP	B-GENE
-	O
positive	O
malignant	O
cells	O
,	O
which	O
were	O
distinguishable	O
from	O
MRP	B-GENE
-	O
positive	O
normal	O
cells	O
.	O
This	O
assay	O
may	O
be	O
valuable	O
for	O
early	O
diagnosis	O
of	O
low	O
but	O
potentially	O
important	O
MRP	B-GENE
expression	O
,	O
which	O
would	O
allow	O
timely	O
application	O
of	O
alternative	O
therapy	O
,	O
perhaps	O
with	O
MRP	B-GENE
-	O
specific	O
blockers	O
.	O
PMID	O
:	O
9341990	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Ann	O
Oncol	O
.	O
2002	O
Jun;13(	O
6	O
)	O
:956-64	O
.	O
Localized	O
unresectable	O
neuroblastoma	O
:	O
results	O
of	O
treatment	O
based	O
on	O
clinical	O
prognostic	O
factors	O
.	O
Garaventa	O
A	O
,	O
Boni	O
L,	O
Lo	O
Piccolo	O
MS	O
,	O
Tonini	O
GP	O
,	O
Gambini	O
C	O
,	O
Mancini	O
A	O
,	O
Tonegatti	O
L,	O
Carli	O
M,	O
di	O
Montezemolo	O
LC	O
,	O
Di	O
Cataldo	O
A	O
,	O
Casale	O
F	O
,	O
Mazzocco	O
K,	O
Cecchetto	O
G	O
,	O
Rizzo	O
A	O
,	O
Bernardi	O
B	O
;	O
Italian	O
Cooperative	O
Group	O
for	O
Neuroblastoma	O
.	O
Department	O
of	O
Hematology	O
--Oncology	O
,	O
Giannina	O
Gaslini	O
Children	O
's	O
Hospital	O
,	O
Genova	O
,	O
Italy	O
.	O
albertogaraventa@ospedale	O
-	O
gaslini.ge	O
.it	O
BACKGROUND	O
:	O
We	O
previously	O
reported	O
that	O
stage	O
3	O
neuroblastoma	O
comprises	O
(	O
i)	O
a	O
low-risk	O
group	O
including	O
all	O
infants	O
(	O
age	O
0-11	O
months	O
)	O
as	O
well	O
as	O
older	O
children	O
with	O
non	O
-	O
abdominal	O
primaries	O
,	O
and	O
(ii)	O
a	O
high	O
-risk	O
group	O
made	O
up	O
of	O
children	O
>1	O
year	O
of	O
age	O
with	O
abdominal	O
primaries	O
.	O
Aggressive	O
chemotherapy	O
was	O
effective	O
only	O
in	O
the	O
latter	O
group	O
.	O
PATIENTS	O
AND	O
TREATMENT	O
:	O
On	O
this	O
basis	O
,	O
in	O
1990	O
we	O
designed	O
a	O
new	O
protocol	O
by	O
which	O
all	O
low-risk	O
patients	O
received	O
standard	O
-dose	O
chemotherapy	O
,	O
while	O
the	O
high	O
-risk	O
ones	O
received	O
very	O
aggressive	O
chemotherapy	O
.	O
RESULTS	O
:	O
Between	O
November	O
1990	O
and	O
December	O
1997	O
a	O
total	O
of	O
95	O
eligible	O
and	O
evaluable	O
children	O
were	O
enrolled	O
:	O
47	O
were	O
low-risk	O
(	O
35	O
infants	O
and	O
12	O
>1	O
year	O
of	O
age	O
at	O
diagnosis	O
and	O
having	O
non	O
-	O
abdominal	O
primaries	O
)	O
,	O
and	O
48	O
were	O
high	O
-risk	O
(	O
being	O
>1	O
year	O
of	O
age	O
and	O
having	O
abdominal	O
primaries	O
)	O
.	O
Of	O
the	O
47	O
low-risk	O
patients	O
,	O
five	O
relapsed	O
and	O
four	O
subsequently	O
died	O
.	O
The	O
5-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
91	O
%	O
.	O
Of	O
the	O
48	O
patients	O
in	O
the	O
high	O
-risk	O
group	O
,	O
22	O
relapsed	O
or	O
progressed	O
,	O
18	O
of	O
whom	O
died	O
from	O
their	O
disease	O
and	O
two	O
from	O
toxicity	O
,	O
and	O
one	O
was	O
lost	O
to	O
follow-up	O
.	O
The	O
5-	O
year	O
OS	O
was	O
60	O
%	O
.	O
Univariate	O
analysis	O
showed	O
that	O
age	O
,	O
site	O
of	O
primary	O
,	O
risk-group	O
,	O
urine	O
vanillylmandelic	O
excretion	O
,	O
plasma	O
levels	O
of	O
lactate	B-GENE
dehydrogenase	I-GENE
,	O
ferritin	B-GENE
and	O
neurone	B-GENE
-	I-GENE
specific	I-GENE
enolase	I-GENE
,	O
and	O
MYCN	B-GENE
status	O
correlated	O
with	O
outcome	O
.	O
However	O
,	O
multivariate	O
analysis	O
showed	O
that	O
only	O
MYCN	B-GENE
status	O
retained	O
prognostic	O
value	O
.	O
CONCLUSIONS	O
:	O
In	O
low-risk	O
stage	O
3	O
neuroblastoma	O
,	O
standard	O
-dose	O
chemotherapy	O
is	O
associated	O
with	O
an	O
excellent	O
chance	O
of	O
being	O
cured	O
.	O
Aggressive	O
chemotherapy	O
is	O
effective	O
for	O
high	O
-risk	O
patients	O
,	O
but	O
results	O
are	O
still	O
unsatisfactory	O
.	O
MYCN	B-GENE
gene	O
amplification	O
is	O
a	O
prognostic	O
indicator	O
for	O
most	O
,	O
but	O
not	O
all	O
,	O
treatment	O
failures	O
.	O
PMID	O
:	O
12123342	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

DNA	O
Cell	O
Biol	O
.	O
1994	O
May	O
;13(	O
5	O
)	O
:461	O
-	O
71	O
.	O
Human	O
dTMP	B-GENE
kinase	I-GENE
:	O
gene	O
expression	O
and	O
enzymatic	O
activity	O
coinciding	O
with	O
cell	O
cycle	O
progression	O
and	O
cell	O
growth	O
.	O
Huang	O
SH	O
,	O
Tang	O
A	O
,	O
Drisco	O
B	O
,	O
Zhang	O
SQ	O
,	O
Seeger	O
R	O
,	O
Li	O
C	O
,	O
Jong	O
A	O
.	O
Department	O
of	O
Pediatrics	O
and	O
Microbiology	O
,	O
University	O
of	O
Southern	O
California	O
School	O
of	O
Medicine	O
,	O
Los	O
Angeles	O
90027	O
.	O
dTMP	B-GENE
kinase	I-GENE
(	O
E.C.2.7.4.9.	O
)	O
catalyzes	O
the	O
phosphorylation	O
of	O
dTMP	O
to	O
the	O
corresponding	O
diphosphate	O
.	O
This	O
enzyme	O
is	O
essential	O
for	O
DNA	O
synthesis	O
in	O
vivo	O
and	O
is	O
an	O
important	O
intermediate	O
enzyme	O
in	O
the	O
pathway	O
of	O
many	O
pyrimidine	O
analog	O
drugs	O
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
isolation	O
of	O
the	O
human	O
dTMP	B-GENE
kinase	I-GENE
gene	O
by	O
functional	O
complementation	O
of	O
a	O
Saccharomyces	O
cerevisiae	O
cell	O
cycle	O
mutant	O
,	O
cdc8	O
.	O
The	O
cDNA	O
sequence	O
revealed	O
an	O
open	O
reading	O
frame	O
that	O
encodes	O
a	O
protein	O
with	O
the	O
molecular	O
weight	O
of	O
23,806	O
.	O
The	O
deduced	O
protein	O
sequence	O
was	O
compared	O
to	O
known	O
dTMP	B-GENE
kinase	I-GENE
sequences	O
from	O
different	O
organisms	O
.	O
Although	O
functionally	O
complementary	O
and	O
structurally	O
conserved	O
,	O
expressed	O
human	O
dTMP	B-GENE
kinase	I-GENE
in	O
yeast	O
shows	O
little	O
enzymatic	O
activity	O
.	O
In	O
contrast	O
,	O
active	O
human	O
dTMP	B-GENE
kinase	I-GENE
can	O
be	O
expressed	O
from	O
the	O
gene	O
cloned	O
into	O
the	O
baculovirus	O
expression	O
system	O
,	O
as	O
evidenced	O
by	O
increased	O
enzymatic	O
activity	O
by	O
four	O
-	O
to	O
five	O
-	O
fold	O
.	O
Unlike	O
yeast	O
dTMP	B-GENE
kinase	I-GENE
,	O
human	O
dTMP	B-GENE
kinase	I-GENE
does	O
not	O
contain	O
a	O
cysteine	O
residue	O
after	O
the	O
conserved	O
glycine	O
-rich	O
loop	O
,	O
but	O
its	O
enzymatic	O
activity	O
is	O
still	O
affected	O
by	O
the	O
sulfhydryl	O
inhibitor	O
,	O
5,5'-dithio	O
-	O
bis(	O
2-nitrobenzoic	O
acid	O
)	O
(	O
DTNB	O
)	O
.	O
The	O
levels	O
of	O
dTMP	B-GENE
kinase	I-GENE
mRNA	O
and	O
its	O
enzymatic	O
activity	O
fluctuate	O
during	O
the	O
cell	O
cycle	O
,	O
peaking	O
at	O
the	O
S	O
phase	O
.	O
Thus	O
,	O
like	O
Saccharomyces	O
cerevisiae	O
CDC8	O
(	O
encoding	O
dTMP	B-GENE
kinase	I-GENE
)	O
,	O
the	O
human	O
homolog	O
mRNA	O
and	O
enzymatic	O
activity	O
are	O
also	O
cell	O
cycle	O
regulated	O
.	O
We	O
have	O
also	O
examined	O
four	O
neuroblastoma	O
cell	O
lines	O
for	O
dTMP	B-GENE
kinase	I-GENE
mRNA	O
levels	O
and	O
its	O
kinase	B-GENE
activities	O
,	O
which	O
appear	O
to	O
vary	O
according	O
to	O
cell	O
growth	O
rate	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
the	O
dTMP	B-GENE
kinase	I-GENE
gene	O
and	O
its	O
activity	O
coincide	O
with	O
various	O
stages	O
of	O
cell	O
growth	O
.	O
The	O
identification	O
of	O
the	O
human	O
dTMP	B-GENE
kinase	I-GENE
gene	O
and	O
expression	O
of	O
its	O
product	O
in	O
the	O
baculovirus	O
expression	O
system	O
should	O
facilitate	O
study	O
of	O
the	O
mechanism	O
of	O
gene	O
regulation	O
and	O
its	O
role	O
in	O
pyrimidine	O
metabolism	O
.	O
PMID	O
:	O
8024690	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1992	O
Jun	O
1;89	O
(	O
11	O
)	O
:	O
4874	O
-	O
8.	O
Loss	O
of	O
tumorigenicity	O
of	O
rat	O
glioblastoma	O
directed	O
by	O
episome	O
-	O
based	O
antisense	O
cDNA	O
transcription	O
of	O
insulin	B-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factor	I-GENE
I.	I-GENE
Trojan	O
J,	O
Blossey	O
BK	O
,	O
Johnson	O
TR	O
,	O
Rudin	O
SD	O
,	O
Tykocinski	O
M,	O
Ilan	O
J,	O
Ilan	O
J.	O
Department	O
of	O
Anatomy	O
,	O
Case	O
Western	O
Reserve	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Cleveland	O
,	O
OH	O
44106	O
.	O
Malignant	O
glioma	O
is	O
the	O
most	O
common	O
brain	O
tumor	O
.	O
The	O
molecular	O
basis	O
of	O
glioma	O
tumorigenicity	O
has	O
not	O
been	O
defined	O
.	O
Cultured	O
glioma	O
cells	O
accumulate	O
high	O
levels	O
of	O
insulin	B-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factor	I-GENE
I	I-GENE
(	O
IGF-I	B-GENE
)	O
transcripts	O
.	O
We	O
asked	O
whether	O
IGF-	B-GENE
I	I-GENE
expression	O
is	O
coupled	O
to	O
tumorigenicity	O
,	O
using	O
a	O
combined	O
in	O
vivo	O
/in	O
vitro	O
system	O
employing	O
antisense	O
RNA	O
for	O
IGF-I.	B-GENE
An	O
antisense	O
IGF-	B-GENE
I	I-GENE
expression	O
construct	O
in	O
an	O
expression	O
vector	O
that	O
incorporates	O
Epstein	O
-	O
Barr	O
virus	O
replicative	O
signals	O
and	O
the	O
ZnSO4	O
-	O
inducible	O
metallothionein	B-GENE
I	I-GENE
transcriptional	O
promoter	O
was	O
assembled	O
.	O
Stable	O
glioma	O
transfectants	O
were	O
derived	O
from	O
C6	O
glioma	O
cells	O
,	O
which	O
constitutively	O
express	O
IGF-I	B-GENE
.	O
B-	O
104	O
neuroblastoma	O
cells	O
,	O
derived	O
originally	O
from	O
the	O
same	O
tumor	O
but	O
not	O
expressing	O
IGF-I	B-GENE
,	O
were	O
also	O
transfected	O
as	O
controls	O
.	O
In	O
the	O
absence	O
of	O
ZnSO4	O
,	O
the	O
C6	O
transfectants	O
expressed	O
high	O
levels	O
of	O
IGF-	B-GENE
I	I-GENE
mRNA	O
and	O
protein	O
as	O
detected	O
by	O
in	O
situ	O
hybridization	O
and	O
immunocytochemistry	O
,	O
respectively	O
.	O
Addition	O
of	O
ZnSO4	O
in	O
the	O
culture	O
medium	O
resulted	O
in	O
high	O
levels	O
of	O
antisense	O
transcript	O
accumulation	O
and	O
dramatically	O
decreased	O
levels	O
of	O
endogenous	O
IGF-	B-GENE
I	I-GENE
mRNA	O
and	O
IGF-	B-GENE
I	I-GENE
protein	O
.	O
Subcutaneous	O
injection	O
of	O
either	O
nontransfected	O
C6	O
parental	O
cells	O
or	O
C6	O
cells	O
transfected	O
with	O
vector	O
without	O
IGF-	B-GENE
I	I-GENE
sequences	O
into	O
rats	O
resulted	O
in	O
large	O
tumors	O
after	O
2	O
weeks	O
,	O
as	O
did	O
transfected	O
and	O
nontransfected	O
B-	O
104	O
cells	O
.	O
However	O
,	O
the	O
rats	O
injected	O
with	O
transfected	O
C6	O
cells	O
yielded	O
no	O
tumors	O
after	O
40	O
weeks	O
of	O
observation	O
.	O
Two	O
weeks	O
after	O
injection	O
of	O
the	O
transfected	O
C6	O
cells	O
a	O
small	O
cyst	O
was	O
apparent	O
in	O
six	O
rats	O
.	O
Histologic	O
sections	O
revealed	O
a	O
few	O
glioma	O
cells	O
infiltrated	O
by	O
a	O
large	O
number	O
of	O
mononuclear	O
cells	O
.	O
No	O
infiltration	O
of	O
mononuclear	O
cells	O
was	O
apparent	O
in	O
the	O
glioma	O
tumors	O
resulting	O
from	O
injection	O
of	O
parental	O
(	O
nontransfected	O
)	O
cells	O
,	O
suggesting	O
that	O
the	O
parental	O
cells	O
,	O
but	O
not	O
the	O
antisense	O
IGF-	B-GENE
I	I-GENE
transfectants	O
,	O
escape	O
the	O
host	O
immune	O
response	O
.	O
PMID	O
:	O
1594587	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2000	O
Jan	O
28;275	O
(	O
4	O
)	O
:	O
2911-23	O
.	O
The	O
homeodomain	O
protein	O
Arix	B-GENE
promotes	O
protein	B-GENE
kinase	I-GENE
A	I-GENE
-	O
dependent	O
activation	O
of	O
the	O
dopamine	B-GENE
beta-hydroxylase	I-GENE
promoter	O
through	O
multiple	O
elements	O
and	O
interaction	O
with	O
the	O
coactivator	O
cAMP	B-GENE
-response	I-GENE
element	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
.	O
Swanson	O
DJ	O
,	O
Adachi	O
M,	O
Lewis	O
EJ.	O
Department	O
of	O
Biochemistry	O
,	O
Oregon	O
Health	O
Sciences	O
University	O
,	O
Portland	O
,	O
Oregon	O
97201	O
,	O
USA	O
.	O
The	O
differentiation	O
and	O
maintenance	O
of	O
a	O
neurotransmitter	O
phenotype	O
is	O
guided	O
by	O
the	O
interaction	O
of	O
exogenous	O
cues	O
with	O
intrinsic	O
genetic	O
machinery	O
.	O
For	O
the	O
noradrenergic	O
phenotype	O
,	O
these	O
influences	O
combine	O
to	O
activate	O
the	O
expression	O
of	O
the	O
catecholaminergic	O
biosynthetic	O
enzymes	O
tyrosine	B-GENE
hydroxylase	I-GENE
and	O
dopamine	B-GENE
beta-hydroxylase	I-GENE
(	O
DBH	B-GENE
)	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
molecular	O
mechanisms	O
by	O
which	O
the	O
transcription	O
factor	O
Arix	B-GENE
/	O
Phox2a	B-GENE
contributes	O
to	O
DBH	B-GENE
gene	O
transcription	O
.	O
We	O
have	O
evaluated	O
the	O
contribution	O
of	O
individual	O
homeodomain	O
binding	O
sites	O
in	O
the	O
rat	O
DBH	B-GENE
promoter	O
region	O
and	O
find	O
that	O
all	O
are	O
essential	O
for	O
both	O
basal	O
and	O
cAMP	B-GENE
-	I-GENE
dependent	I-GENE
protein	I-GENE
kinase	I-GENE
A	I-GENE
(	O
PKA	B-GENE
)	O
-	O
stimulated	O
transcription	O
.	O
Using	O
mammalian	O
one	O
-hybrid	O
and	O
two	O
-	O
hybrid	O
systems	O
,	O
we	O
demonstrate	O
that	O
recruitment	O
of	O
Arix	B-GENE
to	O
the	O
positions	O
of	O
homeodomain	O
core	O
recognition	O
sites	O
1	O
and	O
2	O
at	O
-	O
153	O
to	O
-	O
166	O
of	O
the	O
DBH	B-GENE
gene	O
restores	O
complete	O
responsiveness	O
of	O
the	O
promoter	O
to	O
PKA	B-GENE
in	O
SHSY-	O
5Y	O
neuroblastoma	O
and	O
HepG2	O
hepatoma	O
cells	O
.	O
Intracellular	O
Arix	B-GENE
Arix	B-GENE
interactions	O
are	O
evident	O
and	O
may	O
contribute	O
to	O
the	O
interdependence	O
of	O
homeodomain	O
binding	O
sites	O
.	O
Analysis	O
of	O
functional	O
domains	O
of	O
Arix	B-GENE
reveals	O
an	O
N-terminal	O
activation	O
domain	O
and	O
a	O
C-terminal	O
repression	O
domain	O
.	O
The	O
N	O
terminus	O
of	O
Arix	O
contains	O
an	O
amino	O
acid	O
motif	O
similar	O
to	O
a	O
region	O
in	O
Brachyury	B-GENE
and	O
Pax9	B-GENE
transcription	O
factors	O
.	O
The	O
N-terminal	O
activation	O
domain	O
of	O
Arix	B-GENE
interacts	O
with	O
the	O
transcriptional	O
co	O
-	O
activator	O
,	O
cAMP	B-GENE
-response	I-GENE
element	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
,	O
which	O
potentiates	O
transcription	O
from	O
the	O
DBH	B-GENE
promoter	O
in	O
a	O
PKA	B-GENE
-	O
dependent	O
manner	O
.	O
The	O
present	O
study	O
supports	O
the	O
hypothesis	O
that	O
the	O
paired	O
-	O
like	O
homeodomain	O
protein	O
,	O
Arix	B-GENE
,	O
acts	O
as	O
a	O
critical	O
phenotype	O
-	O
specific	O
regulator	O
of	O
the	O
DBH	B-GENE
promoter	O
by	O
serving	O
as	O
an	O
integrator	O
of	O
signal	O
-	O
dependent	O
transcription	O
activators	O
within	O
the	O
network	O
of	O
the	O
general	O
transcription	O
machinery	O
.	O
PMID	O
:	O
10644760	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurovirol	O
.	O
1997	O
Aug;	O
3(	O
4	O
)	O
:247	O
-64	O
.	O
Deletion	O
of	O
the	O
S	O
component	O
inverted	O
repeat	O
sequence	O
c'	O
and	O
the	O
nonessential	O
genes	O
U(S)1	B-GENE
through	O
U(S)5	B-GENE
from	O
the	O
herpes	O
simplex	O
virus	O
type	O
1	O
genome	O
substantially	O
impairs	O
productive	O
viral	O
infection	O
in	O
cell	O
culture	O
and	O
pathogenesis	O
in	O
the	O
rat	O
central	O
nervous	O
system	O
.	O
Rasty	O
S	O
,	O
Poliani	O
PL	O
,	O
Fink	O
DJ	O
,	O
Glorioso	O
JC	O
.	O
Department	O
of	O
Molecular	O
Genetics	O
and	O
Biochemistry	O
,	O
University	O
of	O
Pittsburgh	O
School	O
of	O
Medicine	O
,	O
Pennsylvania	O
15261	O
,	O
USA	O
.	O
A	O
distinctive	O
feature	O
of	O
the	O
genetic	O
make	O
-	O
up	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV-1	O
)	O
,	O
a	O
human	O
neurotropic	O
virus	O
,	O
is	O
that	O
approximately	O
half	O
of	O
the	O
81	O
known	O
viral	O
genes	O
are	O
not	O
absolutely	O
required	O
for	O
productive	O
infection	O
in	O
Vero	O
cells	O
,	O
and	O
most	O
can	O
be	O
individually	O
deleted	O
without	O
substantially	O
impairing	O
viral	O
replication	O
in	O
cell	O
culture	O
.	O
If	O
large	O
blocks	O
of	O
contiguous	O
viral	O
genes	O
could	O
be	O
replaced	O
with	O
foreign	O
DNA	O
sequences	O
,	O
it	O
would	O
be	O
possible	O
to	O
engineer	O
highly	O
attenuated	O
recombinant	O
HSV-1	O
gene	O
transfer	O
vectors	O
capable	O
of	O
carrying	O
large	O
cellular	O
genes	O
or	O
multiple	O
genes	O
having	O
related	O
functions	O
.	O
We	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
an	O
HSV-1	O
mutant	O
,	O
designated	O
d311	O
,	O
containing	O
a	O
12	O
kb	O
deletion	O
of	O
viral	O
DNA	O
located	O
between	O
the	O
L-S	O
Junction	O
a	O
sequence	O
and	O
the	O
U(S)6	B-GENE
gene	O
,	O
spanning	O
the	O
S	O
component	O
inverted	O
repeat	O
sequence	O
c'	O
and	O
the	O
nonessential	O
genes	O
U(S)1	B-GENE
through	O
U(S)5	B-GENE
.	O
Replication	O
of	O
d311	B-GENE
was	O
totally	O
inhibited	O
in	O
rat	O
B103	O
and	O
mouse	O
Neuro-2A	O
neuroblastoma	O
cell	O
lines	O
,	O
and	O
was	O
reduced	O
by	O
over	O
three	O
orders	O
of	O
magnitude	O
in	O
human	O
SK-N-SH	O
neuroblastoma	O
cells	O
compared	O
to	O
wild-type	O
(	O
wt	O
)	O
HSV-1	O
KOS	O
.	O
This	O
suggested	O
that	O
the	O
deleted	O
genes	O
,	O
while	O
nonessential	O
for	O
replication	O
in	O
Vero	O
cells	O
,	O
play	O
an	O
important	O
role	O
in	O
HSV	O
replication	O
in	O
neuronal	O
cells	O
,	O
particularly	O
those	O
of	O
rodent	O
origin	O
.	O
Unlike	O
wt	O
KOS	O
which	O
replicated	O
locally	O
and	O
spread	O
to	O
other	O
regions	O
of	O
brain	O
following	O
stereotactic	O
inoculation	O
into	O
rat	O
hippocampus	O
,	O
d311	O
was	O
unable	O
to	O
replicate	O
and	O
spread	O
within	O
the	O
brain	O
,	O
and	O
did	O
not	O
cause	O
any	O
apparent	O
local	O
neuronal	O
cell	O
damage	O
.	O
These	O
results	O
demonstrate	O
that	O
d311	O
is	O
highly	O
attenuated	O
for	O
the	O
rat	O
central	O
nervous	O
system	O
.	O
d311	O
and	O
other	O
mutants	O
of	O
HSV	O
containing	O
major	O
deletions	O
of	O
the	O
nonessential	O
genes	O
within	O
U(S)	B-GENE
have	O
the	O
potential	O
to	O
serve	O
as	O
useful	O
tools	O
for	O
gene	O
transfer	O
applications	O
to	O
brain	O
.	O
PMID	O
:	O
9291233	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Endocrinology	O
.	O
2001	O
May	O
;142(	O
5	O
)	O
:193	O
5-49	O
.	O
Expression	O
of	O
the	O
human	O
beta	B-GENE
(3)	I-GENE
-adrenergic	I-GENE
receptor	I-GENE
gene	O
in	O
SK-N-MC	O
cells	O
is	O
under	O
the	O
control	O
of	O
a	O
distal	O
enhancer	O
.	O
Susulic	O
VS	O
,	O
LaVallette	O
L,	O
Duzic	O
E	O
,	O
Chen	O
L,	O
Shuey	O
D	O
,	O
Karathanasis	O
SK	O
,	O
Steiner	O
KE.	O
Metabolic	O
Diseases	O
Department	O
,	O
Wyeth-	O
Ayerst	O
Laboratories	O
,	O
Inc.	O
,	O
CN	O
8000	O
,	O
Princeton	O
,	O
New	O
Jersey	O
08543	O
,	O
USA	O
.	O
susuliv@war	O
.wyeth.com	O
Mechanisms	O
of	O
transcriptional	O
regulation	O
of	O
the	O
human	O
beta	B-GENE
(3)	I-GENE
-adrenergic	I-GENE
receptor	I-GENE
were	O
studied	O
using	O
SK-N-MC	O
cells	O
,	O
a	O
human	O
neuroblastoma	O
cell	O
line	O
that	O
expresses	O
beta	B-GENE
(3)	I-GENE
-	I-GENE
and	O
beta	B-GENE
(1)	I-GENE
-	I-GENE
adrenergic	I-GENE
receptors	I-GENE
endogenously	O
.	O
Deletions	O
spanning	O
different	O
portions	O
of	O
a	O
7-	O
kb	O
5'	O
-flanking	O
region	O
of	O
the	O
human	O
beta	B-GENE
(3)	I-GENE
-adrenergic	I-GENE
receptor	I-GENE
gene	O
were	O
linked	O
to	O
a	O
luciferase	B-GENE
reporter	I-GENE
and	O
transfected	O
in	O
SK-N-MC	O
,	O
CV-1	O
,	O
and	O
HeLa	O
cells	O
.	O
Maximal	O
luciferase	B-GENE
activity	O
was	O
observed	O
when	O
a	O
200	O
-	O
bp	O
region	O
located	O
between	O
-	O
6.5	O
and	O
-	O
6.3	O
kb	O
from	O
the	O
translation	O
start	O
site	O
was	O
present	O
.	O
This	O
region	O
functioned	O
only	O
in	O
SK-N-MC	O
cells	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
of	O
nuclear	O
extracts	O
from	O
SK-N-MC	O
,	O
CV-1	O
,	O
and	O
HeLa	O
cells	O
using	O
double	O
stranded	O
oligonucleotides	O
spanning	O
different	O
portions	O
of	O
the	O
200	O
-	O
bp	O
region	O
as	O
probes	O
and	O
transient	O
transfection	O
studies	O
revealed	O
the	O
existence	O
of	O
three	O
cis	O
-	O
acting	O
regulatory	O
elements	O
:	O
A	O
)	O
-	O
6.468	O
kb-AGGTGGACT	O
-	O
-	O
6.458	O
kb	O
,	O
B	O
)	O
-	O
6.448	O
kb-GCCTCTCTGGGGAGCAGCTTCTCC	O
-6.428	O
kb	O
,	O
and	O
C)	O
-	O
6.405	O
kb-20	O
repeats	O
of	O
CCTT-6.385	O
kb	O
.	O
These	O
elements	O
act	O
together	O
to	O
achieve	O
full	O
transcriptional	O
activity	O
.	O
Mutational	O
analysis	O
,	O
antibody	O
supershift	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
competition	O
experiments	O
indicated	O
that	O
element	O
A	O
binds	O
the	O
transcription	B-GENE
factor	I-GENE
Sp1	I-GENE
,	O
element	O
B	O
binds	O
protein(s)	O
present	O
only	O
in	O
nuclear	O
extracts	O
from	O
SK-N-MC	O
cells	O
and	O
brown	O
adipose	O
tissue	O
,	O
and	O
element	O
C	O
binds	O
protein(s)	O
present	O
in	O
both	O
SK-N-MC	O
and	O
HeLa	O
cells	O
.	O
In	O
addition	O
,	O
element	O
C	O
exhibits	O
characteristics	O
of	O
an	O
S1	B-GENE
nuclease	I-GENE
-hypersensitive	O
site	O
.	O
These	O
data	O
indicate	O
that	O
cell	O
-	O
specific	O
positive	O
cis	O
-	O
regulatory	O
elements	O
located	O
6.5	O
kb	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
may	O
play	O
an	O
important	O
role	O
in	O
transcriptional	O
regulation	O
of	O
the	O
human	O
beta	B-GENE
(3)	I-GENE
-adrenergic	I-GENE
receptor	I-GENE
.	O
These	O
data	O
also	O
suggest	O
that	O
brown	O
adipose	O
tissue	O
-	O
specific	O
transcription	O
factor(s)	O
may	O
be	O
involved	O
in	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
beta	B-GENE
(3)	I-GENE
-adrenergic	I-GENE
receptor	I-GENE
gene	O
.	O
PMID	O
:	O
11316759	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

N	O
Engl	O
J	O
Med	O
.	O
1999	O
Jun	O
24;340(	O
25	O
)	O
:1954	O
-	O
61	O
.	O
Comment	O
in	O
:	O
N	O
Engl	O
J	O
Med	O
.	O
1999	O
Jun	O
24;340(	O
25	O
)	O
:1992	O
-3.	O
Gain	O
of	O
chromosome	O
arm	O
17q	O
and	O
adverse	O
outcome	O
in	O
patients	O
with	O
neuroblastoma	O
.	O
Bown	O
N	O
,	O
Cotterill	O
S	O
,	O
Lastowska	O
M,	O
O'Neill	O
S	O
,	O
Pearson	O
AD	O
,	O
Plantaz	O
D	O
,	O
Meddeb	O
M,	O
Danglot	O
G	O
,	O
Brinkschmidt	O
C	O
,	O
Christiansen	O
H,	O
Laureys	O
G	O
,	O
Speleman	O
F	O
,	O
Nicholson	O
J,	O
Bernheim	O
A	O
,	O
Betts	O
DR	O
,	O
Vandesompele	O
J,	O
Van	O
Roy	O
N	O
.	O
Department	O
of	O
Human	O
Genetics	O
,	O
University	O
of	O
Newcastle	O
upon	O
Tyne	O
,	O
United	O
Kingdom	O
.	O
nicholas	O
.bown@ncl	O
.ac.uk	O
BACKGROUND	O
:	O
Gain	O
of	O
genetic	O
material	O
from	O
chromosome	O
arm	O
17q	O
(	O
gain	O
of	O
segment	O
17q21-qter	O
)	O
is	O
the	O
most	O
frequent	O
cytogenetic	O
abnormality	O
of	O
neuroblastoma	O
cells	O
.	O
This	O
gain	O
has	O
been	O
associated	O
with	O
advanced	O
disease	O
,	O
patients	O
who	O
are	O
>	O
or	O
=1	O
year	O
old	O
,	O
deletion	O
of	O
chromosome	O
arm	O
1p	O
,	O
and	O
amplification	O
of	O
the	O
N-myc	B-GENE
oncogene	O
,	O
all	O
of	O
which	O
predict	O
an	O
adverse	O
outcome	O
.	O
We	O
investigated	O
these	O
associations	O
and	O
evaluated	O
the	O
prognostic	O
importance	O
of	O
the	O
status	O
of	O
chromosome	O
17	O
.	O
METHODS	O
:	O
We	O
compiled	O
molecular	O
cytogenetic	O
analyses	O
of	O
chromosome	O
17	O
in	O
primary	O
neuroblastomas	O
in	O
313	O
patients	O
at	O
six	O
European	O
centers	O
.	O
Clinical	O
and	O
survival	O
information	O
were	O
collected	O
,	O
along	O
with	O
data	O
on	O
1p	O
,	O
N-myc	B-GENE
,	O
and	O
ploidy	O
.	O
RESULTS	O
:	O
Unbalanced	O
gain	O
of	O
segment	O
17q21-qter	O
was	O
found	O
in	O
53.7	O
percent	O
of	O
the	O
tumors	O
,	O
whereas	O
the	O
chromosome	O
was	O
normal	O
in	O
46.3	O
percent	O
.	O
The	O
gain	O
of	O
17q	O
was	O
characteristic	O
of	O
advanced	O
tumors	O
and	O
of	O
tumors	O
in	O
children	O
>	O
or	O
=1	O
year	O
of	O
age	O
and	O
was	O
strongly	O
associated	O
with	O
the	O
deletion	O
of	O
1p	O
and	O
amplification	O
of	O
N-myc	B-GENE
.	O
No	O
tumor	O
showed	O
amplification	O
of	O
N-myc	B-GENE
in	O
the	O
absence	O
of	O
either	O
deletion	O
of	O
1p	O
or	O
gain	O
of	O
17q	O
.	O
Gain	O
of	O
17q	O
was	O
a	O
significant	O
predictive	O
factor	O
for	O
adverse	O
outcome	O
in	O
univariate	O
analysis	O
.	O
Among	O
the	O
patients	O
with	O
this	O
abnormality	O
,	O
overall	O
survival	O
at	O
five	O
years	O
was	O
30.6	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
21	O
to	O
40	O
percent	O
)	O
,	O
as	O
compared	O
with	O
86.0	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
78	O
to	O
91	O
percent	O
)	O
among	O
those	O
with	O
normal	O
17q	O
status	O
.	O
in	O
multivariate	O
analysis	O
,	O
gain	O
of	O
17q	O
was	O
the	O
most	O
powerful	O
prognostic	O
factor	O
,	O
followed	O
by	O
the	O
presence	O
of	O
stage	O
4	O
disease	O
and	O
deletion	O
of	O
1p	O
(	O
hazard	O
ratios	O
,	O
3.4	O
,	O
2.3	O
,	O
and	O
1.9	O
,	O
respectively	O
)	O
.	O
CONCLUSIONS	O
:	O
Gain	O
of	O
chromosome	O
segment	O
17q21-qter	O
is	O
an	O
important	O
prognostic	O
factor	O
in	O
children	O
with	O
neuroblastoma	O
.	O
Publication	O
Types	O
:	O
Multicenter	O
Study	O
PMID	O
:	O
10379019	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Brain	O
Res	O
Rev	O
.	O
2000	O
Apr;32	O
(	O
1	O
)	O
:	O
308-15	O
.	O
Gap	O
junctions	O
:	O
the	O
"	O
kiss	O
of	O
death	O
"	O
and	O
the	O
"	O
kiss	O
of	O
life"	O
.	O
Andrade-Rozental	O
AF	O
,	O
Rozental	O
R	O
,	O
Hopperstad	O
MG	O
,	O
Wu	O
JK	O
,	O
Vrionis	O
FD	O
,	O
Spray	O
DC.	O
Department	O
of	O
Neuroscience	O
,	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
,	O
Montefiore	O
Medical	O
Center	O
,	O
Bronx	O
,	O
NY	O
10461	O
,	O
USA	O
.	O
rozental@aecom.yu.edu	O
Cells	O
expressing	O
herpes	B-GENE
simplex-thymidine	I-GENE
kinase	I-GENE
(	O
HSV-tk	B-GENE
)	O
can	O
be	O
killed	O
"	O
in	O
vitro	O
"	O
within	O
5	O
days	O
of	O
treatment	O
with	O
20	O
microM	O
ganciclovir	O
(	O
GCV	O
)	O
and	O
transmit	O
this	O
toxicity	O
to	O
adjacent	O
cells	O
lacking	O
HSV-tk	B-GENE
;	O
this	O
phenomenon	O
was	O
termed	O
"	O
bystander	O
effect	O
"	O
or	O
"	O
kiss	O
of	O
death"	O
.	O
On	O
testing	O
a	O
large	O
number	O
of	O
cell	O
lines	O
in	O
vitro	O
,	O
a	O
wide	O
range	O
of	O
sensitivity	O
to	O
GCV	O
-	O
mediated	O
bystander	O
killing	O
has	O
been	O
reported	O
.	O
Although	O
intercellular	O
transfer	O
of	O
GCV	O
metabolites	O
through	O
gap	O
junction	O
channels	O
seems	O
to	O
be	O
a	O
likely	O
mechanism	O
for	O
the	O
"	O
kiss	O
of	O
death"	O
,	O
some	O
studies	O
suggest	O
that	O
other	O
pathways	O
may	O
contribute	O
to	O
induced	O
apoptosis	O
of	O
neighboring	O
cells	O
.	O
To	O
further	O
investigate	O
the	O
mechanism	O
underlying	O
cell	O
death	O
mediated	O
by	O
HSV-tk	B-GENE
and	O
to	O
evaluate	O
the	O
efficacy	O
of	O
gap	O
junction	O
channels	O
formed	O
by	O
different	O
connexins	B-GENE
in	O
this	O
process	O
,	O
we	O
have	O
stably	O
transfected	O
a	O
virtually	O
uncoupled	O
mouse	O
neuroblastoma	O
cell	O
line	O
(	O
N2A	O
cells	O
)	O
with	O
different	O
connexin	B-GENE
-	O
types	O
expressed	O
by	O
neural	O
cells	O
(	O
Cx32	B-GENE
,	O
Cx37	B-GENE
,	O
Cx40	B-GENE
,	O
Cx43	B-GENE
)	O
and	O
co	O
-	O
cultured	O
these	O
cells	O
with	O
N2A	O
cells	O
stably	O
transfected	O
with	O
Cx37	B-GENE
and	O
HSV-tk	B-GENE
.	O
Here	O
,	O
we	O
confirm	O
our	O
previous	O
studies	O
and	O
those	O
of	O
others	O
that	O
the	O
extent	O
of	O
cell	O
death	O
and	O
sensitivity	O
to	O
GCV	O
depend	O
on	O
the	O
degree	O
of	O
connexin	B-GENE
expression	O
in	O
transfectants	O
.	O
Further	O
,	O
we	O
show	O
that	O
the	O
bystander	O
effect	O
also	O
depends	O
on	O
which	O
connexin	B-GENE
is	O
expressed	O
;	O
reported	O
disparities	O
regarding	O
the	O
extent	O
of	O
GCV	O
-	O
mediated	O
cellular	O
apoptosis	O
are	O
likely	O
due	O
both	O
to	O
the	O
degree	O
of	O
functional	O
coupling	O
and	O
the	O
type	O
of	O
connexin	B-GENE
expressed	O
.	O
These	O
results	O
support	O
the	O
notion	O
that	O
gap	O
junction	O
hemichannels	O
formed	O
of	O
certain	O
connexins	B-GENE
are	O
more	O
likely	O
than	O
others	O
to	O
pair	O
functionally	O
with	O
Cx37	B-GENE
,	O
and	O
suggest	O
co	O
-	O
transfection	O
strategies	O
that	O
might	O
prove	O
effective	O
in	O
sensitizing	O
tumor	O
cell	O
populations	O
to	O
GCV	O
.	O
In	O
addition	O
,	O
potential	O
applications	O
are	O
discussed	O
for	O
use	O
of	O
the	O
"	O
good	O
Samaritan	O
effect	O
"	O
,	O
a	O
mechanism	O
by	O
which	O
bystander	O
cells	O
have	O
been	O
suggested	O
to	O
prevent	O
cytotoxicity	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
10751679	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
1998	O
Nov;71	O
(	O
5	O
)	O
:193	O
5-43	O
.	O
Characterization	O
of	O
the	O
phosphoinositide	B-GENE
-	I-GENE
linked	I-GENE
dopamine	I-GENE
receptor	I-GENE
in	O
a	O
mouse	O
hippocampal	O
-	O
neuroblastoma	O
hybrid	O
cell	O
line	O
.	O
Jin	O
LQ	O
,	O
Cai	O
G	O
,	O
Wang	O
HY	O
,	O
Smith	O
C	O
,	O
Friedman	O
E.	O
Department	O
of	O
Pharmacology	O
,	O
MCP-Hahnemann	O
School	O
of	O
Medicine	O
,	O
Allegheny	O
University	O
of	O
the	O
Health	O
Sciences	O
,	O
Philadelphia	O
,	O
Pennsylvania	O
19129	O
,	O
USA	O
.	O
Previous	O
studies	O
have	O
established	O
that	O
dopamine	O
(	O
DA	O
)	O
can	O
stimulate	O
phosphoinositide	O
(	O
PI	O
)	O
metabolism	O
in	O
the	O
CNS	O
and	O
in	O
the	O
periphery	O
.	O
The	O
present	O
study	O
summarizes	O
our	O
attempt	O
to	O
find	O
a	O
cell	O
line	O
that	O
expresses	O
this	O
dopaminergic	O
system	O
.	O
We	O
describe	O
that	O
the	O
stable	O
clonal	O
HN33	O
.11	O
cell	O
line	O
,	O
established	O
by	O
fusion	O
of	O
mouse	O
hippocampal	O
cells	O
with	O
neuroblastoma	O
cells	O
(	O
N18TG2	O
)	O
that	O
originate	O
from	O
A	O
/	O
J	O
mouse	O
,	O
natively	O
expresses	O
the	O
D1	B-GENE
DA	I-GENE
receptor	I-GENE
system	O
that	O
couples	O
to	O
PI	O
hydrolysis	O
.	O
In	O
this	O
cell	O
line	O
,	O
500	O
microM	O
DA	O
or	O
SKF38393	O
produced	O
43	O
and	O
75	O
%	O
increases	O
in	O
inositol	O
phosphate	O
(	O
IP	O
)	O
accumulations	O
,	O
respectively	O
.	O
In	O
contrast	O
,	O
noradrenaline	O
or	O
5-hydroxytryptamine	O
did	O
not	O
affect	O
IP	O
accumulations	O
.	O
The	O
formation	O
of	O
IP	O
that	O
was	O
stimulated	O
by	O
DA	O
or	O
SKF38393	O
was	O
selectively	O
blocked	O
by	O
the	O
D1	B-GENE
DA	I-GENE
receptor	I-GENE
antagonist	O
SCH23390	O
with	O
IC50	O
values	O
of	O
13	O
and	O
16	O
microM	O
.	O
This	O
response	O
was	O
not	O
mediated	O
by	O
the	O
D1A	B-GENE
DA	I-GENE
receptor	I-GENE
and	O
was	O
cyclic	O
AMP	O
-	O
independent	O
,	O
as	O
HN33	O
.11	O
cells	O
did	O
not	O
express	O
this	O
receptor	O
,	O
and	O
DA	O
or	O
SKF38393	O
was	O
unable	O
to	O
stimulate	O
the	O
formation	O
of	O
cyclic	O
AMP	O
.	O
In	O
Ca2	O
+	O
-free	O
/	O
100	O
microM	O
EGTA	O
medium	O
,	O
basal	O
IP	O
level	O
was	O
reduced	O
by	O
31.5	O
%	O
,	O
but	O
SKF38393	O
-	O
stimulated	O
PI	O
hydrolysis	O
was	O
not	O
affected	O
.	O
SKF38393	O
-	O
stimulated	O
IP	O
accumulation	O
was	O
also	O
not	O
affected	O
by	O
pertussis	B-GENE
toxin	I-GENE
(	O
PTX	B-GENE
)	O
treatment	O
(	O
200	O
ng	O
/	O
ml	O
)	O
,	O
suggesting	O
that	O
this	O
dopaminergic	O
response	O
is	O
mediated	O
by	O
PTX	B-GENE
-	I-GENE
insensitive	I-GENE
G	I-GENE
proteins	I-GENE
.	O
Co	O
-	O
immunoprecipitation	O
studies	O
indicated	O
that	O
in	O
membranes	O
of	O
HN33	O
.11	O
cells	O
,	O
D1	B-GENE
-	O
like	O
binding	O
sites	O
are	O
coupled	O
to	O
G	B-GENE
alpha(q)	I-GENE
protein	O
.	O
Blockade	O
of	O
SKF38393	O
-	O
induced	O
PI	O
hydrolysis	O
with	O
antiserum	O
against	O
phospholipase	B-GENE
C	I-GENE
(	I-GENE
PLC	I-GENE
)	I-GENE
isozymes	I-GENE
,	O
performed	O
in	O
permeabilized	O
cells	O
,	O
as	O
well	O
as	O
co	O
-	O
immunoprecipitation	O
studies	O
implicate	O
PLCbeta3	B-GENE
and	O
PLCbeta4	B-GENE
in	O
this	O
dopaminergically	O
mediated	O
PI	O
hydrolysis	O
cascade	O
.	O
The	O
results	O
indicate	O
that	O
HN33	O
.11	O
cells	O
express	O
a	O
D1	B-GENE
-	I-GENE
like	I-GENE
DA	I-GENE
receptor	I-GENE
that	O
couples	O
to	O
PLCbeta	B-GENE
3	I-GENE
/	O
4	B-GENE
via	O
G	B-GENE
alpha(q)	I-GENE
protein	O
.	O
These	O
cells	O
may	O
therefore	O
be	O
a	O
useful	O
model	O
system	O
for	O
investigating	O
this	O
receptor	O
system	O
.	O
PMID	O
:	O
9798918	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Neuroendocrinology	O
.	O
1996	O
Feb;6	O
3(	O
2	O
)	O
:	O
18	O
8	O
-	O
97	O
.	O
Somatostatin	B-GENE
-	I-GENE
14	I-GENE
mainly	O
binds	O
the	O
somatostatin	B-GENE
receptor	I-GENE
subtype	I-GENE
2	I-GENE
in	O
human	O
neuroblastoma	O
tumors	O
.	O
Prevost	O
G	O
,	O
Veber	O
N	O
,	O
Viollet	O
C	O
,	O
Roubert	O
V	O
,	O
Roubert	O
P,	O
Benard	O
J,	O
Eden	O
P.	O
Institut	O
d'Oncologie	O
Cellulaire	O
et	O
Moleculaire	O
Humaine	O
,	O
Bobigny	O
,	O
France	O
.	O
Neuroblastoma	O
is	O
a	O
pediatric	O
cancer	O
for	O
which	O
a	O
cure	O
is	O
elusive	O
for	O
most	O
children	O
with	O
disseminated	O
disease	O
.	O
Neuroblastomas	O
possess	O
receptors	O
for	O
somatostatin	B-GENE
(	O
SS	B-GENE
)	I-GENE
.	O
Some	O
SS	B-GENE
analogues	O
can	O
inhibit	O
their	O
proliferation	O
.	O
In	O
addition	O
,	O
when	O
SS	B-GENE
analogues	O
were	O
used	O
as	O
agents	O
for	O
scintigraphy	O
,	O
neuroblastoma	O
tumor	O
sites	O
can	O
be	O
localized	O
with	O
high	O
efficiency	O
.	O
In	O
this	O
study	O
,	O
to	O
better	O
characterize	O
the	O
SS	B-GENE
receptor	I-GENE
subtype(s)	I-GENE
(	O
sst1-	B-GENE
5	I-GENE
)	O
present	O
in	O
primary	O
tumors	O
and	O
metastases	O
of	O
neuroblastoma	O
,	O
we	O
show	O
that	O
:	O
(1)	O
The	O
ligand	O
125I	O
-Tyr11-SS	O
-14	O
binding	O
on	O
membrane	O
proteins	O
from	O
primary	O
tumors	O
and	O
metastases	O
of	O
neuroblastoma	O
cell	O
line	O
IGR-N-91	O
developed	O
in	O
nude	O
mice	O
shows	O
similar	O
values	O
of	O
Kd	O
(	O
in	O
order	O
of	O
0.1	O
nM	O
)	O
and	O
Bmax	O
(	O
in	O
order	O
of	O
fmol	O
/	O
mg	O
)	O
by	O
filter	O
-	O
retention	O
assay	O
.	O
These	O
data	O
are	O
close	O
to	O
those	O
measured	O
on	O
two	O
other	O
neuroblastoma	O
cell	O
lines	O
:	O
SK-N-SH	O
and	O
IGR-N-835	O
or	O
to	O
that	O
measured	O
on	O
the	O
rat	O
cerebral	O
cortex	O
.	O
(2)	O
The	O
IGR-N-91	O
sublines	O
derived	O
from	O
primary	O
tumor	O
and	O
metastases	O
show	O
one	O
major	O
complex	O
of	O
57	O
kD	O
by	O
the	O
chemical	O
cross	O
-	O
linking	O
assay	O
using	O
the	O
ligands	O
:	O
125I-SS	O
-14	O
and	O
125I-BIM23014	O
.	O
One	O
similar	O
major	O
complex	O
of	O
57	O
kD	O
was	O
also	O
detected	O
in	O
SK-N-SH	O
and	O
IGR-N-835	O
or	O
in	O
the	O
cerebral	O
cortex	O
.	O
(	O
3	O
)	O
Addition	O
of	O
excess	O
nonlabeled	O
peptides	O
selective	O
for	O
sst2	B-GENE
(	O
BIM23014	O
,	O
BIM23060	O
,	O
BIM23068	O
)	O
suppressed	O
the	O
formation	O
of	O
the	O
complex	O
57	O
kD	O
whereas	O
addition	O
of	O
BIM23052	O
or	O
BIM23056	O
(	O
sst5	B-GENE
and	O
sst3	B-GENE
selective	O
respectively	O
)	O
does	O
not	O
.	O
This	O
pharmacological	O
profile	O
corresponds	O
to	O
sst2	B-GENE
.	O
(4)	O
Only	O
RNA	O
message	O
of	O
sst2	B-GENE
gene	O
is	O
detected	O
in	O
IGR-N-91	O
cells	O
and	O
its	O
metastases	O
derived	O
sublines	O
by	O
reverse	O
-	O
transcription	O
-	O
polymerase	B-GENE
chain	O
reaction	O
and	O
Northern	O
hybridization	O
in	O
keeping	O
with	O
the	O
presence	O
of	O
sst2	B-GENE
.	O
(	O
5	O
)	O
In	O
human	O
biopsies	O
,	O
the	O
complex	O
of	O
57	O
kD	O
corresponding	O
to	O
sst2	B-GENE
is	O
consistently	O
detected	O
in	O
three	O
samples	O
of	O
the	O
histological	O
subset	O
of	O
the	O
disease	O
:	O
benign	O
ganglioneuroma	O
,	O
ganglioneuroblastoma	O
and	O
immature	O
neuroblastoma	O
.	O
Therefore	O
,	O
the	O
sst2	B-GENE
should	O
be	O
considered	O
as	O
the	O
primary	O
target	O
to	O
develop	O
more	O
potent	O
SS	O
analogues	O
for	O
neuroblastoma	O
therapy	O
or	O
/	O
and	O
scintigraphy	O
.	O
PMID	O
:	O
9053784	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2003	O
Nov;87	O
(	O
3	O
)	O
:	O
620-	O
30	O
.	O
Fe(II)	O
-	O
induced	O
DNA	O
damage	O
in	O
alpha	B-GENE
-	I-GENE
synuclein	I-GENE
-	O
transfected	O
human	O
dopaminergic	O
BE(2)-M17	O
neuroblastoma	O
cells	O
:	O
detection	O
by	O
the	O
Comet	O
assay	O
.	O
Martin	O
FL	O
,	O
Williamson	O
SJ	O
,	O
Paleologou	O
KE	O
,	O
Hewitt	O
R	O
,	O
El	O
-Agnaf	O
OM	O
,	O
Allsop	O
D.	O
Lewy	O
bodies	O
in	O
the	O
brains	O
of	O
patients	O
with	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
contain	O
aggregates	O
of	O
alpha	B-GENE
-	I-GENE
synuclein	I-GENE
(	O
alpha	B-GENE
-	I-GENE
syn	I-GENE
)	O
.	O
Missense	O
mutations	O
(	O
A	O
53	O
T	O
or	O
A	O
30	O
P	O
)	O
in	O
the	O
gene	O
encoding	O
alpha	B-GENE
-	I-GENE
syn	I-GENE
are	O
responsible	O
for	O
rare	O
,	O
inherited	O
forms	O
of	O
PD	O
.	O
In	O
this	O
study	O
,	O
we	O
explored	O
the	O
susceptibility	O
of	O
untransfected	O
human	O
dopaminergic	O
BE(2)-M17	O
neuroblastoma	O
cells	O
,	O
cells	O
transfected	O
with	O
vector	O
only	O
,	O
or	O
cells	O
transfected	O
with	O
wild-type	O
alpha	B-GENE
-	I-GENE
syn	I-GENE
,	O
A	B-GENE
30	I-GENE
P	I-GENE
alpha	I-GENE
-	I-GENE
syn	I-GENE
or	O
A	B-GENE
53	I-GENE
T	I-GENE
alpha	I-GENE
-	I-GENE
syn	I-GENE
to	O
Fe(II)	O
-	O
induced	O
DNA	O
damage	O
in	O
the	O
form	O
of	O
single	O
-	O
strand	O
breaks	O
(	O
SSBs	O
)	O
.	O
DNA	O
SSBs	O
were	O
detected	O
following	O
2	O
-	O
h	O
treatments	O
with	O
various	O
concentrations	O
of	O
Fe(II)	O
(	O
0.01	O
-	O
100.0	O
microm	O
)	O
,	O
using	O
the	O
alkaline	O
single	O
cell	O
-	O
gel	O
electrophoresis	O
(	O
'Comet'	O
)	O
assay	O
and	O
quantified	O
by	O
measuring	O
comet	O
tail	O
length	O
(	O
CTL	O
)	O
microm	O
)	O
.	O
Fe(II)	O
treatment	O
induced	O
significant	O
increases	O
in	O
CTL	O
in	O
cells	O
transfected	O
with	O
A	B-GENE
30	I-GENE
P	I-GENE
alpha	I-GENE
-	I-GENE
syn	I-GENE
or	O
A	B-GENE
53	I-GENE
T	I-GENE
alpha	I-GENE
-	I-GENE
syn	I-GENE
,	O
even	O
at	O
the	O
lowest	O
concentrations	O
of	O
Fe(II)	O
tested	O
.	O
In	O
comparison	O
,	O
untransfected	O
cells	O
,	O
vector	O
control	O
cells	O
or	O
cells	O
transfected	O
with	O
wild-type	O
alpha	B-GENE
-	I-GENE
syn	I-GENE
exhibited	O
increases	O
in	O
SSBs	O
only	O
when	O
exposed	O
to	O
concentrations	O
of	O
1.0	O
microm	O
Fe(II)	O
and	O
above	O
.	O
Even	O
when	O
exposed	O
to	O
higher	O
concentrations	O
(	O
10.0	O
-	O
100.0	O
microm	O
)	O
of	O
Fe(II)	O
,	O
untransfected	O
cells	O
,	O
vector	O
control	O
cells	O
or	O
cells	O
transfected	O
with	O
wild-type	O
alpha	B-GENE
-	I-GENE
syn	I-GENE
were	O
less	O
susceptible	O
to	O
DNA	O
-	O
damage	O
induction	O
than	O
cells	O
transfected	O
with	O
A	B-GENE
30	I-GENE
P	I-GENE
alpha	I-GENE
-	I-GENE
syn	I-GENE
or	O
A	B-GENE
53	I-GENE
T	I-GENE
alpha	I-GENE
-	I-GENE
syn	I-GENE
.	O
Incorporation	O
of	O
DNA	O
-	O
repair	O
inhibitors	O
,	O
hydroxyurea	O
and	O
cytosine	O
arabinoside	O
,	O
enhanced	O
the	O
sensitivity	O
of	O
DNA	O
damage	O
detection	O
.	O
Susceptibility	O
to	O
Fe(II)	O
-	O
induced	O
DNA	O
damage	O
appeared	O
to	O
be	O
dependent	O
on	O
alpha	B-GENE
-	I-GENE
syn	I-GENE
status	O
because	O
cells	O
transfected	O
with	O
wild-type	O
alpha	B-GENE
-	I-GENE
syn	I-GENE
or	O
A	B-GENE
53	I-GENE
T	I-GENE
alpha	I-GENE
-	I-GENE
syn	I-GENE
were	O
equally	O
susceptible	O
to	O
the	O
damaging	O
effects	O
of	O
the	O
mitochondrial	O
respiratory	O
chain	O
inhibitor	O
rotenone	O
.	O
Overall	O
,	O
our	O
data	O
are	O
suggestive	O
of	O
an	O
enhanced	O
susceptibility	O
to	O
the	O
toxic	O
effects	O
of	O
Fe(II)	O
in	O
neuroblastoma	O
cells	O
transfected	O
with	O
mutant	O
alpha	B-GENE
-	I-GENE
syn	I-GENE
associated	O
with	O
inherited	O
forms	O
of	O
PD	O
.	O
PMID	O
:	O
14535945	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Mol	O
Neurosci	O
.	O
1997	O
Feb;	O
8	O
(	O
1	O
)	O
:	O
63	O
-	O
73	O
.	O
Sequences	O
in	O
the	O
proximal	O
5	O
'	O
flanking	O
region	O
of	O
the	O
rat	O
neuron	B-GENE
-	I-GENE
specific	I-GENE
enolase	I-GENE
(	O
NSE	B-GENE
)	O
gene	O
are	O
sufficient	O
for	O
cell	O
type	O
-	O
specific	O
reporter	O
gene	O
expression	O
.	O
Twyman	O
RM	O
,	O
Jones	O
EA	O
.	O
Department	O
of	O
Biological	O
Sciences	O
,	O
University	O
of	O
Warwick	O
,	O
Coventry	O
,	O
UK.	O
We	O
investigated	O
the	O
regulation	O
of	O
the	O
rat	O
neuron	B-GENE
-	I-GENE
specific	I-GENE
enolase	I-GENE
gene	O
using	O
a	O
transient	O
transfection	O
approach	O
.	O
Recent	O
transgenic	O
mouse	O
studies	O
have	O
shown	O
that	O
a	O
1.8	O
-	O
kb	O
segment	O
of	O
the	O
rat	O
NSE	B-GENE
gene	O
5	O
'	O
flanking	O
region	O
,	O
including	O
the	O
first	O
(	O
noncoding	O
)	O
exon	O
but	O
not	O
the	O
first	O
intron	O
,	O
is	O
able	O
to	O
drive	O
expression	O
of	O
a	O
reporter	O
gene	O
in	O
parallel	O
with	O
endogenous	O
NSE	B-GENE
.	O
These	O
data	O
suggest	O
that	O
cis	O
-	O
acting	O
elements	O
responsible	O
for	O
the	O
spatial	O
and	O
temporal	O
pattern	O
of	O
NSE	B-GENE
gene	O
expression	O
are	O
located	O
within	O
the	O
proximal	O
1.8	O
kb	O
of	O
the	O
5	O
'	O
flanking	O
sequence	O
.	O
To	O
further	O
investigate	O
this	O
region	O
,	O
we	O
joined	O
the	O
1.8	O
-	O
kb	O
regulatory	O
cassette	O
to	O
the	O
cat	B-GENE
reporter	I-GENE
gene	O
and	O
generated	O
a	O
number	O
of	O
constructs	O
in	O
which	O
the	O
flanking	O
sequence	O
was	O
progressively	O
deleted	O
from	O
the	O
5	O
'	O
end	O
.	O
These	O
constructs	O
were	O
tested	O
by	O
transient	O
transfection	O
into	O
neuronal	O
and	O
nonneuronal	O
cells	O
,	O
followed	O
by	O
an	O
assay	O
for	O
CAT	B-GENE
activity	O
.	O
We	O
found	O
that	O
as	O
little	O
as	O
255	O
bp	O
of	O
5	O
'	O
flanking	O
sequence	O
was	O
able	O
to	O
confer	O
cell	O
type	O
-	O
specificity	O
on	O
the	O
reporter	O
gene	O
.	O
Further	O
truncation	O
to	O
120	O
bp	O
of	O
5	O
'	O
sequence	O
resulted	O
in	O
a	O
sharp	O
downregulation	O
of	O
reporter	O
activity	O
in	O
PC12	O
cells	O
but	O
a	O
significant	O
rise	O
in	O
both	O
Neuro-2A	O
neuroblastoma	O
cells	O
and	O
nonneuronal	O
Ltk	O
-	O
cells	O
,	O
indicating	O
that	O
cis	O
-	O
acting	O
elements	O
controlling	O
the	O
regulation	O
of	O
NSE	B-GENE
in	O
Ltk	O
-	O
,	O
Neuro-2A	O
,	O
and	O
PC12	O
cells	O
may	O
lie	O
within	O
the	O
135	O
bp	O
region	O
covered	O
by	O
this	O
deletion	O
.	O
This	O
region	O
contains	O
an	O
AP-2	B-GENE
site	O
and	O
an	O
element	O
similar	O
in	O
sequence	O
and	O
position	O
to	O
a	O
motif	O
identified	O
in	O
the	O
proximal	O
promoter	O
region	O
of	O
the	O
neuron	B-GENE
-	I-GENE
specific	I-GENE
peripherin	I-GENE
gene	O
.	O
Reduction	O
to	O
95	O
bp	O
of	O
5	O
'	O
sequence	O
resulted	O
in	O
a	O
slight	O
downregulation	O
of	O
CAT	B-GENE
activity	O
in	O
all	O
cell	O
lines	O
tested	O
,	O
and	O
further	O
truncation	O
to	O
65	O
bp	O
of	O
5	O
'	O
sequence	O
caused	O
a	O
universal	O
reduction	O
to	O
background	O
levels	O
of	O
CAT	B-GENE
activity	O
,	O
concomitant	O
with	O
the	O
disruption	O
of	O
the	O
basal	O
NSE	B-GENE
promoter	O
.	O
Our	O
results	O
show	O
that	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
NSE	B-GENE
gene	O
is	O
capable	O
of	O
conferring	O
cell	O
type	O
-	O
specificity	O
on	O
a	O
heterologous	O
gene	O
in	O
transfected	O
cells	O
and	O
that	O
elements	O
responsible	O
for	O
this	O
are	O
located	O
within	O
the	O
proximal	O
255	O
bp	O
.	O
PMID	O
:	O
9061616	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Brain	O
Res	O
Rev	O
.	O
2001	O
Nov;37	O
(	O
1-3	O
)	O
:	O
33	O
5-42	O
.	O
Estrogen	O
neuroprotection	O
:	O
the	O
involvement	O
of	O
the	O
Bcl-2	B-GENE
binding	O
protein	O
BNIP2	B-GENE
.	O
Belcredito	O
S	O
,	O
Vegeto	O
E	O
,	O
Brusadelli	O
A	O
,	O
Ghisletti	O
S	O
,	O
Mussi	O
P,	O
Ciana	O
P,	O
Maggi	O
A	O
.	O
Center	O
of	O
Excellence	O
for	O
Neurodegenerative	O
Disorders	O
and	O
Department	O
of	O
Pharmacological	O
Sciences	O
University	O
of	O
Milan	O
,	O
Via	O
Balzaretti	O
9	O
,	O
20133	O
,	O
Milan	O
,	O
Italy	O
.	O
To	O
identify	O
genes	O
selectively	O
induced	O
by	O
estrogens	O
in	O
cells	O
of	O
neural	O
origin	O
we	O
have	O
treated	O
with	O
a	O
low	O
concentration	O
of	O
17	O
beta-estradiol	O
(	O
E2	O
)	O
the	O
estrogen	B-GENE
-	I-GENE
receptor	I-GENE
positive	O
SK-ER3	O
neuroblastoma	O
cells	O
and	O
we	O
have	O
isolated	O
messages	O
modulated	O
by	O
the	O
hormonal	O
treatment	O
at	O
short	O
(	O
1	O
h	O
)	O
and	O
longer	O
(	O
17	O
h	O
)	O
times	O
.	O
By	O
using	O
the	O
ddPCR	O
approach	O
we	O
identified	O
numerous	O
messages	O
which	O
content	O
was	O
significantly	O
and	O
reproducibly	O
altered	O
by	O
the	O
hormonal	O
treatment	O
.	O
Among	O
these	O
messages	O
we	O
focused	O
our	O
attention	O
on	O
bnip2	B-GENE
,	O
which	O
expression	O
was	O
inhibited	O
by	O
estradiol	O
.	O
bnip2	B-GENE
was	O
found	O
to	O
be	O
a	O
member	O
of	O
the	O
BNIP	B-GENE
family	O
of	O
genes	O
of	O
unknown	O
physiological	O
activity	O
at	O
the	O
time	O
.	O
Investigations	O
carried	O
out	O
in	O
our	O
laboratory	O
proved	O
a	O
strong	O
correlation	O
between	O
the	O
increased	O
expression	O
of	O
bnip2	B-GENE
gene	O
and	O
cell	O
death	O
induced	O
by	O
toxic	O
stimuli	O
.	O
Furthermore	O
,	O
we	O
showed	O
that	O
transfection	O
of	O
the	O
bnip2	B-GENE
cDNA	O
results	O
in	O
massive	O
cell	O
death	O
and	O
Bcl-2	B-GENE
overexpression	O
counteracts	O
the	O
toxic	O
effect	O
of	O
bnip2	B-GENE
.	O
These	O
findings	O
suggest	O
that	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
genes	O
either	O
interact	O
or	O
act	O
in	O
an	O
opposite	O
manner	O
on	O
the	O
same	O
mechanisms	O
triggering	O
the	O
apoptotic	O
cascade	O
of	O
events	O
.	O
Time	O
-	O
course	O
experiments	O
carried	O
out	O
in	O
different	O
cell	O
systems	O
and	O
with	O
a	O
variety	O
of	O
neurotoxic	O
agents	O
proved	O
a	O
strong	O
correlation	O
between	O
estrogen	O
-	O
induced	O
decrease	O
in	O
bnip2	B-GENE
expression	O
and	O
the	O
time	O
required	O
for	O
estrogen	O
to	O
exert	O
its	O
protective	O
effect	O
.	O
These	O
observations	O
led	O
us	O
to	O
hypothesize	O
an	O
involvement	O
of	O
bnip2	B-GENE
in	O
estrogen	O
effects	O
on	O
cell	O
survival	O
.	O
The	O
finding	O
that	O
bnip2	B-GENE
is	O
developmentally	O
regulated	O
may	O
suggest	O
a	O
role	O
of	O
this	O
gene	O
in	O
those	O
brain	O
areas	O
where	O
the	O
differentiation	O
is	O
orchestrated	O
by	O
estradiol	O
.	O
Investigations	O
in	O
non	O
-	O
neural	O
cells	O
show	O
that	O
bnip2	B-GENE
is	O
the	O
mediator	O
of	O
the	O
anti	O
-	O
apoptotic	O
activity	O
of	O
estrogens	O
in	O
a	O
variety	O
of	O
cells	O
and	O
thus	O
might	O
represent	O
an	O
important	O
target	O
for	O
the	O
evaluation	O
of	O
the	O
activity	O
of	O
novel	O
synthetic	O
ligands	O
for	O
the	O
estrogen	B-GENE
receptor	I-GENE
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
11744098	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Pharmacol	O
.	O
1998	O
Sep;125(	O
2	O
)	O
:	O
347	O
-	O
56	O
.	O
Enhanced	O
expression	O
of	O
G	B-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
receptor	I-GENE
kinase	I-GENE
2	I-GENE
selectively	O
increases	O
the	O
sensitivity	O
of	O
A2A	B-GENE
adenosine	I-GENE
receptors	I-GENE
to	O
agonist	O
-	O
induced	O
desensitization	O
.	O
Mundell	O
SJ	O
,	O
Luty	O
JS	O
,	O
Willets	O
J,	O
Benovic	O
JL	O
,	O
Kelly	O
E.	O
Department	O
of	O
Pharmacology	O
,	O
School	O
of	O
Medical	O
Sciences	O
,	O
University	O
of	O
Bristol	O
,	O
UK.	O
1	O
.	O
G	B-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
receptor	I-GENE
kinases	I-GENE
(	O
GRKs	B-GENE
)	O
are	O
thought	O
to	O
be	O
important	O
in	O
mediating	O
the	O
agonist	O
-	O
induced	O
phosphorylation	O
and	O
consequent	O
desensitization	O
of	O
G	B-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
receptor	I-GENE
(	O
GPCR	B-GENE
)	O
responses	O
.	O
We	O
have	O
previously	O
shown	O
that	O
stable	O
expression	O
of	O
a	O
dominant	O
negative	O
mutant	O
G	B-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
receptor	I-GENE
kinase	I-GENE
2	I-GENE
(	O
GRK2	B-GENE
)	O
construct	O
in	O
NG108-15	O
mouse	O
neuroblastoma	O
x	O
rat	O
glioma	O
cells	O
suppresses	O
the	O
agonist	O
-	O
induced	O
desensitization	O
of	O
A2A	B-GENE
and	O
A2B	B-GENE
adenosine	I-GENE
receptor	I-GENE
-	I-GENE
stimulated	I-GENE
adenylyl	I-GENE
cyclase	I-GENE
activity	O
(	O
Mundell	O
et	O
al.	O
,	O
1997	O
)	O
.	O
To	O
further	O
determine	O
the	O
role	O
of	O
GRK2	B-GENE
in	O
agonist	O
-	O
induced	O
desensitization	O
of	O
these	O
adenosine	B-GENE
receptors	I-GENE
,	O
we	O
stably	O
overexpressed	O
wild	O
type	O
GRK2	B-GENE
in	O
NG108-15	O
cells	O
.	O
2.	O
In	O
homogenates	O
prepared	O
from	O
cells	O
overexpressing	O
GRK2	B-GENE
,	O
the	O
acute	O
stimulation	O
of	O
adenylyl	B-GENE
cyclase	I-GENE
by	O
activation	O
of	O
A2A	B-GENE
and	O
A2B	B-GENE
adenosine	I-GENE
receptors	I-GENE
was	O
markedly	O
reduced	O
,	O
but	O
could	O
be	O
reversed	O
by	O
pretreating	O
the	O
cells	O
with	O
AD	B-GENE
(	O
adenosine	B-GENE
deaminase	I-GENE
)	O
,	O
to	O
remove	O
extracellular	O
adenosine	O
from	O
the	O
medium	O
.	O
On	O
the	O
other	O
hand	O
,	O
acute	O
stimulation	O
of	O
adenylyl	B-GENE
cyclase	I-GENE
by	O
secretin	B-GENE
,	O
iloprost	O
,	O
NaF	O
and	O
forskolin	O
was	O
the	O
same	O
in	O
GRK2	B-GENE
overexpressing	O
cells	O
and	O
plasmid	O
-	O
transfected	O
control	O
cells	O
.	O
3	O
.	O
Cells	O
overexpressing	O
GRK2	B-GENE
were	O
more	O
sensitive	O
to	O
adenosine	B-GENE
receptor	I-GENE
agonist	O
-	O
induced	O
desensitization	O
than	O
plasmid	O
-	O
transfected	O
control	O
cells	O
.	O
This	O
effect	O
was	O
selective	O
since	O
the	O
agonist	O
sensitivity	O
of	O
desensitization	O
for	O
secretin	B-GENE
and	O
IP-prostanoid	B-GENE
receptor	I-GENE
-	O
stimulated	O
adenylyl	B-GENE
cyclase	I-GENE
activity	O
was	O
not	O
affected	O
by	O
GRK2	B-GENE
overexpression	O
.	O
4	O
.	O
These	O
results	O
further	O
implicate	O
GRK2	B-GENE
as	O
the	O
likely	O
mechanism	O
by	O
which	O
A2	B-GENE
adenosine	I-GENE
receptors	I-GENE
undergo	O
short	O
-	O
term	O
desensitization	O
in	O
NG108-15	O
cells	O
,	O
and	O
indicate	O
that	O
even	O
when	O
overexpressed	O
,	O
GRK2	B-GENE
retains	O
its	O
substrate	O
specificity	O
for	O
native	O
receptors	O
in	O
intact	O
cells	O
.	O
Furthermore	O
,	O
the	O
susceptibility	O
of	O
GPCRs	B-GENE
to	O
desensitization	O
appears	O
to	O
depend	O
on	O
the	O
level	O
of	O
GRK	B-GENE
expression	O
,	O
such	O
that	O
in	O
cells	O
that	O
express	O
high	O
levels	O
of	O
GRK2	B-GENE
,	O
low	O
agonist	O
concentrations	O
may	O
be	O
sufficient	O
to	O
trigger	O
GRK	B-GENE
-	O
mediated	O
desensitization	O
.	O
PMID	O
:	O
9786508	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2002	O
Dec	O
1;	O
62(	O
23	O
)	O
:	O
7004-11	O
.	O
Von	B-GENE
Hippel	I-GENE
-	I-GENE
Lindau	I-GENE
tumor	I-GENE
suppressor	I-GENE
protein	O
transforms	O
human	O
neuroblastoma	O
cells	O
into	O
functional	O
neuron	O
-	O
like	O
cells	O
.	O
Murata	O
H,	O
Tajima	O
N	O
,	O
Nagashima	O
Y	O
,	O
Yao	O
M,	O
Baba	O
M,	O
Goto	O
M,	O
Kawamoto	O
S	O
,	O
Yamamoto	O
I	O
,	O
Okuda	O
K,	O
Kanno	O
H.	O
Departments	O
of	O
Neurosurgery	O
,	O
Yokohama	O
City	O
University	O
School	O
of	O
Medicine	O
,	O
Yokohama	O
236	O
-0004	O
,	O
Japan	O
.	O
Von	B-GENE
Hippel	I-GENE
-	I-GENE
Lindau	I-GENE
(	I-GENE
VHL	I-GENE
)	I-GENE
tumor	I-GENE
suppressor	I-GENE
protein	O
is	O
expressed	O
in	O
neurons	O
of	O
the	O
central	O
nervous	O
system	O
and	O
plays	O
an	O
important	O
role	O
during	O
the	O
neuronal	O
differentiation	O
of	O
central	O
nervous	O
system	O
progenitor	O
cells	O
.	O
To	O
elucidate	O
the	O
neuronal	O
differentiating	O
potential	O
of	O
VHL	B-GENE
protein	O
in	O
neuroblastoma	O
cells	O
,	O
we	O
overexpressed	O
or	O
inhibited	O
VHL	B-GENE
protein	O
in	O
human	O
neuroblastoma	O
cells	O
(	O
SY	O
-	O
SH5Y	O
)	O
,	O
and	O
examined	O
the	O
morphological	O
change	O
,	O
expressions	O
of	O
neuronal	O
markers	O
,	O
and	O
electrophysiological	O
functions	O
.	O
Here	O
we	O
show	O
that	O
with	O
VHL	B-GENE
gene	O
transduction	O
SY	O
-	O
SH5Y	O
cells	O
stably	O
expressing	O
the	O
VHL	B-GENE
protein	O
had	O
neurite	O
-	O
like	O
processes	O
with	O
varicosities	O
,	O
showed	O
the	O
distinct	O
expression	O
of	O
the	O
neuronal	O
markers	O
neuropeptide	B-GENE
Y	I-GENE
and	O
neurofilament	B-GENE
200	I-GENE
,	O
acquired	O
regulated	O
neurosecretion	O
competence	O
in	O
response	O
to	O
depolarizing	O
and	O
cholinergic	O
stimuli	O
,	O
and	O
had	O
large	O
voltage	O
-	O
gated	O
fast	O
sodium	O
currents	O
and	O
delayed	O
rectifier	O
potassium	O
(	O
Kv	O
)	O
currents	O
compatible	O
with	O
those	O
of	O
functional	O
neurons	O
.	O
In	O
addition	O
,	O
they	O
displayed	O
inactivated	O
ether	B-GENE
-	I-GENE
a	I-GENE
-	I-GENE
go	I-GENE
-	I-GENE
go	I-GENE
potassium	I-GENE
channels	I-GENE
related	O
to	O
the	O
promotion	O
of	O
the	O
cell	O
cycle	O
and	O
to	O
the	O
termination	O
of	O
differentiation	O
.	O
Also	O
,	O
by	O
treatment	O
with	O
retinoic	O
acid	O
,	O
they	O
rapidly	O
underwent	O
cell	O
death	O
related	O
to	O
apoptosis	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
induction	O
of	O
neuronal	O
function	O
by	O
VHL	B-GENE
protein	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
the	O
cell	O
cycle	O
.	O
In	O
contrast	O
,	O
the	O
inhibition	O
of	O
endogenous	O
expression	O
of	O
VHL	B-GENE
protein	O
with	O
antisense	O
-	O
orientated	O
VHL	B-GENE
gene	O
transduction	O
reduced	O
such	O
neuronal	O
properties	O
inherent	O
to	O
these	O
cells	O
,	O
including	O
the	O
capacity	O
for	O
activation	O
of	O
ether	B-GENE
-	I-GENE
a	I-GENE
-	I-GENE
go	I-GENE
-	I-GENE
go	I-GENE
channels	I-GENE
.	O
In	O
conclusion	O
,	O
VHL	B-GENE
protein	O
has	O
a	O
neuronal	O
differentiating	O
potential	O
to	O
transform	O
neuroblastoma	O
cells	O
into	O
functional	O
neuron	O
-	O
like	O
cells	O
.	O
Our	O
finding	O
of	O
the	O
neuronal	O
differentiation	O
of	O
neuroblastoma	O
cells	O
under	O
the	O
control	O
of	O
the	O
VHL	B-GENE
gene	O
may	O
contribute	O
to	O
the	O
development	O
of	O
clinical	O
techniques	O
for	O
neuronal	O
regeneration	O
in	O
the	O
case	O
of	O
intractable	O
neuronal	O
diseases	O
and	O
for	O
differentiation	O
therapy	O
against	O
neuroblastomas	O
.	O
PMID	O
:	O
12460920	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1994	O
Dec	O
1;54	O
(	O
23	O
)	O
:6017-	O
21	O
.	O
Complete	O
regression	O
of	O
human	O
fibrosarcoma	O
xenografts	O
after	O
local	O
Newcastle	O
disease	O
virus	O
therapy	O
.	O
Lorence	O
RM	O
,	O
Katubig	O
BB	O
,	O
Reichard	O
KW	O
,	O
Reyes	O
HM	O
,	O
Phuangsab	O
A	O
,	O
Sassetti	O
MD	O
,	O
Walter	O
RJ	O
,	O
Peeples	O
ME.	O
Department	O
of	O
Pathology	O
,	O
Rush	O
-	O
Prebyterian-St	O
.	O
Luke	O
's	O
Medical	O
Center	O
,	O
Chicago	O
,	O
IL	O
60612-3833	O
.	O
We	O
have	O
recently	O
demonstrated	O
that	O
a	O
single	O
local	O
injection	O
of	O
the	O
avian	O
pathogen	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
;	O
strain	O
73	O
-	O
T	O
)	O
causes	O
complete	O
regression	O
of	O
human	O
neuroblastoma	O
xenografts	O
in	O
athymic	O
mice	O
(	O
R	O
.	O
M	O
.	O
Lorence	O
,	O
K	O
.	O
W	O
.	O
Reichard	O
,	O
B	O
.	O
B	O
.	O
Katubig	O
,	O
H	O
.	O
M	O
.	O
Reyes	O
,	O
A	O
.	O
Phuangsab	O
,	O
B	O
.	O
R	O
.	O
Mitchell	O
,	O
C	O
.	O
J	O
.	O
Cascino	O
,	O
R	O
.	O
J	O
.	O
Walter	O
,	O
and	O
M	O
.	O
E	O
.	O
Peeples	O
.	O
J	O
.	O
Natl	O
.	O
Cancer	O
Inst	O
.	O
,	O
86	O
:	O
1228	O
-	O
1233	O
,	O
1994	O
)	O
.	O
In	O
this	O
report	O
,	O
we	O
tried	O
to	O
determine	O
if	O
this	O
in	O
vivo	O
antineoplastic	O
effect	O
of	O
NDV	O
extends	O
to	O
human	O
sarcomas	O
.	O
Athymic	O
mice	O
with	O
s	O
.	O
c	O
.	O
HT1080	O
fibrosarcoma	O
xenografts	O
(	O
7	O
-	O
14	O
mm	O
)	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
and	O
treated	O
i	O
.	O
t	O
.	O
with	O
a	O
single	O
injection	O
of	O
either	O
10	O
(	O
7	O
)	O
plaque	O
-	O
forming	O
units	O
of	O
NDV	O
or	O
phosphate	O
-	O
buffered	O
saline	O
.	O
Complete	O
tumor	O
regression	O
occurred	O
in	O
8	O
of	O
10	O
mice	O
treated	O
with	O
NDV	O
while	O
unabated	O
tumor	O
growth	O
occurred	O
in	O
all	O
9	O
mice	O
treated	O
with	O
phosphate	O
-	O
buffered	O
saline	O
(	O
P	O
<	O
0.001	O
)	O
.	O
To	O
determine	O
if	O
complete	O
tumor	O
regression	O
was	O
long	O
lasting	O
,	O
the	O
8	O
mice	O
were	O
monitored	O
for	O
1	O
year	O
,	O
during	O
which	O
time	O
no	O
tumor	O
recurred	O
.	O
To	O
test	O
the	O
antitumor	O
effects	O
of	O
NDV	O
on	O
tumors	O
derived	O
from	O
a	O
fresh	O
human	O
sarcoma	O
,	O
a	O
similar	O
experiment	O
was	O
performed	O
in	O
athymic	O
mice	O
using	O
TH15145	O
synovial	O
sarcoma	O
xenografts	O
at	O
their	O
first	O
and	O
second	O
passages	O
.	O
Of	O
9	O
mice	O
with	O
TH15145	O
xenografts	O
,	O
a	O
single	O
i	O
.	O
t	O
.	O
injection	O
of	O
NDV	O
(	O
10	O
(	O
7	O
)	O
plaque	O
-	O
forming	O
units	O
)	O
caused	O
complete	O
regression	O
of	O
3	O
tumors	O
and	O
>	O
80	O
%	O
regression	O
in	O
3	O
more	O
tumors	O
.	O
In	O
contrast	O
,	O
tumors	O
in	O
all	O
5	O
mice	O
treated	O
with	O
phosphate	O
-	O
buffered	O
saline	O
exhibited	O
unabated	O
growth	O
(	O
P	O
<	O
0.03	O
for	O
>	O
80	O
%	O
tumor	O
regression	O
)	O
.	O
Since	O
HT1080	O
fibrosarcoma	O
cells	O
express	O
the	O
N	B-GENE
-	I-GENE
ras	I-GENE
oncogene	O
,	O
we	O
explored	O
the	O
effects	O
that	O
transfection	O
of	O
this	O
oncogene	O
has	O
on	O
the	O
sensitivity	O
to	O
NDV	O
.	O
Cultured	O
human	O
fibroblasts	O
that	O
were	O
made	O
tumorigenic	O
following	O
N	B-GENE
-	I-GENE
ras	I-GENE
-	O
transfection	O
were	O
found	O
to	O
be	O
1000	O
-	O
fold	O
more	O
sensitive	O
to	O
NDV	O
than	O
normal	O
fibroblasts	O
in	O
a	O
cytotoxicity	O
assay	O
.	O
Oncogene	O
expression	O
by	O
the	O
HT1080	O
fibrosarcoma	O
may	O
therefore	O
contribute	O
to	O
the	O
long	O
-	O
lasting	O
complete	O
regression	O
of	O
this	O
sarcoma	O
following	O
a	O
single	O
local	O
injection	O
of	O
NDV	O
.	O
PMID	O
:	O
7954437	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
.	O
1993	O
Nov	O
11	O
;55	O
(	O
5	O
)	O
:	O
817-	O
23	O
.	O
Uncoordinate	O
induction	O
and	O
differential	O
regulation	O
of	O
HLA	B-GENE
class	I-GENE
-	I-GENE
I	I-GENE
and	O
class	B-GENE
-	I-GENE
II	I-GENE
expression	O
by	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
in	O
differentiating	O
human	O
neuroblastoma	O
cells	O
.	O
Ponzoni	O
M,	O
Guarnaccia	O
F	O
,	O
Corrias	O
MV	O
,	O
Cornaglia-Ferraris	O
P.	O
Oncology	O
Research	O
Laboratory	O
,	O
G.	O
Gaslini	O
Children	O
's	O
Hospital	O
,	O
Genoa	O
,	O
Italy	O
.	O
Recombinant	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
(	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
)	O
has	O
recently	O
been	O
shown	O
to	O
be	O
one	O
of	O
the	O
most	O
effective	O
inducers	O
of	O
neuroblastoma	O
(	O
NB	O
)	O
cell	O
differentiation	O
.	O
Since	O
increasing	O
evidence	O
indicates	O
that	O
expression	O
of	O
MHC	B-GENE
class	I-GENE
-	I-GENE
I	I-GENE
and	O
class	B-GENE
-	I-GENE
II	I-GENE
antigens	O
by	O
tumour	O
cells	O
is	O
important	O
for	O
immunorecognition	O
and	O
cell	O
targeting	O
,	O
we	O
tested	O
whether	O
induction	O
of	O
NB	O
cell	O
differentiation	O
by	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
is	O
followed	O
by	O
expression	O
of	O
HLA	B-GENE
class	I-GENE
-	I-GENE
I	I-GENE
and	O
class	B-GENE
-	I-GENE
II	I-GENE
molecules	O
.	O
LAN	O
-	O
5	O
human	O
NB	O
cell	O
line	O
completely	O
lacks	O
HLA	B-GENE
class	I-GENE
-	I-GENE
I	I-GENE
antigens	O
.	O
Their	O
expression	O
was	O
induced	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
.	O
HLA	B-GENE
class	I-GENE
-	I-GENE
II	I-GENE
molecules	O
are	O
also	O
absent	O
on	O
LAN	O
-	O
5	O
cells	O
,	O
but	O
only	O
DP	B-GENE
antigens	O
were	O
dose	O
-	O
dependently	O
induced	O
by	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
,	O
while	O
DR	B-GENE
and	O
DQ	B-GENE
molecules	O
were	O
unaffected	O
by	O
the	O
treatment	O
.	O
To	O
confirm	O
and	O
extend	O
the	O
immunological	O
data	O
to	O
all	O
the	O
class	B-GENE
-	I-GENE
II	I-GENE
molecules	O
,	O
we	O
performed	O
Northern	O
blot	O
analysis	O
,	O
observing	O
that	O
DP	B-GENE
alpha	I-GENE
mRNA	O
was	O
induced	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O
DO	B-GENE
beta	I-GENE
and	O
DZ	B-GENE
alpha	I-GENE
genes	O
were	O
also	O
induced	O
peaking	O
after	O
3	O
days	O
of	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
treatment	O
.	O
DR	B-GENE
beta	I-GENE
and	O
DQ	B-GENE
beta	I-GENE
genes	O
,	O
which	O
were	O
not	O
induced	O
by	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
,	O
gave	O
a	O
normal	O
pattern	O
of	O
enzyme	O
restriction	O
by	O
Southern	O
blot	O
.	O
To	O
get	O
an	O
insight	O
into	O
the	O
regulation	O
of	O
HLA	B-GENE
class	I-GENE
-	I-GENE
II	I-GENE
gene	O
expression	O
in	O
the	O
neuronal	O
model	O
,	O
we	O
measured	O
the	O
decline	O
of	O
the	O
steady	O
-	O
state	O
HLA	B-GENE
class	I-GENE
-	I-GENE
II	I-GENE
mRNA	O
.	O
DO	B-GENE
beta	I-GENE
mRNA	O
rapidly	O
returned	O
to	O
baseline	O
level	O
after	O
removing	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
,	O
while	O
the	O
decay	O
rates	O
of	O
DP	B-GENE
alpha	I-GENE
and	O
DZ	B-GENE
alpha	I-GENE
mRNA	O
were	O
very	O
slow	O
.	O
This	O
might	O
indicate	O
different	O
regulation	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
for	O
DO	B-GENE
beta	I-GENE
mRNA	O
with	O
respect	O
to	O
DP	B-GENE
alpha	I-GENE
and	O
DZ	B-GENE
alpha	I-GENE
mRNA	O
.	O
To	O
strengthen	O
these	O
findings	O
we	O
evaluated	O
the	O
half	O
-	O
lives	O
of	O
the	O
mRNA	O
after	O
IFN	B-GENE
-	I-GENE
gamma	I-GENE
induction	O
by	O
means	O
of	O
actinomycin	O
D	O
treatment	O
.	O
HLA	B-GENE
-	I-GENE
DO	I-GENE
beta	I-GENE
mRNA	O
had	O
a	O
shorter	O
half	O
-	O
life	O
,	O
while	O
DZ	B-GENE
alpha	I-GENE
and	O
DP	B-GENE
alpha	I-GENE
had	O
a	O
longer	O
decay	O
rate	O
.	O
Finally	O
,	O
we	O
report	O
that	O
treatment	O
of	O
LAN	O
-	O
5	O
cells	O
with	O
cycloheximide	O
did	O
not	O
alter	O
the	O
rate	O
of	O
transcription	O
of	O
the	O
HLA	B-GENE
-	I-GENE
DP	I-GENE
alpha	I-GENE
gene	O
,	O
suggesting	O
that	O
no	O
protein	O
factor(s)	O
is	O
/	O
are	O
needed	O
to	O
maintain	O
DP	B-GENE
alpha	I-GENE
gene	O
expression	O
.	O
PMID	O
:	O
8244579	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
.	O
2002	O
Jul	O
12;277(	O
28	O
)	O
:25798-	O
814	O
.	O
Epub	O
2002	O
Apr	O
17	O
.	O
Complex	O
regulation	O
of	O
human	O
neuronal	B-GENE
nitric	I-GENE
-	I-GENE
oxide	I-GENE
synthase	I-GENE
exon	O
1c	O
gene	O
transcription	O
.	O
Essential	O
role	O
of	O
Sp	B-GENE
and	O
ZNF	B-GENE
family	O
members	O
of	O
transcription	O
factors	O
.	O
Saur	O
D	O
,	O
Seidler	O
B	O
,	O
Paehge	O
H,	O
Schusdziarra	O
V	O
,	O
Allescher	O
HD.	O
Department	O
of	O
Internal	O
Medicine	O
II	O
,	O
Technische	O
Universitat	O
Munchen	O
,	O
Germany	O
.	O
Saur@lrz.tu-muenchen	O
.de	O
Neuronal	B-GENE
nitric	I-GENE
-	I-GENE
oxide	I-GENE
synthase	I-GENE
(	O
nNOS	B-GENE
)	O
is	O
expressed	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
and	O
shows	O
a	O
complex	O
transcriptional	O
regulation	O
with	O
the	O
presence	O
of	O
nine	O
alternative	O
first	O
exons	O
(	O
1a	O
-	O
1i	O
)	O
resulting	O
in	O
nNOS	B-GENE
transcripts	O
with	O
differing	O
5'	O
-	O
untranslated	O
regions	O
.	O
We	O
previously	O
demonstrated	O
that	O
nNOS	B-GENE
exon	O
1c	O
,	O
one	O
of	O
the	O
predominant	O
transcripts	O
in	O
the	O
human	O
gastrointestinal	O
tract	O
,	O
is	O
driven	O
by	O
a	O
separate	O
promoter	O
(	O
Saur	O
,	O
D	O
.	O
,	O
Paehge	O
,	O
H	O
.	O
,	O
Schusdziarra	O
,	O
V	O
.	O
,	O
and	O
Allescher	O
,	O
H	O
.	O
D	O
.	O
(	O
2000	O
)	O
Gastroenterology	O
118	O
,	O
849	O
-	O
858	O
)	O
.	O
The	O
present	O
study	O
focused	O
on	O
the	O
quantitative	O
expression	O
of	O
nNOS	B-GENE
first	O
exon	O
variants	O
in	O
different	O
human	O
tissues	O
and	O
the	O
characterization	O
of	O
the	O
basal	O
nNOS	B-GENE
exon	O
1c	O
promoter	O
.	O
In	O
human	O
brain	O
,	O
skeletal	O
muscle	O
,	O
colon	O
,	O
and	O
TGW	O
-	O
nu	O
-	O
I	O
neuroblastoma	O
cells	O
,	O
first	O
exon	O
expression	O
patterns	O
were	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
.	O
In	O
these	O
tissues	O
/	O
cells	O
exon	O
1c	O
was	O
one	O
of	O
the	O
most	O
abundant	O
first	O
exons	O
of	O
nNOS	B-GENE
.	O
By	O
transient	O
transfections	O
of	O
TGW	O
-	O
nu	O
-	O
I	O
and	O
HeLa	O
cells	O
with	O
reporter	O
plasmids	O
containing	O
a	O
series	O
of	O
5	O
'	O
and	O
3	O
'	O
deletions	O
in	O
the	O
exon	O
1c	O
regulatory	O
region	O
,	O
the	O
minimal	O
TATA	O
-	O
less	O
promoter	O
was	O
localized	O
within	O
44	O
base	O
pairs	O
.	O
Gel	O
mobility	O
shift	O
assays	O
of	O
this	O
cis	O
-	O
regulatory	O
region	O
revealed	O
a	O
high	O
complexity	O
of	O
the	O
basal	O
promoter	O
with	O
a	O
cooperative	O
binding	O
of	O
several	O
transcription	O
factors	O
,	O
like	O
Sp	B-GENE
and	O
ZNF	B-GENE
family	O
members	O
.	O
When	O
the	O
Sp	B-GENE
binding	O
site	O
of	O
the	O
minimal	O
promoter	O
construct	O
was	O
mutated	O
,	O
promoter	O
activity	O
was	O
completely	O
abolished	O
in	O
both	O
cell	O
lines	O
,	O
whereas	O
mutation	O
of	O
the	O
common	O
binding	O
site	O
of	O
ZNF76	B-GENE
and	O
ZNF143	B-GENE
resulted	O
in	O
a	O
decrease	O
of	O
53	O
%	O
in	O
TGW	O
-	O
nu	O
-	O
I	O
and	O
37	O
%	O
in	O
HeLa	O
cells	O
.	O
In	O
Drosophila	O
Schneider	O
cells	O
expression	O
of	O
Sp1	B-GENE
,	O
the	O
long	O
Sp3	B-GENE
isoform	O
,	O
ZNF76	B-GENE
and	O
ZNF143	B-GENE
potently	O
transactivated	O
the	O
nNOS	B-GENE
exon	O
1c	O
promoter	O
.	O
These	O
results	O
identify	O
the	O
critical	O
regulatory	O
region	O
for	O
the	O
nNOS	B-GENE
exon	O
1c	O
basal	O
promoter	O
and	O
stress	O
the	O
functional	O
importance	O
of	O
multiple	O
protein	O
complexes	O
involving	O
Sp	B-GENE
and	O
ZNF	B-GENE
families	O
of	O
transcription	O
factors	O
in	O
regulating	O
nNOS	B-GENE
exon	O
1c	O
transcription	O
.	O
PMID	O
:	O
11960979	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
1991	O
Dec	O
1;5	O
1(	O
23	O
Pt	O
1	O
)	O
:	O
633	O
8-45	O
.	O
Differential	O
expression	O
of	O
N	B-GENE
-	I-GENE
myc	I-GENE
in	O
phenotypically	O
distinct	O
subclones	O
of	O
a	O
human	O
neuroblastoma	O
cell	O
line	O
.	O
Foley	O
J,	O
Cohn	O
SL	O
,	O
Salwen	O
HR	O
,	O
Chagnovich	O
D	O
,	O
Cowan	O
J,	O
Mason	O
KL	O
,	O
Parysek	O
LM	O
.	O
Department	O
of	O
Anatomy	O
and	O
Cell	O
Biology	O
,	O
University	O
of	O
Cincinnati	O
,	O
Ohio	O
45267	O
-0521	O
.	O
Neuroblastomas	O
are	O
malignant	O
childhood	O
neoplasms	O
that	O
arise	O
from	O
derivatives	O
of	O
the	O
neural	O
crest	O
.	O
We	O
report	O
the	O
characterization	O
of	O
a	O
new	O
neuroblastoma	O
cell	O
line	O
,	O
designated	O
NBL	O
-	O
W	O
,	O
derived	O
from	O
the	O
primary	O
tumor	O
of	O
a	O
patient	O
with	O
stage	O
IVS	O
disease	O
(	O
S	O
.	O
L	O
.	O
Cohn	O
,	O
C	O
.	O
V	O
.	O
Herst	O
,	O
H	O
.	O
S	O
.	O
Maurer	O
,	O
and	O
S	O
.	O
T	O
.	O
Rosen	O
,	O
J	O
.	O
Clin	O
.	O
Oncol	O
.	O
,	O
5	O
:	O
1441	O
-	O
1444	O
,	O
1987	O
)	O
according	O
to	O
the	O
criteria	O
of	O
Evans	O
[	O
A	O
.	O
E	O
.	O
Evans	O
,	O
G	O
.	O
J	O
.	O
D'Angio	O
,	O
and	O
J	O
.	O
Randolf	O
,	O
Cancer	O
(	O
Phila	O
.	O
)	O
,	O
27	O
:	O
374	O
-	O
378	O
,	O
1971	O
]	O
.	O
Neurite	O
-	O
bearing	O
(	O
N	O
)	O
and	O
substrate	O
-	O
adherent	O
(	O
S	O
)	O
cell	O
lines	O
have	O
been	O
subcloned	O
from	O
the	O
parent	O
line	O
.	O
N	O
and	O
S	O
cells	O
can	O
interconvert	O
,	O
and	O
both	O
cell	O
types	O
label	O
with	O
the	O
neural	B-GENE
crest	I-GENE
cell	I-GENE
surface	I-GENE
marker	I-GENE
antibody	I-GENE
,	O
HNK	B-GENE
-	I-GENE
1	I-GENE
.	O
Cells	O
in	O
the	O
subcloned	O
lines	O
and	O
in	O
the	O
parent	O
line	O
have	O
been	O
shown	O
by	O
Southern	O
blot	O
analysis	O
to	O
contain	O
approximately	O
100	O
copies	O
of	O
the	O
N	B-GENE
-	I-GENE
myc	I-GENE
gene	O
.	O
Cytogenetic	O
analysis	O
shows	O
a	O
homogeneously	O
staining	O
region	O
present	O
on	O
chromosome	O
19	O
.	O
Although	O
these	O
subclones	O
are	O
of	O
identical	O
genotype	O
,	O
the	O
S	O
cells	O
express	O
lower	O
amounts	O
of	O
N	B-GENE
-	I-GENE
myc	I-GENE
mRNA	O
and	O
protein	O
as	O
compared	O
to	O
the	O
N	O
cells	O
.	O
N	O
cells	O
express	O
several	O
neuronal	O
proteins	O
including	O
the	O
neurotransmitter	O
-	O
processing	O
enzymes	O
tyrosine	B-GENE
hydroxylase	I-GENE
and	O
dopamine	B-GENE
beta	I-GENE
-	I-GENE
hydroxylase	I-GENE
,	O
the	O
neuronal	O
intermediate	O
filament	O
proteins	O
peripherin	B-GENE
and	O
NF66	B-GENE
/	O
alpha	B-GENE
-	I-GENE
internexin	I-GENE
,	O
and	O
the	O
neural	B-GENE
cell	I-GENE
adhesion	I-GENE
molecule	I-GENE
.	O
S	O
cells	O
generally	O
lack	O
neuronal	O
markers	O
but	O
express	O
the	O
mesenchymal	O
intermediate	O
filament	O
protein	O
vimentin	B-GENE
,	O
and	O
a	O
small	O
subset	O
of	O
the	O
S	O
cells	O
express	O
glial	B-GENE
fibrillary	I-GENE
acidic	I-GENE
protein	O
.	O
Some	O
S	O
cells	O
were	O
labeled	O
weakly	O
with	O
neural	B-GENE
cell	I-GENE
adhesion	I-GENE
molecule	I-GENE
antibody	I-GENE
;	O
others	O
were	O
negative	O
.	O
S	O
cells	O
did	O
not	O
express	O
the	O
glial	O
marker	O
S	B-GENE
-	I-GENE
100	I-GENE
or	O
a	O
melanocyte	O
marker	O
,	O
tyrosinase	B-GENE
.	O
Thus	O
,	O
S	O
cells	O
express	O
the	O
neural	O
crest	O
marker	O
HNK	B-GENE
-	I-GENE
1	I-GENE
but	O
do	O
not	O
express	O
a	O
set	O
of	O
antigens	O
characteristic	O
of	O
any	O
known	O
cell	O
type	O
derived	O
from	O
the	O
neural	O
crest	O
.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
suggestion	O
that	O
differential	O
N	B-GENE
-	I-GENE
myc	I-GENE
expression	O
may	O
be	O
involved	O
in	O
the	O
interconversion	O
of	O
N	O
and	O
S	O
cells	O
but	O
indicate	O
that	O
the	O
S	O
cell	O
phenotype	O
need	O
not	O
represent	O
a	O
highly	O
differentiated	O
neural	O
crest	O
derivative	O
.	O
PMID	O
:	O
1933896	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2000	O
Dec	O
15	O
;60	O
(	O
24	O
)	O
:	O
7048	O
-51	O
.	O
Sporadic	O
and	O
familial	O
pheochromocytomas	O
are	O
associated	O
with	O
loss	O
of	O
at	O
least	O
two	O
discrete	O
intervals	O
on	O
chromosome	O
1p	O
.	O
Benn	O
DE	O
,	O
Dwight	O
T	O
,	O
Richardson	O
AL	O
,	O
Delbridge	O
L,	O
Bambach	O
CP	O
,	O
Stowasser	O
M,	O
Gordon	O
RD	O
,	O
Marsh	O
DJ	O
,	O
Robinson	O
BG.	O
Cancer	O
Genetics	O
,	O
Kolling	O
Institute	O
of	O
Medical	O
Research	O
,	O
Royal	O
North	O
Shore	O
Hospital	O
,	O
St.	O
Leonards	O
,	O
New	O
South	O
Wales	O
,	O
Australia	O
.	O
Pheochromocytomas	O
are	O
tumors	O
of	O
the	O
adrenal	O
medulla	O
originating	O
in	O
the	O
chromaffin	O
cells	O
derived	O
from	O
the	O
neural	O
crest	O
.	O
Ten	O
%	O
of	O
these	O
tumors	O
are	O
associated	O
with	O
the	O
familial	O
cancer	O
syndromes	O
multiple	O
endocrine	O
neoplasia	O
type	O
2	O
,	O
von	O
Hippel	O
-	O
Lindau	O
disease	O
(	O
VHL	B-GENE
)	O
,	O
and	O
rarely	O
,	O
neurofibromatosis	O
type	O
1	O
,	O
in	O
which	O
germ	O
-	O
line	O
mutations	O
have	O
been	O
identified	O
in	O
RET	B-GENE
,	O
VHL	B-GENE
,	O
and	O
NF1	B-GENE
,	O
respectively	O
.	O
In	O
both	O
the	O
sporadic	O
and	O
familial	O
form	O
of	O
pheochromocytoma	O
,	O
allelic	O
loss	O
at	O
1p	O
,	O
3p	O
,	O
17p	O
,	O
and	O
22q	O
has	O
been	O
reported	O
,	O
yet	O
the	O
molecular	O
pathogenesis	O
of	O
these	O
tumors	O
is	O
largely	O
unknown	O
.	O
Allelic	O
loss	O
at	O
chromosome	O
1p	O
has	O
also	O
been	O
reported	O
in	O
other	O
endocrine	O
tumors	O
,	O
such	O
as	O
medullary	O
thyroid	O
cancer	O
and	O
tumors	O
of	O
the	O
parathyroid	O
gland	O
,	O
as	O
well	O
as	O
in	O
tumors	O
of	O
neural	O
crest	O
origin	O
including	O
neuroblastoma	O
and	O
malignant	O
melanoma	O
.	O
In	O
this	O
study	O
,	O
we	O
performed	O
fine	O
structure	O
mapping	O
of	O
deletions	O
at	O
chromosome	O
1p	O
in	O
familial	O
and	O
sporadic	O
pheochromocytomas	O
to	O
identify	O
discrete	O
regions	O
likely	O
housing	O
tumor	O
suppressor	O
genes	O
involved	O
in	O
the	O
development	O
of	O
these	O
tumors	O
.	O
Ten	O
microsatellite	O
markers	O
spanning	O
a	O
region	O
of	O
approximately	O
70	O
cM	O
(	O
1pter	O
to	O
1p34.3	O
)	O
were	O
used	O
to	O
screen	O
20	O
pheochromocytomas	O
from	O
19	O
unrelated	O
patients	O
for	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
.	O
LOH	O
was	O
detected	O
at	O
five	O
or	O
more	O
loci	O
in	O
8	O
of	O
13	O
(	O
61	O
%	O
)	O
sporadic	O
samples	O
and	O
at	O
five	O
or	O
more	O
loci	O
in	O
four	O
of	O
five	O
(	O
80	O
%	O
)	O
tumor	O
samples	O
from	O
patients	O
with	O
multiple	O
endocrine	O
neoplasia	O
type	O
2	O
.	O
No	O
LOH	O
at	O
1p	O
was	O
detected	O
in	O
pheochromocytomas	O
from	O
two	O
VHL	B-GENE
patients	O
.	O
Analysis	O
of	O
the	O
combined	O
sporadic	O
and	O
familial	O
tumor	O
data	O
suggested	O
three	O
possible	O
regions	O
of	O
common	O
somatic	O
loss	O
,	O
designated	O
as	O
PC1	O
(	O
D1S243	O
to	O
D1S244	O
)	O
,	O
PC2	O
(	O
D1S228	O
to	O
D1S507	O
)	O
,	O
and	O
PC3	O
(	O
D1S507	O
toward	O
the	O
centromere	O
)	O
.	O
We	O
propose	O
that	O
chromosome	O
1p	O
may	O
be	O
the	O
site	O
of	O
at	O
least	O
three	O
putative	O
tumor	O
suppressor	O
loci	O
involved	O
in	O
the	O
tumorigenesis	O
of	O
pheochromocytomas	O
.	O
At	O
least	O
one	O
of	O
these	O
loci	O
,	O
PC2	O
spanning	O
an	O
interval	O
of	O
<	O
3.8	O
cM	O
,	O
is	O
likely	O
to	O
have	O
a	O
broader	O
role	O
in	O
the	O
development	O
of	O
endocrine	O
malignancies	O
.	O
PMID	O
:	O
11156410	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2001	O
Jan	O
1;61	O
(	O
1	O
)	O
:153	O
-	O
61	O
.	O
In	O
situ	O
expression	O
of	O
soluble	B-GENE
B7	I-GENE
-	I-GENE
1	I-GENE
in	O
the	O
context	O
of	O
oncolytic	O
herpes	O
simplex	O
virus	O
induces	O
potent	O
antitumor	O
immunity	O
.	O
Todo	O
T	O
,	O
Martuza	O
RL	O
,	O
Dallman	O
MJ	O
,	O
Rabkin	O
SD.	O
Department	O
of	O
Neurosurgery	O
,	O
Georgetown	O
University	O
Medical	O
Center	O
,	O
Washington	O
,	O
DC	O
20007	O
,	O
USA	O
.	O
todo@helix.mgh	O
.harvard	O
.edu	O
In	O
vivo	O
delivery	O
of	O
immunomodulatory	B-GENE
genes	O
is	O
a	O
promising	O
strategy	O
for	O
solid	O
tumor	O
vaccination	O
.	O
A	O
drawback	O
is	O
that	O
it	O
necessitates	O
induction	O
of	O
a	O
large	O
effect	O
from	O
transgene	O
expression	O
in	O
a	O
small	O
percentage	O
of	O
tumor	O
cells	O
.	O
Although	O
the	O
B7	B-GENE
family	O
is	O
known	O
to	O
be	O
the	O
most	O
potent	O
of	O
the	O
costimulatory	O
molecules	O
,	O
gene	O
transduction	O
of	O
B7	B-GENE
alone	O
has	O
not	O
been	O
effective	O
in	O
inducing	O
antitumor	O
immunity	O
in	O
nonimmunogenic	O
tumors	O
by	O
ex	O
vivo	O
methods	O
,	O
much	O
less	O
in	O
vivo	O
.	O
We	O
have	O
developed	O
a	O
novel	O
approach	O
where	O
a	O
gene	O
encoding	O
soluble	B-GENE
B7	I-GENE
-	I-GENE
1	I-GENE
,	O
a	O
fusion	O
protein	O
of	O
the	O
extracellular	O
domain	O
of	O
murine	O
B7	B-GENE
-	I-GENE
1	I-GENE
and	O
the	O
Fc	O
portion	O
of	O
human	O
IgG1	B-GENE
,	O
is	O
delivered	O
to	O
tumor	O
cells	O
in	O
vivo	O
in	O
the	O
context	O
of	O
an	O
oncolytic	O
replication	O
-	O
competent	O
herpes	O
simplex	O
virus	O
,	O
and	O
the	O
gene	O
product	O
is	O
secreted	O
by	O
tumor	O
cells	O
rather	O
than	O
expressed	O
on	O
the	O
cell	O
surface	O
.	O
Defective	O
herpes	O
simplex	O
virus	O
vectors	O
containing	O
the	O
B7	B-GENE
-	I-GENE
1	I-GENE
-	O
immunoglobulin	B-GENE
(	O
B7	B-GENE
-	I-GENE
1	I-GENE
-	O
Ig	B-GENE
)	O
fusion	O
transgene	O
(	O
dvB7Ig	O
)	O
were	O
generated	O
using	O
G207	O
as	O
a	O
helper	O
virus	O
and	O
tested	O
in	O
the	O
poorly	O
immunogenic	O
murine	O
neuroblastoma	O
,	O
Neuro2a	O
,	O
in	O
syngeneic	O
A	O
/	O
J	O
mice	O
.	O
Intraneoplastic	O
inoculation	O
of	O
dvB7Ig	O
/	O
G207	O
at	O
a	O
low	O
titer	O
successfully	O
inhibited	O
the	O
growth	O
of	O
established	O
s	O
.	O
c	O
.	O
tumors	O
,	O
despite	O
the	O
expression	O
of	O
B7	B-GENE
-	I-GENE
1	I-GENE
-	O
Ig	B-GENE
being	O
detected	O
in	O
only	O
1	O
%	O
or	O
fewer	O
of	O
tumor	O
cells	O
at	O
the	O
inoculation	O
site	O
,	O
and	O
prolonged	O
the	O
survival	O
of	O
mice	O
bearing	O
intracerebral	O
tumors	O
.	O
Immunohistochemistry	O
of	O
dvB7Ig	O
/	O
G207	O
-	O
inoculated	O
tumors	O
revealed	O
a	O
significant	O
increase	O
in	O
CD4	B-GENE
+	O
and	O
CD8	B-GENE
+	O
T	O
-	O
cell	O
infiltration	O
compared	O
with	O
control	O
tumors	O
inoculated	O
with	O
defective	O
vector	O
expressing	O
alkaline	B-GENE
phosphatase	I-GENE
(	O
dvAP	O
/	O
G207	O
)	O
.	O
The	O
antitumor	O
effect	O
of	O
dvB7Ig	O
/	O
G207	O
was	O
not	O
manifested	O
in	O
athymic	O
mice	O
.	O
In	O
vivo	O
depletion	O
of	O
immune	O
cell	O
subsets	O
in	O
A	O
/	O
J	O
mice	O
further	O
revealed	O
that	O
CD8	B-GENE
+	O
T	O
cells	O
,	O
but	O
not	O
CD4	B-GENE
+	O
T	O
cells	O
,	O
were	O
required	O
.	O
Animals	O
cured	O
of	O
their	O
tumors	O
by	O
dvB7Ig	O
/	O
G207	O
treatment	O
were	O
protected	O
against	O
rechallenge	O
with	O
a	O
lethal	O
dose	O
of	O
Neuro2a	O
cells	O
but	O
not	O
SaI	O
/	O
N	O
cells	O
.	O
The	O
results	O
demonstrate	O
that	O
the	O
use	O
of	O
soluble	B-GENE
B7	I-GENE
-	I-GENE
1	I-GENE
for	O
immune	O
gene	O
therapy	O
is	O
a	O
potent	O
and	O
clinically	O
applicable	O
means	O
of	O
in	O
situ	O
cancer	O
vaccination	O
.	O
PMID	O
:	O
11196154	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
.	O
2001	O
Sep	O
15	O
;61	O
(	O
18	O
)	O
:6892	O
-8.	O
Comment	O
in	O
:	O
Cancer	O
Res	O
.	O
2002	O
May	O
15	O
;62(	O
10	O
)	O
:	O
2986-7;	O
author	O
reply	O
2988	O
-	O
9.	O
Cancer	O
Res	O
.	O
2002	O
May	O
15	O
;62(	O
10	O
)	O
:	O
2987	O
-	O
8;	O
author	O
reply	O
2988	O
-	O
9.	O
Neuroblastic	O
and	O
Schwannian	O
stromal	O
cells	O
of	O
neuroblastoma	O
are	O
derived	O
from	O
a	O
tumoral	O
progenitor	O
cell	O
.	O
Mora	O
J,	O
Cheung	O
NK	O
,	O
Juan	O
G	O
,	O
Illei	O
P,	O
Cheung	O
I	O
,	O
Akram	O
M,	O
Chi	O
S	O
,	O
Ladanyi	O
M,	O
Cordon	O
-	O
Cardo	O
C	O
,	O
Gerald	O
WL.	O
Department	O
of	O
Pediatrics	O
,	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
New	O
York	O
10021	O
,	O
USA	O
.	O
The	O
coexistence	O
of	O
neuroblastic	O
and	O
Schwannian	O
stromal	O
(	O
SS	O
)	O
cells	O
in	O
differentiating	O
neuroblastoma	O
(	O
NB	O
)	O
,	O
and	O
derivation	O
of	O
Schwannian	O
-	O
like	O
cells	O
from	O
neuroblastic	O
clones	O
in	O
vitro	O
,	O
were	O
accepted	O
previously	O
as	O
evidence	O
of	O
a	O
common	O
pluripotent	O
tumor	O
stem	O
line	O
.	O
This	O
paradigm	O
was	O
challenged	O
when	O
SS	O
cells	O
were	O
suggested	O
to	O
be	O
reactive	O
in	O
nature	O
.	O
The	O
advent	O
of	O
microdissection	O
techniques	O
,	O
PCR	O
-	O
based	O
allelic	O
analysis	O
,	O
and	O
in	O
situ	O
fluorescent	O
cytometry	O
made	O
possible	O
the	O
analysis	O
of	O
pure	O
cell	O
populations	O
in	O
fresh	O
surgical	O
specimens	O
,	O
allowing	O
unequivocal	O
determination	O
of	O
clonal	O
origins	O
of	O
various	O
cell	O
subtypes	O
.	O
To	O
overcome	O
the	O
complexity	O
and	O
heterogeneity	O
of	O
three	O
-	O
dimensional	O
tissue	O
structure	O
,	O
we	O
used	O
:	O
(	O
a	O
)	O
Laser	O
-	O
Capture	O
Microdissection	O
to	O
obtain	O
histologically	O
homogeneous	O
cell	O
subtype	O
populations	O
for	O
allelotype	O
analysis	O
at	O
chromosomes	O
1p36	O
,	O
11q23	O
,	O
14q32	O
,	O
and	O
17q	O
and	O
study	O
of	O
MYCN	B-GENE
copy	O
number	O
;	O
(	O
b	O
)	O
multiparametric	O
analysis	O
by	O
Laser	O
-	O
Scanning	O
Cytometry	O
of	O
morphology	O
,	O
DNA	O
content	O
,	O
and	O
immunophenotype	O
of	O
intact	O
cells	O
from	O
touch	O
imprints	O
;	O
and	O
(	O
c	O
)	O
bicolor	O
fluorescence	O
in	O
situ	O
hybridization	O
on	O
touch	O
imprints	O
from	O
manually	O
microdissected	O
neuroblast	O
and	O
stroma	O
-	O
rich	O
areas	O
.	O
Histologically	O
distinct	O
SS	O
and	O
neuroblastic	O
cells	O
isolated	O
by	O
Laser	O
-	O
Capture	O
Microdissection	O
had	O
the	O
same	O
genetic	O
composition	O
in	O
27	O
of	O
28	O
NB	O
analyzed	O
by	O
allelic	O
imbalance	O
and	O
gene	O
copy	O
number	O
.	O
In	O
all	O
20	O
cases	O
studied	O
by	O
Laser	O
-	O
Scanning	O
Cytometry	O
,	O
SS	O
cells	O
identified	O
by	O
morphology	O
and	O
S	B-GENE
-	I-GENE
100	I-GENE
immunostaining	O
had	O
identical	O
DNA	O
content	O
and	O
GD2	O
-	O
staining	O
pattern	O
as	O
their	O
neuroblastic	O
counterparts	O
.	O
In	O
7	O
cases	O
,	O
fluorescence	O
in	O
situ	O
hybridization	O
demonstrated	O
the	O
same	O
chromosomal	O
makeup	O
for	O
SS	O
and	O
neuroblastic	O
cells	O
.	O
These	O
results	O
provide	O
unequivocal	O
evidence	O
that	O
neuroblastic	O
and	O
SS	O
cells	O
in	O
NB	O
are	O
derived	O
from	O
genetically	O
identical	O
neoplastic	O
cells	O
and	O
support	O
the	O
classical	O
paradigm	O
that	O
NB	O
arises	O
from	O
tumoral	O
cells	O
capable	O
of	O
development	O
along	O
multiple	O
lineages	O
.	O
PMID	O
:	O
11559566	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Ann	O
Biol	O
Clin	O
(	O
Paris	O
)	O
.	O
2002	O
Jan-	O
Feb;60	O
(	O
1	O
)	O
:15-36	O
.	O
[	O
Biochemical	O
diagnosis	O
of	O
pheochromocytoma	O
and	O
neuroblastomas	O
]	O
[	O
Article	O
in	O
French	O
]	O
Candito	O
M,	O
Billaud	O
E	O
,	O
Chauffert	O
M,	O
Cottet-Emard	O
JM	O
,	O
Desmoulin	O
D	O
,	O
Garnier	O
JP	O
,	O
Greffe	O
J,	O
Hirth	O
C	O
,	O
Jacob	O
N	O
,	O
Millot	O
F	O
,	O
Nignan	O
A	O
,	O
Patricot	O
MC	O
,	O
Peyrin	O
L,	O
Plouin	O
PF.	O
Laboratoire	O
de	O
biochimie	O
,	O
Hopital	O
Pasteur	O
,	O
30	O
,	O
avenue	O
de	O
la	O
Voie-Romaine	O
,	O
BP	O
69	O
,	O
06002	O
Nice	O
cedex	O
1	O
.	O
Pheochromocytoma	O
and	O
neuroblastoma	O
are	O
distinct	O
tumours	O
,	O
but	O
their	O
biological	O
diagnosis	O
is	O
based	O
on	O
secretion	O
increase	O
of	O
one	O
or	O
several	O
catecholamines	O
.	O
Assays	O
have	O
to	O
be	O
very	O
sensible	O
and	O
specific	O
for	O
an	O
early	O
diagnosis	O
.	O
24	O
hours	O
urinary	O
catecholamines	O
and	O
metabolites	O
are	O
currently	O
measured	O
,	O
but	O
technical	O
improvements	O
permit	O
plasma	O
metanephrine	O
assay	O
,	O
an	O
excellent	O
indicator	O
of	O
pheochromocytoma	O
.	O
HPLC	O
coupled	O
to	O
electrochemical	O
detection	O
represents	O
the	O
most	O
efficient	O
methodology	O
.	O
After	O
a	O
review	O
of	O
urinary	O
and	O
plasma	O
assay	O
methods	O
,	O
the	O
authors	O
show	O
usual	O
values	O
of	O
catecholamines	O
,	O
metanephrines	O
,	O
HVA	O
and	O
VMA	O
,	O
according	O
to	O
ages	O
,	O
and	O
give	O
examples	O
of	O
results	O
encountered	O
in	O
classical	O
or	O
not	O
tumours	O
and	O
in	O
falsely	O
positive	O
cases	O
.	O
Urinary	O
metanephrine	O
assay	O
is	O
the	O
most	O
sensible	O
and	O
specific	O
in	O
biological	O
diagnosis	O
of	O
pheochromocytoma	O
,	O
while	O
catecholamines	O
and	O
VMA	O
assays	O
lack	O
of	O
sensibility	O
.	O
Results	O
have	O
to	O
be	O
given	O
by	O
24	O
hours	O
and	O
by	O
creatinine	O
ratio	O
.	O
Metanephrine	O
assay	O
can	O
be	O
performed	O
also	O
in	O
plasma	O
and	O
exhibits	O
the	O
same	O
interest	O
.	O
However	O
,	O
in	O
urine	O
as	O
in	O
plasma	O
,	O
in	O
case	O
of	O
renal	O
failure	O
,	O
results	O
cannot	O
be	O
interpreted	O
.	O
Neuroblastoma	O
biological	O
diagnosis	O
is	O
based	O
classically	O
on	O
HVA	O
,	O
VMA	O
,	O
and	O
dopamine	O
assays	O
,	O
nowadays	O
only	O
in	O
24	O
hours	O
urine	O
(	O
or	O
in	O
urinary	O
micturition	O
for	O
screening	O
)	O
,	O
and	O
results	O
are	O
also	O
expressed	O
as	O
creatinine	O
ratio	O
.	O
But	O
even	O
if	O
several	O
assays	O
are	O
advisable	O
,	O
5	O
%	O
of	O
the	O
neuroblastoma	O
cases	O
do	O
not	O
produce	O
increased	O
catecholamine	O
values	O
.	O
In	O
some	O
cases	O
,	O
metanephrine	O
assay	O
could	O
be	O
of	O
interest	O
.	O
After	O
the	O
age	O
of	O
12	O
months	O
,	O
clinical	O
expression	O
of	O
neuroblastoma	O
is	O
dramatic	O
in	O
70	O
%	O
of	O
cases	O
.	O
So	O
,	O
a	O
biological	O
screening	O
has	O
been	O
experimented	O
in	O
several	O
countries	O
including	O
France	O
.	O
A	O
French	O
translation	O
of	O
the	O
consensus	O
conference	O
report	O
(	O
1998	O
)	O
is	O
appended	O
,	O
which	O
shows	O
the	O
complexity	O
of	O
neuroblastoma	O
screening	O
.	O
Now	O
,	O
there	O
is	O
no	O
evidence	O
that	O
early	O
tumour	O
detection	O
by	O
screening	O
lessens	O
the	O
mortality	O
rate	O
,	O
but	O
a	O
weak	O
benefit	O
is	O
not	O
excluded	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
11830391	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
J.	O
2001	O
Dec	O
15;360	O
(	O
Pt	O
3	O
)	O
:683	O
-	O
9.	O
Proprotein	B-GENE
convertase	I-GENE
PACE4	I-GENE
is	O
down	O
-	O
regulated	O
by	O
the	O
basic	B-GENE
helix	I-GENE
-	I-GENE
loop	I-GENE
-	I-GENE
helix	I-GENE
transcription	I-GENE
factor	I-GENE
hASH	I-GENE
-	I-GENE
1	I-GENE
and	O
MASH	B-GENE
-	I-GENE
1	I-GENE
.	O
Yoshida	O
I	O
,	O
Koide	O
S	O
,	O
Hasegawa	O
SI	O
,	O
Nakagawara	O
A	O
,	O
Tsuji	O
A	O
,	O
Matsuda	O
Y	O
.	O
Department	O
of	O
Biological	O
Science	O
and	O
Technology	O
,	O
Faculty	O
of	O
Engineering	O
,	O
The	O
University	O
of	O
Tokushima	O
,	O
2-1	O
Minamijosanjima	O
,	O
Tokushima	O
770	O
-	O
8506	O
,	O
Japan	O
.	O
PACE4	B-GENE
is	O
a	O
mammalian	O
subtilisin	B-GENE
-	O
like	O
proprotein	O
convertase	B-GENE
that	O
activates	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
(	I-GENE
TGF	I-GENE
)	I-GENE
-	I-GENE
beta	I-GENE
-	O
related	O
proteins	O
such	O
as	O
bone	B-GENE
morphogenetic	I-GENE
protein	I-GENE
2	I-GENE
(	O
BMP2	B-GENE
)	O
,	O
BMP4	B-GENE
and	O
Nodal	O
and	O
exhibits	O
a	O
dynamic	O
expression	O
pattern	O
during	O
embryogenesis	O
.	O
We	O
recently	O
determined	O
that	O
the	O
1	O
kb	O
5'	O
-	O
upstream	O
region	O
of	O
the	O
PACE4	B-GENE
gene	O
contains	O
12	O
E	O
-	O
box	O
(	O
E1	O
-	O
E12	O
)	O
elements	O
and	O
that	O
an	O
E	O
-	O
box	O
cluster	O
(	O
E4	O
-	O
E9	O
)	O
acts	O
as	O
a	O
negative	O
regulator	O
[	O
Tsuji	O
,	O
Yoshida	O
,	O
Hasegawa	O
,	O
Bando	O
,	O
Yoshida	O
,	O
Koide	O
,	O
Mori	O
and	O
Matsuda	O
(	O
1999	O
)	O
J	O
.	O
Biochem	O
.	O
(	O
Tokyo	O
)	O
126	O
,	O
494	O
-	O
502	O
]	O
.	O
It	O
is	O
known	O
that	O
the	O
mammalian	B-GENE
achaete	I-GENE
-	I-GENE
scute	I-GENE
homologue	I-GENE
1	I-GENE
(	O
MASH	B-GENE
-	I-GENE
1	I-GENE
)	O
binds	O
specifically	O
to	O
an	O
E	O
-	O
box	O
(	O
CACCTG	O
)	O
sequence	O
in	O
collaboration	O
with	O
E47	B-GENE
,	O
a	O
ubiquitously	O
expressed	O
basic	B-GENE
helix	I-GENE
-	I-GENE
loop	I-GENE
-	I-GENE
helix	I-GENE
(	I-GENE
bHLH	I-GENE
)	I-GENE
factor	I-GENE
.	O
To	O
identify	O
the	O
roles	O
of	O
the	O
bHLH	B-GENE
factor	I-GENE
and	O
E	O
-	O
box	O
elements	O
in	O
regulating	O
PACE4	B-GENE
gene	O
expression	O
in	O
neural	O
development	O
,	O
we	O
analysed	O
the	O
effects	O
of	O
human	B-GENE
achaete	I-GENE
-	I-GENE
scute	I-GENE
homologue	I-GENE
1	I-GENE
(	O
hASH	B-GENE
-	I-GENE
1	I-GENE
)	O
on	O
PACE4	B-GENE
gene	O
expression	O
with	O
various	O
neuroblastoma	O
cell	O
lines	O
.	O
The	O
expressions	O
of	O
PACE4	B-GENE
and	O
hASH	B-GENE
-	I-GENE
1	I-GENE
are	O
correlated	O
inversely	O
in	O
these	O
cell	O
lines	O
.	O
The	O
overexpression	O
of	O
hASH	B-GENE
-	I-GENE
1	I-GENE
or	O
MASH	B-GENE
-	I-GENE
1	I-GENE
causes	O
a	O
marked	O
decrease	O
in	O
endogenous	O
PACE4	B-GENE
gene	O
expression	O
but	O
has	O
no	O
effect	O
on	O
the	O
expression	O
of	O
other	O
subtilisin	B-GENE
-	O
like	O
proprotein	O
convertases	B-GENE
such	O
as	O
furin	B-GENE
,	O
PC5	B-GENE
/	I-GENE
6	I-GENE
and	O
PC7	B-GENE
/	I-GENE
8	I-GENE
.	O
In	O
contrast	O
,	O
other	O
neural	B-GENE
bHLH	I-GENE
factors	I-GENE
(	O
MATH	B-GENE
-	I-GENE
1	I-GENE
,	O
MATH	B-GENE
-	I-GENE
2	I-GENE
,	O
neurogenin	B-GENE
1	I-GENE
,	O
neurogenin	B-GENE
2	I-GENE
,	O
neurogenin	B-GENE
3	I-GENE
and	O
E47	B-GENE
)	O
did	O
not	O
affect	O
PACE4	B-GENE
gene	O
expression	O
.	O
Furthermore	O
,	O
an	O
E	O
-	O
box	O
cluster	O
was	O
a	O
negative	O
regulatory	O
element	O
for	O
the	O
promoter	O
activity	O
in	O
NBL	O
-	O
S	O
cells	O
expressing	O
hASH	B-GENE
-	I-GENE
1	I-GENE
at	O
high	O
level	O
as	O
determined	O
by	O
a	O
luciferase	B-GENE
assay	O
.	O
Binding	O
of	O
hASH	B-GENE
-	I-GENE
1	I-GENE
to	O
the	O
E	O
-	O
box	O
cluster	O
was	O
confirmed	O
by	O
gel	O
mobility	O
-	O
shift	O
assay	O
.	O
In	O
the	O
present	O
study	O
we	O
identified	O
the	O
PACE4	B-GENE
gene	O
as	O
one	O
of	O
the	O
targets	O
of	O
hASH	B-GENE
-	I-GENE
1	I-GENE
,	O
which	O
is	O
a	O
key	O
factor	O
in	O
the	O
initiation	O
of	O
neural	O
differentiation	O
.	O
These	O
results	O
suggest	O
that	O
the	O
alteration	O
of	O
PACE4	B-GENE
gene	O
expression	O
by	O
hASH	B-GENE
-	I-GENE
1	I-GENE
causes	O
rapid	O
changes	O
in	O
the	O
biological	O
activities	O
of	O
TGF	B-GENE
-	I-GENE
beta	I-GENE
-	O
related	O
proteins	O
via	O
post	O
-	O
translational	O
modification	O
of	O
these	O
proteins	O
.	O
PMID	O
:	O
11736660	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Nucl	O
Med	O
Mol	O
Imaging	O
.	O
2004	O
Jan	O
27	O
[Epub	O
ahead	O
of	O
print	O
]	O
Targeting	O
of	O
lacZ	B-GENE
reporter	I-GENE
gene	O
expression	O
with	O
radioiodine	O
-	O
labelled	O
phenylethyl	O
-	O
beta	O
-	O
d	O
-	O
thiogalactopyranoside	O
.	O
Lee	O
KH	O
,	O
Byun	O
SS	O
,	O
Choi	O
JH	O
,	O
Paik	O
JY	O
,	O
Choe	O
YS	O
,	O
Kim	O
BT.	O
Department	O
of	O
Nuclear	O
Medicine	O
,	O
Samsung	O
Medical	O
Center	O
,	O
Sungkyunkwan	O
University	O
School	O
of	O
Medicine	O
,	O
50	O
Ilwondong	O
,	O
Kangnamgu	O
,	O
Seoul	O
,	O
Korea	O
.	O
There	O
has	O
recently	O
been	O
increasing	O
interest	O
in	O
the	O
development	O
of	O
radioprobes	O
that	O
specifically	O
target	O
proteins	O
transcribed	O
from	O
expression	O
of	O
reporter	O
genes	O
of	O
interest	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
radioprobe	O
that	O
targets	O
one	O
of	O
the	O
most	O
widely	O
used	O
reporter	O
genes	O
,	O
the	O
bacterial	O
lacZ	B-GENE
gene	O
.	O
We	O
synthesised	O
and	O
purified	O
radioiodine	O
-	O
labelled	O
phenylethyl	O
-	O
beta	O
-	O
d	O
-	O
thiogalactopyranoside	O
(	O
PETG	O
)	O
,	O
a	O
competitive	O
inhibitor	O
specific	O
against	O
Escherichia	O
coli	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
.	O
We	O
showed	O
that	O
[(125)I]iodo	O
-	O
PETG	O
specifically	O
binds	O
to	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
as	O
verified	O
by	O
column	O
chromatography	O
and	O
polyacrylamide	O
gel	O
electrophoresis	O
after	O
incubation	O
of	O
radiotracer	O
with	O
the	O
protein	O
.	O
We	O
also	O
showed	O
through	O
enzyme	O
kinetic	O
studies	O
that	O
iodo	O
-	O
PETG	O
retains	O
inhibitory	O
action	O
against	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
activity	O
.	O
COS	O
-	O
7	O
cells	O
infected	O
with	O
a	O
recombinant	O
adenovirus	O
expressing	O
the	O
lacZ	B-GENE
gene	O
had	O
viral	O
titre	O
-	O
dependent	O
enhancements	O
in	O
[(125)I]iodo	O
-	O
PETG	O
uptake	O
(	O
r(2)	O
=	O
0.897	O
;	O
P	O
=	O
0.001	O
)	O
,	O
which	O
reached	O
up	O
to	O
642.5	O
%	O
+/-	O
16.7	O
%	O
of	O
control	O
levels	O
(	O
P	O
<	O
0.00001	O
)	O
.	O
Moreover	O
,	O
the	O
level	O
of	O
uptake	O
was	O
highly	O
correlated	O
to	O
luminescent	O
measurements	O
of	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
activity	O
(	O
r(2)	O
=	O
0.878	O
;	O
P	O
<	O
0.0001	O
)	O
.	O
These	O
results	O
confirm	O
that	O
radioiodine	O
-	O
labelled	O
PETG	O
specifically	O
targets	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
and	O
that	O
its	O
uptake	O
rates	O
faithfully	O
reflect	O
levels	O
of	O
expression	O
of	O
the	O
lacZ	B-GENE
reporter	I-GENE
gene	O
.	O
Further	O
investigations	O
were	O
performed	O
in	O
nude	O
mice	O
bearing	O
human	O
neuroblastoma	O
tumours	O
transferred	O
with	O
the	O
lacZ	B-GENE
gene	O
.	O
Compared	O
with	O
control	O
tumours	O
,	O
lacZ	B-GENE
-	O
expressing	O
tumours	O
were	O
slightly	O
better	O
visualised	O
on	O
[(123)I]iodo	O
-	O
PETG	O
images	O
and	O
had	O
a	O
modest	O
increase	O
in	O
tumour	O
to	O
muscle	O
count	O
ratio	O
(	O
2.6	O
+/-	O
0.2	O
vs	O
1.9	O
+/-	O
0.1	O
,	O
P	O
<	O
0.05	O
)	O
.	O
The	O
present	O
results	O
provide	O
proof	O
-	O
of	O
-	O
principle	O
for	O
the	O
potential	O
of	O
radiolabelled	O
inhibitors	O
as	O
promising	O
radiotracers	O
to	O
monitor	O
lacZ	B-GENE
gene	O
expression	O
levels	O
.	O
Future	O
modifications	O
to	O
improve	O
cell	O
permeability	O
should	O
enhance	O
in	O
vivo	O
contrast	O
levels	O
and	O
may	O
allow	O
the	O
use	O
of	O
radiolabelled	O
beta	B-GENE
-	I-GENE
galactosidase	I-GENE
inhibitors	O
for	O
non	O
-	O
invasive	O
monitoring	O
of	O
lacZ	B-GENE
gene	O
expression	O
.	O
PMID	O
:	O
14745516	O
[	O
PubMed	O
-	O
as	O
supplied	O
by	O
publisher	O
]	O

J	O
Mol	O
Biol	O
.	O
1989	O
Dec	O
5;210(	O
3	O
)	O
:	O
417-27	O
.	O
Parvalbumin	B-GENE
genes	O
from	O
human	O
and	O
rat	O
are	O
identical	O
in	O
intron	O
/	O
exon	O
organization	O
and	O
contain	O
highly	O
homologous	O
regulatory	O
elements	O
and	O
coding	O
sequences	O
.	O
Berchtold	O
MW	O
.	O
Institut	O
fur	O
Pharmakologie	O
und	O
Biochemie	O
,	O
Universitat	O
Zurich	O
,	O
Switzerland	O
.	O
The	O
structural	O
organization	O
of	O
the	O
chromosomal	O
gene	O
for	O
human	O
parvalbumin	B-GENE
was	O
determined	O
mostly	O
by	O
sequencing	O
exons	O
and	O
intron	O
exon	O
junctions	O
of	O
a	O
7500	O
base	O
-	O
pair	O
(	O
bp	O
)	O
long	O
genomic	O
clone	O
derived	O
from	O
a	O
chromosome	O
22	O
-	O
specific	O
gene	O
library	O
.	O
Four	O
exons	O
coding	O
for	O
100	O
from	O
a	O
total	O
of	O
109	O
amino	O
acids	O
were	O
detected	O
in	O
this	O
clone	O
and	O
472	O
bp	O
of	O
the	O
5'	O
-	O
flanking	O
region	O
were	O
sequenced	O
.	O
The	O
region	O
corresponding	O
to	O
the	O
C	O
-	O
terminal	O
amino	O
acids	O
101	O
to	O
109	O
of	O
human	O
parvalbumin	B-GENE
was	O
determined	O
by	O
sequencing	O
a	O
cDNA	O
fragment	O
derived	O
from	O
human	O
brain	O
mRNA	O
after	O
amplification	O
by	O
the	O
polymerase	B-GENE
chain	O
reaction	O
.	O
The	O
first	O
intron	O
is	O
placed	O
7	O
bp	O
upstream	O
from	O
the	O
ATG	O
translation	O
start	O
signal	O
,	O
whereas	O
all	O
other	O
splice	O
sites	O
divide	O
putative	O
Ca2	O
+	O
-	O
binding	O
domains	O
.	O
All	O
intron	O
positions	O
coincide	O
exactly	O
with	O
those	O
reported	O
for	O
the	O
rat	O
parvalbumin	B-GENE
gene	O
.	O
The	O
5	O
'	O
mRNA	O
leader	O
sequence	O
has	O
a	O
similarity	O
of	O
57	O
%	O
,	O
the	O
coding	O
region	O
of	O
91	O
%	O
and	O
the	O
3	O
'	O
non	O
-	O
coding	O
region	O
of	O
83	O
%	O
to	O
the	O
corresponding	O
rat	O
sequences	O
.	O
Only	O
nine	O
conservative	O
amino	O
acid	O
replacements	O
were	O
observed	O
between	O
human	O
and	O
rat	O
parvalbumins	B-GENE
.	O
The	O
predicted	O
secondary	O
structures	O
for	O
human	O
,	O
rat	O
,	O
mouse	O
and	O
rabbit	O
parvalbumins	B-GENE
are	O
very	O
similar	O
,	O
indicating	O
a	O
strong	O
structural	O
relationship	O
among	O
mammalian	O
parvalbumins	B-GENE
.	O
Several	O
elements	O
with	O
potential	O
transcription	O
regulatory	O
activities	O
were	O
found	O
in	O
the	O
region	O
immediately	O
5	O
'	O
to	O
the	O
transcription	O
start	O
site	O
including	O
a	O
TATA	O
box	O
(	O
TATATA	O
)	O
and	O
a	O
CAAT	O
box	O
(	O
CCAAAAT	O
)	O
.	O
Several	O
regions	O
in	O
the	O
putative	O
promoter	O
are	O
strongly	O
conserved	O
between	O
the	O
human	O
and	O
rat	O
parvalbumin	B-GENE
genes	O
.	O
One	O
of	O
these	O
with	O
a	O
length	O
of	O
32	O
bp	O
is	O
identical	O
with	O
the	O
rat	O
counterpart	O
and	O
has	O
a	O
high	O
degree	O
of	O
homology	O
to	O
a	O
promoter	O
region	O
in	O
the	O
myosin	B-GENE
light	I-GENE
chain	I-GENE
3F	I-GENE
gene	O
,	O
which	O
is	O
expressed	O
in	O
fast	O
contracting	O
/	O
relaxing	O
muscle	O
fibers	O
(	O
anaerobic	O
/	O
type	O
IIb	O
)	O
,	O
the	O
cell	O
type	O
that	O
also	O
exhibits	O
highest	O
levels	O
of	O
parvalbumin	B-GENE
expression	O
.	O
The	O
human	O
parvalbumin	B-GENE
mRNA	O
contains	O
the	O
putative	O
polyadenylation	O
signal	O
AATAAA	O
13	O
nucleotides	O
upstream	O
from	O
the	O
polyadenylation	O
site	O
.	O
A	O
700	O
-	O
nucleotide	O
long	O
parvalbumin	B-GENE
mRNA	I-GENE
is	O
synthesized	O
at	O
low	O
levels	O
in	O
the	O
human	O
cerebellum	O
as	O
well	O
as	O
in	O
the	O
neuroblastoma	O
cell	O
line	O
SK	O
-	O
N	O
-	O
BE	O
.	O
PMID	O
:	O
2614829	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
.	O
2001	O
Oct;32(	O
2	O
)	O
:	O
126-35	O
.	O
Combined	O
M	O
-	O
FISH	O
and	O
CGH	O
analysis	O
allows	O
comprehensive	O
description	O
of	O
genetic	O
alterations	O
in	O
neuroblastoma	O
cell	O
lines	O
.	O
Van	O
Roy	O
N	O
,	O
Van	O
Limbergen	O
H,	O
Vandesompele	O
J,	O
Van	O
Gele	O
M,	O
Poppe	O
B	O
,	O
Salwen	O
H,	O
Laureys	O
G	O
,	O
Manoel	O
N	O
,	O
De	O
Paepe	O
A	O
,	O
Speleman	O
F.	O
Centre	O
for	O
Medical	O
Genetics	O
,	O
Ghent	O
University	O
Hospital	O
,	O
De	O
Pintelaan	O
185	O
,	O
9000	O
Ghent	O
,	O
Belgium	O
.	O
Cancer	O
cell	O
lines	O
are	O
essential	O
gene	O
discovery	O
tools	O
and	O
have	O
often	O
served	O
as	O
models	O
in	O
genetic	O
and	O
functional	O
studies	O
of	O
particular	O
tumor	O
types	O
.	O
One	O
of	O
the	O
future	O
challenges	O
is	O
comparison	O
and	O
interpretation	O
of	O
gene	O
expression	O
data	O
with	O
the	O
available	O
knowledge	O
on	O
the	O
genomic	O
abnormalities	O
in	O
these	O
cell	O
lines	O
.	O
In	O
this	O
context	O
,	O
accurate	O
description	O
of	O
these	O
genomic	O
abnormalities	O
is	O
required	O
.	O
Here	O
,	O
we	O
show	O
that	O
a	O
combination	O
of	O
M	O
-	O
FISH	O
with	O
banding	O
analysis	O
,	O
standard	O
FISH	O
,	O
and	O
CGH	O
allowed	O
a	O
detailed	O
description	O
of	O
the	O
genetic	O
alterations	O
in	O
16	O
neuroblastoma	O
cell	O
lines	O
.	O
In	O
total	O
,	O
14	O
cryptic	O
chromosome	O
rearrangements	O
were	O
detected	O
,	O
including	O
a	O
balanced	O
t	O
2	O
;	O
4	O
(	O
p24	O
3	O
q	O
34.3	O
)	O
translocation	O
in	O
cell	O
line	O
NBL	O
-	O
S	O
,	O
with	O
the	O
2p24	O
breakpoint	O
located	O
at	O
about	O
40	O
kb	O
from	O
MYCN	B-GENE
.	O
The	O
chromosomal	O
origin	O
of	O
22	O
marker	O
chromosomes	O
and	O
41	O
cytogenetically	O
undefined	O
translocated	O
segments	O
was	O
determined	O
.	O
Chromosome	O
arm	O
2	O
short	O
arm	O
translocations	O
were	O
observed	O
in	O
six	O
cell	O
lines	O
(	O
38	O
%	O
)	O
with	O
and	O
five	O
(	O
31	O
%	O
)	O
without	O
MYCN	B-GENE
amplification	O
,	O
leading	O
to	O
partial	O
chromosome	O
arm	O
2p	O
gain	O
in	O
all	O
but	O
one	O
cell	O
line	O
and	O
loss	O
of	O
material	O
in	O
the	O
various	O
partner	O
chromosomes	O
,	O
including	O
1p	O
and	O
11q	O
.	O
These	O
2p	O
gains	O
were	O
often	O
masked	O
in	O
the	O
GGH	O
profiles	O
due	O
to	O
MYCN	B-GENE
amplification	O
.	O
The	O
commonly	O
overrepresented	O
region	O
was	O
chromosome	O
segment	O
2pter	O
-	O
2p22	O
,	O
which	O
contains	O
the	O
MYCN	B-GENE
gene	O
,	O
and	O
five	O
out	O
of	O
eleven	O
2p	O
breakpoints	O
clustered	O
to	O
the	O
interface	O
of	O
chromosome	O
bands	O
2p16	O
and	O
2p21	O
.	O
In	O
neuroblastoma	O
cell	O
line	O
SJNB	O
-	O
12	O
,	O
with	O
double	O
minutes	O
(	O
dmins	O
)	O
but	O
no	O
MYCN	B-GENE
amplification	O
,	O
the	O
dmins	O
were	O
shown	O
to	O
be	O
derived	O
from	O
16q22-q23	O
sequences	O
.	O
The	O
ATBF1	B-GENE
gene	O
,	O
an	O
AT	B-GENE
-	I-GENE
binding	I-GENE
transcription	I-GENE
factor	I-GENE
involved	O
in	O
normal	O
neurogenesis	O
and	O
located	O
at	O
16q22.2	O
,	O
was	O
shown	O
to	O
be	O
present	O
in	O
the	O
amplicon	O
.	O
This	O
is	O
the	O
first	O
report	O
describing	O
the	O
possible	O
implication	O
of	O
ATBF1	B-GENE
in	O
neuroblastoma	O
cells	O
.	O
We	O
conclude	O
that	O
a	O
combined	O
approach	O
of	O
M	O
-	O
FISH	O
,	O
cytogenetics	O
,	O
and	O
CGH	O
allowed	O
a	O
more	O
complete	O
and	O
accurate	O
description	O
of	O
the	O
genetic	O
alterations	O
occurring	O
in	O
the	O
investigated	O
cell	O
lines	O
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11550280	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Med	O
Genet	O
.	O
2003	O
Jun;40	O
(	O
6	O
)	O
:	O
424-30	O
.	O
Association	O
of	O
3'	O
-	O
UTR	O
polymorphisms	O
of	O
the	O
oxidised	O
LDL	B-GENE
receptor	I-GENE
1	I-GENE
(	O
OLR1	B-GENE
)	O
gene	O
with	O
Alzheimer's	O
disease	O
.	O
Lambert	O
JC	O
,	O
Luedecking	O
-	O
Zimmer	O
E	O
,	O
Merrot	O
S	O
,	O
Hayes	O
A	O
,	O
Thaker	O
U	O
,	O
Desai	O
P,	O
Houzet	O
A	O
,	O
Hermant	O
X	O
,	O
Cottel	O
D	O
,	O
Pritchard	O
A	O
,	O
Iwatsubo	O
T	O
,	O
Pasquier	O
F	O
,	O
Frigard	O
B	O
,	O
Conneally	O
PM	O
,	O
Chartier-Harlin	O
MC	O
,	O
DeKosky	O
ST	O
,	O
Lendon	O
C	O
,	O
Mann	O
D	O
,	O
Kamboh	O
MI	O
,	O
Amouyel	O
P.	O
Unite	O
INSERM	O
508	O
,	O
Institut	O
Pasteur	O
de	O
Lille	O
,	O
BP	O
245	O
,	O
1	O
rue	O
du	O
Professeur	O
Calmette	O
,	O
59019	O
Lille	O
Cedex	O
,	O
France	O
.	O
jean	O
-	O
charles	O
.lambert@pasteur	O
-	O
lille	O
.fr	O
Although	O
possession	O
of	O
the	O
epsilon	O
4	O
allele	O
of	O
the	O
apolipoprotein	B-GENE
E	I-GENE
gene	O
appears	O
to	O
be	O
an	O
important	O
biological	O
marker	O
for	O
Alzheimer's	O
disease	O
(	O
AD	O
)	O
susceptibility	O
,	O
strong	O
evidence	O
indicates	O
that	O
at	O
least	O
one	O
additional	O
risk	O
gene	O
exists	O
on	O
chromosome	O
12	O
.	O
Here	O
,	O
we	O
describe	O
an	O
association	O
of	O
the	O
3'	O
-	O
UTR	O
+	O
1073	O
C	O
/	O
T	O
polymorphism	O
of	O
the	O
OLR1	B-GENE
(	O
oxidised	B-GENE
LDL	I-GENE
receptor	I-GENE
1	I-GENE
)	O
on	O
chromosome	O
12	O
with	O
AD	O
in	O
French	O
sporadic	O
(	O
589	O
cases	O
and	O
663	O
controls	O
)	O
and	O
American	O
familial	O
(	O
230	O
affected	O
sibs	O
and	O
143	O
unaffected	O
sibs	O
)	O
populations	O
.	O
The	O
age	O
and	O
sex	O
adjusted	O
odds	O
ratio	O
between	O
the	O
CC	O
+	O
CT	O
genotypes	O
versus	O
the	O
TT	O
genotypes	O
was	O
1.56	O
(	O
p	O
=	O
0.001	O
)	O
in	O
the	O
French	O
sample	O
and	O
1.92	O
(	O
p	O
=	O
0.02	O
)	O
in	O
the	O
American	O
sample	O
.	O
Furthermore	O
,	O
we	O
have	O
discovered	O
a	O
new	O
T	O
/	O
A	O
polymorphism	O
two	O
bases	O
upstream	O
of	O
the	O
+	O
1073	O
C	O
/	O
T	O
polymorphism	O
.	O
This	O
+	O
1071	O
T	O
/	O
A	O
polymorphism	O
was	O
not	O
associated	O
with	O
the	O
disease	O
,	O
although	O
it	O
may	O
weakly	O
modulate	O
the	O
impact	O
of	O
the	O
+	O
1073	O
C	O
/	O
T	O
polymorphism	O
.	O
Using	O
3'	O
-	O
UTR	O
sequence	O
probes	O
,	O
we	O
have	O
observed	O
specific	O
DNA	O
protein	O
binding	O
with	O
nuclear	O
proteins	O
from	O
lymphocyte	O
,	O
astrocytoma	O
,	O
and	O
neuroblastoma	O
cell	O
lines	O
,	O
but	O
not	O
from	O
the	O
microglia	O
cell	O
line	O
.	O
This	O
binding	O
was	O
modified	O
by	O
both	O
the	O
+	O
1071	O
T	O
/	O
A	O
and	O
+	O
1073	O
C	O
/	O
T	O
polymorphisms	O
.	O
In	O
addition	O
,	O
a	O
trend	O
was	O
observed	O
between	O
the	O
presence	O
or	O
absence	O
of	O
the	O
+	O
1073	O
C	O
allele	O
and	O
the	O
level	O
of	O
astrocytic	O
activation	O
in	O
the	O
brain	O
of	O
AD	O
cases	O
.	O
However	O
,	O
Abeta	B-GENE
(	I-GENE
40	I-GENE
)	I-GENE
,	O
Abeta	B-GENE
(	I-GENE
42	I-GENE
)	I-GENE
,	O
Abeta	B-GENE
total	O
,	O
and	O
Tau	B-GENE
loads	O
or	O
the	O
level	O
of	O
microglial	O
cell	O
activation	O
were	O
not	O
modulated	O
by	O
the	O
3'	O
-	O
UTR	O
OLR1	O
polymorphisms	O
.	O
Finally	O
,	O
we	O
assessed	O
the	O
impact	O
of	O
these	O
polymorphisms	O
on	O
the	O
level	O
of	O
OLR1	B-GENE
expression	O
in	O
lymphocytes	O
from	O
AD	O
cases	O
compared	O
with	O
controls	O
.	O
The	O
OLR1	B-GENE
expression	O
was	O
significantly	O
lower	O
in	O
AD	O
cases	O
bearing	O
the	O
CC	O
and	O
CT	O
genotypes	O
compared	O
with	O
controls	O
with	O
the	O
same	O
genotypes	O
.	O
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
genetic	O
variation	O
in	O
the	O
OLR1	B-GENE
gene	O
may	O
modify	O
the	O
risk	O
of	O
AD	O
.	O
Publication	O
Types	O
:	O
Multicenter	O
Study	O
PMID	O
:	O
12807963	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Natl	O
Cancer	O
Inst	O
.	O
1997	O
Sep	O
3;89	O
(	O
17	O
)	O
:	O
1300	O
-	O
10	O
.	O
DR	B-GENE
-	I-GENE
nm23	I-GENE
gene	O
expression	O
in	O
neuroblastoma	O
cells	O
:	O
relationship	O
to	O
integrin	B-GENE
expression	O
,	O
adhesion	O
characteristics	O
,	O
and	O
differentiation	O
.	O
Amendola	O
R	O
,	O
Martinez	O
R	O
,	O
Negroni	O
A	O
,	O
Venturelli	O
D	O
,	O
Tanno	O
B	O
,	O
Calabretta	O
B	O
,	O
Raschella	O
G.	O
Enea	O
,	O
CR	O
-	O
Casaccia	O
,	O
Section	O
of	O
Toxicology	O
and	O
Biomedical	O
Sciences	O
,	O
Rome	O
,	O
Italy	O
.	O
BACKGROUND	O
:	O
Neuroblastoma	O
,	O
a	O
childhood	O
tumor	O
originating	O
from	O
cells	O
of	O
the	O
embryonic	O
neural	O
crest	O
,	O
retains	O
the	O
ability	O
to	O
differentiate	O
,	O
yielding	O
cells	O
with	O
epithelial	O
-	O
Schwann	O
-	O
like	O
,	O
neuronal	O
,	O
or	O
melanocytic	O
characteristics	O
.	O
Since	O
nm23	B-GENE
gene	O
family	O
members	O
have	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
cellular	O
differentiation	O
,	O
as	O
well	O
as	O
in	O
metastasis	O
suppression	O
,	O
we	O
investigated	O
whether	O
and	O
how	O
DR	B-GENE
-	I-GENE
nm23	I-GENE
,	O
a	O
recently	O
identified	O
third	O
member	O
of	O
the	O
human	O
nm23	B-GENE
gene	O
family	O
,	O
might	O
be	O
involved	O
in	O
neuroblastoma	O
differentiation	O
.	O
METHODS	O
:	O
Three	O
neuroblastoma	O
cell	O
lines	O
(	O
human	O
LAN	O
-	O
5	O
,	O
human	O
SK	O
-	O
N	O
-	O
SH	O
,	O
and	O
murine	O
N1E	O
-	O
115	O
)	O
were	O
used	O
in	O
these	O
experiments	O
;	O
cells	O
from	O
two	O
of	O
the	O
lines	O
(	O
SK	O
-	O
N	O
-	O
SH	O
and	O
N1E	O
-	O
115	O
)	O
were	O
also	O
studied	O
after	O
being	O
stably	O
transfected	O
with	O
a	O
plasmid	O
containing	O
a	O
full	O
-	O
length	O
DR	B-GENE
-	I-GENE
nm23	I-GENE
complementary	O
DNA	O
.	O
Cellular	O
expression	O
of	O
specific	O
messenger	O
RNAs	O
and	O
proteins	O
was	O
assessed	O
by	O
use	O
of	O
standard	O
techniques	O
.	O
Cellular	O
adhesion	O
to	O
a	O
variety	O
of	O
protein	O
substrates	O
was	O
also	O
evaluated	O
.	O
RESULTS	O
:	O
DR	B-GENE
-	I-GENE
nm23	I-GENE
messenger	O
RNA	O
levels	O
in	O
nontransfected	O
LAN	O
-	O
5	O
and	O
SK	O
-	O
N	O
-	O
SH	O
cells	O
generally	O
increased	O
with	O
time	O
after	O
exposure	O
to	O
differentiation	O
-	O
inducing	O
conditions	O
;	O
levels	O
of	O
the	O
other	O
two	O
human	O
nm23	B-GENE
messenger	O
RNAs	O
(	O
nm23	B-GENE
-	I-GENE
H1	I-GENE
and	O
nm23	B-GENE
-	I-GENE
H2	I-GENE
)	O
remained	O
essentially	O
constant	O
.	O
Transfected	O
SK	O
-	O
N	O
-	O
SH	O
cells	O
overexpressing	O
DR	B-GENE
-	I-GENE
nm23	I-GENE
exhibited	O
some	O
characteristics	O
of	O
differentiated	O
cells	O
(	O
increased	O
vimentin	B-GENE
and	O
collagen	B-GENE
type	I-GENE
IV	I-GENE
expression	O
)	O
even	O
in	O
the	O
absence	O
of	O
differentiation	O
-	O
inducing	O
conditions	O
.	O
Compared	O
with	O
control	O
cells	O
,	O
DR	B-GENE
-	I-GENE
nm23	I-GENE
-	O
transfected	O
cells	O
exposed	O
to	O
differentiation	O
-	O
inducing	O
conditions	O
showed	O
a	O
greater	O
degree	O
of	O
growth	O
arrest	O
(	O
SK	O
-	O
N	O
-	O
SH	O
cells	O
)	O
and	O
greater	O
increases	O
in	O
integrin	B-GENE
protein	O
expression	O
,	O
especially	O
of	O
integrin	B-GENE
beta1	I-GENE
(	O
N1E	O
-	O
115	O
cells	O
)	O
.	O
DR	B-GENE
-	I-GENE
nm23	I-GENE
-	O
transfected	O
N1E	O
-	O
115	O
cells	O
also	O
showed	O
a	O
marked	O
increase	O
in	O
adhesion	O
to	O
collagen	B-GENE
type	I-GENE
I	I-GENE
-	O
coated	O
tissue	O
culture	O
plates	O
that	O
was	O
inhibited	O
by	O
preincubation	O
with	O
an	O
anti	B-GENE
-	I-GENE
integrin	I-GENE
beta1	I-GENE
antibody	I-GENE
.	O
CONCLUSIONS	O
:	O
DR	B-GENE
-	I-GENE
nm23	I-GENE
gene	O
expression	O
appears	O
to	O
be	O
associated	O
with	O
differentiation	O
in	O
neuroblastoma	O
cells	O
and	O
may	O
affect	O
cellular	O
adhesion	O
through	O
regulation	O
of	O
integrin	B-GENE
protein	O
expression	O
.	O
PMID	O
:	O
9293921	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Med	O
Chem	O
.	O
1995	O
Oct	O
27	O
;	O
38	O
(	O
22	O
)	O
:	O
4579-86	O
.	O
Y1	B-GENE
and	O
Y2	B-GENE
receptor	I-GENE
selective	O
neuropeptide	B-GENE
Y	I-GENE
analogues	O
:	O
evidence	O
for	O
a	O
Y1	B-GENE
receptor	I-GENE
subclass	O
.	O
Kirby	O
DA	O
,	O
Koerber	O
SC	O
,	O
May	O
JM	O
,	O
Hagaman	O
C	O
,	O
Cullen	O
MJ	O
,	O
Pelleymounter	O
MA	O
,	O
Rivier	O
JE	O
.	O
Clayton	O
Foundation	O
Laboratories	O
for	O
Peptide	O
Biology	O
,	O
Salk	O
Institute	O
,	O
La	O
Jolla	O
,	O
California	O
92037	O
,	O
USA	O
.	O
Neuropeptide	B-GENE
Y	I-GENE
(	O
NPY	B-GENE
)	O
,	O
a	O
36	O
-	O
residue	O
polypeptide	O
produced	O
abundantly	O
in	O
both	O
nervous	O
and	O
peripheral	O
tissues	O
,	O
appears	O
to	O
play	O
a	O
significant	O
role	O
in	O
the	O
regulation	O
of	O
diverse	O
biological	O
processes	O
,	O
including	O
feeding	O
behavior	O
and	O
cardiovascular	O
and	O
psychotropic	O
functions	O
.	O
The	O
actions	O
of	O
NPY	B-GENE
are	O
mediated	O
through	O
effective	O
binding	O
to	O
specific	O
receptors	O
of	O
which	O
two	O
,	O
designated	O
Y1	B-GENE
and	O
Y2	B-GENE
,	O
have	O
been	O
well	O
characterized	O
.	O
A	O
shortened	O
cyclic	O
analogue	O
of	O
NPY	B-GENE
,	O
des-AA10-17-cyclo-7/21[Cys7,21]NPY	B-GENE
,	O
was	O
shown	O
to	O
retain	O
high	O
affinity	O
for	O
both	O
human	O
neuroblastoma	O
SK-N-MC	O
and	O
SK-N-BE2	O
cell	O
types	O
(	O
expressing	O
Y1	B-GENE
and	O
Y2	B-GENE
receptors	I-GENE
,	O
respectively	O
)	O
.	O
Increasing	O
the	O
size	O
of	O
the	O
ring	O
(	O
des-AA10-17-cyclo-2/27[Cys2,27]NPY	B-GENE
)	O
in	O
the	O
present	O
study	O
produced	O
a	O
high	O
-	O
affinity	O
analogue	O
(	O
Ki	O
=	O
3.0	O
vs	O
0.3	O
nM	O
for	O
NPY	B-GENE
)	O
that	O
bound	O
exclusively	O
to	O
Y2	B-GENE
receptors	I-GENE
.	O
Using	O
the	O
feedback	O
from	O
structure	O
-	O
activity	O
relationships	O
,	O
we	O
also	O
describe	O
the	O
optimization	O
of	O
specific	O
substitutions	O
and	O
bridging	O
arrangements	O
leading	O
to	O
the	O
production	O
of	O
other	O
truncated	O
,	O
high	O
-	O
affinity	O
Y1	B-GENE
selective	O
analogues	O
which	O
bind	O
,	O
as	O
does	O
NPY	B-GENE
itself	O
,	O
in	O
the	O
low-nanomolar	O
range	O
.	O
Of	O
greatest	O
significance	O
,	O
des-AA10-17-cyclo-7/21[Cys7,21,Pro34]NPY	B-GENE
(	O
11	O
)	O
was	O
found	O
to	O
possess	O
agonistic	O
properties	O
with	O
an	O
affinity	O
comparable	O
to	O
that	O
of	O
the	O
native	O
NPY	B-GENE
molecule	O
when	O
tested	O
for	O
its	O
ability	O
to	O
inhibit	O
norepinephrine	O
-	O
stimulated	O
cAMP	O
release	O
in	O
SK-N-MC	O
human	O
neuroblastoma	O
cells	O
.	O
Compound	O
11	O
also	O
caused	O
an	O
increase	O
in	O
blood	O
pressure	O
in	O
anesthetized	O
rats	O
.	O
However	O
,	O
in	O
two	O
central	O
nervous	O
system	O
models	O
of	O
Y1	B-GENE
receptor	I-GENE
function	O
,	O
stimulation	O
of	O
feeding	O
and	O
anxiolytic	O
activity	O
,	O
this	O
analogue	O
was	O
inactive	O
,	O
which	O
suggests	O
the	O
presence	O
of	O
a	O
new	O
subclass	O
of	O
receptors	O
.	O
In	O
summary	O
,	O
the	O
present	O
results	O
demonstrate	O
that	O
residues	O
10-17	O
of	O
NPY	B-GENE
are	O
not	O
directly	O
involved	O
in	O
either	O
Y1	B-GENE
or	O
Y2	B-GENE
receptor	I-GENE
recognition	O
or	O
activation	O
.	O
This	O
suggests	O
that	O
the	O
selectivity	O
of	O
NPY	B-GENE
receptors	I-GENE
is	O
highly	O
dependent	O
on	O
subtle	O
conformational	O
changes	O
such	O
as	O
the	O
substitution	O
of	O
residue	O
34	O
to	O
a	O
proline	O
or	O
the	O
introduction	O
of	O
intramolecular	O
constraints	O
.	O
Additionally	O
,	O
we	O
have	O
produced	O
an	O
analogue	O
of	O
NPY	B-GENE
that	O
selectively	O
activates	O
peripheral	O
NPY	B-GENE
Y1	I-GENE
receptors	I-GENE
.	O
PMID	O
:	O
7473586	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1995	O
Jul	O
18	O
;	O
92	O
15	O
)	O
:	O
6778	O
-	O
82	O
.	O
Identification	O
of	O
the	O
human	O
prostatic	B-GENE
carcinoma	I-GENE
oncogene	I-GENE
PTI-1	I-GENE
by	O
rapid	O
expression	O
cloning	O
and	O
differential	O
RNA	O
display	O
.	O
Shen	O
R	O
,	O
Su	O
ZZ	O
,	O
Olsson	O
CA	O
,	O
Fisher	O
PB	O
.	O
Department	O
of	O
Pathology	O
,	O
Columbia	O
University	O
,	O
College	O
of	O
Physicians	O
and	O
Surgeons	O
,	O
New	O
York	O
,	O
NY	O
10032	O
,	O
USA	O
.	O
Elucidating	O
the	O
relevant	O
genomic	O
changes	O
mediating	O
development	O
and	O
evolution	O
of	O
prostate	O
cancer	O
is	O
paramount	O
for	O
effective	O
diagnosis	O
and	O
therapy	O
.	O
A	O
putative	O
dominant	O
-	O
acting	O
nude	O
mouse	O
prostatic	O
carcinoma	O
tumor	O
-	O
inducing	O
gene	O
,	O
PTI-1	B-GENE
,	O
has	O
been	O
cloned	O
that	O
is	O
expressed	O
in	O
patient	O
-	O
derived	O
human	O
prostatic	O
carcinomas	O
but	O
not	O
in	O
benign	O
prostatic	O
hypertrophy	O
or	O
normal	O
prostate	O
tissue	O
.	O
PTI-1	B-GENE
was	O
detected	O
by	O
cotransfecting	O
human	O
prostate	O
carcinoma	O
DNA	O
into	O
CREF-Trans	O
6	O
cells	O
,	O
inducing	O
tumors	O
in	O
nude	O
mice	O
,	O
and	O
isolating	O
genes	O
displaying	O
increased	O
expression	O
in	O
tumor	O
-	O
derived	O
cells	O
by	O
using	O
differential	O
RNA	O
display	O
(	O
DD	O
)	O
.	O
Screening	O
a	O
human	O
prostatic	O
carcinoma	O
(	O
LNCaP	O
)	O
cDNA	O
library	O
with	O
a	O
214	O
-bp	O
DNA	O
fragment	O
found	O
by	O
DD	O
permitted	O
the	O
cloning	O
of	O
a	O
full-length	O
2.0-kb	O
PTI-1	O
cDNA	O
.	O
Sequence	O
analysis	O
indicates	O
that	O
PTI-1	B-GENE
is	O
a	O
gene	O
containing	O
a	O
630	O
-	O
bp	O
5'	O
sequence	O
and	O
a	O
3'	O
sequence	O
homologous	O
to	O
a	O
truncated	O
and	O
mutated	O
form	O
of	O
human	O
elongation	B-GENE
factor	I-GENE
1	I-GENE
alpha	I-GENE
.	O
In	O
vitro	O
translation	O
demonstrates	O
that	O
the	O
PTI-1	B-GENE
cDNA	O
encodes	O
a	O
predominant	O
approximately	O
46-kDa	O
protein	O
.	O
Probing	O
Northern	O
blots	O
with	O
a	O
DNA	O
fragment	O
corresponding	O
to	O
the	O
5'	O
region	O
of	O
PTI-1	B-GENE
identifies	O
multiple	O
PTI-1	B-GENE
transcripts	O
in	O
RNAs	O
from	O
human	O
carcinoma	O
cell	O
lines	O
derived	O
from	O
the	O
prostate	O
,	O
lung	O
,	O
breast	O
,	O
and	O
colon	O
.	O
In	O
contrast	O
,	O
PTI-1	B-GENE
RNA	O
is	O
not	O
detected	O
in	O
human	O
melanoma	O
,	O
neuroblastoma	O
,	O
osteosarcoma	O
,	O
normal	O
cerebellum	O
,	O
or	O
glioblastoma	O
multiforme	O
cell	O
lines	O
.	O
By	O
using	O
a	O
pair	O
of	O
primers	O
recognizing	O
a	O
280	O
-	O
bp	O
region	O
within	O
the	O
630-bp	O
5'	O
PTI-1	B-GENE
sequence	O
,	O
reverse	O
transcription-PCR	O
detects	O
PTI-1	B-GENE
expression	O
in	O
patient	O
-	O
derived	O
prostate	O
carcinomas	O
but	O
not	O
in	O
normal	O
prostate	O
or	O
benign	O
hypertrophic	O
prostate	O
tissue	O
.	O
In	O
contrast	O
,	O
reverse	O
transcription-PCR	O
detects	O
prostate	O
-	O
specific	O
antigen	O
expression	O
in	O
all	O
of	O
the	O
prostate	O
tissues	O
.	O
These	O
results	O
indicate	O
that	O
PTI-1	B-GENE
may	O
be	O
a	O
member	O
of	O
a	O
class	O
of	O
oncogenes	O
that	O
could	O
affect	O
protein	O
translation	O
and	O
contribute	O
to	O
carcinoma	O
development	O
in	O
human	O
prostate	O
and	O
other	O
tissues	O
.	O
The	O
approaches	O
used	O
,	O
rapid	O
expression	O
cloning	O
with	O
the	O
CREF-Trans	O
6	O
system	O
and	O
the	O
DD	O
strategy	O
,	O
should	O
prove	O
widely	O
applicable	O
for	O
identifying	O
and	O
cloning	O
additional	O
human	O
oncogenes	O
.	O
PMID	O
:	O
7542776	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Lab	O
Invest	O
.	O
1996	O
Nov	O
;	O
75	O
(	O
5	O
)	O
:	O
659-75	O
.	O
A	O
developmental	O
model	O
of	O
neuroblastoma	O
:	O
differentiating	O
stroma	O
-	O
poor	O
tumors	O
'	O
progress	O
along	O
an	O
extra-adrenal	O
chromaffin	O
lineage	O
.	O
Hoehner	O
JC	O
,	O
Gestblom	O
C	O
,	O
Hedborg	O
F	O
,	O
Sandstedt	O
B	O
,	O
Olsen	O
L	O
,	O
Pahlman	O
S	O
.	O
Department	O
of	O
Pathology	O
,	O
Uppsala	O
University	O
Hospital	O
,	O
Sweden	O
.	O
The	O
prognosis	O
of	O
children	O
with	O
neuroblastoma	O
(	O
NB	O
)	O
is	O
dependent	O
upon	O
the	O
patient	O
's	O
age	O
at	O
diagnosis	O
,	O
the	O
location	O
of	O
the	O
primary	O
tumor	O
,	O
and	O
histologic	O
tumor	O
cell	O
differentiation	O
.	O
These	O
characteristics	O
,	O
as	O
well	O
as	O
the	O
presumption	O
that	O
NB	O
results	O
from	O
clonal	O
expansion	O
of	O
primitive	O
cells	O
involved	O
in	O
sympathetic	O
nervous	O
system	O
(	O
SNS	O
)	O
development	O
,	O
predict	O
that	O
a	O
model	O
of	O
tumorigenesis	O
based	O
upon	O
normal	O
fetal	O
SNS	O
histogenesis	O
might	O
indicate	O
tumor	O
progenitor	O
status	O
and	O
define	O
biologic	O
and	O
clinical	O
behavior	O
.	O
Immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
were	O
used	O
to	O
examine	O
a	O
panel	O
of	O
marker	O
gene	O
products	O
predicted	O
or	O
shown	O
to	O
be	O
expressed	O
during	O
SNS	O
development	O
in	O
the	O
normal	O
human	O
fetal	O
SNS	O
from	O
8	O
to	O
24	O
weeks'	O
gestational	O
age	O
.	O
A	O
similar	O
analysis	O
was	O
performed	O
in	O
a	O
selection	O
of	O
clinical	O
NB	O
tumors	O
,	O
and	O
the	O
results	O
were	O
compared	O
.	O
n	O
a	O
subset	O
of	O
differentiating	O
,	O
often	O
extra-adrenal	O
NB	O
tumors	O
in	O
patients	O
who	O
frequently	O
had	O
a	O
favorable	O
outcome	O
;	O
advancing	O
morphologic	O
tumor	O
cell	O
differentiation	O
spatially	O
paralleled	O
an	O
advancing	O
fetal	O
extra-adrenal	O
chromaffin	O
marker	O
gene	O
expression	O
phenotype	O
(	O
ie	O
,	O
increasing	O
TrkA	B-GENE
,	O
TrkC	B-GENE
,	O
TH	B-GENE
,	O
IGF-2	B-GENE
,	O
and	O
neuron-specific	B-GENE
enolase	I-GENE
expression	O
but	O
a	O
lack	O
of	O
phenylethanolamine	B-GENE
N-methyltransferase	I-GENE
expression	O
)	O
.	O
In	O
these	O
tumors	O
,	O
expression	O
of	O
gene	O
products	O
associated	O
with	O
normal	O
fetal	O
sympathetic	O
ganglionic	O
differentiation	O
(	O
ie	O
,	O
Bcl-2	B-GENE
,	O
HNK-1	B-GENE
,	O
and	O
neuropeptide	B-GENE
Y	I-GENE
)	O
was	O
lost	O
with	O
morphologic	O
tumor	O
cell	O
differentiation	O
.	O
In	O
contrast	O
,	O
undifferentiated	O
tumors	O
,	O
the	O
majority	O
of	O
which	O
were	O
high	O
stage	O
,	O
adrenal	O
in	O
origin	O
,	O
and	O
prognostically	O
unfavorable	O
,	O
displayed	O
marker	O
expression	O
characteristics	O
mirroring	O
that	O
of	O
an	O
early	O
fetal	O
ganglionic	O
lineage	O
.	O
Thus	O
,	O
we	O
show	O
that	O
morphologic	O
differentiation	O
in	O
stroma-poor	O
NB	O
tumors	O
,	O
long	O
held	O
as	O
an	O
important	O
prognostic	O
feature	O
in	O
tumor	O
grading	O
systems	O
,	O
often	O
corresponds	O
to	O
an	O
extra-adrenal	O
chromaffin	O
rather	O
than	O
a	O
ganglion	O
cell	O
or	O
adrenal	O
medullary	O
chromaffin	O
phenotype	O
.	O
Understanding	O
the	O
biology	O
of	O
extra-adrenal	O
chromaffin	O
tissues	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
clinically	O
less	O
aggressive	O
nature	O
of	O
differentiating	O
NB	O
tumors	O
and	O
suggest	O
potential	O
mechanisms	O
for	O
spontaneous	O
regression	O
and/or	O
treatment	O
response	O
.	O
PMID	O
:	O
8941212	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Ann	O
N	O
Y	O
Acad	O
Sci	O
.	O
1990	O
;	O
611	O
:	O
7-26	O
.	O
Neuropeptide	B-GENE
Y	I-GENE
receptor	I-GENE
subtypes	O
,	O
Y1	B-GENE
and	O
Y2	B-GENE
.	O
Wahlestedt	O
C	O
,	O
Grundemar	O
L	O
,	O
Hakanson	O
R	O
,	O
Heilig	O
M	O
,	O
Shen	O
GH	O
,	O
Zukowska-Grojec	O
Z	O
,	O
Reis	O
DJ.	O
Department	O
of	O
Neurology	O
and	O
Neuroscience	O
,	O
Cornell	O
University	O
Medical	O
College	O
,	O
New	O
York	O
,	O
New	O
York	O
10021	O
.	O
Heterogeneity	O
among	O
NPY	B-GENE
(	O
and	O
PYY	B-GENE
)	O
receptors	O
was	O
first	O
proposed	O
on	O
the	O
basis	O
of	O
studies	O
on	O
sympathetic	O
neuroeffector	O
junctions	O
,	O
where	O
NPY	B-GENE
(	O
and	O
PYY	B-GENE
)	O
can	O
exert	O
three	O
types	O
of	O
action	O
:	O
1	O
)	O
a	O
direct	O
(	O
e.g.	O
,	O
vasoconstrictor	O
)	O
response	O
;	O
2	O
)	O
a	O
postjunctional	O
potentiating	O
effect	O
on	O
NE-evoked	O
vasoconstriction	O
;	O
and	O
3	O
)	O
a	O
prejunctional	O
suppression	O
of	O
stimulated	O
NE	O
release	O
;	O
the	O
two	O
latter	O
phenomena	O
are	O
probably	O
reciprocal	O
,	O
since	O
NE	O
affect	O
NPY	B-GENE
mechanisms	O
similarly	O
.	O
It	O
was	O
found	O
that	O
amidated	O
C-terminal	O
NPY	B-GENE
(	O
or	O
PYY	B-GENE
)	O
fragments	O
,	O
e	O
.g.	O
,	O
NPY	B-GENE
13-36	O
,	O
could	O
stimulate	O
selectively	O
prejunctional	O
NPY	B-GENE
/	O
PYY	B-GENE
receptors	I-GENE
,	O
which	O
were	O
termed	O
Y2	B-GENE
-	I-GENE
receptors	I-GENE
.	O
Consequently	O
,	O
the	O
postjunctional	O
receptors	O
which	O
were	O
activated	O
poorly	O
by	O
NPY	B-GENE
/	O
PYY	B-GENE
fragments	O
,	O
were	O
termed	O
Y1-receptors	B-GENE
.	O
Later	O
work	O
has	O
indicated	O
that	O
the	O
Y2-receptor	B-GENE
may	O
occur	O
postjunctionally	O
in	O
selected	O
sympathetic	O
effector	O
systems	O
.	O
The	O
central	O
nervous	O
system	O
appears	O
to	O
contain	O
a	O
mixture	O
of	O
Y1-	B-GENE
and	O
Y2	B-GENE
-	I-GENE
receptors	I-GENE
as	O
indicated	O
by	O
functional	O
as	O
well	O
as	O
binding	O
studies	O
.	O
For	O
instance	O
,	O
NPY	B-GENE
and	O
NPY	B-GENE
13-36	O
produced	O
diametrically	O
opposite	O
effects	O
on	O
behavioral	O
activity	O
,	O
indicating	O
the	O
action	O
of	O
the	O
parent	O
peptide	O
on	O
two	O
distinct	O
receptors	O
.	O
Cell	O
lines	O
,	O
most	O
importantly	O
neuroblastomas	O
,	O
with	O
exclusive	O
populations	O
of	O
Y1-	B-GENE
or	O
Y2	B-GENE
-	I-GENE
receptors	I-GENE
,	O
have	O
been	O
characterized	O
by	O
binding	O
and	O
second	O
messenger	O
studies	O
.	O
In	O
this	O
work	O
,	O
selective	O
agonists	O
for	O
the	O
two	O
receptor	O
subtypes	O
were	O
used	O
.	O
Work	O
of	O
many	O
investigators	O
has	O
formed	O
the	O
basis	O
for	O
subclassifying	O
NPY	B-GENE
/	O
PYY	B-GENE
effects	O
being	O
mediated	O
by	O
either	O
Y1-	B-GENE
or	O
Y2	B-GENE
-	I-GENE
receptors	I-GENE
.	O
A	O
preliminary	O
subclassification	O
based	O
on	O
effects	O
of	O
NPY	B-GENE
,	O
PYY	B-GENE
,	O
fragments	O
and/or	O
analogs	O
is	O
provided	O
in	O
Table	O
6	O
.	O
It	O
is	O
,	O
however	O
,	O
to	O
be	O
expected	O
that	O
further	O
receptor	O
heterogeneity	O
will	O
be	O
revealed	O
in	O
the	O
future	O
.	O
It	O
is	O
argued	O
that	O
mast	O
cells	O
possess	O
atypical	O
NPY	B-GENE
/	O
PYY	B-GENE
receptors	O
.	O
The	O
histamine	O
release	O
associated	O
with	O
stimulation	O
of	O
the	O
latter	O
receptors	O
may	O
,	O
at	O
least	O
in	O
part	O
,	O
underlie	O
the	O
capacity	O
of	O
NPY	B-GENE
as	O
well	O
as	O
of	O
short	O
C-terminal	O
fragments	O
to	O
reduce	O
blood	O
pressure	O
.	O
Fragments	O
,	O
such	O
as	O
NPY	B-GENE
22-36	O
,	O
appear	O
to	O
be	O
relatively	O
selective	O
vasodepressor	O
agents	O
because	O
of	O
their	O
weak	O
vasopressor	O
properties	O
.(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Academic	O
PMID	O
:	O
2174225	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Biol	O
Chem	O
.	O
2001	O
Feb	O
16	O
;	O
276	O
(	O
7	O
)	O
:	O
4923-31	O
.	O
Epub	O
2000	O
Nov	O
15	O
.	O
HERG	O
K	O
+	O
channels	O
activation	O
during	O
beta(1)	B-GENE
integrin	I-GENE
-	O
mediated	O
adhesion	O
to	O
fibronectin	B-GENE
induces	O
an	O
up-regulation	O
of	O
alpha(v)beta(3)	B-GENE
integrin	I-GENE
in	O
the	O
preosteoclastic	O
leukemia	O
cell	O
line	O
FLG	O
29.1	O
.	O
Hofmann	O
G	O
,	O
Bernabei	O
PA	O
,	O
Crociani	O
O	O
,	O
Cherubini	O
A	O
,	O
Guasti	O
L	O
,	O
Pillozzi	O
S	O
,	O
Lastraioli	O
E	O
,	O
Polvani	O
S	O
,	O
Bartolozzi	O
B	O
,	O
Solazzo	O
V	O
,	O
Gragnani	O
L	O
,	O
Defilippi	O
P	O
,	O
Rosati	O
B	O
,	O
Wanke	O
E	O
,	O
Olivotto	O
M	O
,	O
Arcangeli	O
A	O
.	O
Department	O
of	O
Experimental	O
Pathology	O
and	O
Oncology	O
,	O
University	O
of	O
Firenze	O
,	O
Viale	O
G.	O
B.	O
Morgagni	O
,	O
50	O
,	O
50134	O
Florence	O
,	O
Italy	O
.	O
Integrin	B-GENE
receptors	I-GENE
have	O
been	O
demonstrated	O
to	O
mediate	O
either	O
"	O
inside-to-out	O
"	O
and	O
"	O
outside-to-in	O
"	O
signals	O
,	O
and	O
by	O
this	O
way	O
are	O
capable	O
of	O
regulating	O
many	O
cellular	O
functions	O
,	O
such	O
as	O
cell	O
growth	O
and	O
differentiation	O
,	O
cell	O
migration	O
,	O
and	O
activation	O
.	O
Among	O
the	O
various	O
integrin	B-GENE
-	O
centered	O
signaling	O
pathways	O
discovered	O
so	O
far	O
,	O
we	O
demonstrated	O
that	O
the	O
modulation	O
of	O
the	O
electrical	O
potential	O
of	O
the	O
plasma	O
membrane	O
(	O
V(REST)	O
)	O
is	O
an	O
early	O
integrin	B-GENE
-	O
mediated	O
signal	O
,	O
which	O
is	O
related	O
to	O
neurite	O
emission	O
in	O
neuroblastoma	O
cells	O
.	O
This	O
modulation	O
is	O
sustained	O
by	O
the	O
activation	O
of	O
HERG	O
K(+)	O
channels	O
,	O
encoded	O
by	O
the	O
ether-a-go-go-related	B-GENE
gene	I-GENE
(	O
herg	B-GENE
)	O
.	O
The	O
involvement	O
of	O
integrin	B-GENE
-	O
mediated	O
signaling	O
is	O
being	O
discovered	O
in	O
the	O
hemopoietic	O
system	O
:	O
in	O
particular	O
,	O
osteoclasts	O
are	O
generated	O
as	O
well	O
as	O
induced	O
to	O
differentiate	O
by	O
interaction	O
of	O
osteoclast	O
progenitors	O
with	O
the	O
stromal	O
cells	O
,	O
through	O
the	O
involvement	O
of	O
integrin	B-GENE
receptors	I-GENE
.	O
We	O
studied	O
the	O
effects	O
of	O
cell	O
interaction	O
with	O
the	O
extracellular	O
matrix	O
protein	O
fibronectin	B-GENE
(	O
FN	B-GENE
)	O
in	O
a	O
human	O
leukemic	O
preosteoclastic	O
cell	O
line	O
(	O
FLG	O
29.1	O
cells	O
)	O
,	O
which	O
has	O
been	O
demonstrated	O
to	O
express	O
HERG	O
currents	O
.	O
We	O
report	O
here	O
that	O
FLG	O
29.1	O
cells	O
indeed	O
adhere	O
to	O
purified	O
FN	B-GENE
through	O
integrin	B-GENE
receptors	I-GENE
,	O
and	O
that	O
this	O
adhesion	O
induces	O
an	O
osteoclast	O
phenotype	O
in	O
these	O
cells	O
,	O
as	O
evidenced	O
by	O
the	O
appearance	O
of	O
tartrate	B-GENE
-	I-GENE
resistant	I-GENE
acid	I-GENE
phosphatase	I-GENE
,	O
as	O
well	O
as	O
by	O
the	O
increased	O
expression	O
of	O
CD51	B-GENE
/	O
alpha(v)beta(3)	B-GENE
integrin	I-GENE
and	O
calcitonin	B-GENE
receptor	I-GENE
.	O
An	O
early	O
activation	O
of	O
HERG	O
current	O
(	O
I(HERG)	O
)	O
,	O
without	O
any	O
increase	O
in	O
herg	B-GENE
RNA	O
or	O
modifications	O
of	O
HERG	B-GENE
protein	O
was	O
also	O
observed	O
in	O
FN	B-GENE
-	O
adhering	O
cells	O
.	O
This	O
activation	O
is	O
apparently	O
sustained	O
by	O
the	O
beta(1	B-GENE
)	I-GENE
integrin	I-GENE
subunit	I-GENE
activation	O
,	O
through	O
the	O
involvement	O
of	O
a	O
pertussis-toxin	B-GENE
sensitive	I-GENE
G(i)	I-GENE
protein	I-GENE
,	O
and	O
appears	O
to	O
be	O
a	O
determinant	O
signal	O
for	O
the	O
up-regulation	O
of	O
alpha(v)beta(3)	B-GENE
integrin	I-GENE
,	O
as	O
well	O
as	O
for	O
the	O
increased	O
expression	O
of	O
calcitonin	B-GENE
receptor	I-GENE
.	O
PMID	O
:	O
11080495	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Peptides	O
.	O
2002	O
Sep;23(	O
9	O
)	O
:1557	O
-	O
65	O
.	O
Antisense	O
peptide	O
nucleic	O
acids	O
conjugated	O
to	O
somatostatin	B-GENE
analogs	O
and	O
targeted	O
at	O
the	O
n	B-GENE
-	I-GENE
myc	I-GENE
oncogene	O
display	O
enhanced	O
cytotoxity	O
to	O
human	O
neuroblastoma	O
IMR32	O
cells	O
expressing	O
somatostatin	B-GENE
receptors	I-GENE
.	O
Sun	O
L,	O
Fuselier	O
JA	O
,	O
Murphy	O
WA	O
,	O
Coy	O
DH	O
.	O
Department	O
of	O
Medicine	O
,	O
Peptide	O
Research	O
Laboratories	O
,	O
Tulane	O
Health	O
Sciences	O
Center	O
,	O
Tulane	O
University	O
School	O
of	O
Medicine	O
,	O
1430	O
Tulane	O
Avenue	O
,	O
New	O
Orleans	O
,	O
LA	O
70112-2699	O
,	O
USA	O
.	O
Peptide	O
nucleic	O
acid	O
(	O
PNA	O
)	O
sequences	O
are	O
synthetic	O
versions	O
of	O
naturally	O
occurring	O
oligonucleotides	O
which	O
display	O
improved	O
binding	O
properties	O
to	O
DNA	O
and	O
RNA	O
,	O
but	O
are	O
still	O
poorly	O
internalized	O
across	O
cell	O
membranes	O
.	O
In	O
an	O
effort	O
to	O
employ	O
the	O
rapid	O
binding	O
/	O
internalization	O
properties	O
of	O
somatostatin	B-GENE
agonist	O
analogs	O
and	O
the	O
over	O
-	O
expression	O
of	O
somatostatin	B-GENE
receptors	I-GENE
on	O
many	O
types	O
of	O
tumor	O
cells	O
,	O
PNAs	O
complementary	O
to	O
target	O
sites	O
throughout	O
5'-UTR	O
,	O
translation	O
start	O
site	O
and	O
coding	O
region	O
of	O
the	O
n	B-GENE
-	I-GENE
myc	I-GENE
oncogene	O
were	O
conjugated	O
to	O
a	O
somatostatin	B-GENE
analog	O
(	O
SSA	O
)	O
with	O
retention	O
of	O
high	O
somatostatin	B-GENE
biological	O
potency	O
.	O
IMR32	O
cells	O
,	O
which	O
over	O
-	O
express	O
somatostatin	B-GENE
receptor	I-GENE
type	I-GENE
2	I-GENE
(	O
SSTR2	B-GENE
)	O
and	O
contain	O
the	O
n	B-GENE
-	I-GENE
myc	I-GENE
oncogene	O
,	O
were	O
treated	O
with	O
these	O
PNA	O
-SSA	O
conjugates	O
.	O
The	O
results	O
show	O
that	O
PNA	O
conjugates	O
targeted	O
to	O
the	O
5'-UTR	O
terminus	O
and	O
to	O
regions	O
at	O
or	O
close	O
to	O
the	O
translation	O
start	O
site	O
could	O
effectively	O
inhibit	O
n	B-GENE
-	I-GENE
myc	I-GENE
gene	O
expression	O
and	O
cell	O
growth	O
,	O
whereas	O
the	O
non	O
-	O
conjugate	O
PNAs	O
were	O
without	O
effect	O
at	O
similar	O
doses	O
.	O
The	O
most	O
potent	O
inhibition	O
of	O
cell	O
growth	O
was	O
achieved	O
with	O
PNAs	O
binding	O
to	O
the	O
translation	O
start	O
site	O
,	O
but	O
those	O
complementary	O
to	O
the	O
middle	O
coding	O
region	O
or	O
middle	O
upstream	O
site	O
between	O
5'-UTR	O
and	O
translation	O
start	O
site	O
displayed	O
no	O
inhibition	O
of	O
gene	O
expression	O
.	O
These	O
observations	O
were	O
extended	O
to	O
four	O
other	O
cell	O
lines	O
:	O
GH3	O
cells	O
which	O
express	O
SSTRs	B-GENE
with	O
the	O
n	B-GENE
-	I-GENE
myc	I-GENE
gene	O
,	O
SKNSH	O
cells	O
containing	O
a	O
silent	O
n	B-GENE
-	I-GENE
myc	I-GENE
gene	O
without	O
SSTR2	B-GENE
,	O
HT-29	O
cells	O
carrying	O
the	O
c-myc	B-GENE
but	O
no	O
n	B-GENE
-	I-GENE
myc	I-GENE
gene	O
,	O
and	O
CHO-K1	O
cells	O
lacking	O
SSTR2	B-GENE
with	O
n	B-GENE
-	I-GENE
myc	I-GENE
gene	O
.	O
The	O
results	O
show	O
that	O
there	O
was	O
almost	O
no	O
effect	O
on	O
these	O
four	O
cell	O
lines	O
.	O
Our	O
study	O
indicates	O
that	O
PNAs	O
conjugated	O
to	O
SSA	O
exhibited	O
improved	O
inhibition	O
of	O
gene	O
expression	O
possibly	O
due	O
to	O
facilitated	O
cellular	O
uptake	O
of	O
the	O
PNAs	O
.	O
These	O
conjugates	O
were	O
mRNA	O
sequence	O
-	O
and	O
SSTR2	B-GENE
-	O
specific	O
suggesting	O
that	O
many	O
other	O
genes	O
associated	O
with	O
tumor	O
growth	O
could	O
be	O
targeted	O
using	O
this	O
approach	O
and	O
that	O
SSA	O
could	O
be	O
a	O
novel	O
and	O
effective	O
transportation	O
vector	O
for	O
the	O
PNA	O
antisense	O
strategy	O
.	O
PMID	O
:	O
12217415	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Brain	O
Res	O
Mol	O
Brain	O
Res	O
.	O
1998	O
Oct	O
1;60	O
(	O
2	O
)	O
:150	O
-	O
9.	O
Tissue	O
-	O
specific	O
enhancement	O
and	O
restriction	O
of	O
galanin	B-GENE
gene	O
expression	O
in	O
transgenic	O
mice	O
by	O
5	O
'	O
flanking	O
sequences	O
.	O
Rokaeus	O
A	O
,	O
Waschek	O
JA	O
.	O
Department	O
of	O
Medical	O
Biochemistry	O
and	O
Biophysics	O
,	O
Karolinska	O
Institutet	O
,	O
S-171	O
77	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
ake	O
.rokaeus@mbb.ki.se	O
Galanin	B-GENE
(	O
GAL	B-GENE
)	O
is	O
a	O
29	O
/	O
30	O
amino	O
acid	O
residue	O
neuropeptide	O
that	O
regulates	O
a	O
wide	O
variety	O
of	O
neuroendocrine	O
functions	O
.	O
Galanin	B-GENE
is	O
expressed	O
in	O
specific	O
populations	O
of	O
neurons	O
in	O
the	O
hypothalamus	O
and	O
other	O
regions	O
of	O
the	O
brain	O
and	O
in	O
numerous	O
peripheral	O
sites	O
.	O
Previous	O
studies	O
in	O
which	O
galanin	B-GENE
-	I-GENE
reporter	I-GENE
genes	O
were	O
transfected	O
into	O
neural	O
crest	O
-	O
derived	O
neuroblastoma	O
and	O
other	O
tumor	O
cells	O
indicated	O
that	O
cell	O
-	O
specific	O
galanin	B-GENE
expression	O
is	O
controlled	O
by	O
gene	O
elements	O
on	O
the	O
5	O
'	O
flanking	O
sequence	O
which	O
enhance	O
and	O
restrict	O
transcriptional	O
activity	O
.	O
To	O
determine	O
how	O
the	O
gene	O
sequences	O
act	O
in	O
vivo	O
,	O
we	O
first	O
determined	O
the	O
distribution	O
of	O
endogenous	O
galanin	B-GENE
gene	O
expression	O
in	O
normal	O
mice	O
.	O
Galanin	B-GENE
mRNA	O
was	O
detected	O
in	O
several	O
parts	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
and	O
in	O
several	O
peripheral	O
organs	O
,	O
including	O
the	O
pituitary	O
,	O
pancreas	O
,	O
small	O
and	O
large	O
intestine	O
,	O
adrenal	O
gland	O
,	O
lung	O
,	O
tongue	O
,	O
testes	O
,	O
ovary	O
-fallopian	O
tubes	O
,	O
and	O
uterus	O
,	O
but	O
not	O
at	O
detectable	O
levels	O
in	O
the	O
heart	O
,	O
liver	O
,	O
kidney	O
,	O
urinary	O
bladder	O
or	O
skeletal	O
muscle	O
.	O
We	O
then	O
created	O
several	O
lines	O
of	O
transgenic	O
mice	O
which	O
contained	O
either	O
5	O
or	O
0.131	O
kilobases	O
(	O
kb	O
)	O
of	O
the	O
bovine	O
galanin	B-GENE
gene	O
5	O
'	O
flanking	O
sequence	O
fused	O
to	O
the	O
luciferase	B-GENE
(	I-GENE
luc	I-GENE
)	I-GENE
reporter	I-GENE
gene	O
(	O
5	O
GAL	B-GENE
-	O
luc	B-GENE
vs.	O
0.1	O
GAL	B-GENE
-	O
luc	B-GENE
mice	O
,	O
respectively	O
)	O
and	O
compared	O
luciferase	B-GENE
activity	O
in	O
these	O
and	O
other	O
organs	O
.	O
In	O
some	O
regions	O
of	O
the	O
CNS	O
that	O
expressed	O
high	O
amounts	O
of	O
galanin	B-GENE
mRNA	O
,	O
such	O
as	O
the	O
spinal	O
cord	O
,	O
hypothalamus	O
,	O
thalamus	O
,	O
and	O
medulla	O
,	O
transgene	O
expression	O
was	O
significantly	O
higher	O
in	O
5	O
GAL	B-GENE
-	O
luc	B-GENE
vs.	O
0.1	O
GAL	B-GENE
-	O
luc	B-GENE
mice	O
,	O
whereas	O
in	O
certain	O
other	O
regions	O
of	O
the	O
brain	O
and	O
in	O
all	O
peripheral	O
organs	O
,	O
the	O
ratio	O
was	O
strikingly	O
reversed	O
.	O
It	O
is	O
concluded	O
that	O
5	O
kb	O
of	O
flanking	O
sequence	O
contains	O
elements	O
that	O
mediate	O
basal	O
transcriptional	O
activity	O
in	O
certain	O
parts	O
of	O
the	O
CNS	O
,	O
but	O
also	O
contains	O
sequences	O
that	O
restrict	O
expression	O
in	O
many	O
tissues	O
.	O
However	O
,	O
because	O
the	O
larger	O
transgene	O
was	O
expressed	O
at	O
very	O
low	O
levels	O
in	O
some	O
peripheral	O
sites	O
of	O
high	O
galanin	B-GENE
expression	O
such	O
as	O
the	O
pituitary	O
,	O
pancreas	O
,	O
adrenal	O
gland	O
,	O
and	O
intestine	O
,	O
it	O
is	O
concluded	O
that	O
sequences	O
on	O
the	O
5	O
kb	O
transgene	O
are	O
not	O
sufficient	O
to	O
direct	O
expression	O
to	O
these	O
peripheral	O
tissues	O
in	O
mice	O
.	O
Copyright	O
1998	O
Elsevier	O
Science	O
B.V	O
.	O
PMID	O
:	O
9757022	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Virol	O
.	O
2000	O
Sep;74	O
(	O
17	O
)	O
:	O
7972	O
-	O
9.	O
In	O
vitro	O
and	O
in	O
vivo	O
infection	O
of	O
neural	O
cells	O
by	O
a	O
recombinant	O
measles	O
virus	O
expressing	O
enhanced	B-GENE
green	I-GENE
fluorescent	I-GENE
protein	I-GENE
.	O
Duprex	O
WP	O
,	O
McQuaid	O
S	O
,	O
Roscic-Mrkic	O
B	O
,	O
Cattaneo	O
R	O
,	O
McCallister	O
C	O
,	O
Rima	O
BK	O
.	O
School	O
of	O
Biology	O
and	O
Biochemistry	O
,	O
The	O
Queen	O
's	O
University	O
of	O
Belfast	O
,	O
Belfast	O
BT9	O
7BL	O
,	O
Northern	O
Ireland	O
,	O
United	O
Kingdom	O
.	O
p.duprex@qub.ac.uk	O
This	O
study	O
focused	O
on	O
the	O
in	O
vitro	O
infection	O
of	O
mouse	O
and	O
human	O
neuroblastoma	O
cells	O
and	O
the	O
in	O
vivo	O
infection	O
of	O
the	O
murine	O
central	O
nervous	O
system	O
with	O
a	O
recombinant	O
measles	O
virus	O
.	O
An	O
undifferentiated	O
mouse	O
neuroblastoma	O
cell	O
line	O
(	O
TMN	O
)	O
was	O
infected	O
with	O
the	O
vaccine	O
strain	O
of	O
measles	O
virus	O
(	O
MVeGFP	O
)	O
,	O
which	O
expresses	O
enhanced	B-GENE
green	I-GENE
fluorescent	I-GENE
protein	I-GENE
(	O
EGFP	B-GENE
)	O
.	O
MVeGFP	O
infected	O
the	O
cells	O
,	O
and	O
cell	O
-to	O
-	O
cell	O
spread	O
was	O
studied	O
by	O
virtue	O
of	O
the	O
resulting	O
EGFP	B-GENE
autofluorescence	O
,	O
using	O
real	O
-time	O
confocal	O
microscopy	O
.	O
Cells	O
were	O
differentiated	O
to	O
a	O
neuronal	O
phenotype	O
,	O
and	O
extended	O
processes	O
,	O
which	O
interconnected	O
the	O
cells	O
,	O
were	O
observed	O
.	O
It	O
was	O
also	O
possible	O
to	O
infect	O
the	O
differentiated	O
neuroblastoma	O
cells	O
(	O
dTMN	O
)	O
with	O
MVeGFP	O
.	O
Single	O
autofluorescent	O
EGFP	B-GENE
-	O
positive	O
cells	O
were	O
selected	O
at	O
the	O
earliest	O
possible	O
point	O
in	O
the	O
infection	O
,	O
and	O
the	O
spread	O
of	O
EGFP	B-GENE
autofluorescence	O
was	O
monitored	O
.	O
In	O
this	O
instance	O
the	O
virus	O
used	O
the	O
interconnecting	O
processes	O
to	O
spread	O
from	O
cell	O
to	O
cell	O
.	O
Human	O
neuroblastoma	O
cells	O
(	O
SH-SY-	O
5Y	O
)	O
were	O
also	O
infected	O
with	O
MVeGFP	O
.	O
The	O
virus	O
infected	O
these	O
cells	O
,	O
and	O
existing	O
processes	O
were	O
used	O
to	O
initiate	O
new	O
foci	O
of	O
infection	O
at	O
distinct	O
regions	O
of	O
the	O
monolayer	O
.	O
Transgenic	O
animals	O
expressing	O
CD46	B-GENE
,	O
a	O
measles	O
virus	O
receptor	O
,	O
and	O
lacking	O
interferon	B-GENE
type	I-GENE
1	I-GENE
receptor	I-GENE
gene	O
were	O
infected	O
intracerebrally	O
with	O
MVeGFP	O
.	O
A	O
productive	O
infection	O
ensued	O
,	O
and	O
the	O
mice	O
exhibited	O
clinical	O
signs	O
of	O
infection	O
,	O
such	O
as	O
ataxia	O
and	O
an	O
awkward	O
gait	O
,	O
identical	O
to	O
those	O
previously	O
observed	O
for	O
the	O
parental	O
virus	O
(	O
Edtag	O
)	O
.	O
Mice	O
were	O
sacrificed	O
,	O
and	O
brain	O
sections	O
were	O
examined	O
for	O
EGFP	B-GENE
autofluorescence	O
by	O
confocal	O
scanning	O
laser	O
microscopy	O
over	O
a	O
period	O
of	O
6	O
h	O
.	O
EGFP	B-GENE
was	O
detected	O
in	O
discrete	O
focal	O
regions	O
of	O
the	O
brain	O
and	O
in	O
processes	O
,	O
which	O
extended	O
deep	O
into	O
the	O
parenchyma	O
.	O
Collectively	O
,	O
these	O
results	O
indicate	O
(	O
i)	O
that	O
MVeGFP	O
can	O
be	O
used	O
to	O
monitor	O
virus	O
replication	O
sensitively	O
,	O
in	O
real	O
time	O
,	O
in	O
animal	O
tissues	O
,	O
(ii)	O
that	O
infection	O
of	O
ependymal	O
cells	O
and	O
neuroblasts	O
provides	O
a	O
route	O
by	O
which	O
measles	O
virus	O
can	O
enter	O
the	O
central	O
nervous	O
system	O
in	O
mouse	O
models	O
of	O
encephalitis	O
,	O
and	O
(iii)	O
that	O
upon	O
infection	O
,	O
the	O
virus	O
spreads	O
transneuronally	O
.	O
PMID	O
:	O
10933705	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochim	O
Biophys	O
Acta	O
.	O
1996	O
Feb	O
2;1310(	O
2	O
)	O
:	O
201-	O
11	O
.	O
Cell	O
-	O
specific	O
regulation	O
of	O
the	O
stably	O
expressed	O
serotonin	B-GENE
5-HT1A	I-GENE
receptor	I-GENE
and	O
altered	O
ganglioside	O
synthesis	O
.	O
Singh	O
JK	O
,	O
Yan	O
Q	O
,	O
Dawson	O
G	O
,	O
Banerjee	O
P.	O
Department	O
of	O
Chemistry	O
,	O
College	O
of	O
Staten	O
Island	O
,	O
NY	O
10314	O
,	O
USA	O
.	O
Neurotransmission	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
neuronal	O
receptors	O
at	O
the	O
synapses	O
,	O
and	O
important	O
cell	O
surface	O
molecules	O
such	O
as	O
gangliosides	O
are	O
pivotal	O
in	O
the	O
maintenance	O
of	O
synaptic	O
contacts	O
.	O
To	O
study	O
the	O
interrelationship	O
between	O
these	O
two	O
classes	O
of	O
molecules	O
,	O
we	O
achieved	O
stable	O
expression	O
of	O
the	O
hippocampus	O
-	O
and	O
CNS	O
-localized	O
serotonin	B-GENE
1A	I-GENE
receptor	I-GENE
(	O
5-HT1A-R	B-GENE
)	O
in	O
three	O
5-HT1A-R	B-GENE
-	O
deficient	O
neuronal	O
cell	O
lines	O
and	O
also	O
the	O
control	O
,	O
non	O
-	O
neural	O
CHO	O
cells	O
.	O
A	O
strong	O
passage	O
dependence	O
of	O
5-HT1A-R	B-GENE
expression	O
,	O
as	O
measured	O
by	O
mRNA	O
levels	O
as	O
well	O
as	O
membrane	O
binding	O
to	O
the	O
selective	O
agonist	O
[3H]8-OH-DPAT	O
,	O
was	O
observed	O
only	O
in	O
the	O
HN2	O
(	O
hippocampal	O
)	O
and	O
NCB	O
-	O
20	O
(	O
CNS	O
)	O
cells	O
which	O
are	O
derived	O
from	O
tissues	O
of	O
natural	O
occurrence	O
of	O
the	O
5-HT1A-R	B-GENE
.	O
A	O
paradigm	O
of	O
stress	O
was	O
obtained	O
by	O
carrying	O
out	O
continuous	O
culture	O
of	O
cells	O
without	O
feeding	O
.	O
During	O
this	O
time	O
a	O
dramatic	O
increase	O
in	O
5-HT1A-R	B-GENE
mRNA	O
and	O
[3H]8-OH-DPAT	O
binding	O
was	O
observed	O
only	O
in	O
the	O
neuronal	O
cells	O
after	O
confluence	O
and	O
during	O
decreased	O
cell	O
viability	O
(	O
days	O
10	O
/	O
11	O
)	O
.	O
This	O
was	O
not	O
due	O
to	O
differentiation	O
,	O
since	O
deliberate	O
serum	O
deprivation	O
and	O
differentiation	O
of	O
cells	O
did	O
not	O
result	O
in	O
any	O
dramatic	O
increase	O
in	O
5-HT1A-R	B-GENE
expression	O
.	O
Analysis	O
of	O
ganglioside	O
synthesis	O
by	O
pulse	O
labeling	O
of	O
the	O
transfected	O
cells	O
produced	O
striking	O
results	O
.	O
In	O
the	O
dorsal	O
root	O
of	O
the	O
ganglion	O
(	O
DRG	O
)	O
derived	O
F-11	O
cells	O
which	O
show	O
low	O
but	O
significant	O
levels	O
of	O
complex	O
gangliosides	O
before	O
transfection	O
,	O
the	O
mere	O
presence	O
of	O
the	O
serotonin	B-GENE
1A	I-GENE
receptor	I-GENE
resulted	O
in	O
a	O
dramatic	O
increase	O
in	O
synthesis	O
of	O
gangliosides	O
comigrating	O
with	O
GM2	O
,	O
GD1a	O
,	O
GD1b	O
,	O
and	O
GT1b	O
(	O
20	O
-	O
fold	O
by	O
densitometry	O
)	O
.	O
In	O
contrast	O
,	O
there	O
was	O
only	O
a	O
2	O
-	O
fold	O
increase	O
in	O
the	O
overall	O
content	O
of	O
complex	O
gangliosides	O
in	O
the	O
presence	O
of	O
the	O
5-HT1A-R	B-GENE
.	O
In	O
the	O
NCB	O
-	O
20	O
cells	O
which	O
contain	O
only	O
GD1a	O
but	O
no	O
GD1b	O
or	O
GT1b	O
before	O
transfection	O
,	O
a	O
decrease	O
in	O
GD1a	O
synthesis	O
was	O
observed	O
following	O
transfection	O
.	O
Also	O
agonist	O
(	O
8-OH-DPAT	O
)	O
binding	O
to	O
the	O
serotonin	B-GENE
1A	I-GENE
receptor	I-GENE
in	O
NCB	O
-	O
20	O
cells	O
produced	O
a	O
3	O
-	O
fold	O
increase	O
in	O
synthesis	O
of	O
a	O
ganglioside	O
comigrating	O
with	O
GM3	O
.	O
Thus	O
,	O
our	O
neuroblastoma	O
transfectants	O
help	O
demonstrate	O
stress	O
-	O
induced	O
regulation	O
of	O
the	O
5-HT1A-R	B-GENE
,	O
which	O
in	O
turn	O
exerts	O
a	O
strong	O
and	O
cell	O
type	O
-	O
specific	O
control	O
over	O
such	O
essential	O
cell	O
-	O
surface	O
determinants	O
like	O
gangliosides	O
.	O
PMID	O
:	O
8611634	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
.	O
1999	O
Dec;81	O
(	O
8	O
)	O
:	O
1402	O
-	O
9.	O
Gain	O
of	O
chromosome	O
arm	O
17q	O
is	O
associated	O
with	O
unfavourable	O
prognosis	O
in	O
neuroblastoma	O
,	O
but	O
does	O
not	O
involve	O
mutations	O
in	O
the	O
somatostatin	B-GENE
receptor	I-GENE
2	I-GENE
(	O
SSTR2	B-GENE
)	O
gene	O
at	O
17q24	O
.	O
Abel	O
F	O
,	O
Ejeskar	O
K,	O
Kogner	O
P,	O
Martinsson	O
T.	O
Department	O
of	O
Clinical	O
Genetics	O
Sahlgrenska	O
University	O
/East	O
,	O
Gothenburg	O
,	O
Sweden	O
.	O
Deletion	O
of	O
chromosome	O
arm	O
1p	O
and	O
amplification	O
of	O
the	O
MYCN	B-GENE
oncogene	O
are	O
well	O
-	O
recognized	O
genetic	O
alterations	O
in	O
neuroblastoma	O
cells	O
.	O
Recently	O
,	O
another	O
alteration	O
has	O
been	O
reported	O
;	O
gain	O
of	O
the	O
distal	O
part	O
of	O
chromosome	O
arm	O
17q	O
.	O
In	O
this	O
study	O
48	O
neuroblastoma	O
tumours	O
were	O
successfully	O
analysed	O
for	O
17q	O
status	O
in	O
relation	O
to	O
known	O
genetic	O
alterations	O
.	O
Chromosome	O
17	O
status	O
was	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O
Thirty-one	O
of	O
the	O
48	O
neuroblastomas	O
(	O
65	O
%	O
)	O
showed	O
17q	O
gain	O
,	O
and	O
this	O
was	O
significantly	O
associated	O
with	O
poor	O
prognosis	O
.	O
As	O
previously	O
reported	O
,	O
17q	O
gain	O
was	O
significantly	O
associated	O
with	O
metastatic	O
stage	O
4	O
neuroblastoma	O
and	O
more	O
frequently	O
detected	O
than	O
both	O
deletion	O
of	O
chromosome	O
arm	O
1p	O
and	O
MYCN	B-GENE
amplification	O
in	O
tumours	O
of	O
all	O
stages	O
.	O
17q	O
gain	O
also	O
showed	O
a	O
strong	O
correlation	O
to	O
survival	O
probability	O
(	O
P	O
=	O
0.0009	O
)	O
.	O
However	O
,	O
the	O
most	O
significant	O
correlation	O
between	O
17q	O
gain	O
and	O
survival	O
probability	O
was	O
observed	O
in	O
children	O
with	O
low	O
-	O
stage	O
tumours	O
(	O
stage	O
1	O
,	O
2	O
,	O
3	O
and	O
4S	O
)	O
,	O
with	O
a	O
survival	O
probability	O
of	O
100	O
%	O
at	O
5	O
years	O
from	O
diagnosis	O
for	O
children	O
with	O
tumours	O
showing	O
no	O
17q	O
gain	O
compared	O
to	O
52.5	O
%	O
for	O
those	O
showing	O
17q	O
gain	O
(	O
P	O
=	O
0.0021	O
)	O
.	O
This	O
suggests	O
that	O
17q	O
gain	O
as	O
a	O
prognostic	O
factor	O
plays	O
a	O
more	O
crucial	O
role	O
in	O
low	O
-	O
stage	O
tumours	O
.	O
Expression	O
of	O
the	O
somatostatin	B-GENE
receptor	I-GENE
2	I-GENE
(	O
SSTR2	B-GENE
)	O
,	O
localized	O
in	O
chromosome	O
region	O
17q24	O
,	O
has	O
in	O
previous	O
studies	O
been	O
shown	O
to	O
be	O
positively	O
related	O
to	O
survival	O
in	O
neuroblastoma	O
.	O
A	O
point	O
mutation	O
in	O
the	O
SSTR2	B-GENE
gene	O
has	O
earlier	O
been	O
reported	O
in	O
a	O
human	O
small	O
-	O
cell	O
lung	O
cancer	O
.	O
In	O
this	O
study	O
,	O
mutation	O
screening	O
of	O
the	O
SSTR2	B-GENE
gene	O
in	O
43	O
neuroblastoma	O
tumours	O
was	O
carried	O
out	O
with	O
polymerase	B-GENE
chain	O
reaction	O
-	O
based	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
/heteroduplex	O
(	O
SSCP	O
/HD	O
)	O
and	O
DNA	O
sequencing	O
,	O
and	O
none	O
of	O
the	O
tumours	O
showed	O
any	O
aberrations	O
in	O
the	O
SSTR2	B-GENE
gene	O
.	O
These	O
data	O
suggest	O
that	O
mutations	O
in	O
the	O
SSTR2	B-GENE
gene	O
are	O
uncommon	O
in	O
neuroblastoma	O
tumours	O
and	O
do	O
not	O
correlate	O
with	O
either	O
the	O
17q	O
gain	O
often	O
seen	O
or	O
the	O
reason	O
some	O
tumours	O
do	O
not	O
express	O
SSTR2	B-GENE
receptors	I-GENE
.	O
Overall	O
,	O
this	O
study	O
indicates	O
that	O
gain	O
of	O
chromosome	O
arm	O
17q	O
is	O
the	O
most	O
frequently	O
occurring	O
genetic	O
alteration	O
,	O
and	O
that	O
it	O
is	O
associated	O
with	O
established	O
prognostic	O
factors	O
.	O
PMID	O
:	O
10604740	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Mol	O
Neurobiol	O
.	O
1992	O
Jun;12(	O
3	O
)	O
:22	O
5-40	O
.	O
A	O
combined	O
evaluation	O
of	O
biochemical	O
and	O
morphological	O
changes	O
during	O
human	O
neuroblastoma	O
cell	O
differentiation	O
.	O
Lanciotti	O
M,	O
Montaldo	O
PG	O
,	O
Folghera	O
S	O
,	O
Lucarelli	O
E	O
,	O
Cornaglia-Ferraris	O
P,	O
Ponzoni	O
M.	O
Pediatric	O
Oncology	O
Research	O
Laboratory	O
,	O
G.	O
Gaslini	O
Children	O
's	O
Hospital	O
,	O
Genoa	O
,	O
Italy	O
.	O
1	O
.	O
The	O
effects	O
of	O
retinoic	O
acid	O
,	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
,	O
cytosine	O
arabinoside	O
,	O
nerve	B-GENE
growth	I-GENE
factor	I-GENE
,	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
,	O
and	O
12-O-tetradecanoylphorbol	O
13-acetate	O
on	O
the	O
human	O
neuroblastoma	O
cell	O
line	O
,	O
LAN-5	O
,	O
were	O
studied	O
.	O
Intracellular	O
levels	O
of	O
acetylcholinesterase	B-GENE
,	O
neuron	O
-	O
specific	O
enolase	B-GENE
,	O
catecholamines	O
and	O
related	O
neurotransmitters	O
,	O
vasointestinal	B-GENE
peptide	I-GENE
,	O
and	O
substance	B-GENE
P	I-GENE
were	O
evaluated	O
after	O
induction	O
.	O
2.	O
Cell	O
morphology	O
was	O
strongly	O
affected	O
by	O
retinoic	O
acid	O
,	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
,	O
cytosine	O
arabinoside	O
,	O
and	O
12-O-tetradecanoylphorbol	O
13-acetate	O
.	O
The	O
main	O
effects	O
of	O
retinoic	O
acid	O
and	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
were	O
the	O
loosening	O
of	O
cell	O
clusters	O
and	O
the	O
extension	O
of	O
long	O
neurites	O
;	O
cytosine	O
arabinoside	O
induced	O
cell	O
body	O
swelling	O
and	O
marked	O
neuritogenesis	O
.	O
Following	O
12-O-tetradecanoylphorbol	O
13-acetate	O
treatment	O
,	O
the	O
cells	O
became	O
small	O
,	O
round	O
,	O
and	O
neuritic	O
.	O
Conversely	O
,	O
modifications	O
induced	O
by	O
nerve	B-GENE
growth	I-GENE
factor	I-GENE
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
were	O
mild	O
.	O
Cell	O
proliferation	O
rate	O
was	O
reduced	O
by	O
retinoic	O
acid	O
,	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
,	O
cytosine	O
arabinoside	O
,	O
and	O
12-O-tetradecanoylphorbol	O
13-acetate	O
,	O
while	O
nerve	B-GENE
growth	I-GENE
factor	I-GENE
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
were	O
devoid	O
of	O
effects	O
.	O
3	O
.	O
Acetylcholinesterase	B-GENE
activity	O
was	O
significantly	O
stimulated	O
by	O
retinoic	O
acid	O
and	O
by	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
.	O
Neuron	O
-	O
specific	O
enolase	B-GENE
activity	O
was	O
unaffected	O
by	O
all	O
treatments	O
except	O
12-O-tetradecanoylphorbol	O
13-acetate	O
,	O
which	O
enhanced	O
it	O
by	O
1.6	O
-	O
fold	O
.	O
4	O
.	O
The	O
cellular	O
catecholamine	O
and	O
related	O
metabolite	O
content	O
was	O
lowered	O
by	O
retinoic	O
acid	O
and	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
,	O
while	O
cytosine	O
arabinoside	O
and	O
,	O
even	O
more	O
,	O
12-O-tetradecanoylphorbol	O
13-acetate	O
showed	O
a	O
stimulatory	O
activity	O
on	O
their	O
intracellular	O
accumulation	O
.	O
5	O
.	O
Finally	O
,	O
the	O
cell	O
-	O
associated	O
vasointestinal	B-GENE
peptide	I-GENE
level	O
was	O
strikingly	O
increased	O
by	O
gamma	B-GENE
-	I-GENE
interferon	I-GENE
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
by	O
retinoic	O
acid	O
,	O
cytosine	O
arabinoside	O
,	O
and	O
12-O-tetradecanoylphorbol	O
13-acetate	O
.	O
6	O
.	O
It	O
is	O
concluded	O
that	O
the	O
most	O
relevant	O
biochemical	O
changes	O
associated	O
with	O
LAN-5	O
cells	O
differentiation	O
involve	O
the	O
repertoire	O
of	O
neurotransmitters	O
and	O
neuropeptides	O
.	O
These	O
events	O
vary	O
in	O
quality	O
and	O
in	O
quantity	O
,	O
likely	O
due	O
to	O
the	O
pattern	O
complexity	O
of	O
gene	O
expression	O
triggered	O
by	O
each	O
inducer	O
in	O
determining	O
the	O
diversity	O
of	O
neuronal	O
phenotypes	O
.	O
PMID	O
:	O
1358448	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Virol	O
.	O
1990	O
Oct;64	O
(	O
10	O
)	O
:	O
5019	O
-	O
28	O
.	O
Activity	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
latency	B-GENE
-	I-GENE
associated	I-GENE
transcript	I-GENE
(	O
LAT	B-GENE
)	O
promoter	O
in	O
neuron	O
-	O
derived	O
cells	O
:	O
evidence	O
for	O
neuron	O
specificity	O
and	O
for	O
a	O
large	O
LAT	B-GENE
transcript	I-GENE
.	O
Zwaagstra	O
JC	O
,	O
Ghiasi	O
H,	O
Slanina	O
SM	O
,	O
Nesburn	O
AB	O
,	O
Wheatley	O
SC	O
,	O
Lillycrop	O
K,	O
Wood	O
J,	O
Latchman	O
DS	O
,	O
Patel	O
K,	O
Wechsler	O
SL	O
.	O
Ophthalmology	O
Research	O
,	O
Cedars-Sinai	O
Medical	O
Center	O
,	O
Los	O
Angeles	O
,	O
California	O
90048	O
-1869	O
.	O
By	O
using	O
chloramphenicol	B-GENE
acetyltransferase	I-GENE
(	O
CAT	B-GENE
)	O
assays	O
in	O
neuron	O
-	O
derived	O
cell	O
lines	O
,	O
we	O
show	O
here	O
that	O
promoter	O
activity	O
associated	O
with	O
the	O
herpes	O
simplex	O
virus	O
type	O
1	O
latency	B-GENE
-	I-GENE
associated	I-GENE
transcript	I-GENE
(	O
LAT	B-GENE
)	O
had	O
neuronal	O
specificity	O
.	O
Promoter	O
activity	O
in	O
these	O
transient	O
CAT	B-GENE
assays	O
coincided	O
with	O
a	O
DNA	O
region	O
containing	O
excellent	O
RNA	B-GENE
polymerase	I-GENE
II	I-GENE
promoter	O
consensus	O
sequences	O
.	O
Primer	O
extension	O
analysis	O
in	O
a	O
LAT	B-GENE
promoter	O
-	O
CAT	B-GENE
plasmid	O
construct	O
placed	O
the	O
start	O
of	O
transcription	O
about	O
28	O
nucleotides	O
from	O
the	O
first	O
T	O
in	O
the	O
consensus	O
TATA	O
box	O
sequence	O
.	O
Neuronal	O
specificity	O
of	O
this	O
promoter	O
was	O
suggested	O
by	O
examining	O
the	O
effect	O
of	O
sequences	O
upstream	O
of	O
the	O
promoter	O
on	O
CAT	B-GENE
activity	O
in	O
neuronal	O
versus	O
nonneuronal	O
cells	O
.	O
In	O
nonneuronal	O
cells	O
,	O
promoter	O
activity	O
was	O
decreased	O
3	O
-	O
to	O
12	O
-	O
fold	O
with	O
the	O
addition	O
of	O
upstream	O
sequences	O
.	O
In	O
contrast	O
,	O
in	O
neuron	O
-	O
derived	O
cells	O
,	O
the	O
addition	O
of	O
upstream	O
sequences	O
did	O
not	O
decrease	O
promoter	O
activity	O
.	O
The	O
LAT	B-GENE
promoter	O
predicted	O
by	O
our	O
transient	O
CAT	B-GENE
assays	O
was	O
located	O
over	O
660	O
nucleotides	O
upstream	O
from	O
the	O
5	O
'	O
end	O
of	O
the	O
previously	O
mapped	O
2-kilobase	O
(	O
kb	O
)	O
LAT	B-GENE
.	O
This	O
unusual	O
location	O
was	O
explained	O
by	O
in	O
situ	O
and	O
Northern	O
(	O
RNA	O
)	O
blot	O
hybridization	O
analyses	O
that	O
suggested	O
that	O
LAT	B-GENE
transcription	O
began	O
near	O
the	O
promoter	O
detected	O
in	O
our	O
CAT	B-GENE
assays	O
,	O
rather	O
than	O
near	O
the	O
5	O
'	O
end	O
of	O
the	O
2-kb	O
LAT	B-GENE
.	O
In	O
situ	O
hybridization	O
with	O
neurons	O
from	O
latently	O
infected	O
rabbits	O
detected	O
small	O
amounts	O
of	O
LAT	B-GENE
RNA	O
within	O
30	O
nucleotides	O
of	O
the	O
consensus	O
TATA	O
box	O
sequence	O
.	O
This	O
suggested	O
that	O
LAT	B-GENE
transcription	O
began	O
near	O
this	O
TATA	O
box.	O
Northern	O
blot	O
hybridization	O
of	O
RNA	O
from	O
ganglia	O
of	O
latently	O
infected	O
rabbits	O
revealed	O
a	O
faint	O
8.3-kb	O
band	O
of	O
the	O
same	O
sense	O
as	O
LAT	B-GENE
.	O
We	O
conclude	O
that	O
(	O
i)	O
the	O
LAT	B-GENE
promoter	O
has	O
neuronal	O
specificity	O
,	O
(ii)	O
the	O
LAT	B-GENE
promoter	O
is	O
located	O
over	O
660	O
nucleotides	O
upstream	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
previously	O
characterized	O
stable	O
2-kb	O
LAT	B-GENE
,	O
(iii)	O
LAT	B-GENE
transcription	O
begins	O
about	O
28	O
nucleotides	O
from	O
the	O
first	O
T	O
of	O
the	O
consensus	O
TATA	O
box	O
sequence	O
and	O
extends	O
to	O
near	O
the	O
first	O
available	O
polyadenylation	O
site	O
approximately	O
8.3	O
kb	O
away	O
,	O
and	O
(	O
iv	O
)	O
this	O
8.3-kb	O
RNA	O
may	O
be	O
an	O
unstable	O
precursor	O
of	O
the	O
more	O
stable	O
2	O
-	O
and	O
1.3-kb	O
LATs	B-GENE
.	O
PMID	O
:	O
2168984	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Diagn	O
Cytopathol	O
.	O
2001	O
Apr;2	O
4(	O
4	O
)	O
:	O
233	O
-	O
9.	O
Role	O
of	O
immunocytochemistry	O
and	O
DNA	O
flow	O
cytometry	O
in	O
the	O
fine	O
-	O
needle	O
aspiration	O
diagnosis	O
of	O
malignant	O
small	O
round	O
-	O
cell	O
tumors	O
.	O
Brahmi	O
U	O
,	O
Rajwanshi	O
A	O
,	O
Joshi	O
K,	O
Ganguly	O
NK	O
,	O
Vohra	O
H,	O
Gupta	O
SK	O
,	O
Dey	O
P.	O
Department	O
of	O
Cytology	O
,	O
Post	O
Graduate	O
Institute	O
of	O
Medical	O
Education	O
and	O
Research	O
,	O
Chandigarh	O
,	O
India	O
.	O
In	O
the	O
present	O
study	O
,	O
DNA	O
flow	O
cytometry	O
(	O
FCM	O
)	O
and	O
immunocytochemistry	O
(	O
ICC	O
)	O
with	O
a	O
selected	O
panel	O
of	O
antibodies	O
were	O
performed	O
on	O
51	O
cases	O
of	O
malignant	O
tumors	O
which	O
were	O
referred	O
for	O
fine	O
-	O
needle	O
aspiration	O
biopsy	O
(	O
FNAB	O
)	O
to	O
our	O
Department	O
of	O
Cytology	O
for	O
the	O
last	O
2	O
yr	O
.	O
Twelve	O
cases	O
were	O
diagnosed	O
as	O
neuroblastoma	O
,	O
16	O
as	O
Ewing	O
's	O
sarcoma	O
,	O
2	O
as	O
retinoblastoma	O
,	O
5	O
as	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
,	O
5	O
as	O
rhabdomyosarcoma	O
,	O
2	O
as	O
peripheral	O
neuroectodermal	O
tumors	O
(	O
PNETs	O
)	O
,	O
and	O
8	O
as	O
Wilms	O
'	O
tumor	O
.	O
Eleven	O
of	O
12	O
neuroblastomas	O
were	O
diploid	O
by	O
FCM	O
,	O
and	O
1	O
was	O
aneuploid	O
,	O
with	O
an	O
S-phase	O
fraction	O
(	O
SPF	O
)	O
of	O
8.3	O
%	O
.	O
Neuron	B-GENE
-	I-GENE
specific	I-GENE
enolase	I-GENE
(	O
NSE	B-GENE
)	O
was	O
negative	O
in	O
3	O
and	O
positive	O
in	O
8	O
cases	O
of	O
neuroblastoma	O
,	O
whereas	O
neuroblastoma	O
marker	O
was	O
positive	O
in	O
3	O
/	O
11	O
.	O
Sixteen	O
of	O
17	O
Ewing	O
's	O
sarcomas	O
were	O
diploid	O
,	O
and	O
1	O
showed	O
tetraploid	O
aneuploidy	O
,	O
with	O
an	O
SPF	O
of	O
10.06	O
%	O
.	O
Eight	O
of	O
13	O
Ewing	O
's	O
sarcomas	O
were	O
positive	O
for	O
Mic-2	B-GENE
gene	O
product	O
(	O
Ewing	O
's	O
marker	O
)	O
.	O
All	O
5	O
NHL	O
were	O
positive	O
for	O
leukocyte-	B-GENE
common	I-GENE
antigen	I-GENE
(	O
LCA	B-GENE
)	O
.	O
Three	O
of	O
5	O
rhabdomyosarcomas	O
were	O
diploid	O
,	O
and	O
2	O
cases	O
showed	O
aneuploidy	O
.	O
Rhabdomyosarcoma	O
showed	O
muscle	O
-	O
specific	O
actin	B-GENE
positivity	O
in	O
4	O
and	O
desmin	B-GENE
positivity	O
in	O
3	O
cases	O
.	O
All	O
3	O
cases	O
of	O
PNET	O
were	O
diploid	O
and	O
positive	O
for	O
the	O
Mic-2	B-GENE
gene	O
product	O
,	O
whereas	O
NSE	B-GENE
and	O
vimentin	B-GENE
were	O
positive	O
in	O
2	O
cases	O
.	O
Both	O
cases	O
of	O
retinoblastoma	O
were	O
diploid	O
.	O
Immunostaining	O
was	O
noncontributory	O
in	O
1	O
case	O
,	O
and	O
the	O
other	O
showed	O
positivity	O
for	O
the	O
retinoblastoma	B-GENE
gene	O
product	O
,	O
NSE	B-GENE
,	O
and	O
chromogranin	B-GENE
.	O
Seven	O
of	O
8	O
Wilms	O
'	O
tumors	O
were	O
diploid	O
,	O
and	O
1	O
showed	O
aneuploid	O
,	O
with	O
an	O
SPF	O
of	O
11.13	O
%	O
.	O
Seven	O
of	O
8	O
Wilms	O
'	O
tumors	O
were	O
positive	O
for	O
cytokeratin	B-GENE
(	O
CK	B-GENE
)	O
,	O
5	O
were	O
positive	O
for	O
NSE	B-GENE
,	O
6	O
were	O
positive	O
for	O
epithelial	B-GENE
membrane	I-GENE
antigen	I-GENE
(	O
EMA	B-GENE
)	O
,	O
and	O
5	O
were	O
positive	O
for	O
vimentin	B-GENE
.	O
FNAB	O
diagnosis	O
of	O
malignant	O
round	O
-	O
cell	O
tumors	O
is	O
difficult	O
only	O
by	O
light	O
microscopy	O
.	O
Due	O
to	O
the	O
availability	O
of	O
specific	O
markers	O
for	O
subgrouping	O
tumors	O
,	O
ICC	O
has	O
proved	O
to	O
be	O
more	O
useful	O
these	O
days	O
,	O
while	O
DNA	O
FCM	O
has	O
little	O
diagnostic	O
value	O
,	O
as	O
most	O
of	O
them	O
are	O
diploid	O
.	O
Further	O
ancillary	O
studies	O
,	O
e	O
.g.	O
,	O
electron	O
microscopy	O
,	O
image	O
analysis	O
,	O
and	O
other	O
molecular	O
investigations	O
,	O
are	O
required	O
to	O
further	O
categorize	O
these	O
tumors	O
more	O
precisely	O
for	O
better	O
clinical	O
management	O
of	O
these	O
cases	O
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11285617	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
.	O
1997	O
Oct;33	O
(	O
12	O
)	O
:1974	O
-	O
8.	O
Analysis	O
of	O
1	O
;	O
17	O
translocation	O
breakpoints	O
in	O
neuroblastoma	O
:	O
implications	O
for	O
mapping	O
of	O
neuroblastoma	B-GENE
genes	O
.	O
Van	O
Roy	O
N	O
,	O
Laureys	O
G	O
,	O
Van	O
Gele	O
M,	O
Opdenakker	O
G	O
,	O
Miura	O
R	O
,	O
van	O
der	O
Drift	O
P,	O
Chan	O
A	O
,	O
Versteeg	O
R	O
,	O
Speleman	O
F.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
University	O
Hospital	O
Ghent	O
,	O
Belgium	O
.	O
Deletions	O
and	O
translocations	O
resulting	O
in	O
loss	O
of	O
distal	O
1p	O
-material	O
are	O
known	O
to	O
occur	O
frequently	O
in	O
advanced	O
neuroblastomas	O
.	O
Fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
)	O
showed	O
that	O
17q	O
was	O
most	O
frequently	O
involved	O
in	O
chromosome	O
1p	O
translocations	O
.	O
A	O
review	O
of	O
the	O
literature	O
shows	O
that	O
10	O
of	O
27	O
cell	O
lines	O
carry	O
1	O
;	O
17	O
translocations	O
.	O
Similar	O
translocations	O
were	O
also	O
observed	O
in	O
primary	O
tumours	O
.	O
Together	O
with	O
the	O
occurrence	O
of	O
a	O
constitutional	O
1	O
;	O
17	O
translocation	O
in	O
a	O
neuroblastoma	O
patient	O
,	O
these	O
observations	O
suggest	O
a	O
particular	O
role	O
for	O
these	O
chromosome	O
re	O
-	O
arrangements	O
in	O
the	O
development	O
of	O
neuroblastoma	O
.	O
Apart	O
from	O
the	O
loss	O
of	O
distal	O
1p	O
-material	O
,	O
these	O
translocations	O
invariably	O
lead	O
to	O
extra	O
copies	O
of	O
17q	O
.	O
This	O
also	O
suggested	O
a	O
possible	O
role	O
for	O
genes	O
on	O
17q	O
in	O
neuroblastoma	O
tumorigenesis	O
.	O
Further	O
support	O
for	O
this	O
hypothesis	O
comes	O
from	O
the	O
observation	O
that	O
in	O
those	O
cell	O
lines	O
without	O
1	O
;	O
17	O
translocations	O
,	O
other	O
chromosome	O
17q	O
translocations	O
were	O
present	O
.	O
These	O
too	O
lead	O
to	O
extra	O
chromosome	O
17q	O
material	O
.	O
Molecular	O
analysis	O
of	O
1	O
;	O
17	O
translocation	O
breakpoints	O
revealed	O
breakpoint	O
heterogeneity	O
both	O
on	O
1p	O
and	O
17q	O
,	O
which	O
suggests	O
the	O
involvement	O
of	O
more	O
than	O
2	O
single	O
genes	O
on	O
1p	O
and	O
17q	O
.	O
The	O
localisation	O
of	O
the	O
different	O
1p	O
-breakpoints	O
occurring	O
in	O
1	O
;	O
17	O
translocations	O
in	O
neuroblastoma	O
are	O
discussed	O
with	O
respect	O
to	O
the	O
recently	O
identified	O
candidate	O
tumor	O
suppressor	O
regions	O
and	O
genes	O
on	O
1p	O
.	O
In	O
this	O
study	O
,	O
we	O
focused	O
on	O
the	O
molecular	O
analysis	O
of	O
the	O
17q	O
breakpoints	O
in	O
1	O
;	O
17	O
translocations	O
.	O
Detailed	O
physical	O
mapping	O
of	O
the	O
constitutional	O
17q	O
breakpoint	O
allowed	O
for	O
the	O
construction	O
of	O
a	O
YAC	O
contig	O
covering	O
the	O
breakpoint	O
.	O
Furthermore	O
,	O
a	O
refined	O
position	O
was	O
determined	O
for	O
a	O
number	O
of	O
17q	O
breakpoints	O
of	O
1	O
;	O
17	O
translocations	O
found	O
in	O
neuroblastoma	O
cell	O
lines	O
.	O
The	O
most	O
distal	O
17q	O
breakpoint	O
was	O
identified	O
in	O
cell	O
line	O
UHG-NP	O
and	O
mapped	O
telomeric	O
to	O
cosmid	O
cCI17-	O
1049	O
(	O
17q21	O
)	O
.	O
This	O
suggests	O
that	O
genes	O
involved	O
in	O
a	O
dosage	O
-	O
dependent	O
manner	O
in	O
the	O
development	O
of	O
neuroblastoma	O
map	O
in	O
the	O
distal	O
segment	O
17q22	O
-qter	O
.	O
Future	O
studies	O
aim	O
at	O
the	O
molecular	O
cloning	O
of	O
1	O
;	O
17	O
translocation	O
breakpoints	O
and	O
at	O
deciphering	O
the	O
mechanisms	O
leading	O
to	O
1	O
;	O
17	O
translocations	O
and	O
possibly	O
to	O
the	O
identification	O
of	O
neuroblastoma	B-GENE
genes	O
at	O
or	O
in	O
the	O
vicinity	O
of	O
these	O
breakpoints	O
.	O
PMID	O
:	O
9516836	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
J.	O
1994	O
Jun	O
15;300	O
(	O
Pt	O
3	O
)	O
:	O
709	O
-15	O
.	O
Agonist	O
regulation	O
of	O
cellular	O
Gs	B-GENE
alpha	I-GENE
-	I-GENE
subunit	I-GENE
levels	O
in	O
neuroblastoma	O
x	O
glioma	O
hybrid	O
NG108-15	O
cells	O
transfected	O
to	O
express	O
different	O
levels	O
of	O
the	O
human	O
beta	B-GENE
2	I-GENE
adrenoceptor	I-GENE
.	O
Adie	O
EJ	O
,	O
Milligan	O
G.	O
Department	O
of	O
Biochemistry	O
,	O
University	O
of	O
Glasgow	O
,	O
Scotland	O
,	O
U.K.	O
Neuroblastoma	O
x	O
glioma	O
hybrid	O
NG108-15	O
cells	O
endogenously	O
express	O
at	O
least	O
three	O
receptors	O
which	O
activate	O
adenylate	B-GENE
cyclase	I-GENE
via	O
the	O
intermediacy	O
of	O
the	O
stimulatory	B-GENE
G-protein	I-GENE
,	O
Gs	B-GENE
.	O
Sustained	O
exposure	O
of	O
the	O
cells	O
to	O
agonists	O
at	O
the	O
IP	B-GENE
prostanoid	I-GENE
receptor	I-GENE
results	O
in	O
a	O
substantial	O
decrease	O
in	O
cellular	O
levels	O
of	O
the	O
alpha	B-GENE
-	I-GENE
subunit	I-GENE
of	I-GENE
Gs	I-GENE
(	O
Gs	B-GENE
alpha	I-GENE
)	O
[McKenzie	O
and	O
Milligan	O
(	O
1990	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
265	O
,	O
17084	O
-17093	O
;	O
Adie	O
,	O
Mullaney	O
,	O
McKenzie	O
and	O
Milligan	O
(	O
1992	O
)	O
Biochem	O
J.	O
285	O
,	O
529	O
-	O
536	O
]	O
.	O
By	O
contrast	O
,	O
equivalent	O
treatments	O
of	O
the	O
cells	O
with	O
agonists	O
at	O
either	O
the	O
A2	B-GENE
adenosine	I-GENE
receptor	I-GENE
or	O
the	O
secretin	B-GENE
receptor	I-GENE
have	O
no	O
measurable	O
effect	O
on	O
cellular	O
amounts	O
of	O
Gs	B-GENE
alpha	I-GENE
.	O
To	O
examine	O
whether	O
this	O
is	O
a	O
feature	O
specific	O
to	O
the	O
IP	B-GENE
prostanoid	I-GENE
receptor	I-GENE
or	O
is	O
related	O
to	O
the	O
level	O
of	O
expression	O
of	O
the	O
individual	O
receptors	O
,	O
NG108-15	O
cells	O
were	O
transfected	O
with	O
a	O
construct	O
containing	O
a	O
human	O
beta	B-GENE
2-adrenoceptor	I-GENE
cDNA	O
under	O
the	O
control	O
of	O
the	O
beta-actin	B-GENE
promoter	O
.	O
Two	O
clones	O
of	O
these	O
cells	O
were	O
examined	O
in	O
detail	O
,	O
beta	O
N22	O
,	O
which	O
expressed	O
some	O
4000	O
fmol	O
/	O
mg	O
of	O
membrane	O
protein	O
,	O
and	O
clone	O
beta	O
N17	O
,	O
which	O
expressed	O
approx.	O
300	O
fmol	O
/	O
mg	O
of	O
membrane	O
protein	O
of	O
the	O
receptor	O
.	O
Exposure	O
of	O
beta	O
N22	O
cells	O
to	O
the	O
beta-adrenergic	O
agonist	O
isoprenaline	O
resulted	O
maximally	O
in	O
some	O
55	O
%	O
decrease	O
in	O
membrane	O
-	O
associated	O
levels	O
of	O
Gs	B-GENE
alpha	I-GENE
,	O
without	O
effect	O
on	O
membrane	O
levels	O
of	O
Gi2	B-GENE
alpha	I-GENE
,	O
Gi3	B-GENE
alpha	I-GENE
,	O
G(	B-GENE
o	I-GENE
)	I-GENE
alpha	I-GENE
or	O
Gq	B-GENE
alpha	I-GENE
/	O
G11	B-GENE
alpha	I-GENE
.	O
Dose	O
-	O
response	O
curves	O
to	O
isoprenaline	O
in	O
beta	O
N22	O
cells	O
indicated	O
that	O
half-maximal	O
down	O
-	O
regulation	O
of	O
Gs	B-GENE
alpha	I-GENE
was	O
produced	O
by	O
approx.	O
1	O
nM	O
agonist	O
.	O
Equivalent	O
exposure	O
of	O
beta	O
N17	O
cells	O
to	O
isoprenaline	O
did	O
not	O
significantly	O
modify	O
levels	O
of	O
any	O
of	O
the	O
G-protein	B-GENE
alpha	I-GENE
subunits	I-GENE
,	O
including	O
Gs	B-GENE
alpha	I-GENE
.	O
In	O
beta	O
N22	O
cells	O
the	O
IP	B-GENE
prostanoid	I-GENE
receptor	I-GENE
was	O
expressed	O
at	O
similar	O
levels	O
to	O
those	O
in	O
wild-type	O
NG108-15	O
cells	O
,	O
and	O
treatment	O
with	O
iloprost	O
resulted	O
in	O
a	O
similar	O
down	O
-	O
regulation	O
of	O
cellular	O
Gs	B-GENE
alpha	I-GENE
levels	O
.	O
Iloprost	O
was	O
also	O
effective	O
in	O
causing	O
down	O
-	O
regulation	O
of	O
Gs	B-GENE
alpha	I-GENE
levels	O
in	O
clone	O
beta	O
N17	O
.	O
Concurrent	O
addition	O
of	O
both	O
isoprenaline	O
and	O
iloprost	O
to	O
clone	O
beta	O
N22	O
resulted	O
in	O
less	O
than	O
additive	O
down	O
-	O
regulation	O
of	O
Gs	B-GENE
alpha	I-GENE
.	O
These	O
results	O
demonstrate	O
that	O
the	O
phenomenon	O
of	O
agonist	O
-	O
induced	O
specific	O
G-protein	B-GENE
down	O
-	O
regulation	O
is	O
determined	O
by	O
the	O
levels	O
of	O
expression	O
of	O
the	O
receptor	O
.	O
PMID	O
:	O
7516655	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurochem	O
.	O
2002	O
May;81	O
(	O
4	O
)	O
:780	O
-	O
91	O
.	O
Tissue	O
transglutaminase	B-GENE
differentially	O
modulates	O
apoptosis	O
in	O
a	O
stimuli	O
-	O
dependent	O
manner	O
.	O
Tucholski	O
J,	O
Johnson	O
GV	O
.	O
Department	O
of	O
Psychiatry	O
and	O
Behavioral	O
Neurobiology	O
,	O
University	O
of	O
Alabama	O
at	O
Birmingham	O
,	O
1720	O
7th	O
Avenue	O
South	O
,	O
SC	O
1061	O
,	O
Birmingham	O
,	O
AL	O
35294	O
-0017	O
,	O
USA	O
.	O
Tissue	O
transglutaminase	B-GENE
is	O
a	O
unique	O
member	O
of	O
the	O
transglutaminase	B-GENE
family	O
as	O
it	O
not	O
only	O
catalyzes	O
a	O
transamidating	O
reaction	O
,	O
but	O
also	O
binds	O
and	O
hydrolyzes	O
GTP	O
and	O
ATP	O
.	O
Tissue	O
transglutaminase	B-GENE
has	O
been	O
reported	O
to	O
be	O
pro	O
-apoptotic	O
,	O
however	O
,	O
conclusive	O
evidence	O
is	O
still	O
lacking	O
.	O
To	O
elucidate	O
the	O
role	O
of	O
tissue	O
transglutaminase	B-GENE
in	O
the	O
apoptotic	O
process	O
human	O
neuroblastoma	O
SH-SY5Y	O
cells	O
were	O
stably	O
transfected	O
with	O
vector	O
only	O
(	O
SH	O
/pcDNA	O
)	O
,	O
wild-type	O
tissue	O
transglutaminase	B-GENE
(	O
SH	O
/tTG	O
)	O
and	O
tissue	O
transglutaminase	B-GENE
that	O
has	O
no	O
transamidating	O
activity	O
but	O
retains	O
its	O
other	O
functions	O
(	O
SH	O
/	O
C277S	O
)	O
.	O
In	O
these	O
studies	O
three	O
different	O
apoptotic	O
stimuli	O
were	O
used	O
osmotic	O
stress	O
,	O
staurosporine	O
treatment	O
and	O
heat	O
shock	O
to	O
delineate	O
the	O
role	O
of	O
tissue	O
transglutaminase	B-GENE
as	O
a	O
transamidating	O
enzyme	O
in	O
the	O
apoptotic	O
process	O
.	O
In	O
SH	O
/tTG	O
cells	O
,	O
osmotic	O
stress	O
and	O
staurosporine	O
treatments	O
resulted	O
in	O
significantly	O
greater	O
caspase-3	B-GENE
activation	O
and	O
apoptotic	O
nuclear	O
changes	O
then	O
in	O
SH	O
/pcDNA	O
or	O
SH	O
/	O
C277S	O
cells	O
.	O
This	O
potentiation	O
of	O
apoptosis	O
in	O
SH	O
/tTG	O
cells	O
was	O
concomitant	O
with	O
a	O
significant	O
increase	O
in	O
the	O
in	O
situ	O
transamidating	O
activity	O
of	O
tissue	O
transglutaminase	B-GENE
.	O
However	O
,	O
in	O
the	O
heat	O
shock	O
paradigm	O
,	O
which	O
did	O
not	O
result	O
in	O
any	O
increase	O
in	O
the	O
transamidating	O
activity	O
in	O
SH	O
/tTG	O
cells	O
,	O
there	O
was	O
a	O
significant	O
attenuation	O
of	O
caspase-3	B-GENE
activity	O
,	O
LDH	B-GENE
release	O
and	O
apoptotic	O
chromatin	B-GENE
condensation	O
in	O
SH	O
/tTG	O
and	O
SH	O
/	O
C277S	O
cells	O
compared	O
with	O
SH	O
/pcDNA	O
cells	O
.	O
These	O
findings	O
indicate	O
for	O
the	O
first	O
time	O
that	O
the	O
effect	O
of	O
tissue	O
transglutaminase	B-GENE
on	O
the	O
apoptotic	O
process	O
is	O
highly	O
dependent	O
on	O
the	O
type	O
of	O
the	O
stimuli	O
and	O
how	O
the	O
transamidating	O
activity	O
of	O
the	O
enzyme	O
is	O
affected	O
.	O
Tissue	O
transglutaminase	B-GENE
facilitates	O
apoptosis	O
in	O
response	O
to	O
stressors	O
that	O
result	O
in	O
an	O
increase	O
in	O
the	O
transamidating	O
activity	O
of	O
the	O
enzyme	O
.	O
However	O
,	O
when	O
the	O
stressors	O
do	O
not	O
result	O
in	O
an	O
increase	O
in	O
the	O
transamidating	O
activity	O
of	O
tissue	O
transglutaminase	B-GENE
,	O
than	O
tissue	O
transglutaminase	B-GENE
can	O
ameliorate	O
the	O
apoptotic	O
response	O
through	O
a	O
mechanism	O
that	O
is	O
independent	O
of	O
its	O
transamidating	O
function	O
.	O
Further	O
,	O
neither	O
the	O
phosphatidylinositol-3-kinase	B-GENE
pathway	O
nor	O
the	O
extracellular	O
-	O
regulated	O
kinase	B-GENE
pathway	O
is	O
downstream	O
of	O
the	O
modulatory	O
effects	O
of	O
wild-type	O
tissue	O
transglutaminase	B-GENE
or	O
C277S	O
-tissue	O
transglutaminase	B-GENE
in	O
the	O
apoptotic	O
cascade	O
.	O
PMID	O
:	O
12065637	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Pharmacol	O
.	O
1999	O
Dec;56	O
(	O
6	O
)	O
:	O
1298-308	O
.	O
Modulation	O
of	O
the	O
K(+)	B-GENE
channels	I-GENE
encoded	O
by	O
the	O
human	O
ether	B-GENE
-	I-GENE
a-	I-GENE
gogo	I-GENE
-	I-GENE
related	I-GENE
gene-1	I-GENE
(	O
hERG1	B-GENE
)	O
by	O
nitric	O
oxide	O
.	O
Taglialatela	O
M,	O
Pannaccione	O
A	O
,	O
Iossa	O
S	O
,	O
Castaldo	O
P,	O
Annunziato	O
L.	O
Section	O
of	O
Pharmacology	O
,	O
Department	O
of	O
Neuroscience	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Naples	O
Federico	O
II	O
,	O
Naples	O
,	O
Italy	O
.	O
mtaglia@unina	O
.it	O
The	O
inhibition	O
of	O
nitric	B-GENE
oxide	I-GENE
synthase	I-GENE
by	O
N-nitro-L-arginine	O
methyl	O
ester	O
(	O
0.03-3	O
mM	O
)	O
dose	O
-	O
dependently	O
reduced	O
nitric	O
oxide	O
(	O
NO(	O
*	O
)	O
)	O
levels	O
and	O
enhanced	O
the	O
outward	O
currents	O
carried	O
by	O
human	O
ether	B-GENE
-	I-GENE
a-	I-GENE
gogo	I-GENE
-	I-GENE
related	I-GENE
gene-1	I-GENE
(	O
hERG1	B-GENE
)	O
K(+)	B-GENE
channels	I-GENE
expressed	O
in	O
Xenopus	O
laevis	O
oocytes	O
,	O
whereas	O
the	O
increase	O
in	O
NO(	O
*	O
)	O
levels	O
achieved	O
by	O
exposure	O
to	O
L-arginine	O
(	O
0.03	O
-	O
10	O
mM	O
)	O
inhibited	O
these	O
currents	O
.	O
Furthermore	O
,	O
four	O
NO(	O
*	O
)	O
donors	O
belonging	O
to	O
such	O
different	O
chemical	O
classes	O
as	O
sodium	O
nitroprusside	O
(	O
1-	O
1000	O
microM	O
)	O
,	O
3-morpholino-	O
sydnonimine	O
(	O
100	O
-	O
1000	O
microM	O
)	O
,	O
(	O
Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-	O
1	O
-	O
ium	O
-1	O
,	O
2-diolate	O
(	O
NOC-18	O
;	O
1-300	O
microM	O
)	O
,	O
and	O
S-nitroso	O
N-acetylpenicillamine	O
(	O
1-300	O
microM	O
)	O
dose	O
-	O
dependently	O
inhibited	O
hERG1	B-GENE
outward	O
K(+)	O
currents	O
.	O
By	O
contrast	O
,	O
the	O
NO(	O
*	O
)	O
donor	O
NOC-18	O
(	O
0.3	O
mM	O
)	O
did	O
not	O
affect	O
other	O
cloned	O
K(+)	B-GENE
channels	I-GENE
such	O
as	O
rat	O
neuroblastoma	O
-	O
glioma	O
K(+)	B-GENE
channel	I-GENE
2	O
,	O
rat	O
delayed	O
rectifier	O
K(+)	B-GENE
channel	I-GENE
1	I-GENE
,	O
bovine	O
ether	B-GENE
-	I-GENE
a-	I-GENE
gogo	I-GENE
gene	I-GENE
,	O
rat	O
ether	B-GENE
-	I-GENE
a-	I-GENE
gogo	I-GENE
-	I-GENE
related	I-GENE
gene	I-GENE
-2	I-GENE
,	O
and	O
rat	O
ether	B-GENE
-	I-GENE
a-	I-GENE
gogo	I-GENE
-	I-GENE
related	I-GENE
gene	I-GENE
-	I-GENE
3	I-GENE
.	O
The	O
inhibitory	O
effect	O
of	O
NO(	O
*	O
)	O
donors	O
on	O
hERG1	B-GENE
K(+)	O
channels	O
was	O
prevented	O
by	O
the	O
NO(	O
*	O
)	O
scavengers	O
2-phenyl-4,4,5,5-tetramethylimidazoline	O
-	O
1-oxyl	O
3-oxide	O
and	O
hemoglobin	B-GENE
.	O
The	O
membrane	O
permeable	O
analog	O
of	O
cGMP	O
,	O
8-bromo-cGMP	O
(	O
1	O
mM	O
)	O
,	O
failed	O
to	O
reproduce	O
the	O
inhibitory	O
action	O
of	O
NO(	O
*	O
)	O
donors	O
on	O
hERG1	B-GENE
outward	O
currents	O
;	O
furthermore	O
,	O
the	O
specific	O
inhibitor	O
of	O
the	O
NO(	B-GENE
*)	I-GENE
-	I-GENE
dependent	I-GENE
guanylyl	I-GENE
cyclase	I-GENE
,	O
1H-[1,2,4]oxadiazolo[4	O
,	O
3-a]quinoxalin	O
-	O
1-one	O
(	O
50	O
microM	O
)	O
,	O
neither	O
interfered	O
with	O
outward	O
hERG1	B-GENE
K(+)	O
currents	O
nor	O
prevented	O
their	O
inhibition	O
by	O
0.3	O
mM	O
NOC-18	O
.	O
Both	O
L-arginine	O
(	O
10	O
mM	O
)	O
and	O
NOC-18	O
(	O
0.3	O
mM	O
)	O
counteracted	O
the	O
stimulatory	O
effect	O
on	O
hERG1	B-GENE
outward	O
currents	O
induced	O
by	O
the	O
radical	O
oxygen	O
species	O
-	O
generating	O
system	O
FeSO(	O
4)	O
(	O
25	O
microM	O
)	O
/ascorbic	O
acid	O
(	O
50	O
microM	O
;	O
Fe	O
/	O
Asc	O
)	O
.	O
Finally	O
,	O
L-arginine	O
(	O
10	O
mM	O
)	O
and	O
NOC-18	O
(	O
0.3	O
mM	O
)	O
inhibited	O
both	O
basal	O
and	O
Fe	O
/	O
Asc	O
(	O
0.1	O
mM	O
/	O
0.2	O
mM	O
)	O
-	O
stimulated	O
lipid	O
peroxidation	O
in	O
X	O
.	O
laevis	O
oocytes	O
.	O
Collectively	O
,	O
the	O
present	O
results	O
suggest	O
that	O
NO(	O
*	O
)	O
,	O
both	O
endogenously	O
produced	O
and	O
pharmacologically	O
delivered	O
,	O
may	O
exert	O
in	O
a	O
cGMP	O
-	O
independent	O
way	O
an	O
inhibitory	O
effect	O
on	O
hERG1	B-GENE
outward	O
K(+)	O
currents	O
via	O
an	O
interaction	O
with	O
radical	O
oxygen	O
species	O
either	O
generated	O
under	O
resting	O
conditions	O
or	O
triggered	O
by	O
Fe	O
/	O
Asc.	O
PMID	O
:	O
10570058	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Pharmacol	O
.	O
1997	O
Jan;120(	O
1	O
)	O
:	O
52	O
-	O
9.	O
Somatostatin	B-GENE
receptors	I-GENE
in	O
Neuro2A	O
neuroblastoma	O
cells	O
:	O
ligand	O
internalization	O
.	O
Koenig	O
JA	O
,	O
Edwardson	O
JM	O
,	O
Humphrey	O
PP	O
.	O
Glaxo	O
Institute	O
of	O
Applied	O
Pharmacology	O
.	O
1	O
.	O
Receptor	O
-	O
dependent	O
internalization	O
of	O
somatostatin	B-GENE
(	O
SRIF	O
)	O
agonists	O
has	O
been	O
a	O
matter	O
of	O
controversy	O
probably	O
because	O
[125I]Tyr11-SRIF-14	O
is	O
rapidly	O
degraded	O
.	O
We	O
have	O
studied	O
the	O
internalization	O
of	O
a	O
stable	O
somatostatin	B-GENE
analogue	O
,	O
[125I]-BIM-23027	O
,	O
in	O
a	O
neuronal	O
cell	O
line	O
,	O
Neuro2A	O
,	O
which	O
natively	O
expresses	O
somatostatin	B-GENE
sst2	I-GENE
receptors	I-GENE
.	O
2.	O
Incubation	O
of	O
Neuro2A	O
cells	O
with	O
[125I]-BIM-23027	O
at	O
37	O
degrees	O
C	O
resulted	O
in	O
a	O
time	O
-	O
dependent	O
internalization	O
of	O
the	O
ligand	O
,	O
which	O
reached	O
a	O
maximum	O
at	O
30	O
min	O
.	O
Acid	O
-	O
washing	O
showed	O
that	O
cell	O
-	O
surface	O
binding	O
of	O
the	O
ligand	O
accounted	O
for	O
only	O
34	O
%	O
of	O
total	O
binding	O
at	O
this	O
time	O
.	O
Internalization	O
was	O
dramatically	O
reduced	O
at	O
15	O
degrees	O
C.	O
3	O
.	O
Internalization	O
of	O
[125I]-BIM-23027	O
was	O
prevented	O
by	O
inclusion	O
of	O
unlabelled	O
somatostatin	B-GENE
receptor	I-GENE
agonists	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O
The	O
IC50	O
values	O
for	O
inhibition	O
of	O
[125I]-BIM-23027	O
internalization	O
were	O
approximately	O
100	O
fold	O
lower	O
than	O
for	O
inhibition	O
of	O
[125I]-BIM-23027	O
binding	O
to	O
membrane	O
homogenates	O
but	O
followed	O
the	O
same	O
rank	O
order	O
of	O
potencies	O
.	O
4	O
.	O
Disruption	O
of	O
G-protein	B-GENE
coupling	O
by	O
treatment	O
with	O
pertussis	B-GENE
toxin	I-GENE
caused	O
a	O
60	O
%	O
reduction	O
in	O
internalization	O
of	O
ligand	O
.	O
A	O
combination	O
of	O
antimycin	O
(	O
50	O
nM	O
)	O
and	O
deoxyglucose	O
(	O
50	O
mM	O
)	O
pretreatment	O
,	O
which	O
leads	O
to	O
a	O
depletion	O
of	O
cellular	O
ATP	O
,	O
decreased	O
internalization	O
of	O
[125I]-BIM-23027	O
by	O
66	O
%	O
of	O
control	O
and	O
increased	O
the	O
proportion	O
of	O
surface	O
-bound	O
ligand	O
.	O
Hypertonic	O
sucrose	O
,	O
which	O
prevents	O
clathrin	O
-	O
mediated	O
endocytosis	O
,	O
reversibly	O
abolished	O
the	O
internalization	O
of	O
ligand	O
without	O
increasing	O
the	O
proportion	O
bound	O
at	O
the	O
cell	O
surface	O
.	O
5	O
.	O
After	O
internalization	O
of	O
[125I]-BIM-23027	O
,	O
approximately	O
half	O
of	O
the	O
ligand	O
was	O
recycled	O
back	O
to	O
the	O
extracellular	O
medium	O
within	O
20	O
min	O
at	O
37	O
degrees	O
C.	O
This	O
finding	O
suggests	O
that	O
the	O
intracellular	O
content	O
of	O
[125I]-BIM-23027	O
reaches	O
a	O
steady	O
state	O
which	O
is	O
determined	O
by	O
the	O
rates	O
of	O
both	O
internalization	O
and	O
recycling	O
of	O
the	O
ligand	O
.	O
In	O
contrast	O
to	O
studies	O
in	O
which	O
the	O
internalization	O
of	O
[125I]	O
-Tyr11-SRIF-14	O
was	O
examined	O
,	O
neither	O
internalized	O
nor	O
recycled	O
[125I]-BIM-23027	O
was	O
degraded	O
to	O
its	O
component	O
amino	O
acids	O
.	O
6	O
.	O
These	O
findings	O
indicate	O
that	O
the	O
somatostatin	B-GENE
agonist	O
,	O
[125I]-BIM-23027	O
,	O
is	O
internalized	O
in	O
a	O
receptor	O
-	O
dependent	O
manner	O
which	O
involves	O
clathrin	B-GENE
-	O
coated	O
pits	O
in	O
Neuro2A	O
cells	O
.	O
Furthermore	O
,	O
much	O
of	O
the	O
internalized	O
ligand	O
is	O
rapidly	O
recycled	O
back	O
to	O
the	O
extracellular	O
medium	O
without	O
undergoing	O
significant	O
degradation	O
.	O
PMID	O
:	O
9117098	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Endocrinol	O
.	O
1990	O
Jan;4(	O
1	O
)	O
:	O
29-	O
38	O
.	O
Identification	O
of	O
rat	O
cell	O
lines	O
that	O
preferentially	O
express	O
insulin	B-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factor	I-GENE
binding	I-GENE
proteins	I-GENE
rlGFBP	B-GENE
-	I-GENE
1	I-GENE
,	O
2	B-GENE
,	O
or	O
3	B-GENE
.	O
Yang	O
YW	O
,	O
Brown	O
AL	O
,	O
Orlowski	O
CC	O
,	O
Graham	O
DE	O
,	O
Tseng	O
LY	O
,	O
Romanus	O
JA	O
,	O
Rechler	O
MM	O
.	O
Growth	O
and	O
Development	O
Section	O
,	O
National	O
Institute	O
of	O
Diabetes	O
and	O
Digestive	O
and	O
Kidney	O
Diseases	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
.	O
The	O
bioavailability	O
and	O
action	O
of	O
the	O
insulin	B-GENE
-	I-GENE
like	I-GENE
growth	I-GENE
factors	I-GENE
(	O
IGFs	B-GENE
)	O
are	O
determined	O
by	O
specific	O
IGF-binding	B-GENE
proteins	I-GENE
(	O
IGFBP	B-GENE
)	O
to	O
which	O
they	O
are	O
complexed	O
.	O
Complementary	O
DNA	O
clones	O
have	O
been	O
isolated	O
that	O
encode	O
three	O
related	O
IGFBPs	B-GENE
:	O
human	O
IGFBP-1	B-GENE
(	O
hIGFBP	B-GENE
-1	I-GENE
)	O
,	O
human	O
IGFBP-3	B-GENE
(	O
hIGFBP	B-GENE
-3	I-GENE
)	O
,	O
and	O
rat	O
IGFBP	B-GENE
-2	I-GENE
(	O
rIGFBP	B-GENE
-2	I-GENE
)	O
.	O
IGFBP-1	B-GENE
and	O
IGFBP-3	B-GENE
are	O
regulated	O
differently	O
in	O
human	O
plasma	O
,	O
suggesting	O
that	O
they	O
have	O
different	O
functions	O
.	O
In	O
order	O
to	O
study	O
the	O
molecular	O
basis	O
of	O
the	O
regulation	O
of	O
the	O
different	O
IGFBPs	B-GENE
,	O
we	O
have	O
identified	O
a	O
panel	O
of	O
rat	O
cell	O
lines	O
that	O
express	O
a	O
single	O
predominant	O
binding	O
protein	O
and	O
developed	O
an	O
assay	O
strategy	O
to	O
distinguish	O
the	O
different	O
binding	O
proteins	O
.	O
Proteins	O
in	O
conditioned	O
medium	O
were	O
examined	O
by	O
ligand	O
blotting	O
,	O
and	O
by	O
immunoprecipitation	O
and	O
immunoblotting	O
using	O
antibodies	O
to	O
rIGFBP	B-GENE
-2	I-GENE
and	O
hIGFBP	B-GENE
-1	I-GENE
;	O
RNAs	O
were	O
hybridized	O
to	O
cDNA	O
probes	O
for	O
rIGFBP	B-GENE
-2	I-GENE
and	O
hIGFBP	B-GENE
-1	I-GENE
.	O
1	O
)	O
C6	O
glial	O
cells	O
and	O
B104	O
neuroblastoma	O
cells	O
express	O
an	O
approximately	O
40	O
kilodalton	O
(	O
kDa	O
)	O
glycosylated	O
binding	O
protein	O
that	O
most	O
likely	O
represents	O
rIGFBP	B-GENE
-3	I-GENE
,	O
the	O
binding	O
subunit	O
of	O
the	O
150	O
kDa	O
IGF	B-GENE
:	O
binding	O
protein	O
complex	O
in	O
adult	O
rat	O
serum	O
.	O
The	O
C6	B-GENE
and	O
B104	B-GENE
binding	O
proteins	O
do	O
not	O
react	O
with	O
antibodies	O
to	O
rIGFBP	B-GENE
-2	I-GENE
,	O
and	O
RNAs	O
from	O
C6	B-GENE
and	O
B104	B-GENE
cells	O
do	O
not	O
hybridize	O
to	O
cDNA	O
probes	O
for	O
rIGFBP	B-GENE
-2	I-GENE
or	O
hIGFBP	B-GENE
-1	I-GENE
.	O
2	O
)	O
BRL-3A	O
,	O
Clone	O
9	O
,	O
and	O
TRL	O
12-15	O
cell	O
lines	O
derived	O
from	O
normal	O
rat	O
liver	O
express	O
rIGFBP	B-GENE
-2	I-GENE
,	O
a	O
30	O
kDa	O
nonglycosylated	O
IGF-binding	B-GENE
protein	I-GENE
that	O
is	O
recognized	O
by	O
antibodies	O
to	O
rIGFBP	B-GENE
-2	I-GENE
but	O
not	O
by	O
antibodies	O
to	O
hIGFBP	B-GENE
-1	I-GENE
.	O
RNAs	O
from	O
these	O
cells	O
hybridize	O
to	O
a	O
rIGFBP	B-GENE
-2	I-GENE
cDNA	O
probe	O
,	O
but	O
not	O
to	O
a	O
hIGFBP-1	B-GENE
probe	O
.	O
3	O
)	O
H35	O
rat	O
hepatoma	O
cells	O
express	O
a	O
30	O
kDa	O
nonglycosylated	O
IGFBP	B-GENE
that	O
is	O
presumptively	O
identified	O
as	O
rIGFBP	B-GENE
-1	I-GENE
.	O
It	O
does	O
not	O
react	O
with	O
antibodies	O
to	O
rIGFBP	B-GENE
-2	I-GENE
,	O
but	O
is	O
recognized	O
by	O
polyclonal	O
and	O
monoclonal	O
antibodies	O
to	O
hIGFBP	B-GENE
-1	I-GENE
.	O
RNA	O
from	O
H35	O
cells	O
hybridizes	O
to	O
a	O
hIGFBP-1	B-GENE
cDNA	O
probe	O
,	O
but	O
not	O
to	O
a	O
rIGFBP	B-GENE
-2	I-GENE
probe	O
.	O
Expression	O
of	O
rIGFBP-1	B-GENE
by	O
the	O
H35	O
cell	O
line	O
has	O
enabled	O
us	O
to	O
establish	O
and	O
validate	O
specific	O
assays	O
for	O
this	O
protein	O
that	O
allow	O
us	O
to	O
study	O
its	O
regulation	O
in	O
intact	O
rats	O
.	O
Identification	O
of	O
a	O
panel	O
of	O
rat	O
cell	O
lines	O
expressing	O
specific	O
IGFBPs	B-GENE
should	O
be	O
useful	O
in	O
elucidating	O
the	O
molecular	O
mechanisms	O
of	O
IGFBP	B-GENE
regulation	O
.	O
PMID	O
:	O
1691442	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurosci	O
.	O
1983	O
Sep;3	O
(	O
9	O
)	O
:1713-27	O
.	O
Induction	O
of	O
differentiation	O
increases	O
Met5-enkephalin	O
and	O
Leu5-enkephalin	O
content	O
in	O
NG108-15	O
hybrid	O
cells	O
:	O
an	O
immunocytochemical	O
and	O
biochemical	O
analysis	O
.	O
Braas	O
KM	O
,	O
Childers	O
SR	O
,	O
U'Prichard	O
DC.	O
Regulation	O
of	O
cellular	O
content	O
of	O
the	O
endogenous	O
opioid	O
peptides	O
Met5-enkephalin	B-GENE
and	O
Leu5-enkephalin	B-GENE
was	O
investigated	O
in	O
neuroblastoma	O
X	O
glioma	O
hybrid	O
cells	O
NG108-15	O
grown	O
in	O
both	O
serum	O
-	O
supplemented	O
and	O
serum	O
-	O
free	O
defined	O
media	O
.	O
Untreated	O
cells	O
and	O
cells	O
induced	O
to	O
differentiate	O
were	O
stained	O
using	O
anti	O
-	O
Met5-enkephalin	B-GENE
and	O
anti	O
-	O
Leu5-enkephalin	B-GENE
with	O
the	O
peroxidase	B-GENE
-	O
antiperoxidase	B-GENE
immunocytochemical	O
technique	O
at	O
the	O
light	O
microscopic	O
level	O
.	O
In	O
untreated	O
NG108-15	O
cells	O
grown	O
in	O
serum	O
-	O
supplemented	O
medium	O
,	O
intense	O
enkephalin	B-GENE
-	O
like	O
immunoreactivity	O
was	O
localized	O
in	O
cell	O
bodies	O
and	O
short	O
processes	O
of	O
a	O
select	O
population	O
of	O
cells	O
.	O
The	O
volume	O
fraction	O
of	O
stained	O
untreated	O
cells	O
remained	O
constant	O
throughout	O
the	O
time	O
period	O
investigated	O
.	O
When	O
cells	O
were	O
induced	O
to	O
differentiate	O
with	O
N6	O
,O2'-dibutyryl	O
adenosine	O
3':5'-cyclic	O
monophosphate	O
(	O
dBcAMP	O
)	O
or	O
8-bromo	O
cyclic	O
adenosine	O
monophosphate	O
(	O
1.0	O
mM	O
)	O
treatment	O
for	O
5	O
days	O
,	O
staining	O
was	O
found	O
throughout	O
the	O
cytoplasm	O
of	O
perikarya	O
and	O
the	O
extensive	O
processes	O
which	O
were	O
expressed	O
,	O
and	O
the	O
volume	O
fraction	O
of	O
stained	O
cells	O
increased	O
over	O
2-	O
fold	O
.	O
Receptor	O
-	O
mediated	O
stimulation	O
of	O
adenylate	B-GENE
cyclase	I-GENE
by	O
prostaglandin	O
E1	O
(	O
10	O
microM	O
)	O
for	O
5	O
days	O
produced	O
results	O
similar	O
to	O
those	O
with	O
dBcAMP	O
.	O
Pure	O
cultures	O
of	O
differentiated	O
cells	O
with	O
intense	O
staining	O
were	O
obtained	O
by	O
further	O
treatment	O
of	O
cultures	O
,	O
grown	O
in	O
the	O
presence	O
or	O
absence	O
of	O
dBcAMP	O
,	O
with	O
arabinosylcytosine	O
(	O
araC	O
)	O
.	O
Untreated	O
,	O
dBcAMP	O
-	O
treated	O
and	O
araC	O
-	O
treated	O
NG108-15	O
cells	O
grown	O
in	O
defined	O
medium	O
expressed	O
staining	O
patterns	O
and	O
volume	O
fractions	O
of	O
stained	O
cells	O
similar	O
to	O
those	O
grown	O
in	O
serum	O
-	O
supplemented	O
medium	O
;	O
sodium	O
butyrate	O
(	O
1.0	O
mM	O
)	O
,	O
however	O
,	O
increased	O
the	O
volume	O
fraction	O
of	O
stained	O
cells	O
grown	O
in	O
defined	O
medium	O
over	O
3	O
-	O
fold	O
,	O
whereas	O
it	O
had	O
little	O
effect	O
on	O
staining	O
of	O
cells	O
grown	O
with	O
serum	O
.	O
The	O
presence	O
of	O
both	O
Met5	B-GENE
-	O
and	O
Leu5	B-GENE
enkephalin	I-GENE
-	O
like	O
activities	O
in	O
NG108-15	O
cells	O
was	O
confirmed	O
in	O
acid	O
extracts	O
of	O
cells	O
by	O
radioreceptor	O
assay	O
after	O
separation	O
by	O
reverse	O
phase	O
high	O
pressure	O
liquid	O
chromatography	O
.	O
Induction	O
of	O
differentiation	O
in	O
NG108-15	O
cells	O
by	O
dBcAMP	O
treatment	O
increased	O
the	O
cellular	O
concentration	O
of	O
both	O
enkephalins	O
to	O
over	O
2	O
times	O
the	O
levels	O
found	O
in	O
untreated	O
cells	O
.	O
The	O
biochemical	O
analysis	O
for	O
Met5-enkephalin	B-GENE
-	O
and	O
Leu5-enkephalin	B-GENE
-	O
like	O
activity	O
compared	O
well	O
with	O
the	O
immunocytochemical	O
data	O
indicating	O
that	O
the	O
enkephalin	O
content	O
is	O
correlated	O
with	O
the	O
state	O
of	O
differentiation	O
of	O
NG108-15	O
cells	O
.	O
PMID	O
:	O
6193253	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neurosci	O
Res	O
.	O
2003	O
Oct	O
1;74	O
(	O
1	O
)	O
:	O
148	O
-59	O
.	O
Overexpression	O
of	O
amyloid	B-GENE
precursor	I-GENE
protein	I-GENE
is	O
associated	O
with	O
degeneration	O
,	O
decreased	O
viability	O
,	O
and	O
increased	O
damage	O
caused	O
by	O
neurotoxins	O
(	O
prostaglandins	O
A1	O
and	O
E2	O
,	O
hydrogen	O
peroxide	O
,	O
and	O
nitric	O
oxide	O
)	O
in	O
differentiated	O
neuroblastoma	O
cells	O
.	O
Hanson	O
AJ	O
,	O
Prasad	O
JE	O
,	O
Nahreini	O
P,	O
Andreatta	O
C	O
,	O
Kumar	O
B	O
,	O
Yan	O
XD	O
,	O
Prasad	O
KN	O
.	O
Center	O
for	O
Vitamins	O
and	O
Cancer	O
Research	O
,	O
Department	O
of	O
Radiology	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Colorado	O
Health	O
Sciences	O
Center	O
,	O
Denver	O
,	O
Colorado	O
,	O
USA	O
.	O
Inflammatory	O
reactions	O
are	O
considered	O
one	O
of	O
the	O
important	O
etiologic	O
factors	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O
Prostaglandins	O
such	O
as	O
PGE2	O
and	O
PGA1	O
and	O
free	O
radicals	O
are	O
some	O
of	O
the	O
agents	O
released	O
during	O
inflammatory	O
reactions	O
,	O
and	O
they	O
are	O
neurotoxic	O
.	O
The	O
mechanisms	O
of	O
their	O
action	O
are	O
not	O
well	O
understood	O
.	O
Increased	O
levels	O
of	O
beta-amyloid	O
fragments	O
(	O
Abeta40	B-GENE
and	O
Abeta42	B-GENE
)	O
,	O
generated	O
through	O
cleavage	O
of	O
amyloid	B-GENE
precursor	I-GENE
protein	I-GENE
(	O
APP	B-GENE
)	O
,	O
oxidative	O
stress	O
,	O
and	O
proteasome	B-GENE
inhibition	O
,	O
are	O
also	O
associated	O
with	O
neurodegeneration	O
in	O
AD	O
brains	O
.	O
Therefore	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
PGs	O
and	O
oxidative	O
stress	O
on	O
the	O
degeneration	O
and	O
viability	O
of	O
cyclic	O
AMP	O
-	O
induced	O
differentiated	O
NB	O
cells	O
overexpressing	O
wild-type	O
APP	B-GENE
(	O
NBP2-PN46	O
)	O
under	O
the	O
control	O
of	O
the	O
CMV	O
promotor	O
in	O
comparison	O
with	O
differentiated	O
vector	O
(	O
NBP2-PN1	O
)	O
or	O
parent	O
(	O
NBP2	O
)	O
control	O
cells	O
.	O
Results	O
showed	O
that	O
differentiated	O
NBP2-PN46	O
cells	O
exhibited	O
enhanced	O
spontaneous	O
degeneration	O
and	O
decreased	O
viability	O
in	O
comparison	O
with	O
differentiated	O
control	O
cells	O
,	O
without	O
changing	O
the	O
level	O
of	O
Abeta40	B-GENE
and	O
Abeta42	B-GENE
.	O
PGA1	O
or	O
PGE2	O
treatment	O
of	O
differentiated	O
cells	O
caused	O
increased	O
degeneration	O
and	O
reduced	O
viability	O
in	O
all	O
three	O
cell	O
lines	O
.	O
These	O
effects	O
of	O
PGs	O
are	O
not	O
due	O
to	O
alterations	O
in	O
the	O
levels	O
of	O
vector	O
-	O
derived	O
APP	B-GENE
mRNA	O
or	O
human	O
APP	B-GENE
holoprotein	I-GENE
,	O
secreted	O
levels	O
of	O
Abeta40	B-GENE
and	O
Abeta42	B-GENE
,	O
or	O
proteasome	B-GENE
activity	O
.	O
H2O2	O
or	O
SIN-1	B-GENE
(	O
an	O
NO	O
donor	O
)	O
treatment	O
did	O
not	O
change	O
vector	O
-	O
derived	O
APP	B-GENE
mRNA	O
levels	O
,	O
but	O
H2O2	O
reduced	O
the	O
level	O
of	O
human	O
APP	B-GENE
protein	O
more	O
than	O
SIN-1	B-GENE
.	O
Furthermore	O
,	O
SIN-1	B-GENE
increased	O
the	O
secreted	O
level	O
of	O
Abeta40	B-GENE
,	O
but	O
not	O
of	O
Abeta42	B-GENE
,	O
whereas	O
H2O2	O
had	O
no	O
effect	O
on	O
the	O
level	O
of	O
secreted	O
Abeta	B-GENE
fragments	O
.	O
Both	O
H2O2	O
and	O
SIN-1	B-GENE
inhibited	O
proteasome	B-GENE
activity	O
in	O
the	O
intact	O
cells	O
.	O
The	O
failure	O
of	O
neurotoxins	O
to	O
alter	O
APP	B-GENE
mRNA	O
levels	O
could	O
be	O
due	O
to	O
the	O
fact	O
that	O
they	O
do	O
not	O
affect	O
CMV	O
promoter	O
activity	O
.	O
These	O
results	O
suggest	O
that	O
the	O
mechanisms	O
of	O
action	O
of	O
PGs	O
on	O
neurodegeneration	O
are	O
different	O
from	O
those	O
of	O
H2O2	O
and	O
SIN-1	B-GENE
and	O
that	O
the	O
mechanisms	O
of	O
neurotoxicity	O
of	O
H2O2	O
and	O
SIN-1	B-GENE
are	O
,	O
at	O
least	O
in	O
part	O
,	O
different	O
from	O
each	O
other	O
.	O
Copyright	O
2003	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
13130517	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Radiology	O
.	O
2001	O
Jan;218	O
(	O
1	O
)	O
:91-4.	O
Case	O
30	O
:	O
Neoplastic	O
marrow	O
infiltration	O
due	O
to	O
neuroblastoma	O
.	O
Herman	O
TE	O
,	O
Siegel	O
MJ.	O
Mallinckrodt	O
Institute	O
of	O
Radiology	O
,	O
Washington	O
University	O
School	O
of	O
Medicine	O
,	O
510	O
S	O
Kingshighway	O
Blvd	O
,	O
St	O
Louis	O
,	O
MO	O
63110	O
,	O
USA	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
11152785	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Endocrinol	O
Metab	O
.	O
2000	O
Oct;8	O
5	O
(	O
10	O
)	O
:	O
3866-73	O
.	O
Quantitative	O
determination	O
of	O
sst2	B-GENE
gene	O
expression	O
in	O
neuroblastoma	O
tumor	O
predicts	O
patient	O
outcome	O
.	O
Raggi	O
CC	O
,	O
Maggi	O
M,	O
Renzi	O
D	O
,	O
Calabro	O
A	O
,	O
Bagnoni	O
ML	O
,	O
Scaruffi	O
P,	O
Tonini	O
GP	O
,	O
Pazzagli	O
M,	O
De	O
Bernardi	O
B	O
,	O
Bernini	O
G	O
,	O
Serio	O
M,	O
Orlando	O
C.	O
Clinical	O
Biochemistry	O
Unit	O
,	O
Department	O
of	O
Clinical	O
Physiopathology	O
,	O
University	O
of	O
Florence	O
,	O
Italy	O
.	O
Neuroblastoma	O
(	O
NB	O
)	O
is	O
the	O
most	O
common	O
pediatric	O
neuroendocrine	O
tumor	O
,	O
and	O
it	O
is	O
characterized	O
by	O
a	O
quite	O
variable	O
clinical	O
course	O
.	O
We	O
previously	O
found	O
a	O
great	O
variability	O
in	O
the	O
expression	O
of	O
somatostatin	B-GENE
receptor	I-GENE
type	I-GENE
2	I-GENE
(	O
sst2	B-GENE
)	O
in	O
several	O
human	O
NB	O
cell	O
lines	O
and	O
primary	O
tumors	O
.	O
In	O
this	O
report	O
we	O
investigated	O
whether	O
expression	O
of	O
sst2	B-GENE
is	O
somehow	O
related	O
to	O
clinical	O
outcome	O
.	O
We	O
performed	O
a	O
retrospective	O
study	O
on	O
54	O
patients	O
with	O
a	O
maximum	O
follow-up	O
of	O
100	O
months	O
.	O
The	O
concentration	O
of	O
specific	O
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
for	O
sst2	B-GENE
was	O
measured	O
by	O
competitive	O
RT-PCR	O
and	O
validated	O
,	O
in	O
a	O
small	O
subset	O
of	O
samples	O
,	O
by	O
quantitative	O
imaging	O
of	O
gene	O
(	O
in	O
situ	O
hybridization	O
)	O
and	O
protein	O
(	O
immunohistochemistry	O
)	O
expression	O
.	O
We	O
found	O
that	O
sst2	B-GENE
mRNA	O
was	O
variably	O
expressed	O
in	O
all	O
NB	O
tumors	O
(	O
range	O
,	O
2.5	O
x	O
10(	O
5	O
)	O
to	O
8	O
x	O
10(	O
9	O
)	O
molecules	O
/	O
microg	O
RNA	O
)	O
with	O
a	O
relevant	O
reduction	O
in	O
the	O
more	O
advanced	O
stage	O
(	O
P	O
<	O
0.01	O
)	O
.	O
Analysis	O
of	O
Kaplan-Meier	O
curves	O
indicated	O
that	O
sst2	B-GENE
expression	O
is	O
positively	O
related	O
to	O
the	O
overall	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
event	O
-	O
free	O
(	O
P	O
<	O
0.0001	O
)	O
survival	O
.	O
Expression	O
of	O
sst2	B-GENE
was	O
negatively	O
related	O
to	O
tumor	O
stage	O
(	O
P	O
<	O
0.02	O
)	O
and	O
MYCN	B-GENE
amplification	O
(	O
P	O
<	O
0.001	O
)	O
,	O
a	O
poor	O
prognostic	O
factor	O
.	O
However	O
,	O
the	O
prognostic	O
information	O
derived	O
from	O
sst2	B-GENE
is	O
apparently	O
independent	O
from	O
MYCN	B-GENE
amplification	O
,	O
as	O
assessed	O
by	O
stratifying	O
sst2	B-GENE
values	O
according	O
to	O
MYCN	B-GENE
.	O
In	O
addition	O
,	O
the	O
expression	O
of	O
sst2	B-GENE
was	O
the	O
only	O
significant	O
prognostic	O
factor	O
(	O
P	O
<	O
0.02	O
)	O
when	O
it	O
was	O
included	O
in	O
a	O
multivariate	O
model	O
containing	O
other	O
well	O
known	O
prognostic	O
factors	O
such	O
as	O
age	O
,	O
stage	O
,	O
and	O
MYCN	B-GENE
amplification	O
.	O
Hence	O
,	O
we	O
propose	O
that	O
sst2	B-GENE
expression	O
represents	O
a	O
new	O
prognostic	O
marker	O
for	O
NB	O
.	O
The	O
main	O
clinical	O
value	O
of	O
a	O
quantitative	O
measure	O
of	O
sst2	B-GENE
lies	O
in	O
its	O
ability	O
to	O
detect	O
patients	O
at	O
low	O
risk	O
,	O
independently	O
from	O
other	O
prognostic	O
factor	O
,	O
including	O
MYCN	B-GENE
amplification	O
.	O
PMID	O
:	O
11061551	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Pharmacol	O
.	O
2000	O
May	O
15	O
;5	O
9	O
(	O
10	O
)	O
:	O
1305	O
-14	O
.	O
Inhibitory	O
action	O
of	O
1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxam	O
ide	O
(	O
PK	O
11195	O
)	O
on	O
some	O
mononuclear	O
phagocyte	O
functions	O
.	O
Klegeris	O
A	O
,	O
McGeer	O
EG	O
,	O
McGeer	O
PL.	O
Kinsmen	O
Laboratory	O
of	O
Neurological	O
Research	O
,	O
University	O
of	O
British	O
Columbia	O
,	O
Vancouver	O
,	O
BC	O
,	O
Canada	O
.	O
aklegeri@interchange	O
.ubc.ca	O
Peripheral	B-GENE
benzodiazepine	I-GENE
receptors	I-GENE
(	O
PBRs	B-GENE
)	O
are	O
widely	O
distributed	O
throughout	O
the	O
body	O
,	O
but	O
their	O
functions	O
are	O
unknown	O
.	O
They	O
are	O
found	O
on	O
mononuclear	O
phagocytes	O
,	O
and	O
they	O
are	O
up	O
-	O
regulated	O
in	O
a	O
number	O
of	O
neurological	O
and	O
other	O
disease	O
states	O
.	O
We	O
explored	O
the	O
functional	O
consequences	O
of	O
PBR	B-GENE
ligand	O
binding	O
to	O
mononuclear	O
-	O
derived	O
cells	O
using	O
the	O
high	O
-	O
affinity	O
ligands	O
1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxam	O
ide	O
(	O
PK	O
11195	O
)	O
and	O
4'-chlorodiazepam	O
(	O
7-	O
chloro-	O
5-(4'-chlorophenyl)-1	O
,	O
3-dihydro-1-methyl-2H-1,4-benzodiazepin	O
-	O
2-one	O
;	O
Ro	O
5-4864	O
)	O
.	O
The	O
functions	O
were	O
the	O
following	O
:	O
respiratory	O
burst	O
;	O
secretion	O
of	O
glutamate	O
,	O
interleukin	B-GENE
-	I-GENE
1beta	I-GENE
(	O
IL-1beta	B-GENE
)	O
,	O
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	I-GENE
(	O
TNF	B-GENE
-	I-GENE
alpha	I-GENE
)	O
;	O
toxicity	O
of	O
culture	O
supernatants	O
towards	O
SH-SY5Y	O
human	O
neuroblastoma	O
cells	O
;	O
and	O
expression	O
of	O
the	O
inflammatory	O
surface	O
markers	O
HLA-	B-GENE
DR	I-GENE
and	O
Fcgamma	B-GENE
RII	I-GENE
(	O
CDw32	B-GENE
)	O
.	O
PK	O
11195	O
inhibited	O
the	O
respiratory	O
burst	O
response	O
,	O
reduced	O
release	O
of	O
glutamate	O
and	O
IL-1beta	B-GENE
,	O
and	O
suppressed	O
secretion	O
of	O
products	O
cytotoxic	O
to	O
neuronal	O
cells	O
.	O
Selectivity	O
was	O
suggested	O
by	O
the	O
failure	O
of	O
PK	O
11195	O
to	O
influence	O
TNF	B-GENE
-alpha	I-GENE
secretion	O
or	O
expression	O
of	O
HLA-	B-GENE
DR	I-GENE
and	O
CDw32	B-GENE
.	O
Powerful	O
ligands	O
of	O
PBRs	B-GENE
,	O
such	O
as	O
PK	O
11195	O
,	O
may	O
be	O
useful	O
inhibitors	O
of	O
selective	O
macrophage	O
functions	O
,	O
retarding	O
both	O
local	O
and	O
systemic	O
inflammation	O
.	O
Since	O
PK	O
11195	O
readily	O
enters	O
the	O
brain	O
,	O
it	O
may	O
be	O
beneficial	O
in	O
treating	O
central	O
as	O
well	O
as	O
peripheral	O
inflammatory	O
diseases	O
.	O
PMID	O
:	O
10736431	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Klin	O
Khir	O
.	O
1999	O
;(	O
8	O
)	O
:	O
53	O
.	O
[Observation	O
of	O
neuroblastoma	O
transformation	O
into	O
ganglioneuroma	O
in	O
a	O
child	O
]	O
[	O
Article	O
in	O
Russian	O
]	O
Kononuchenko	O
VP	O
,	O
Litovka	O
VK	O
,	O
Zhurilo	O
IP	O
.	O
Publication	O
Types	O
:	O
Case	O
Reports	O
PMID	O
:	O
10584504	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Q	O
J	O
Nucl	O
Med	O
.	O
1999	O
Sep;43(	O
3	O
)	O
:	O
217-	O
23	O
.	O
Nuclear	O
medicine	O
imaging	O
of	O
pheochromocytoma	O
and	O
neuroblastoma	O
.	O
Sisson	O
JC	O
,	O
Shulkin	O
BL.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
University	O
of	O
Michigan	O
Health	O
Systems	O
,	O
Ann	O
Arbor	O
,	O
USA	O
.	O
Both	O
pheochromocytomas	O
and	O
neuroblastomas	O
can	O
now	O
be	O
identified	O
and	O
located	O
with	O
a	O
high	O
level	O
of	O
accuracy	O
.	O
Scintigraphy	O
with	O
MIBG	O
has	O
become	O
an	O
indispensable	O
diagnostic	O
method	O
for	O
defining	O
the	O
extent	O
and	O
location	O
of	O
many	O
if	O
not	O
most	O
pheochromocytomas	O
.	O
To	O
define	O
the	O
stage	O
,	O
to	O
document	O
the	O
course	O
and	O
to	O
evaluate	O
the	O
response	O
to	O
therapies	O
in	O
patients	O
with	O
neuroblastoma	O
,	O
imaging	O
with	O
MIBG	O
is	O
now	O
essential	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
10568137	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
.	O
1999	O
Aug	O
19;262(	O
1	O
)	O
:	O
132	O
-8.	O
Computational	O
EST	O
database	O
analysis	O
identifies	O
a	O
novel	O
member	O
of	O
the	O
neuropoietic	O
cytokine	B-GENE
family	O
.	O
Shi	O
Y	O
,	O
Wang	O
W	O
,	O
Yourey	O
PA	O
,	O
Gohari	O
S	O
,	O
Zukauskas	O
D	O
,	O
Zhang	O
J,	O
Ruben	O
S	O
,	O
Alderson	O
RF.	O
Department	O
of	O
Molecular	O
Biology	O
,	O
Department	O
of	O
Pharmacology	O
,	O
Department	O
of	O
Protein	O
Expression	O
,	O
Human	O
Genome	O
Sciences	O
,	O
Inc.	O
,	O
9410	O
Key	O
West	O
Avenue	O
,	O
Rockville	O
,	O
Maryland	O
20850	O
,	O
USA	O
.	O
A	O
novel	O
member	O
of	O
the	O
neuropoietic	O
cytokine	B-GENE
family	O
has	O
been	O
cloned	O
and	O
the	O
protein	O
expressed	O
and	O
characterized	O
.	O
In	O
an	O
effort	O
to	O
identify	O
novel	O
secreted	O
proteins	O
,	O
an	O
algorithm	O
incorporating	O
neural	O
network	O
algorithms	O
was	O
applied	O
to	O
a	O
large	O
EST	O
database	O
.	O
A	O
full	O
-	O
length	O
clone	O
was	O
identified	O
that	O
is	O
1710	O
bp	O
in	O
length	O
and	O
has	O
a	O
single	O
open	O
reading	O
frame	O
of	O
225	O
amino	O
acids	O
.	O
This	O
new	O
cytokine	B-GENE
is	O
most	O
homologous	O
to	O
cardiotrophin	B-GENE
-1	I-GENE
,	O
having	O
a	O
similarity	O
and	O
an	O
identity	O
of	O
46	O
and	O
29	O
%	O
,	O
respectively	O
,	O
and	O
therefore	O
we	O
have	O
named	O
it	O
cardiotrophin	B-GENE
-	I-GENE
like	I-GENE
cytokine	I-GENE
(	O
CLC	B-GENE
)	O
.	O
Northern	O
hybridization	O
analysis	O
identified	O
a	O
1.4-kb	O
messenger	O
RNA	O
that	O
is	O
highly	O
expressed	O
in	O
spleen	O
and	O
peripheral	O
leukocytes	O
.	O
Purified	O
recombinant	O
CLC	B-GENE
induced	O
the	O
activation	O
of	O
NFkappaB	B-GENE
and	O
SRE	B-GENE
reporter	I-GENE
constructs	O
in	O
the	O
TF-1	O
,	O
U937	O
,	O
and	O
M1	O
cell	O
lines	O
.	O
Furthermore	O
,	O
the	O
signal	O
transduction	O
pathway	O
for	O
CLC	B-GENE
was	O
characterized	O
in	O
the	O
neuroblastoma	O
cell	O
line	O
SK-N-MC	O
and	O
found	O
to	O
involve	O
tyrosine	O
phosphorylation	O
of	O
gp130	B-GENE
and	O
STAT-1	B-GENE
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
PMID	O
:	O
10448081	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1999	O
Jul	O
20;96	O
(	O
15	O
)	O
:	O
8591-6.	O
Tumor	O
-	O
targeted	O
IL-2	B-GENE
amplifies	O
T	O
cell	O
-	O
mediated	O
immune	O
response	O
induced	O
by	O
gene	O
therapy	O
with	O
single-chain	B-GENE
IL-12	I-GENE
.	O
Lode	O
HN	O
,	O
Xiang	O
R	O
,	O
Duncan	O
SR	O
,	O
Theofilopoulos	O
AN	O
,	O
Gillies	O
SD	O
,	O
Reisfeld	O
RA.	O
The	O
Scripps	O
Research	O
Institute	O
,	O
Department	O
of	O
Immunology	O
,	O
10550	O
North	O
Torrey	O
Pines	O
Road	O
,	O
La	O
Jolla	O
,	O
CA	O
92037	O
,	O
USA	O
.	O
Induction	O
,	O
maintenance	O
,	O
and	O
amplification	O
of	O
tumor	O
-	O
protective	O
immunity	O
after	O
cytokine	B-GENE
gene	O
therapy	O
is	O
essential	O
for	O
the	O
clinical	O
success	O
of	O
immunotherapeutic	O
approaches	O
.	O
We	O
investigated	O
whether	O
this	O
could	O
be	O
achieved	O
by	O
single-chain	B-GENE
IL-12	I-GENE
(	O
scIL-12	B-GENE
)	O
gene	O
therapy	O
followed	O
by	O
tumor	O
-	O
targeted	O
IL-2	B-GENE
using	O
a	O
fusion	O
protein	O
containing	O
a	O
tumor	B-GENE
-	I-GENE
specific	I-GENE
recombinant	I-GENE
anti	I-GENE
-	I-GENE
ganglioside	I-GENE
GD(2	I-GENE
)	I-GENE
antibody	I-GENE
and	O
IL-2	B-GENE
(	O
ch14.18-IL-2	B-GENE
)	O
in	O
a	O
poorly	O
immunogenic	O
murine	O
neuroblastoma	O
model	O
.	O
Herein	O
,	O
we	O
demonstrate	O
the	O
absence	O
of	O
liver	O
and	O
bone	O
marrow	O
metastases	O
after	O
a	O
lethal	O
challenge	O
with	O
NXS2	O
wild-type	O
cells	O
only	O
in	O
mice	O
(	O
five	O
of	O
six	O
animals	O
)	O
vaccinated	O
with	O
scIL-12	B-GENE
-	O
producing	O
NXS2	O
cells	O
and	O
given	O
a	O
booster	O
injection	O
of	O
low-dose	O
ch14.18-IL-2	B-GENE
fusion	O
protein	O
.	O
This	O
tumor	O
-	O
protective	O
immunity	O
was	O
effective	O
3	O
months	O
after	O
initial	O
vaccination	O
,	O
in	O
contrast	O
to	O
control	O
animals	O
treated	O
with	O
a	O
nonspecific	O
fusion	O
protein	O
or	O
an	O
equivalent	O
mixture	O
of	O
antibody	B-GENE
and	O
IL-2	B-GENE
.	O
Only	O
vaccinated	O
mice	O
receiving	O
the	O
tumor	O
-	O
specific	O
ch14.18-IL-2	B-GENE
fusion	O
protein	O
revealed	O
a	O
reactivation	O
of	O
CD8	B-GENE
T	O
cells	O
and	O
subsequent	O
MHC	O
class	O
I-	O
restricted	O
tumor	O
target	O
cell	O
lysis	O
in	O
vitro	O
.	O
The	O
sequential	O
increase	O
in	O
the	O
usage	O
of	O
TCR	B-GENE
chains	I-GENE
Vbeta	I-GENE
11	I-GENE
and	O
-	B-GENE
13	I-GENE
in	O
mouse	O
CD8	B-GENE
T	O
cells	O
after	O
vaccination	O
and	O
amplification	O
with	O
ch14.18-IL-2	B-GENE
suggests	O
that	O
the	O
initial	O
polyclonal	O
CD8	B-GENE
T	O
cell	O
response	O
is	O
effectively	O
boosted	O
by	O
targeted	O
IL-2	B-GENE
.	O
In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
a	O
successful	O
boost	O
of	O
a	O
partially	O
protective	O
memory	O
T	O
cell	O
immune	O
response	O
that	O
is	O
induced	O
by	O
scIL-12	B-GENE
gene	O
therapy	O
could	O
be	O
generated	O
by	O
tumor	O
-	O
specific	O
targeting	O
of	O
IL-2	B-GENE
with	O
a	O
ch14.18-IL-2	B-GENE
fusion	O
protein	O
.	O
This	O
approach	O
could	O
increase	O
success	O
rates	O
of	O
clinical	O
cancer	O
vaccine	O
trials	O
.	O
PMID	O
:	O
10411920	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Regul	O
Pept	O
.	O
1999	O
Feb	O
5;79(	O
2-3	O
)	O
:153	O
-	O
8.	O
CGRP	B-GENE
27-37	O
analogues	O
with	O
high	O
affinity	O
to	O
the	O
CGRP1	B-GENE
receptor	I-GENE
show	O
antagonistic	O
properties	O
in	O
a	O
rat	O
blood	O
flow	O
assay	O
.	O
Rist	O
B	O
,	O
Lacroix	O
JS	O
,	O
Entzeroth	O
M,	O
Doods	O
HN	O
,	O
Beck	O
-Sickinger	O
AG.	O
Department	O
of	O
Pharmacy	O
,	O
ETH	O
Zurich	O
,	O
Switzerland	O
.	O
CGRP	B-GENE
Y0	O
-	O
28-37	O
is	O
known	O
as	O
a	O
selective	O
CGRP1	B-GENE
receptor	I-GENE
antagonist	O
.	O
We	O
succeeded	O
in	O
optimising	O
the	O
CGRP1	B-GENE
receptor	I-GENE
affinity	O
of	O
this	O
fragment	O
by	O
multiple	O
amino	O
acid	O
replacement	O
.	O
The	O
analogues	O
[	O
p34	B-GENE
,	O
F35	B-GENE
]	O
CGRP	B-GENE
27-37	O
and	O
[	O
D31	B-GENE
,	O
p34	B-GENE
,	O
F35	B-GENE
]	O
CGRP	B-GENE
27-37	O
exhibit	O
a	O
100	O
-	O
fold	O
increased	O
affinity	O
compared	O
to	O
the	O
unmodified	O
segment	O
.	O
Receptor	O
binding	O
studies	O
were	O
performed	O
with	O
human	O
neuroblastoma	O
cells	O
SK-N-MC	O
,	O
which	O
selectively	O
express	O
the	O
hCGRP1	B-GENE
receptor	I-GENE
.	O
Blood	O
flow	O
,	O
which	O
is	O
increased	O
by	O
exogenous	O
CGRP	B-GENE
,	O
was	O
measured	O
in	O
the	O
right	O
femoral	O
artery	O
.	O
Preincubation	O
of	O
the	O
rats	O
with	O
[	O
p34	B-GENE
,	O
F35	B-GENE
]	O
CGRP	B-GENE
27-37	O
and	O
[	O
D31	B-GENE
,	O
p34	B-GENE
,	O
F35	B-GENE
]	O
CGRP	B-GENE
27-37	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
CGRP	B-GENE
induced	O
increase	O
in	O
vascular	O
conductance	O
indicating	O
the	O
antagonistic	O
properties	O
of	O
these	O
compounds	O
.	O
Interestingly	O
,	O
an	O
exchange	O
of	O
the	O
amino	O
acid	O
Asn	O
31	O
to	O
Asp	O
31	O
in	O
[	O
p34	B-GENE
,	O
F35	B-GENE
]	O
CGRP	B-GENE
27-37	O
shortened	O
the	O
period	O
of	O
the	O
antagonistic	O
effect	O
significantly	O
,	O
suggestive	O
of	O
a	O
different	O
rate	O
of	O
metabolism	O
for	O
the	O
two	O
ligands	O
.	O
Secondary	O
structure	O
investigations	O
obtained	O
by	O
circular	O
dichroism	O
measurements	O
revealed	O
that	O
an	O
increase	O
in	O
ordered	O
structure	O
correlates	O
with	O
high	O
binding	O
affinity	O
.	O
PMID	O
:	O
10100929	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Pharmacol	O
.	O
1999	O
Feb;55	O
(	O
2	O
)	O
:	O
263	O
-	O
8.	O
Replacement	O
of	O
threonine	O
394	O
by	O
alanine	O
facilitates	O
internalization	O
and	O
resensitization	O
of	O
the	O
rat	O
mu	B-GENE
opioid	I-GENE
receptor	I-GENE
.	O
Wolf	O
R	O
,	O
Koch	O
T	O
,	O
Schulz	O
S	O
,	O
Klutzny	O
M,	O
Schroder	O
H,	O
Raulf	O
E	O
,	O
Buhling	O
F	O
,	O
Hollt	O
V	O
.	O
Department	O
of	O
Pharmacology	O
and	O
Toxicology	O
,	O
Otto-von	O
-	O
Guericke	O
University	O
,	O
Magdeburg	O
,	O
Germany	O
.	O
Signaling	O
of	O
G	B-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
receptors	I-GENE
is	O
terminated	O
by	O
phosphorylation	O
of	O
intracellular	O
serine	O
and	O
threonine	O
residues	O
.	O
Resensitization	O
of	O
these	O
receptors	O
requires	O
internalization	O
and	O
subsequent	O
dephosphorylation	O
.	O
We	O
have	O
recently	O
shown	O
that	O
the	O
resensitization	O
rate	O
of	O
the	O
rat	O
micro	B-GENE
opioid	I-GENE
receptor	I-GENE
(	O
MOR	B-GENE
)	O
isoforms	O
MOR1	B-GENE
and	O
MOR1B	B-GENE
is	O
mainly	O
determined	O
by	O
the	O
amino	O
acid	O
composition	O
of	O
their	O
alternatively	O
spliced	O
C-terminal	O
tails	O
.	O
Upon	O
agonist	O
stimulation	O
,	O
MOR1B	B-GENE
passes	O
through	O
an	O
accelerated	O
cycle	O
of	O
receptor	O
endocytosis	O
and	O
reactivation	O
,	O
which	O
in	O
turn	O
promotes	O
a	O
greater	O
resistance	O
to	O
agonist	O
-	O
induced	O
desensitization	O
,	O
as	O
compared	O
with	O
MOR1	B-GENE
.	O
Given	O
the	O
fact	O
that	O
MOR1B	B-GENE
lacks	O
only	O
one	O
putative	O
phosphorylation	O
site	O
(	O
T	O
394	O
of	O
MOR1	B-GENE
)	O
,	O
we	O
replaced	O
this	O
threonine	O
by	O
an	O
alanine	O
and	O
stably	O
expressed	O
the	O
wild-type	O
MOR1	B-GENE
and	O
its	O
T	O
394	O
A	O
mutant	O
in	O
mouse	O
neuroblastoma	O
Neuro2a	O
cells	O
.	O
We	O
show	O
that	O
during	O
prolonged	O
[D-	B-GENE
Ala2	I-GENE
,	O
MePhe4	B-GENE
,	O
Gly5-ol	B-GENE
]	O
enkephalin	B-GENE
exposure	O
(	O
5	O
h	O
)	O
,	O
the	O
T	O
394	O
A	O
receptor	O
mutant	O
desensitized	O
at	O
a	O
slower	O
rate	O
than	O
MOR1	B-GENE
.	O
In	O
contrast	O
,	O
T	O
394	O
A	O
is	O
more	O
rapidly	O
removed	O
from	O
the	O
cell	O
surface	O
than	O
MOR1	B-GENE
,	O
as	O
determined	O
by	O
flow	O
cytometry	O
using	O
epitope	O
-	O
tagged	O
receptors	O
.	O
This	O
fast	O
internalization	O
was	O
followed	O
by	O
immediate	O
resensitization	O
of	O
T	O
394	O
A	O
during	O
20	O
min	O
of	O
agonist	O
removal	O
while	O
the	O
wild-type	O
MOR1	B-GENE
remained	O
inactive	O
.	O
Similar	O
to	O
MOR1B	B-GENE
,	O
rapid	O
internalization	O
and	O
reactivation	O
of	O
T	O
394	O
A	O
may	O
explain	O
its	O
delayed	O
desensitization	O
.	O
These	O
findings	O
suggest	O
that	O
T	O
394	O
represents	O
a	O
negative	O
regulatory	O
signal	O
for	O
MOR1	B-GENE
internalization	O
.	O
Furthermore	O
,	O
phosphorylation	O
of	O
this	O
threonine	O
residue	O
may	O
influence	O
the	O
time	O
course	O
of	O
micro	B-GENE
opioid	I-GENE
receptor	I-GENE
resensitization	O
.	O
PMID	O
:	O
9927617	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
.	O
1998	O
Dec	O
22;95	O
(	O
26	O
)	O
:15406-11	O
.	O
PTEN	B-GENE
/	O
MMAC1	B-GENE
/	O
TEP1	B-GENE
suppresses	O
the	O
tumorigenicity	O
and	O
induces	O
G1	O
cell	O
cycle	O
arrest	O
in	O
human	O
glioblastoma	O
cells	O
.	O
Li	O
DM	O
,	O
Sun	O
H.	O
Department	O
of	O
Genetics	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
333	O
Cedar	O
Street	O
,	O
New	O
Haven	O
,	O
CT	O
06520	O
,	O
USA	O
.	O
PTEN	B-GENE
/	O
MMAC1	B-GENE
/	O
TEP1	B-GENE
is	O
a	O
tumor	O
suppressor	O
that	O
possesses	O
intrinsic	O
phosphatase	B-GENE
activity	O
.	O
Deletions	O
or	O
mutations	O
of	O
its	O
encoding	O
gene	O
are	O
associated	O
with	O
a	O
variety	O
of	O
human	O
cancers	O
.	O
However	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
by	O
which	O
this	O
important	O
tumor	O
suppressor	O
regulates	O
cell	O
growth	O
.	O
Here	O
,	O
we	O
show	O
that	O
PTEN	B-GENE
expression	O
potently	O
suppressed	O
the	O
growth	O
and	O
tumorigenicity	O
of	O
human	O
glioblastoma	O
U87MG	O
cells	O
.	O
The	O
growth	O
suppression	O
activity	O
of	O
PTEN	B-GENE
was	O
mediated	O
by	O
its	O
ability	O
to	O
block	O
cell	O
cycle	O
progression	O
in	O
the	O
G1	O
phase	O
.	O
Such	O
an	O
arrest	O
correlated	O
with	O
a	O
significant	O
increase	O
of	O
the	O
cell	O
cycle	O
kinase	B-GENE
inhibitor	O
p27	B-GENE
(	O
KIP1	B-GENE
)	O
and	O
a	O
concomitant	O
decrease	O
in	O
the	O
activities	O
of	O
the	O
G1	B-GENE
cyclin	I-GENE
-	I-GENE
dependent	I-GENE
kinases	I-GENE
.	O
PTEN	B-GENE
expression	O
also	O
led	O
to	O
the	O
inhibition	O
of	O
Akt	B-GENE
/	O
protein	B-GENE
kinase	I-GENE
B	I-GENE
,	O
a	O
serine	B-GENE
-threonine	I-GENE
kinase	I-GENE
activated	O
by	O
the	O
phosphatidylinositol	B-GENE
3-kinase	I-GENE
(	O
PI	B-GENE
3-kinase	I-GENE
)	O
signaling	O
pathway	O
.	O
In	O
addition	O
,	O
the	O
effect	O
of	O
PTEN	B-GENE
on	O
p27	B-GENE
(	O
KIP1	B-GENE
)	O
and	O
the	O
cell	O
cycle	O
can	O
be	O
mimicked	O
by	O
treatment	O
of	O
U87MG	O
cells	O
with	O
LY294002	O
,	O
a	O
selective	O
inhibitor	O
of	O
PI	B-GENE
3-kinase	I-GENE
.	O
Taken	O
together	O
,	O
our	O
studies	O
suggest	O
that	O
the	O
PTEN	B-GENE
tumor	O
suppressor	O
modulates	O
G1	O
cell	O
cycle	O
progression	O
through	O
negatively	O
regulating	O
the	O
PI	B-GENE
3-kinase	I-GENE
/	O
Akt	B-GENE
signaling	O
pathway	O
,	O
and	O
one	O
critical	O
target	O
of	O
this	O
signaling	O
process	O
is	O
the	O
cyclin	B-GENE
-	I-GENE
dependent	I-GENE
kinase	I-GENE
inhibitor	O
p27	B-GENE
(	O
KIP1	B-GENE
)	O
.	O
PMID	O
:	O
9860981	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

